"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Simple Family Members,Simple Family Member Jurisdictions,Extended Family Size,Extended Family Members,Extended Family Member Jurisdictions,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2013/0178914 A1,088-366-887-252-89X,2013-07-11,2013,US 201313781186 A,2013-02-28,US 201313781186 A;;US 201113106747 A;;US 14206305 A;;US 54326400 A,2000-04-05,NEUROSTIMULATOR INVOLVING STIMULATION STRATEGIES AND PROCESS FOR USING IT,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",NEUROPACE INC;;NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/088-366-887-252-89X,Patent Application,yes,0,2,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/36,607/45,0,0,,,,EXPIRED
2,US,B2,US 9451891 B2,061-631-376-949-809,2016-09-27,2016,US 201414562135 A,2014-12-05,US 201414562135 A;;US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC;;NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/061-631-376-949-809,Granted Patent,yes,99,0,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61B5/00;;A61B5/04;;A61B5/0476;;A61B5/07;;A61M5/142;;A61N1/05;;A61N1/36,,37,21,067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;028-133-278-688-002;;009-347-841-916-604;;007-919-147-709-849;;059-752-522-673-716;;018-508-980-173-266;;066-655-225-086-020;;048-972-669-828-271;;009-758-570-877-426;;112-917-826-767-538;;124-403-369-942-149;;056-361-838-782-639;;030-458-658-036-396;;059-959-153-435-269,10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1159/000099878;;9711758;;10.1111/j.1528-1157.1995.tb01667.x;;8001511;;10.1097/00001665-199203000-00002;;1391237;;8065447;;10.1038/370615a0;;8134429;;10.1097/00006534-199404000-00008;;10.1212/wnl.45.12.2250;;8848202;;10.1097/00004691-199903000-00005;;10359498;;10.1016/0267-6605(93)90085-l;;10146240;;1298420;;10.1097/00001665-199212000-00003;;52443;;10.1016/0013-4694(75)90051-6;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;10563620;;10.1212/wnl.53.8.1731,"Adriano, K.P. et al. (1994), ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants"" Journal of Applied Biomaterials 5: 133-140.;;Cooper, I.S. et al. (1974), ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man"" In The Cerebellum Epilepsy and Behavior. Cooper I.S. et al. eds. Plenum Press:New York pp. 119-171.;;Cooper, I.S. et al. (1977-1978), ""Safety and Efficacy of Chronic Cerebellar Stimulation"" Appl. Neurophysiol. 40:124-134.;;Cooper, I.S. and Upton, A.R.M. (1978), ""Effects of Cerebellar Stimulation on Epilepsy the EEG and Cerebral Palsy in Man"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb W.A. et al. eds. Elsevier Scientific Publishing: Amsterdam pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992), ""Cerebellar Stimulation for Seizure Control: 17-Year Study"" Stereotact. Funct. Neurosurg. 58:200-208.;;Lee, S.A. et al., ""Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy"" Epilepsia 2000 41 (3): 297-307.;;Lesser, R.P. et al, ""Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation"" Neurologogy 1999; 53 (December): 2073-81.;;Schiller, Y et al., ""Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes"" Epilepsia 1998; 39(4): 380-88.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. et al. (1997), ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patents with Intractable Epilepsy"" Stereotact Funct Neurosurg 69:221-224.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Apr. 13, 2006).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450)(Oct. 18, 2005).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 1, 2004).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264 (Apr. 20, 2006).;;Velasco, F. et al. (1995), ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies"" Epilepsia 36(1):63-71.;;Thaller, S.R. et al.(1992), ""Use of Biodegradable Plates and Screws in a Rabbit Model"" Journal of Craniofacial Surgery 2(4):168-173.;;Schiff, S. et al. (1994), ""Controlling Chaos in the Brain"" Nature 370:615-620.;;Sayler, K.E. et al. (1994). ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles"" Plastic and Reconstructive Surgery 93(4):705-713.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring"" Neurology 45:2250-2254.;;Osario, I. et al. (1995). ""A Method for Accurate Automated Real-Time Seizure Detection"" Epilepsia 36 (supplement 4):4 Abstract No. 1.04.;;Gotman, J. (1999), ""Automatic Detection of Seizures and Spikes"" Journal of Clinical Neurophysiology 16(2): 130-140.;;Gerlach, K.L. (1993), ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology"" Clinical Materials 13:21-28.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study"" Journal of Craniofacial Surgery 3(4):190-196.;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Apr. 20, 2006).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Oct. 14, 2005).;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 8, 2004).;;Wagner, H.R. et al. ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization"" Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;Spencer, S.S. et al. ""Morphological Patterns of Seizures Recorded Intracranially"" Epilepsia 199233(3): 537-45.;;Limousin, P. ""Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor"" J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Active).;;Morris III, G.L. et al. ""Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy"" Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).",EXPIRED
3,US,A1,US 2004/0153129 A1,082-001-738-439-925,2004-08-05,2004,US 62582903 A,2003-07-22,US 62582903 A;;US 72480500 A;;US 54326400 A;;US 37367699 A;;US 62897700 A;;US 45030399 A;;US 95786997 A,1997-10-27,System and method for controlling neurological disorders with spatially separated detection and therapy locations,A system and method for controlling epilepsy and other neurological disorders by providing electrical stimulation to a patient's brain in response to detected neurological conditions. An implantable device includes a stimulation subsystem coupled to a stimulation electrode to provide responsive electrical brain stimulation in response to an event detected via an on-board processor's analysis of data received from a detection subsystem coupled to a detection electrode located in a different portion of the patient's brain.,NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL ROBERT E;;FISCHELL DAVID R,,https://lens.org/082-001-738-439-925,Patent Application,yes,8,125,3,164-607-216-081-54X;;082-001-738-439-925;;079-411-409-996-070,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/0529;;A61B5/0002;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61M5/14276;;A61N1/0534;;A61N1/36064;;A61N1/36082;;A61N1/0529;;A61B5/0002;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61M5/14276;;A61N1/0534;;A61N1/36064;;A61N1/36082,A61B5/00;;A61B5/0476;;A61M5/142;;A61N1/36,607/62,0,0,,,,DISCONTINUED
4,US,A1,US 2013/0102833 A1,128-620-827-527-919,2013-04-25,2013,US 201213714387 A,2012-12-13,US 201213714387 A;;US 70069210 A;;US 40457906 A;;US 1462804 A,2004-12-15,MODULATION AND ANALYSIS OF CEREBRAL PERFUSION IN EPILEPSY AND OTHER NEUROLOGICAL DISORDERS,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC;;NEUROPACE INC,JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2009-04-24),https://lens.org/128-620-827-527-919,Patent Application,yes,2,11,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61N2/02;;A61F7/00;;A61N1/36;;A61N5/06;;A61N7/00,600/13;;607/88;;607/96;;607/45;;601/2,0,0,,,,EXPIRED
5,US,B1,US 6597954 B1,164-607-216-081-54X,2003-07-22,2003,US 72480500 A,2000-11-28,US 72480500 A;;US 62897700 A;;US 45030399 A;;US 95786997 A;;US 54326400 A;;US 37367699 A,1997-10-27,System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes,A system and method for controlling epilepsy and other neurological disorders by providing electrical stimulation to a patient's brain in response to detected neurological conditions. An implantable device includes a stimulation subsystem coupled to a stimulation electrode to provide responsive electrical brain stimulation in response to an event detected via an on-board processor's analysis of data received from a detection subsystem coupled to a detection electrode located in a different portion of the patient's brain.,NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL ROBERT E;;FISCHELL DAVID R,NEUROSPACE INC (2001-06-07),https://lens.org/164-607-216-081-54X,Granted Patent,yes,3,466,3,164-607-216-081-54X;;082-001-738-439-925;;079-411-409-996-070,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/0529;;A61B5/0002;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61M5/14276;;A61N1/0534;;A61N1/36064;;A61N1/36082;;A61N1/0529;;A61B5/0002;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61M5/14276;;A61N1/0534;;A61N1/36064;;A61N1/36082,A61B5/00;;A61B5/0476;;A61M5/142;;A61N1/36,607/62;;607/45;;600/544,0,0,,,,EXPIRED
6,US,A1,US 2013/0184780 A1,146-812-252-066-128,2013-07-18,2013,US 201313784569 A,2013-03-04,US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,DIFFERENTIAL NEUROSTIMULATION THERAPY DRIVEN BY PHYSIOLOGICAL THERAPY,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC;;NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/146-812-252-066-128,Patent Application,yes,6,7,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/36;;A61M5/142,607/45,0,0,,,,EXPIRED
7,US,A1,US 2013/0184604 A1,092-603-879-602-870,2013-07-18,2013,US 201313783143 A,2013-03-01,US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,SYSTEMS AND METHODS FOR INTERACTING WITH AN IMPLANTABLE MEDICAL DEVICE,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC;;NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/092-603-879-602-870,Patent Application,yes,1,0,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61N1/36;;A61B5/375;;A61N1/372,600/545;;607/45,0,0,,,,EXPIRED
8,US,A1,US 2008/0046026 A1,002-251-031-096-201,2008-02-21,2008,US 92566807 A,2007-10-26,US 92566807 A;;US 1462804 A,2004-12-15,MODULATION AND ANALYSIS OF CEREBRAL PERFUSION IN EPILEPSY AND OTHER NEUROLOGICAL DISORDERS,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2007-05-16),https://lens.org/002-251-031-096-201,Patent Application,yes,15,16,6,002-251-031-096-201;;069-686-345-844-480;;011-310-459-968-81X;;107-377-055-316-476;;105-617-775-657-09X;;171-621-506-522-002,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082;;A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082,A61N1/05,607/45,0,0,,,,ACTIVE
9,US,A1,US 2009/0069863 A1,011-310-459-968-81X,2009-03-12,2009,US 92565507 A,2007-10-26,US 92565507 A;;US 1462804 A,2004-12-15,MODULATION AND ANALYSIS OF CEREBRAL PERFUSION IN EPILEPSY AND OTHER NEUROLOGICAL DISORDERS,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2007-05-16),https://lens.org/011-310-459-968-81X,Patent Application,yes,15,5,6,002-251-031-096-201;;069-686-345-844-480;;011-310-459-968-81X;;107-377-055-316-476;;105-617-775-657-09X;;171-621-506-522-002,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082;;A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082,A61N1/36;;A61B5/145,607/45;;600/309,0,0,,,,ACTIVE
10,US,B2,US 7341562 B2,107-377-055-316-476,2008-03-11,2008,US 1462804 A,2004-12-15,US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2007-05-16),https://lens.org/107-377-055-316-476,Granted Patent,yes,7,42,6,002-251-031-096-201;;069-686-345-844-480;;011-310-459-968-81X;;107-377-055-316-476;;105-617-775-657-09X;;171-621-506-522-002,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082;;A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082,A61B5/026;;A61B5/0295;;A61N1/36,600/504;;607/3;;607/45;;600/309;;600/334;;600/454,6,3,143-388-558-467-689;;124-403-369-942-149;;026-889-963-495-548,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;10.1016/s1095-6433(99)00086-0;;10605067,"J. Gotman, Automatic Seizure Detection: Improvements and Evaluation, Electroencephalog. Clin. Neurophysiol. 1990; 76(4): 317-24.;;H. R. Wagner, et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol. 1975; 39(5): 499-506.;;T. Matsuura et al., Hemodynamics Evoked By Microelectrical Direct Stimulation in Rat Somatosensory Cortex, Comp. Biochem. Physiol. A. Mo. I Integr. Physiol. Sep. 1999; 124(1): 47-52.;;S. Bahar et al., The Relationship Betweeen Cerebral Blood Volume and Oxygenation Following Bipolar Stimulation of the Human Cortex: Evidence for an Initial Dip, AES Dec. 2004 New Orleans Poster Session.;;Printout from website http://www.ncbi.nlm.nih.gov regarding Cyberonics, neurocybernetic prosthesis.;;Printout from Medtronics' website http://www.medtronic.com/physician/activa/index.html regarding ACTIVA device.",ACTIVE
11,US,A1,US 2016/0066816 A1,093-696-327-167-745,2016-03-10,2016,US 201514937725 A,2015-11-10,US 201514937725 A;;US 201414324486 A;;US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,SYSTEMS AND METHODS FOR INTERACTING WITH AN IMPLANTABLE MEDICAL DEVICE,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/093-696-327-167-745,Patent Application,yes,0,3,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61B5/07;;A61B5/00;;A61B5/375;;A61N1/36;;A61N1/372,,0,0,,,,EXPIRED
12,US,A1,US 2006/0129204 A1,069-686-345-844-480,2006-06-15,2006,US 1462804 A,2004-12-15,US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2007-05-16),https://lens.org/069-686-345-844-480,Patent Application,yes,11,57,6,002-251-031-096-201;;069-686-345-844-480;;011-310-459-968-81X;;107-377-055-316-476;;105-617-775-657-09X;;171-621-506-522-002,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082;;A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082,A61N1/08,607/45,0,0,,,,ACTIVE
13,US,A1,US 2014/0257147 A1,131-059-343-374-765,2014-09-11,2014,US 201414282983 A,2014-05-20,US 201414282983 A;;US 201213714387 A;;US 70069210 A;;US 40457906 A;;US 1462804 A;;US 92565507 A;;US 92566807 A,2004-12-15,MODULATION AND ANALYSIS OF CEREBRAL PERFUSION IN EPILEPSY AND OTHER NEUROLOGICAL DISORDERS,"A system includes an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2009-04-24),https://lens.org/131-059-343-374-765,Patent Application,yes,3,13,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61N1/36;;A61F7/12;;A61N5/06;;A61N7/00,601/2;;607/45;;607/113;;607/88,0,0,,,,EXPIRED
14,US,A1,US 2011/0213441 A1,074-475-978-353-041,2011-09-01,2011,US 201113106729 A,2011-05-12,US 201113106729 A;;US 14206305 A;;US 54326400 A,2000-04-05,NEUROSTIMULATOR INVOLVING STIMULATION STRATEGIES AND PROCESS FOR USING IT,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/074-475-978-353-041,Patent Application,yes,99,0,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/36,607/45,0,0,,,,EXPIRED
15,US,A1,US 2011/0213442 A1,124-510-298-765-088,2011-09-01,2011,US 201113106747 A,2011-05-12,US 201113106747 A;;US 14206305 A;;US 54326400 A,2000-04-05,NEUROSTIMULATOR INVOLVING STIMULATION STRATEGIES AND PROCESS FOR USING IT,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/124-510-298-765-088,Patent Application,yes,99,16,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/36,607/45,0,0,,,,EXPIRED
16,US,B2,US 9232903 B2,000-621-022-112-807,2016-01-12,2016,US 201414324486 A,2014-07-07,US 201414324486 A;;US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,Systems and methods for interacting with an implantable medical device,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/000-621-022-112-807,Granted Patent,yes,12,12,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61B5/00;;A61B5/375;;A61N1/36;;A61N1/372,,18,10,124-403-369-942-149;;007-553-739-295-906;;040-286-722-085-497;;112-169-644-935-501;;045-607-627-273-154;;035-148-804-864-21X;;054-255-897-176-362;;020-615-646-149-653;;044-769-545-418-781;;066-017-182-270-154,52443;;10.1016/0013-4694(75)90051-6;;8641236;;10.1111/j.1528-1157.1996.tb00612.x;;10.1111/j.1528-1157.1998.tb01278.x;;9578017;;7588453;;10.1111/j.1528-1157.1995.tb00467.x;;1556879;;10.1097/00005650-199204000-00002;;10.1111/j.1528-1157.2000.tb02220.x;;11156511;;10.1176/jnp.11.4.464;;10570759;;10.1176/ps.39.4.389;;3286472;;1627969;;10.1176/jnp.4.1.85;;10.1111/j.1528-1157.1980.tb04053.x;;7358037,"http://www.medtronic.com/physician/activa ""ACTIVA Therapy Overview"" 1996.;;http://www.siumed.edu/neuro/epilepsy/news/pressreleasesNNSpress.htnnl, ""Cyberonics Inc-Receives FDA Approval Market NeuroCybernetic Prosthesis System for the Treatment of Epilepsy"" Jul. 16, 1997.;;Wagner, H.R., et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Electroencephalogr. Clin. Neurophysiol. 1975; 39(5): 499-506.;;Sherman, D., ""High-Tech Heart Devices Deliver Data Over the Web,"" Reuters News Service (Aug. 8, 2001).;;Medsearch Technologies, Inc., ""MedSearch Technologies, Inc. Develops a Revolutionary Home-Care Wireless Technology Utilizing PDAs-Personal Organizers-As Patient Monitors,"" Business Wire (Sep. 25, 2000).;;Emerson, D., ""Technology Puts Help on the Line,"" Minneapolis-St. Paul Business Journal (Dec. 17, 1999).;;Quality of Life in Epilepsy Inventory: QOLIE-10, Patient Inventory Professional Postgraduate Services, a Division of World Communications Group (1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-31 (Version 1.0), Scoring Manual and Patient Inventory,"" Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-89 (Version 1.0), Scoring Manual and Patient Inventory,"" Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Cramer, J.A., et al., ""A Brief Questionnaire to Screen for Quality of Life in Epilepsy: The QOLIE-10,"" Epilepsia 37(6): 577-582 (1996).;;Cramer, J., et al., ""Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory,"" Epilepsia (1998) 39(1): 81-88 (1998).;;Devinsky, Orrin, et al., ""Development of Quality of Life in Epilepsy Inventory,"" Epilepsia (1995) 36(11): 1089-1104.;;Vickrey, B., et al., ""A Health-Related Quality of Life Instrument for Patients Evaluated for Epilepsy Surgery,"" Medical Care (Apr. 1992), vol. 30, No. 4, pp. 299-319.;;Onuma, T., ""Symposium II: Classification of Psychiatric Symptoms in Patients with Epilepsy,"" Epilepsia (2000) 41 (Suppl. 9): 43-48.;;Lopez-Rodriguez, F., et al., ""Personality Disorders Among Medically Refractory Epileptic Patients,"" J. Neuropsychiatry Clin. Neurosci. (Fall 1999) 11(4): 464-469.;;Neppe, V. M., et al., ""Modern Perspectives on Epilepsy in Relation to Psychiatry: Behavioral Disturbances of Epilepsy,"" Hospital and Community Psychiatry (Apr. 1988) 39(4): 389-396.;;Neppe, V. M., et al., ""The Application of the Screening Cerebral Assessment of Neppe (BROCAS SCAN) to a Neuropsychiatric Population,"" Journal of Neuropsychiatry (Winter 1992) 4: 85-94.;;Dodrill, C.B., et al., ""An Objective Method for the Assessment of Psychological and Social Problems Among Epileptics,"" Epilepsia (1980) 21: 123-135.",EXPIRED
17,US,B2,US 8805514 B2,173-509-107-841-842,2014-08-12,2014,US 201313783143 A,2013-03-01,US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,Systems and methods for interacting with an implantable medical device,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/173-509-107-841-842,Granted Patent,yes,11,1,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61N1/00;;A61B5/375;;A61N1/36;;A61N1/372,607/45;;600/544,19,10,124-403-369-942-149;;007-553-739-295-906;;040-286-722-085-497;;112-169-644-935-501;;045-607-627-273-154;;035-148-804-864-21X;;054-255-897-176-362;;020-615-646-149-653;;044-769-545-418-781;;066-017-182-270-154,52443;;10.1016/0013-4694(75)90051-6;;8641236;;10.1111/j.1528-1157.1996.tb00612.x;;10.1111/j.1528-1157.1998.tb01278.x;;9578017;;7588453;;10.1111/j.1528-1157.1995.tb00467.x;;1556879;;10.1097/00005650-199204000-00002;;10.1111/j.1528-1157.2000.tb02220.x;;11156511;;10.1176/jnp.11.4.464;;10570759;;10.1176/ps.39.4.389;;3286472;;1627969;;10.1176/jnp.4.1.85;;10.1111/j.1528-1157.1980.tb04053.x;;7358037,"ACTIVA Therapy Overview, http://www.medtronic.com/physician/activa,(1996).;;""Cyberonics Inc. Receives FDA Approval to Market NeuroCybernetic Prosthesis System for the Treatment of Epilepsy"", http://www.siumed.edu/neuro/epilepsy/news/pressreleases/VNSpress.html,(Jul. 16, 1997).;;Wagner, H.R. et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization"", Electroencephalogr. Clin. Neurophysiol. 39(5): 499-506,(1975).;;Sherman, D. ""High-Tech Heart Devices Deliver Data Over the Web"", Reuters News Service,(Aug. 8, 2001).;;Medsearch Technologies, Inc ""MedSearch Technologies, Inc. Develops a Revolutionary Home-Care Wireless Technology Utilizing PDAs-Personal Organizers-As Patient Monitors"", Business Wire,(Sep. 25, 2000).;;Emerson, D. ""Technology Puts Help on the Line"", Minneapolis-St. Paul Business Journal,(Dec. 17, 1999).;;""Quality of Life in Epilepsy Inventory: QOLIE-10, Patient Inventory"", Professional Postgraduate Services, a Division of Physician's World Communications Group,(1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-31 (Version 1.0), Scoring Manual and Patient Inventory"", Professional Postgraduate Services, a Division of Physician's World Communications Group,(1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-89 (Version 1.0), Scoring Manual and Patient Inventory"", Professional Postgraduate Services, a Division of Physician's World Communications Group,(1993).;;Cramer, J.A. et al., ""A Brief Questionnaire to Screen for Quality of Life in Epilepsy: The QOLIE-10"", Epilepsia 37(6): 577-582,(1996).;;Cramer, J. et al., ""Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory"", Epilepsia 39(1): 81-88,(1998).;;Devinsky, Orrin et al., ""Development of Quality of Life in Epilepsy Inventory"", Epilepsia 36(11): 1089-1104,(1995).;;Vickrey, B. et al., ""A Health-Related Quality of Life Instrument for Patients Evaluated for Epilepsy Surgery"", Medical Care vol. 30, No. 4, pp. 299-319,(Apr. 1992).;;Onuma, T. ""Symposium II: Classification of Psychiatric Symptoms in Patients with Epilepsy"", Epilepsia 41 (Suppl. 9): 43-48,(2000).;;Lopez-Rodriguez, F. et al., ""Personality Disorders Among Medically Refractory Epileptic Patients"", J. Neuropsychiatry Clin. Neurosci. 11(4): 464-469,(Fall 1999).;;Neppe, V.M. et al., ""Modern Perspectives on Epilepsy in Relation to Psychiatry: Behavioral Disturbances of Epilepsy"", Hospital and Community Psychiatry 39(4): 389-396,(Apr. 1988).;;Neppe, V.M. et al., ""The Application of the Screening Cerebral Assessment of Neppe (BROCAS SCAN) to a Neuropsychiatric Population"", Journal of Neuropsychiatry 4: 85-94,(Winter 1992).;;Dodrill, C.B. et al., ""An Objective Method for the Assessment of Psychological and Social Problems Among Epileptics"", Epilepsia 21: 123-135,(1980).;;http://www.medtronic.com/physician/activa ""ACTIVA Therapy Overview"" 1996.",EXPIRED
18,US,A1,US 2003/0144711 A1,132-566-702-920-354,2003-07-31,2003,US 6004502 A,2002-01-29,US 6004502 A,2002-01-29,Systems and methods for interacting with an implantable medical device,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/132-566-702-920-354,Patent Application,yes,0,190,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61B5/375;;A61N1/36;;A61N1/372,607 6,0,0,,,,DISCONTINUED
19,US,B2,US 8771194 B2,027-397-593-075-735,2014-07-08,2014,US 201213714387 A,2012-12-13,US 201213714387 A;;US 70069210 A;;US 40457906 A;;US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,JOHN MICHAEL S;;PLESS BENJAMIN D;;WINGEIER BRETT M,NEUROPACE INC (2009-04-24),https://lens.org/027-397-593-075-735,Granted Patent,yes,22,9,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61B5/027;;A61B5/02;;A61B8/06,600/468;;600/378;;600/454,19,4,143-388-558-467-689;;124-403-369-942-149;;026-889-963-495-548;;122-023-235-058-123,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;10.1016/s1095-6433(99)00086-0;;10605067;;10.1152/jn.1995.74.6.2767;;8747234,"Amendment Filed on Dec. 20, 2010 for U.S. Appl. No. 11/925,668.;;Office Action (Non-Final Rejection) mailed Apr. 27, 2012 for U.S. Appl. No. 12/700,692.;;Gotnam, J ""Automatic Seizure Detection: Improvements and Evaluation, Electroencephalog. Clin. Neurophysiol."" 1990; 76(4): 317-24.;;Wagner, H. R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol."", 1975; 39(5): 499-506.;;Matsuura, T. et al., ""Hemodynamics Evoked by Microelectrical Direct Stimulation in Rat Somatosensory Cortex, Comp. Biochem. Physiol. A. Mo. I Integr. Physiol."", Sep. 1999; 124(1): 47-52.;;Bahar, S. et al., ""The Relationship Betweeen Cerebral Blood Volume and Oxygenation Following Bipolar Stimulation of the Human Cortex: Evidence for an Initial Dip, AES"", Dec. 2004 New Orleans Poster Session.;;Printout from website http://www.ncbi.nlm.nih.gov regarding Cyberonics, neurocybernetic prosthesis.;;Printout from Medtronics' website http://www.medtronic.com/physician/activa/index.html regarding ACTIVA device.;;U.S. Appl. No. 11/925,668 Office Action mailed Mar. 1, 2010.;;Tarver, T et al., ""An Implantable Neurocybemetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007.;;""ACTIVA Therapy Overview"", http://www.medtronic.com/physician/activa/index.html, Jun. 5, 2007.;;Tavalin, S.J. et al., ""Mechanical Perturbation of Cultured Cortical Neurons Reveals a Stretch-Induced Delayed Depolarization"", J. Neurophysiol. (1995).;;U.S. Appl. No. 11/925,668 Office Action mailed Aug. 19, 2010.;;U.S. Appl. No. 11/925,668 Amendment filed May 26, 2010.;;U.S. Appl. No. 11/925,668 Amendment filed Oct. 19, 2010.;;U.S. Appl. No. 11/925,668 Advisory Action mailed Nov. 10, 2010.;;U.S. Appl. No. 11/925,668 RCE filed Dec. 20, 2010.;;U.S. Appl. No. 11/925,668 Non-Final Rejection mailed Oct. 2, 2012.;;U.S. Appl. No. 11/925,668 Non-Final Office Action response filed Dec. 27, 2012.",EXPIRED
20,US,A1,US 2014/0323902 A1,167-692-945-162-794,2014-10-30,2014,US 201414324486 A,2014-07-07,US 201414324486 A;;US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,SYSTEMS AND METHODS FOR INTERACTING WITH AN IMPLANTABLE MEDICAL DEVICE,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRAIN R M,NEUROPACE INC (2002-05-28),https://lens.org/167-692-945-162-794,Patent Application,yes,1,3,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61N1/372;;A61B5/375;;A61N1/36,600/545;;607/60,0,0,,,,EXPIRED
21,US,A1,US 2016/0361547 A1,048-861-529-805-092,2016-12-15,2016,US 201615246315 A,2016-08-24,US 201615246315 A;;US 201414562135 A;;US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,DIFFERENTIAL NEUROSTIMULATION THERAPY DRIVEN BY PHYSIOLOGICAL THERAPY,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/048-861-529-805-092,Patent Application,yes,2,1,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/36;;A61B5/00;;A61B5/021;;A61B5/026;;A61B5/04;;A61B5/0476;;A61B5/0488;;A61B5/145;;A61M5/142;;A61N1/05,,0,0,,,,EXPIRED
22,US,B2,US 7892182 B2,105-617-775-657-09X,2011-02-22,2011,US 92565507 A,2007-10-26,US 92565507 A;;US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2007-05-16),https://lens.org/105-617-775-657-09X,Granted Patent,yes,15,8,6,002-251-031-096-201;;069-686-345-844-480;;011-310-459-968-81X;;107-377-055-316-476;;105-617-775-657-09X;;171-621-506-522-002,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082;;A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082,A61B5/02,600/561;;600/544;;607/45;;607/139,9,4,143-388-558-467-689;;124-403-369-942-149;;026-889-963-495-548;;122-023-235-058-123,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;10.1016/s1095-6433(99)00086-0;;10605067;;10.1152/jn.1995.74.6.2767;;8747234,"U.S. Appl. No. 11/925,668 Amendment filed May 26, 2010.;;Gotman, J., ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalog. Clin. Neurophysiol (1990) 76(4): 317-24.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. (1975): 39(5): 499-506.;;Matsuura, T., et al., ""Hemodynamics Evoked by Microelectrical Direct Stimulation in Rat Somatosensroy Cortex,"" Comp. Biochem. Physiol. A. Mo. I.. Integr. Physiol. (1999) Spet: 124(1): 47-52.;;Bahar, S et al., ""The Relationship Between Cerebral Blood Volume and Oxygenation Following Bipolar Stimulation of the Human Cortex: Evidence for an Initial Dip,"" American Epilepsy Society, Dec. 2004, New Orleans Poster Session.;;Tarver, T. et al, ""An Implantable Neurocybernetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007.;;Activa Therapy Overview, http://www.medtronic.com/physician/activa/index.html, Jun. 5, 2007.;;U.S. Appl. No. 11/925,668 Office action mailed Mar. 1, 2010.;;Tavalin, S.J., et al., ""Mechanical Perturbation of Cultured Cortical Neurons Reveals a Stretch-Induced Delayed Depolarization,"" J. Neurophysiol. (1995).",ACTIVE
23,US,A1,US 2011/0218591 A1,011-624-965-053-462,2011-09-08,2011,US 201113109970 A,2011-05-17,US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54345000 A;;US 54326400 A,2000-04-05,Differential Neurostimulation Therapy Driven By Physiological Therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/011-624-965-053-462,Patent Application,yes,98,0,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/36;;A61M5/142,607/45,0,0,,,,EXPIRED
24,WO,A1,WO 2004/043536 A1,005-033-057-217-837,2004-05-27,2004,US 0236376 W,2002-11-12,US 0236376 W,2002-11-12,SYSTEM FOR ADAPTIVE BRAIN STIMULATION,An implantable neurostimulator (110) adapted to provide adaptive electrical brain stimulation includes a detection subsystem (422) for isolating an electrographic signal characteristic and a stimulation subsystem (424) for applying an adaptive stimulation signal based at least in part upon the electrographic signal characteristic and correlated with the electrographic signal. Undesired learning of and acclimation to stimulation characteristics are avoided and stimulation efficacy is improved by adapting or otherwise varying the adaptive stimulation signal in relation to the electrographic signal.,NEUROPACE INC,KIRKPATRICK BRUCE;;PLESS BENJAMIN D,,https://lens.org/005-033-057-217-837,Patent Application,yes,11,42,1,005-033-057-217-837,WO,1,005-033-057-217-837,WO,0,A61N1/36135;;A61N1/36064;;A61N1/36082;;A61N1/36135,A61N1/36,,0,0,,,,PENDING
25,US,B2,US 9302111 B2,120-494-017-174-394,2016-04-05,2016,US 201414282983 A,2014-05-20,US 201414282983 A;;US 201213714387 A;;US 70069210 A;;US 40457906 A;;US 1462804 A;;US 92565507 A;;US 92566807 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system includes an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2009-04-24),https://lens.org/120-494-017-174-394,Granted Patent,yes,25,2,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61N1/36;;A61B5/00;;A61B5/02;;A61B5/0476;;A61B5/1455;;A61B5/1459;;A61B8/06;;A61F7/00;;A61F7/12;;A61N2/02;;A61N5/06;;A61N7/00,,20,3,124-403-369-942-149;;026-889-963-495-548;;122-023-235-058-123,52443;;10.1016/0013-4694(75)90051-6;;10.1016/s1095-6433(99)00086-0;;10605067;;10.1152/jn.1995.74.6.2767;;8747234,"""ACTIVA Therapy Overview"", http://www.medtronic.com/physician/activa/index.html, Jun. 5, 2007.;;Wagner, H.R., et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Electroencephalogr. Clin. Neurophysiol. (1975): 39(5): 499-506.;;Bahar, S. et al., ""The Relationship Betweeen Cerebral Blood Volume and Oxygenation Following Bipolar Stimulation of the Human Cortex: Evidence for an Initial Dip, AES"", Dec. 2004 New Orleans Poster Session.;;Matsuura, T., et al., ""Hemodynamics Evoked by Microelectrical Direct Stimulation in Rat Somatosensory Cortex, Comp. Biochem. Physiol. A. Mo. 1 Integr. Physiol."", Sep. 1999; 124(1):47-52.;;Printout from Medtronics' website http://www.medtronic.com/physician/activa/index.html regarding ACTIVA device.;;Printout from website http://www.ncbi.nlm.nih.gov regarding Cyberonics, neurocybernetic prosthesis.;;Tarver, T. et al., ""An Implantable Neurocybernetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007.;;Tavalin, S.J., et al., Mechanical Perturbation of Cultured Cortical Neurons Reveals a Stretch-Induced Delayed Depolarization, J. Neurophysiol. (1995) 74(6): 2767-2773.;;U.S. Appl. No. 11/925,668 Advisory Action mailed Nov. 10, 2010.;;U.S. Appl. No. 11/925,668 Amendment filed May 26, 2010.;;U.S. Appl. No. 11/925,668 Amendment filed Oct. 19, 2010.;;U.S. Appl. No. 11/925,668 Non-Final Office Action response filed Dec. 27, 2012.;;U.S. Appl. No. 11/925,668 Non-Final Rejection mailed Oct. 2, 2012.;;U.S. Appl. No. 11/925,668 Office Action mailed Aug. 19, 2010.;;U.S. Appl. No. 11/925,668 Amendment/RCE filed Dec. 20, 2010.;;U.S. Appl. No. 11/925,668 Office action mailed Mar. 1, 2010.;;Amendment Filed on Dec. 20, 2010 for U.S. Appl. No. 11/925,668.;;Office Action (Non-Final Rejection) mailed Apr. 27, 2012 for U.S. Appl. No. 12/700,692.;;U.S. Appl. No. 11/925,655 Office Action mailed Jun. 28, 2010.;;Notice of Allowance mailed on Dec. 16, 2010 for U.S. Appl. No. 11/925,655.",EXPIRED
26,US,B2,US 9943690 B2,145-269-019-951-00X,2018-04-17,2018,US 201615246351 A,2016-08-24,US 201615246351 A;;US 201414562135 A;;US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/145-269-019-951-00X,Granted Patent,yes,121,2,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61B5/00;;A61B5/021;;A61B5/026;;A61B5/04;;A61B5/0476;;A61B5/0488;;A61B5/07;;A61B5/145;;A61M5/142;;A61N1/05;;A61N1/36,,37,21,067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;028-133-278-688-002;;009-347-841-916-604;;007-919-147-709-849;;059-752-522-673-716;;018-508-980-173-266;;066-655-225-086-020;;048-972-669-828-271;;009-758-570-877-426;;112-917-826-767-538;;124-403-369-942-149;;056-361-838-782-639;;030-458-658-036-396;;059-959-153-435-269,10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1159/000099878;;9711758;;10.1111/j.1528-1157.1995.tb01667.x;;8001511;;10.1097/00001665-199203000-00002;;1391237;;8065447;;10.1038/370615a0;;8134429;;10.1097/00006534-199404000-00008;;10.1212/wnl.45.12.2250;;8848202;;10.1097/00004691-199903000-00005;;10359498;;10.1016/0267-6605(93)90085-l;;10146240;;1298420;;10.1097/00001665-199212000-00003;;52443;;10.1016/0013-4694(75)90051-6;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;10563620;;10.1212/wnl.53.8.1731,"Adriano, K.P. et al. (1994), “Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants” Journal of Applied Biomaterials 5: 133-140.;;Cooper, I.S. et al. (1974), “The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man” In the Cerebellum Epilepsy and Behavior. Cooper I.S. et al. eds. Plenum Press:New York pp. 119-171.;;Cooper, I.S. et al. (1977-1978), “Safety and Efficacy of Chronic Cerebellar Stimulation” Appl. Neurophysiol. 40:124-134.;;Cooper, I.S. and Upton, A.R.M. (1978), “Effects of Cerebellar Stimulation on Epilepsy the EEG and Cerebral Palsy in Man” In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb W.A. et al. eds. Elsevier Scientific Publishing: Amsterdam pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992), “Cerebellar Stimulation for Seizure Control: 17-Year Study” Stereotact. Funct. Neurosurg. 58:200-208.;;Lee, S.A. et al., “Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy” Epilepsia 2000 41 (3): 297-307.;;Lesser, R.P. et al, “Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation” Neurologogy 1999; 53 (December): 2073-81.;;Schiller, Y et al., “Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes” Epilepsia 1998; 39(4): 380-88.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. et al. (1997), “Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patents with Intractable Epilepsy” Stereotact Funct Neurosurg 69:221-224.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (dated Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (dated Apr. 13, 2006).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450)(dated Oct. 18, 2005).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (dated Mar. 1, 2004).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264 (dated Apr. 20, 2006).;;Velasco, F. et al. (1995), “Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies” Epilepsia 36(1):63-71.;;Thaller, S.R. et al.(1992), “Use of Biodegradable Plates and Screws in a Rabbit Model” Journal of Craniofacial Surgery 2(4):168-173.;;Schiff, S. et al. (1994), “Controlling Chaos in the Brain” Nature 370:615-620.;;Sayler, K.E. et al. (1994). “A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles” Plastic and Reconstructive Surgery 93(4):705-713.;;Qu, H. and Gotman, J. (1995). “A Seizure Warning System for Long-Term Epilepsy Monitoring” Neurology 45:2250-2254.;;Osario, I. et al. (1995). “A Method for Accurate Automated Real-Time Seizure Detection” Epilepsia 36 (supplement 4):4 Abstract No. 1.04.;;Gotman, J. (1999), “Automatic Detection of Seizures and Spikes” Journal of Clinical Neurophysiology 16(2): 130-140.;;Gerlach, K.L. (1993), “In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology” Clinical Materials 13:21-28.;;Eppley, B.L. and Sadove, A.M. (1992). “Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study” Journal of Craniofacial Surgery 3(4):190-196.;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Apr. 20, 2006).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Oct. 14, 2005).;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Mar. 8, 2004).;;Wagner, H.R. et al. “Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization” Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;Spencer, S.S. et al. “Morphological Patterns of Seizures Recorded Intracranially” Epilepsia 199233(3): 537-45.;;Limousin, P. “Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor” J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Active).;;Morris III, G.L. et al. “Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy” Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).",EXPIRED
27,US,A1,US 2010/0137937 A1,168-437-865-717-989,2010-06-03,2010,US 70069210 A,2010-02-04,US 70069210 A;;US 40457906 A;;US 1462804 A,2004-12-15,Modulation and Analysis of Cerebral Perfusion In Epilepsy and Other Neurological Disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2009-04-24),https://lens.org/168-437-865-717-989,Patent Application,yes,18,30,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61N1/36;;A61B5/1459,607/45;;600/339,0,0,,,,INACTIVE
28,US,A1,US 2017/0203111 A1,160-623-908-763-861,2017-07-20,2017,US 201715480292 A,2017-04-05,US 201715480292 A;;US 201514937725 A;;US 201414324486 A;;US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,SYSTEMS AND METHODS FOR INTERACTING WITH AN IMPLANTABLE MEDICAL DEVICE,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/160-623-908-763-861,Patent Application,yes,8,0,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61N1/372;;A61B5/00;;A61B5/375;;A61N1/36,,0,0,,,,DISCONTINUED
29,US,B1,US 6480743 B1,118-644-614-747-786,2002-11-12,2002,US 96294001 A,2001-09-24,US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,System and method for adaptive brain stimulation,An implantable neurostimulator adapted to provide adaptive electrical brain stimulation includes a detection subsystem for isolating an electrographic signal characteristic and a stimulation system for applying an adaptive stimulation signal based at least in part upon the electrographic signal characteristic and correlated with the electrographic signal. Undesired learning of and acclimation to stimulation characteristics are avoided and stimulation efficacy is improved by adapting or otherwise varying the adaptive stimulation signal in relation to the electrographic signal.,NEUROPACE INC,KIRKPATRICK BRUCE;;PLESS BENJAMIN D,NEUROPACE INC (2001-09-24),https://lens.org/118-644-614-747-786,Granted Patent,yes,2,605,1,118-644-614-747-786,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36135;;A61N1/36064;;A61N1/3615;;A61N1/36167;;A61N1/36135;;A61N1/36064;;A61N1/3615;;A61N1/36167,A61N1/36,607/45,0,0,,,,EXPIRED
30,US,B2,US 9649049 B2,196-978-125-358-316,2017-05-16,2017,US 201514937725 A,2015-11-10,US 201514937725 A;;US 201414324486 A;;US 201313783143 A;;US 55495909 A;;US 6004502 A,2002-01-29,Systems and methods for interacting with an implantable medical device,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/196-978-125-358-316,Granted Patent,yes,14,17,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61B5/00;;A61B5/07;;A61B5/375;;A61N1/36;;A61N1/372,,18,10,007-553-739-295-906;;040-286-722-085-497;;112-169-644-935-501;;066-017-182-270-154;;054-255-897-176-362;;020-615-646-149-653;;044-769-545-418-781;;035-148-804-864-21X;;045-607-627-273-154;;124-403-369-942-149,8641236;;10.1111/j.1528-1157.1996.tb00612.x;;10.1111/j.1528-1157.1998.tb01278.x;;9578017;;7588453;;10.1111/j.1528-1157.1995.tb00467.x;;10.1111/j.1528-1157.1980.tb04053.x;;7358037;;10.1176/jnp.11.4.464;;10570759;;10.1176/ps.39.4.389;;3286472;;1627969;;10.1176/jnp.4.1.85;;10.1111/j.1528-1157.2000.tb02220.x;;11156511;;1556879;;10.1097/00005650-199204000-00002;;52443;;10.1016/0013-4694(75)90051-6,"http://www.medtronic.com/physician/activa “ACTIVA Therapy Overview” 1996.;;Emerson, D., “Technology Puts Help on the Line,” Minneapolis-St. Paul Business Journal (Dec. 17, 1999).;;Cramer, JA, et al., “A Brief Questionnaire to Screen for Quality of Life in Epilepsy: The QOLIE-I0,” Epilepsia 37(6): 577-582 (1996).;;Cramer, J., et al., “Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory,” Epilepsia (1998) 39(1): 81-88 (1998).;;Devinsky, Orrin, et al., “Development of Quality of Life in Epilepsy Inventory,” Epilepsia (1995) 36(11): 1089-1104.;;Dodrill, C.B., et al., “An Objective Method for the Assessment of Psychological and Social Problems Among Epileptics,” Epilepsia (1980) 21: 123-135.;;http://www.siumed.edu/neuro/epilepsy/news/pressreleasesNNSpress.html, “Cyberonics Inc— Receives FDA Approval Market NeuroCybernetic Prosthesis System for the Treatment of Epilepsy” Jul. 16, 1997.;;Lopez-Rodriguez, F., et al., “Personality Disorders Among Medically Refractory Epileptic Patients,” J. Neuropsychiatry Clin. Neurosci. (Fall 1999) 11 (4): 464-469.;;Medsearch Technologies, Inc., “MedSearch Technologies, Inc. Develops a Revolutionary Home-Care Wireless Technology Utilizing PDAs—Personal Organizers—As Patient Monitors,” Business Wire (Sep. 25, 2000).;;Neppe, V. M., et al., “Modern Perspectives on Epilepsy in Relation to Psychiatry: Behavioral Disturbances of Epilepsy,” Hospital and Community Psychiatry (Apr. 1988) 39(4): 389-396.;;Neppe, V. M., et al., “The Application of the Screening Cerebral Assessment of Neppe (BROCAS SCAN) to a Neuropsychiatric Population,” Journal of Neuropsychiatry (Winter 1992) 4: 85-94.;;Onuma, T., “Symposium II: Classification of Psychiatric Symptoms in Patients with Epilepsy,” Epilepsia (2000) 41 (Suppl. 9): 43-48.;;Quality of Life in Epilepsy Inventory: QOLIE-I0, Patient Inventory Professional Postgraduate Services, a Division of World Communications Group (1993).;;Sherman, D., “High-Tech Heart Devices Deliver Data Over the Web,” Reuters News Service (Aug. 8, 2001).;;Vickrey, B. et al., “Quality of Life in Epilepsy QOLIE-31 (Version 1.0), Scoring Manual and Patient Inventory,” Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B. et al., “Quality of Life in Epilepsy QOLIE-89 (Version 1.0), Scoring Manual and Patient Inventory,” Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B., et al., “A Health-Related Quality of Life Instrument for Patients Evaluated for Epilepsy Surgery,” Medical Care (Apr. 1992), vol. 30, No. 4, pp. 299-319.;;Wagner, H.R., et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Electroencephalogr. Clin. Neurophysiol. 1975; 39(5): 499-506.",EXPIRED
31,US,B2,US 8694106 B2,089-133-065-882-20X,2014-04-08,2014,US 201313781186 A,2013-02-28,US 201313781186 A;;US 201113106747 A;;US 14206305 A;;US 54326400 A,2000-04-05,Neurostimulator involving stimulation strategies and process for using it,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/089-133-065-882-20X,Granted Patent,yes,100,11,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/00;;A61B5/04;;A61N1/36,607/45;;607/62;;600/544,32,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"Andriano, K.P. et al., ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants"", Journal of Applied Biomaterials. 5, (1994),133-140.;;Chkhenkeli, S.A. and, Chkhenkeli, I.S. et al., (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patents with Intractable Epilepsy,"" Stereotact Funct Neurosurg 69:221-224.;;Cooper, I.S. et al., ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man"", In the Cerebellum, Epilepsy, and Behavior. Pleman Press:New York, (1974),119-171.;;Cooper, I.S. et al., ""Saftey and Efficacy of Chronic Cerebellar Stimulation"", Appl. Neurophysiol. 40, (1977/78),124-134.;;Cooper, I.S. et al., ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man"", In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, (1978),349-354.;;Davis, R. et al., ""Cerebellar Stimulation for Seizure Control: 17-Year Study"", Stereotact. Funct. Neurosurg. 58, (1992),200-208.;;Eppley, B.L. et al., ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study"", Journal of Craniofacial Surgery 3(4), (1992),190-196.;;Gerlach, K.L. ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology"", Clinical Materials. 13, (1993),21-28.;;Gotman, J. ""Automatic Detection of Seizures and Spikes"", Journal of Clinical Neurophysiology. 16(2), (1999),130-140.;;Osario, I. et al., ""A Method for Accurate Automated Real-Time Seizure Detection"", Epilepsia, 36(supplement 4), (1995),4.;;Qu, H. et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring"", Neurology. 45, (1995),2250-2254.;;Sayler, K.E. et al., ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles"", Plastic and Reconstructive Surgery 93(4), (1994),705-713.;;Schiff, S. et al., ""Controlling Chaos in the Brain"", Nature. 370, (1994),615-620.;;Thaller, S.R. et al., ""Use of Biodegradable Plates and Screws in a Rabbit Model"", Journal of Craniofacial Surgery 2(4), (1992),168-173.;;Velasco, F. et al., ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies"", Epilepsia. 36(1), (1995),63-71.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Communication Dated Mar. 1, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303246., (Mar. 1, 2004),1.;;Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246., (Oct. 18, 2005),1.;;Applicant Response dated Apr. 13, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246., (Apr. 13, 2006),1.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303246., (Mar. 9, 2007),1.;;Communication Dated Mar. 8, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303245., (Mar. 8, 2004),3.;;Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245., (Oct. 14, 2005),3.;;Applicant Response dated Apr. 20, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245., (Apr. 20, 2006),3.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303245., (Mar. 9, 2007),3.;;U.S. Appl. No. 13/106,729 Office action mailed Jul. 25, 2011.;;U.S. Appl. No. 13/106,729 Office action mailed Nov. 14, 2011.;;U.S. Appl. No. 13/106,729 Office action mailed Apr. 25, 2012.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.",EXPIRED
32,EP,A2,EP 1145735 A2,017-566-714-168-420,2001-10-17,2001,EP 01303245 A,2001-04-05,US 54326400 A,2000-04-05,Neurostimulator involving stimulation strategies,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies. <IMAGE>",NEUROPACE INC,PLESS BENJAMIN D,,https://lens.org/017-566-714-168-420,Patent Application,yes,1,59,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/36,,0,0,,,,DISCONTINUED
33,US,A1,US 2013/0123600 A1,014-819-362-714-574,2013-05-16,2013,US 201213673312 A,2012-11-09,US 201213673312 A;;US 201161558382 P,2011-11-10,Multimodal Brain Sensing Lead,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC;;NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/014-819-362-714-574,Patent Application,yes,43,33,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61B5/0478;;A61N1/36,600/378;;607/45,0,0,,,,ACTIVE
34,US,A1,US 2006/0265022 A1,055-445-056-422-200,2006-11-23,2006,US 40457906 A,2006-04-14,US 40457906 A;;US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,JOHN MICHAEL S;;PLESS BENJAMIN D,NEUROPACE INC (2006-06-14),https://lens.org/055-445-056-422-200,Patent Application,yes,15,232,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61N1/18,607/45,0,0,,,,INACTIVE
35,US,A1,US 2013/0072810 A1,146-724-208-359-687,2013-03-21,2013,US 201213679925 A,2012-11-16,US 201213679925 A;;US 81119007 A;;US 24409302 A,2002-09-13,Spatiotemporal Pattern Recognition for Neurological Event Detection and Prediction in an Implantable Device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in one or more electrographic signals received from a patient's brain. The features and window-based characteristics are employed within the framework of a programmable finite state machine to identify patterns and sequences in and across the electrographic signals, facilitating early and reliable detection and prediction of complex spatiotemporal neurological events in real time, and enabling responsive action by the implantable device.",NEUROPACE INC;;NEUROPACE INC,WINGEIER BRETT M;;TCHENG THOMAS K,NEUROPACE INC (2003-01-31),https://lens.org/146-724-208-359-687,Patent Application,yes,1,5,6,146-724-208-359-687;;196-087-925-463-182;;094-670-667-520-593;;001-478-838-231-224;;089-776-054-750-753;;162-237-890-566-997,US,6,146-724-208-359-687;;196-087-925-463-182;;001-478-838-231-224;;094-670-667-520-593;;089-776-054-750-753;;162-237-890-566-997,US,0,A61B5/0031;;A61B5/076;;A61B5/369;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/369;;A61B5/0031;;A61B5/076;;A61B5/165;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/7257,A61B5/00;;A61B5/07;;A61B5/374,600/544,0,0,,,,EXPIRED
36,US,B2,US 7966073 B2,143-164-892-494-217,2011-06-21,2011,US 43619106 A,2006-05-16,US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/143-164-892-494-217,Granted Patent,yes,93,60,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61M5/142;;A61N1/36,607/45,30,21,028-133-278-688-002;;132-849-338-722-860;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;059-959-153-435-269;;030-458-658-036-396;;056-361-838-782-639;;124-403-369-942-149;;067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1159/000099878;;9711758;;312191;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10563620;;10.1212/wnl.53.8.1731;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;52443;;10.1016/0013-4694(75)90051-6;;10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"Chkhenkeli, S., et al., ""Effects of Therapeutic Stimulation of Nucleus Caudate on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact. Funct. Neurosurg., 1997, 69: 221-224.;;Cooper, I.S., et al., ""Effects of Cerebellar Stimulation on Epilepsy, the EEG, and Cerebral Palsy in Man,"" Electroencephalogr. Clin. Neurophysiol. 1978; 34: 349-54.;;Lee, S.A., et al. ""Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy,"" Epilepsia, 2000, 41(3): 297-307.;;Lesser, R.P. et al., ""Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation,"" Neurologogy 1999; 53 (December): 2073-81.;;Schiller, Y, et al., ""Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes,"" Epilepsia, 1998; 39(4): 380-88.;;Morris III, G.L., et al. ""Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy,""Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).;;Limousin, P., ""Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor,"" J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Activa).;;Spencer, S.S., et al., ""Morphological Patterns of Seizures Recorded Intracranially,"" Epilepsia, 1992, 33(3): 537-45.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;Andriano, K.P., et al., ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical implants,"" Journal of Applied Biornaterials (1994) 5: 133-140.;;Cooper, I.S., et al., ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" in the Cerebellum, Epilepsy and Behavior, Cooper, I.S., et al., eds. Pleman Press: New York (1974) pp. 119-171.;;Cooper, I.S., et al., ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. (1977/1978) 40: 124-134.;;Davis, R. et al,, ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. (1992) 58: 200-208.;;Eppley, B.L., et al., ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery (1992) 3(4): 190-196.;;Gerlach, K. L., ""In-Vivo and Clinical Evaluations of Poly(L-Lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials (1993) 13: 21-28.;;Gotman, J., ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology (1999) 16(2): 130-140.;;Osario, I., et al., ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia (1995) 36 (Suppl. 4): 4, Abstract No. 1.04.;;Qu, H., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-2254.;;Sayler, K.E., et al., ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery (1994) 93(4): 705-713.;;Schiff, S., et al., ""Controlling Chaos in the Brain,"" Nature (1994) 370: 615-620.;;Thaller, S.R., at al., ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery (1992) 2(4): 168-173.;;Velasco, F., et al., ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia (1995) 36(1): 63-71.;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 8, 2004).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Oct. 14, 2005).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Apr. 20, 2006).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 9, 2007).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 1, 2004).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Oct. 18, 2005).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Apr. 13, 2006).;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 9, 2007).",EXPIRED
37,EP,B1,EP 1335668 B1,080-376-485-083-622,2006-07-19,2006,EP 01989852 A,2001-11-02,US 0145784 W;;US 70632200 A,2000-11-03,DETECTING NEUROLOGICAL DYSFUNCTION,,NEUROPACE INC,PLESS BENJAMIN D,"NEUROPACE, INC. (2006-06-21)",https://lens.org/080-376-485-083-622,Granted Patent,yes,2,5,8,080-376-485-083-622;;102-337-319-556-716;;005-647-902-336-726;;055-393-605-610-094;;104-675-024-894-755;;146-079-896-660-406;;044-081-410-481-26X;;069-442-335-156-173,WO;;EP;;CA;;DE;;US,8,080-376-485-083-622;;102-337-319-556-716;;005-647-902-336-726;;055-393-605-610-094;;146-079-896-660-406;;104-675-024-894-755;;044-081-410-481-26X;;069-442-335-156-173,WO;;EP;;CA;;DE;;US,0,A61B5/6864;;A61B5/0031;;A61B5/377;;A61B5/4094;;A61B5/7203;;A61N1/36064;;A61N1/36135;;A61B5/6864;;A61B5/0031;;A61B5/383;;A61B5/4094;;A61B5/7203;;A61N1/36064;;A61N1/36135,A61B5/0484;;A61B5/00;;A61N1/36,,0,0,,,,EXPIRED
38,US,B2,US 9878160 B2,174-318-359-062-890,2018-01-30,2018,US 201615246315 A,2016-08-24,US 201615246315 A;;US 201414562135 A;;US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/174-318-359-062-890,Granted Patent,yes,121,1,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61B5/00;;A61B5/021;;A61B5/026;;A61B5/04;;A61B5/0476;;A61B5/0488;;A61B5/07;;A61B5/145;;A61M5/142;;A61N1/05;;A61N1/36,,37,21,067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;028-133-278-688-002;;009-347-841-916-604;;007-919-147-709-849;;059-752-522-673-716;;018-508-980-173-266;;066-655-225-086-020;;048-972-669-828-271;;009-758-570-877-426;;112-917-826-767-538;;124-403-369-942-149;;056-361-838-782-639;;030-458-658-036-396;;059-959-153-435-269,10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1159/000099878;;9711758;;10.1111/j.1528-1157.1995.tb01667.x;;8001511;;10.1097/00001665-199203000-00002;;1391237;;8065447;;10.1038/370615a0;;8134429;;10.1097/00006534-199404000-00008;;10.1212/wnl.45.12.2250;;8848202;;10.1097/00004691-199903000-00005;;10359498;;10.1016/0267-6605(93)90085-l;;10146240;;1298420;;10.1097/00001665-199212000-00003;;52443;;10.1016/0013-4694(75)90051-6;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;10563620;;10.1212/wnl.53.8.1731,"Adriano, K.P. et al. (1994), “Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants” Journal of Applied Biomaterials 5: 133-140.;;Cooper, I.S. et al. (1974), “The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man” In The Cerebellum Epilepsy and Behavior. Cooper I.S. et al. eds. Plenum Press:New York pp. 119-171.;;Cooper, I.S. et al. (1977-1978), “Safety and Efficacy of Chronic Cerebellar Stimulation” Appl. Neurophysiol. 40:124-134.;;Cooper, I.S. and Upton, A.R.M. (1978), “Effects of Cerebellar Stimulation on Epilepsy the EEG and Cerebral Palsy in Man” In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb W.A. et al. eds. Elsevier Scientific Publishing: Amsterdam pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992), “Cerebellar Stimulation for Seizure Control: 17-Year Study” Stereotact. Funct. Neurosurg. 58:200-208.;;Lee, S.A. et al., “Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy” Epilepsia 2000 41 (3): 297-307.;;Lesser, R.P. et al, “Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation” Neurologogy 1999; 53 (December): 2073-81.;;Schiller, Y et al., “Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes” Epilepsia 1998; 39(4): 380-88.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. et al. (1997), “Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patents with Intractable Epilepsy” Stereotact Funct Neurosurg 69:221-224.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (dated Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (dated Apr. 13, 2006).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450)(dated Oct. 18, 2005).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (dated Mar. 1, 2004).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264 (dated Apr. 20, 2006).;;Velasco, F. et al. (1995), “Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies” Epilepsia 36(1):63-71.;;Thaller, S.R. et al.(1992), “Use of Biodegradable Plates and Screws in a Rabbit Model” Journal of Craniofacial Surgery 2(4):168-173.;;Schiff, S. et al. (1994), “Controlling Chaos in the Brain” Nature 370:615-620.;;Sayler, K.E. et al. (1994). “A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles” Plastic and Reconstructive Surgery 93(4):705-713.;;Qu, H. and Gotman, J. (1995). “A Seizure Warning System for Long-Term Epilepsy Monitoring” Neurology 45:2250-2254.;;Osario, I. et al. (1995). “A Method for Accurate Automated Real-Time Seizure Detection” Epilepsia 36 (supplement 4):4 Abstract No. 1.04.;;Gotman, J. (1999), “Automatic Detection of Seizures and Spikes” Journal of Clinical Neurophysiology 16(2): 130-140.;;Gerlach, K.L. (1993), “In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology” Clinical Materials 13:21-28.;;Eppley, B.L. and Sadove, A.M. (1992). “Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study” Journal of Craniofacial Surgery 3(4):190-196.;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Apr. 20, 2006).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Oct. 14, 2005).;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (dated Mar. 8, 2004).;;Wagner, H.R. et al. “Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization” Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;Spencer, S.S. et al. “Morphological Patterns of Seizures Recorded Intracranially” Epilepsia 199233(3): 537-45.;;Limousin, P. “Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor” J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Active).;;Morris III, G.L. et al. “Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy” Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).",EXPIRED
39,EP,A3,EP 1145735 A3,129-800-313-548-338,2004-04-21,2004,EP 01303245 A,2001-04-05,US 54326400 A,2000-04-05,Neurostimulator involving stimulation strategies,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",NEUROPACE INC,PLESS BENJAMIN D,,https://lens.org/129-800-313-548-338,Search Report,yes,5,0,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/36,,0,0,,,,DISCONTINUED
40,US,A1,US 2011/0004282 A1,109-551-255-125-088,2011-01-06,2011,US 87186510 A,2010-08-30,US 87186510 A;;US 70454907 A,2007-02-08,Drug Eluting Lead Systems,"Medical electrical lead systems and related methods are described. The lead systems may be configured to be at least partially implanted in neural tissue of a subject, such as a brain of a subject. Some variations of the lead systems may comprise a lead body, an electrode connected to the lead body, and a bioactive agent. The electrode and/or lead body may comprise a substrate, and the bioactive agent may be supported by the substrate (e.g., by a substantial portion of the area of the substrate). Examples of bioactive agents that may be used in the lead system include bioactive agents that promote neural adhesion and living cells that have been biologically manipulated, engineered cells, and cells of a particular phenotype and/or adapted to induce a desired neural or glial response. Methods described herein may comprise contacting the substrate of a lead body and/or an electrode of a medical electrical lead system with at least one bioactive agent, where the lead body and the electrode are connected to each other.",NEUROPACE INC,BOLING C LANCE;;CHAO DANIEL;;MORRELL MARTHA J;;PLESS BENJAMIN D;;TCHENG THOMAS K;;WINGEIER BRETT M,NEUROPACE INC (2007-04-18),https://lens.org/109-551-255-125-088,Patent Application,yes,67,0,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,0,A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10;;A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10,A61N1/05,607/116,0,0,,,,DISCONTINUED
41,US,B2,US 8934980 B2,153-973-094-235-643,2015-01-13,2015,US 201313784569 A,2013-03-04,US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/153-973-094-235-643,Granted Patent,yes,105,14,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61M5/142;;A61N1/05;;A61N1/36,607/45,37,21,067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;028-133-278-688-002;;009-347-841-916-604;;007-919-147-709-849;;059-752-522-673-716;;018-508-980-173-266;;066-655-225-086-020;;048-972-669-828-271;;009-758-570-877-426;;112-917-826-767-538;;124-403-369-942-149;;056-361-838-782-639;;030-458-658-036-396;;059-959-153-435-269,10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1159/000099878;;9711758;;10.1111/j.1528-1157.1995.tb01667.x;;8001511;;10.1097/00001665-199203000-00002;;1391237;;8065447;;10.1038/370615a0;;8134429;;10.1097/00006534-199404000-00008;;10.1212/wnl.45.12.2250;;8848202;;10.1097/00004691-199903000-00005;;10359498;;10.1016/0267-6605(93)90085-l;;10146240;;1298420;;10.1097/00001665-199212000-00003;;52443;;10.1016/0013-4694(75)90051-6;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;10563620;;10.1212/wnl.53.8.1731,"Adriano, K.P. et al., (1994). ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants,"" Journal of Applied Biomaterials 5: 133-140.;;Cooper, I.S. et al., (1974). ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" In The Cerebellum, Epilepsy, and Behavior. Cooper, I.S. et al., eds., Plenum Press:New York, pp. 119-171.;;Cooper, I.S. et al., (1977/1978). ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. 40:124-134.;;Cooper, I.S. and Upton, A.R.M. (1978). ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992). ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. 58:200-208.;;Lee, S.A. et al., ""Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy"", Epilepsia, 2000, 41 (3): 297-307.;;Lesser, R.P. et al., ""Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation"", Neurologogy 1999; 53 (Dec.): 2073-81.;;Schiller, Y et al., ""Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes"", Epilepsia, 1998; 39(4): 380-88.;;Chkhenkeli, S.A. and, Chkhenkeli, I.S. et al., (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patents with Intractable Epilepsy,"" Stereotact Funct Neurosurg 69:221-224.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Apr. 13, 2006).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450)(Oct. 18, 2005).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 1, 2004).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 9, 2007).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264 (Apr. 20, 2006).;;Velasco, F. et al., (1995). ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia 36(1):63-71.;;Thaller, S.R. et al., (1992). ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery 2(4):168-173.;;Schiff, S. et al., (1994). ""Controlling Chaos in the Brain,"" Nature 370:615-620.;;Sayler, K.E. et al., (1994). ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery 93(4):705-713.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology 45:2250-2254.;;Osario, I. et al., (1995). ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia, 36(supplement 4):4, Abstract No. 1.04.;;Gotman, J. (1999). ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology 16(2): 130-140.;;Gerlach, K.L. (1993). ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials 13:21-28.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery 3(4):190-196.;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Apr. 20, 2006).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Oct. 14, 2005).;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 8, 2004).;;Wagner, H.R. et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization"", Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;Spencer, S.S. et al., ""Morphological Patterns of Seizures Recorded Intracranially"", Epilepsia, 1992,33(3): 537-45.;;Limousin, P. ""Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor"", J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Activa).;;Morris III, G.L. et al., ""Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy,"" Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).",EXPIRED
42,US,B2,US 7819812 B2,183-832-713-296-293,2010-10-26,2010,US 40457906 A,2006-04-14,US 40457906 A;;US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC,JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2006-06-14),https://lens.org/183-832-713-296-293,Granted Patent,yes,15,37,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61B5/02;;A61B8/00,600/504;;607/45;;600/333;;600/334;;600/454,11,4,143-388-558-467-689;;124-403-369-942-149;;026-889-963-495-548;;122-023-235-058-123,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;10.1016/s1095-6433(99)00086-0;;10605067;;10.1152/jn.1995.74.6.2767;;8747234,"U.S. Appl. No. 11/925,668 Office Action mailed Mar. 1, 2010.;;Gotman, J., ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalog. Clin. Neurophysiol. (1990) 76(4): 317-24.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. (1975): 39(5): 499-506.;;Matsuura, T., et al., ""Hemodynamics Evoked by Microelectrical Direct Stimulation in Rat Somatosensroy Cortex,"" Comp. Biochem. Physiol. A. Mo. I.. Integr. Physiol. (1999) Spet: 124(1): 47-52.;;Bahar, S et al., ""The Relationship Between Cerebral Blood Volume and Oxygenation Following Bipolar Stimulation of the Human Cortex: Evidence for an Initial Dip,"" American Epilepsy Society, Dec. 2004, New Orleans Poster Session.;;Tarver, T. et al, ""An Implantable Neurocybemetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007.;;ACTIVA Therapy Overview, http://www.medtronic.com/physician/activa/index.html, Jun. 5, 2007.;;Tavalin, S.J. et al., ""Mechanical Pertubation of Cultured Cortical Neurons Reveals a Stretch-Induced Delayed Depolarization,"" J. Neurophysiol. (1995).;;U.S. Appl. No. 11/925,668 filed May 26, 2010.;;U.S. Appl. No. 11/925,655 Office Action mailed Jun. 28, 2010.;;U.S. Appl. No. 11/925,668 Office action mailed Aug. 19, 2010.",INACTIVE
43,US,A1,US 2015/0087934 A1,044-511-791-743-100,2015-03-26,2015,US 201414562135 A,2014-12-05,US 201414562135 A;;US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,DEVICES AND METHODS FOR MONITORING PHYSIOLOGICAL INFORMATION RELATING TO SLEEP WITH AN IMPLANTABLE DEVICE,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/044-511-791-743-100,Patent Application,yes,0,6,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61B5/04;;A61B5/00;;A61B5/0476;;A61B5/07;;A61M5/142;;A61N1/36,600/302,0,0,,,,EXPIRED
44,US,A1,US 2016/0367814 A1,188-537-368-246-024,2016-12-22,2016,US 201615246351 A,2016-08-24,US 201615246351 A;;US 201414562135 A;;US 201313784569 A;;US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,DIFFERENTIAL NEUROSTIMULATION THERAPY DRIVEN BY PHYSIOLOGICAL THERAPY,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/188-537-368-246-024,Patent Application,yes,1,5,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/36;;A61B5/00;;A61B5/04;;A61B5/0476;;A61B5/07;;A61M5/142;;A61N1/05,,0,0,,,,EXPIRED
45,US,A1,US 2002/0169485 A1,047-380-325-824-394,2002-11-14,2002,US 12193302 A,2002-04-12,US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345095 A,1995-10-16,Differential neurostimulation therapy driven by physiological context,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/047-380-325-824-394,Patent Application,yes,1,293,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61M5/142;;A61N1/36,607/48,0,0,,,,DISCONTINUED
46,EP,A2,EP 1145736 A2,061-206-050-442-20X,2001-10-17,2001,EP 01303246 A,2001-04-05,US 54345000 A,2000-04-05,Multimodal neurostimulator,"This is directed to an implantable multimodal neurostimulator having improved efficacy in treating epilepsy and other neurological disorders and to processes of using that neurostimulator. The neurostimulator itself generally has two modes of electrical stimulation: the first involves delivering a non-responsive electrical stimulation signal which is applied to the central nervous system to reduce the likelihood of a seizure or other undesirable neurological even from occurring, and a second mode that involves delivering electrical stimulation signal or signals when epileptiform waveforms are impending or extant. The responsive electrical stimulation signal or signals are intended to terminate epileptiform activity, e.g., to desynchronize abnormally synchronous brain electrical activity. Alternatively, the second mode may be used to deliver sensory stimulation, e.g., a scalp or sound stimulation, to the patient rather than deliver electrical stimulation to the patient. Finally, the implanted neurostimulator may be used by a physician to induce epileptiform activity and then verify the effectiveness of the parameters of the first and second neurostimulation signal or signals. <IMAGE>",NEUROPACE INC,PLESS BENJAMIN D,,https://lens.org/061-206-050-442-20X,Patent Application,yes,0,73,7,024-096-457-615-102;;128-755-226-255-290;;017-686-610-075-111;;087-979-855-502-888;;158-501-983-099-369;;061-206-050-442-20X;;008-166-797-662-811,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36064,A61N1/36,,0,0,,,,DISCONTINUED
47,US,B2,US 10279191 B2,149-299-558-743-667,2019-05-07,2019,US 201715613093 A,2017-06-02,US 201715613093 A;;US 201615137670 A;;US 201514688935 A;;US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,Low frequency neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-08-25),https://lens.org/149-299-558-743-667,Granted Patent,yes,59,0,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/04;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02,,53,48,025-992-119-710-993;;018-769-436-346-405;;034-215-008-256-505;;049-764-006-876-782;;058-474-962-345-026;;100-329-685-384-712;;028-400-352-294-444;;000-907-476-829-590;;070-549-885-927-855;;117-280-426-177-420;;020-862-494-916-996;;021-307-591-737-010;;002-610-549-523-468;;063-749-422-355-89X;;003-567-098-113-528;;121-395-139-132-160;;068-670-171-691-134;;017-065-379-332-717;;013-545-706-354-946;;030-983-039-493-075;;003-490-521-438-037;;038-125-139-467-43X;;003-243-554-446-676;;045-313-415-627-674;;032-584-602-403-660;;091-138-016-549-341;;058-790-540-596-874;;021-657-845-715-349;;064-273-086-002-360;;070-826-749-769-613;;035-990-338-077-706;;143-828-927-516-199;;038-980-231-466-699;;134-661-542-323-873;;013-676-649-177-997;;058-990-110-607-410;;002-344-382-871-989;;031-445-476-481-273;;058-904-960-260-878;;174-178-036-962-905;;143-398-932-451-548;;021-154-759-818-769;;041-461-559-713-466;;150-796-039-433-379;;024-657-104-096-682;;029-497-167-480-309;;042-629-324-644-008;;085-169-832-606-660,10.1177/155005948801900404;;3060288;;10.1016/0920-1211(89)90029-6;;2731520;;8730820;;10.1097/00001756-199601310-00035;;10.1097/00001756-199511000-00018;;8595196;;9875279;;10.1006/exnr.1998.6932;;10.1016/s0168-5597(97)00096-8;;9474057;;7225959;;10.1017/s0317167100042864;;10482807;;10.1016/s0006-8993(99)01731-x;;3808255;;10.1097/00006123-198701000-00030;;10.1097/00019052-199806000-00003;;9642537;;10.1159/000125575;;402170;;1663448;;10.1016/0013-4694(85)91075-2;;2408867;;7250277;;10.1016/0014-4886(81)90057-1;;9448642;;10.1016/s0924-980x(97)00036-2;;10.1016/0013-4694(94)00249-k;;7530636;;10.1523/jneurosci.15-01-00604.1995;;pmc6578315;;7823167;;10.1016/0920-1211(95)00025-6;;8536671;;10.1111/j.1528-1157.1965.tb03782.x;;14337460;;9749744;;10.1046/j.1460-9568.1998.00090.x;;10.1016/s0006-8993(97)01118-9;;9439820;;10646759;;10.1016/s1361-8415(98)80008-x;;10.1111/j.1528-1157.1992.tb02192.x;;1396427;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;7284903;;10.1017/s0317167100043286;;6512714;;10.1080/00223980.1984.9712600;;2429284;;10.1111/j.1540-8159.1986.tb05426.x;;10.1016/0014-4886(69)90128-9;;4981856;;6970503;;10.1007/978-3-7091-8592-6_31;;10910346;;10.1038/35018000;;10.1111/j.1600-0404.1994.tb05195.x;;8155315;;10.1016/0896-6273(94)90205-4;;10.1152/jn.1998.79.3.1592;;9497437;;10.1212/wnl.53.7.1462;;10534252;;10590958;;10.1097/00006123-199505000-00025;;7540735;;10.1227/00006123-199505000-00025;;3770122;;10.1016/0014-4886(86)90105-6;;10.3171/jns.1970.32.5.0553;;5438095;;804233;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;8190292;;10.1212/wnl.44.5.884;;6603358;;10.1111/j.1528-1157.1983.tb04915.x;;1162603;;10.1016/0013-4694(67)90188-5;;4168976;;14439711;;10.3171/jns.1960.17.1.0055;;3321152;;10.1016/0278-5846(87)90018-2;;10.1007/s004150050482;;10552238,"Staton, et al., “The electroencephalographic pattern during electroconvulsive therapy. V. Observations on the origin of phase III delta energy and the mechanism of action of ECT.” Clin. Electroencephalogry 10: 176-198 (1988).;;Ullal, et al., “Low frequency stimulation induces an increase in after-discharge thresholds in hippocampal and amygdaloid kindling.” Epilepsy Res. 3: 232-235 (1989).;;Wang et al., “LTD and LTP induced by transcranial magnetic stimulation in auditory cortex.” Neuroreport 7: 521-525 (1996).;;Weiss, et al., “Quenching: inhibition of development and expression of amygdala kindled seizures with low frequency stimulation.” NeuroReport 6: 217-276 (1995).;;Weiss, et al., “Quenching revisited: low level direct current inhibits amygdala-kindled seizures.” Experimental Neurology 154: 185-192 (1998).;;Roland et al., “The production of brain lesions with electric currents.” J. Neurosurg. 14: 302-328 (1957).;;Wasserman, “Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Mag Stim . . . ” Electroencehp. & Clin. Neurophys. 108: 1-16 (1998).;;Gaito et al., “The effect of several intertrial intervals on the 1 Hz interference effect.” Le J. Canadien des Sci. Neurol. 8: 61-65 (1981).;;Adamec, “Evidence that limbic neural plasticity in the right hemisphere mediates partial kindling induced increases in anxiety-like behavior.” Brain Res. 839: 133-152 (1999).;;Agnew et al., “Considerations for safety in the use of extracranial stimulation for motor evoked potentials.” Neurosurgery 20: 143-147 (1987).;;Aurora et al, “Brain excitability in migraine: evidence from transcranial magnetic stimulation studies.” Current Opinion in Neurology 11: 205-209 (1998).;;Bartlett et al., “Deleterious effects of prolonged electrical excitation of striate cortex in macaques.” Brain Behav. Evol. 14: 46-66 (1977).;;Bridgers, “The safety of transcranial magnetic stimulation reconsidered: evidence regarding cognitive and other cerebral effects.” Magnetic Motor Stimulation: Basic Principles and Clinical Experience, EEG Suppl. 43: 170-179 (1991).;;Buzsaki et al., “Depth profiles of hippocampal rhythmic slow activity (theta rhythm) depend on behavior.” Electroencephologr Clin. Neurophys. 61: 77-88 (1985).;;Cain, et al., “Kindling with low-frequency stimulation: generality, transfer and recruiting effects.” Exper. Neurol. 73: 219-232 (1981).;;Chen et al., “Safety of different inter-train intervals for repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters.” Electroencephologr. Clin. Neurophys. 105: 415-421 (1997).;;Classen et al., “Epileptic seizures triggered directly by focal transcranial magnetic stimulation.” Electroencephologr. Clin. Neurophys. 94: 19-25 (1995).;;Contreras et al., “Cellular basis of EEG rhythms: a study of dynamic corticothalmic relationships.” J. Neurosci. 15: 604-622 (1995).;;Dennison et al., “Persistence of kindling: effect of partial kindling, retention interval, kindling site and stimulation parameters.” Epilepsy Res. 21: 171-182 (1995).;;Dow, “Extrinsic regulatory mechanisms of seizure activity.” Epilepsia 6: 122-140 (1965).;;Elger et al., “Short communication seizure prediction by non-linear time series analysis of brain electrical activity.” European J. Neuroscience 10: 786-789 (1998).;;Emori et al., “Changes in paired-pulse depression during the triggering of seizures by 2 Hz dentate gyrus stimulation: the effect of kindling.” Brain Res. 776: 250-254 (1997).;;Ettinger et al., “Experimentation with a transcranial magnetic stimulation system for functional brain mapping.” Medical Image Analysis vol. 2, No. 2: 133-142 (1998).;;Fischer et al., “Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of intractable seizures.” Epilepsia 33: 841-851 (1992).;;Gaito et al., “Interference effect of 3 Hz brain stimulation on kindling behavior induced by 60 Hz stimulation.” Epilepsia 21: 73-84 (1980).;;Gaito, “The effect of variable duration one Hertz interference on kindling.” Le J. Canadien des Sci. Neurol. 7: 59-64 (1980).;;Gaito et al., “The effect of low frequency and direct current stimulation on the kindling phenomenon in rats.” Le J. Canadien des Sci. Neurol. 8(3): 249-253 (1981).;;Gaito, “Suppression of kindling behavior.” J. Psychology 118: 113-125 (1984).;;Girvin, “Cerebral (cortical) biostimulation.” PACE 9: 764-771 (1986).;;Goddard et al., “A permanent change in brain function resulting from daily electrical stimulation” Exper. Neurol. 25: 295-330 (1967).;;Goodman, “Experimental models of status epilepticus.” in S. L. Peterson et al. eds, Neuropharmacology Methods in Epilepsy Research. CRC Press, 95-125 (1998).;;Gybels et al., “Electrical stimulation of the central gray for pain relief in human autopsy data.” Acta Neurochirugica Supp. 30: 259-268 (1980).;;Hallett, “Transcranial magnetic stimulation and the human brain.” Nature 406: 147-150 (2000).;;Jennum et al., “Transcranial magnetic stimulation: its role in the evaluation of patients with partial epilepsy.” Acta Neurol. Scand. Suppl. 152: 93-96 (1994).;;Krauss et al., “Cerebellar and thalamic stimulation for epilepsy.” in O. Devinsky et al. eds, Electrical and Magnetic Stimulation of the Brain and Spinal Cord. New York: Raven Press, Ltd. 231-245 (1993).;;Kreindler, “Active arrest mechanisms of epileptic seizures.” Epilepsia 2: 329-337 (1962).;;Linden, “Long-term synaptic depression in the mammalian brain.” Neuron 12: 457-472 (1994).;;Leung et al., “Theta-frequency resonance in hippocampal CA1 neurons in vitro demonstrated by sinusoidal current injection.” J. Neurophysiol. 79: 1592-1596 (1998).;;MacDonnell et al., “Motor cortex localization using functional MRI and transcranial magnetic stimulation.” Neurology 53: 1462-1467 (1999).;;De Noordhout et al., “Transcranial magnetic stimulation in migraine.” Transcranial Magnetic Stimulation, EEG Suppl. 51: 260-264 (1999).;;Migita et al., “Transcranial magnetic coil stimulation of motor cortex in patients with central pain.” Neurosurgery vol. 36, No. 5: 1037-1040 (1995).;;Minabe et al., “Low-frequency kindling as a new experimental model of epilepsy.” Exper. Neurol. 94: 317-323 (1986).;;Mortimer et al., “Experimental nondestructive electrical stimulation of the brain and spinal cord.” J. Neurosurg. 32: 553-559 (1970).;;Ojemann et al., “Stereotactic and other procedures for epilepsy,” in D.P. Purpura et al. eds, Neurosurgical Management of the Epilepsies, Advances in Neurology 8: 241-263 (1975).;;Osorio et al., “Real-time automated detection and quantitative analysis of seizures and short-term prediction of clinical onset.” Epilepsia 39: 615-627 (1998).;;Pascual-Leone et al., “Akinesia in Parkinson's disease.” Neurology 44: 884-891 (1994).;;Psatta, “Control of chronic experimental focal epilepsy by feedback caudatum stimulations.” Epilepsia 24: 444-454 (1983).;;Pudenz et al., “Electrical stimulation of the brain. II. effects on the blood-brain barrier.” Surg. Neurol. 4: 265-270 (1975).;;Reimer et al., “Effects of cerebellar stimulation on cobalt-induced epilepsy in the cat.” Electroenceph. Clin. Neurophysiol. 23: 456-462 (1967).;;Rowland et al., “The production of brain lesions with electric currents.” J. Neurosurg. 17: 55-69 (1960).;;Schmutz, “Relevance of kindling and related processes to human epileptogenesis.” Prog. Neuro-Psychopharm. & Biol. Psychiat. 11: 505-525 (1987).;;Schulze-Bonhage et al., “Safety of single and repetitive focal transcranial magnetic stimuli as assessed by intracranial EEG recordings in patients with partial epilepsy.” J. Neurol. 246: 914-919 (1999).;;Sramka et al., “Observation of kindling phenomenon in treatment of pain by stimulation in thalamus,” in W.H. Sweet et al., eds. Neurosurgical Treatment in Psychiatry, Pain and Epilepsy. Baltimore: University Park Press 651-654 (1977).",EXPIRED
48,WO,A1,WO 2002/036003 A1,146-079-896-660-406,2002-05-10,2002,US 0145784 W,2001-11-02,US 70632200 A,2000-11-03,DETECTING NEUROLOGICAL DYSFUNCTION,"A system and method for determining and predicting a patient's susceptibility to neurological dysfunction based on measured electrophysiological parameters employs a self-contained implantable device (110) with depth electrodes (612, 614, 616, 618) implanted in desired locations in the patient's brain. The patient's neurological tissue is stimulated to determine excitability and refractoriness (or inhibition period) parameters, which are employed to identify susceptibility to abnormal neurological activity, particularly epileptic seizures.",NEUROPACE INC,PLESS BENJAMIN D,,https://lens.org/146-079-896-660-406,Patent Application,yes,5,70,8,080-376-485-083-622;;102-337-319-556-716;;005-647-902-336-726;;055-393-605-610-094;;104-675-024-894-755;;146-079-896-660-406;;044-081-410-481-26X;;069-442-335-156-173,WO;;EP;;CA;;DE;;US,8,080-376-485-083-622;;102-337-319-556-716;;005-647-902-336-726;;055-393-605-610-094;;146-079-896-660-406;;104-675-024-894-755;;044-081-410-481-26X;;069-442-335-156-173,WO;;EP;;CA;;DE;;US,0,A61B5/6864;;A61B5/0031;;A61B5/377;;A61B5/4094;;A61B5/7203;;A61N1/36064;;A61N1/36135;;A61B5/6864;;A61B5/0031;;A61B5/383;;A61B5/4094;;A61B5/7203;;A61N1/36064;;A61N1/36135,A61B5/00;;A61B5/0484;;A61N1/36,,0,0,,,,PATENTED
49,US,B2,US 7844345 B2,042-997-482-963-986,2010-11-30,2010,US 70454907 A,2007-02-08,US 70454907 A,2007-02-08,Drug eluting lead systems,"Medical electrical lead systems and related methods are described. The lead systems may be configured to be at least partially implanted in neural tissue of a subject, such as a brain of a subject. Some variations of the lead systems may comprise a lead body, an electrode connected to the lead body, and a bioactive agent. The electrode and/or lead body may comprise a substrate, and the bioactive agent may be supported by the substrate (e.g., by a substantial portion of the area of the substrate). Examples of bioactive agents that may be used in the lead system include antiproliferative agents, bactericidal agents, bacteriostatic agents, antiepileptic agents, and/or antifungal agents. Methods described herein may comprise coating a lead body and/or an electrode of a medical electrical lead system with at least one bioactive agent, where the lead body and the electrode are connected to each other.",NEUROPACE INC,BOLING C LANCE;;CHAO DANIEL;;MORRELL MARTHA J;;PLESS BENJAMIN D;;TCHENG THOMAS K;;WINGEIER BRETT M,NEUROPACE INC (2007-04-18),https://lens.org/042-997-482-963-986,Granted Patent,yes,60,22,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,0,A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10;;A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10,A61N1/00,607/116,14,6,078-011-754-012-619;;125-373-393-924-516;;011-003-220-418-314;;035-504-916-619-225;;017-151-528-619-262;;033-799-424-376-448,10.1097/00007691-200110000-00006;;11591899;;10.1126/science.290.5496.1532;;11090343;;10.1149/1.1393450;;10.1016/0966-7822(94)90032-9;;10.1517/17425247.1.1.37;;16296719;;pmc1361256;;pmc6792642;;9547224;;10.1523/jneurosci.18-09-03158.1998,"Anonymous. (2006). ""Ommaya Reservoir,"" located at , last visited on Sep. 18, 2006, six pages.;;Cavuoto, J. (Jan. 2002). ""Biomaterials Key Factor in Next-Generation Electrodes,"" Neurotech Business Report 2(1):3-5.;;Christensen, J. et al. (Oct. 2001). ""Plasma Concentration of Topiramate Correlates with Cerebrospinal Fluid Concentration,"" Therapeutic Drug Monitoring 23(5):529-535.;;Craighead, H.G. (Nov. 24, 2000). ""Nanoelectromechanical Systems,"" Science 290:1532-1535.;;Doose, D.R. et al. (2002). ""Topiramate: Chemistry, Biotransformation, and Pharmacokinetics,"" Chapter 78, in Antiepileptic Drugs, 5th Edition, Levy, R.H. et al. eds., Lippincott Williams & Wilkins: Philadelphia, PA, pp. 727-734.;;Ghosh, S. et al. (May 2000). ""Electrochemical Characterization of Poly(3,4-ethylene dioxythiophene) Based Conducting Hydrogel Networks,"" J. of the Electrochem. Soc. 147(5):1872-1877.;;Gilmore, K. et al. (1994). ""Preparation of Hydrogel/Conducting Polymer Composites,"" Polymer Gels and Networks 2(2):135-143.;;Martin, D.C. et al. ""Bio-Electronic Implantable Device Coating Applications,"" in White Paper: Bioactive Conducting Polymer Coatings for Biomedical Devices, University of Michigan, four pages. (in internal database as of Aug. 30, 2006).;;Olsen, R.W. (2002). ""Phenobarbital and Other Barbiturates: Mechanisms of Action,"" Chapter 50, in Antiepileptic Drugs, 5th Edition, Levy, R.H. et al. eds., Lippincott Williams & Wilkins: Philadelphia, PA, pp. 489-495.;;Pitt, W.G. et al. (Nov. 2004). ""Ultrasonic Drug Delivery-A General Review,"" Expert Opinion on Drug Delivery 1(1):37-56.;;Rusakov, D.A. et al. (May 1, 1998). ""Extrasynaptic Glutamate Diffusion in the Hippocampus:Ultrastructural Constraints, Uptake, and Receptor Activation,"" The J. of Neurosci. 18(9):3158-3170.;;Non-Final Office Action mailed on Sep. 8, 2009, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007, eight pages.;;Non-Final Office Action mailed on Mar. 31, 2009, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007, twenty-seven pages.;;Non-Final Office Action mailed on Feb. 25, 2010, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007, ten pages.",INACTIVE
50,US,A1,US 2008/0058664 A1,024-692-761-819-805,2008-03-06,2008,US 51279906 A,2006-08-29,US 51279906 A,2006-08-29,"Patient event recording and reporting apparatus, system, and method","According to various embodiments, a portable, patient-triggered device to record symptoms experienced by a patient along with time and date, and a bidirectional data link to communicate with an implantable medical device to download corresponding electrographic signal records and/or diagnostic data for later relay to a server are presented. According to some embodiments, the portable device can also deliver visual and audio queries to the patient on a scheduled basis to encourage compliance with a treatment regimen. According to an embodiment, the data link between the portable device and the implantable medical device is wireless. According to various other embodiments, the data link between the portable device and the server can be wired or wireless. The portable device can be configured as a watch, a key fob, a pendant, or the like.",NEUROPACE INC,MIRRO EMILY,NEUROPACE INC (2006-08-29),https://lens.org/024-692-761-819-805,Patent Application,yes,13,47,1,024-692-761-819-805,US,1,024-692-761-819-805,US,0,A61N1/37211;;A61B5/0002;;A61B5/4094;;A61N1/37211;;A61B5/0002;;A61B5/4094,A61B5/04,600/523,0,0,,,,DISCONTINUED
51,AU,A1,AU 2015/268576 A1,067-954-416-708-722,2015-12-24,2015,AU 2015/268576 A,2015-12-08,AU 2014/203524 A;;AU 2015/268576 A,2014-06-27,"Systems, methods and devices for a skull/brain interface","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain. -102-",NEUROPACE INC,WINGEIER BRETT;;TCHENG THOMAS;;CHAO DANIEL;;PLESS BENJAMIN,,https://lens.org/067-954-416-708-722,Patent Application,no,0,2,2,067-954-416-708-722;;167-606-908-208-972,AU,2,067-954-416-708-722;;167-606-908-208-972,AU,0,,A61N1/05,,0,0,,,,INACTIVE
52,US,B1,US 6466822 B1,158-501-983-099-369,2002-10-15,2002,US 54345000 A,2000-04-05,US 54345000 A,2000-04-05,Multimodal neurostimulator and process of using it,"This is directed to an implantable multimodal neurostimulator having improved efficacy in treating epilepsy and other neurological disorders and to processes of using that neurostimulator. The neurostimulator itself generally has two modes of electrical stimulation: the first involves delivering a non-responsive electrical stimulation signal which is applied to the central nervous system to reduce the likelihood of a seizure or other undesirable neurological even from occurring, and a second mode that involves delivering electrical stimulation signal or signals when epileptiform waveforms are impending or extant. The responsive electrical stimulation signal or signals are intended to terminate epileptiform activity, e.g., to desynchronize abnormally synchronous brain electrical activity. Alternatively, the second mode may be used to deliver sensory stimulation, e.g., a scalp or sound stimulation, to the patient rather than deliver electrical stimulation to the patient. Finally, the implanted neurostimulator may be used by a physician to induce epileptiform activity and then verify the effectiveness of the parameters of the first and second neurostimulation signal or signals.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/158-501-983-099-369,Granted Patent,yes,82,281,7,024-096-457-615-102;;128-755-226-255-290;;017-686-610-075-111;;087-979-855-502-888;;158-501-983-099-369;;061-206-050-442-20X;;008-166-797-662-811,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36064,A61N1/36,607/45,15,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"Andriano, K.P. et al. (1994). ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants,"" Journal of Applied Biomaterials 5:133-140.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact Funct Neurosurg 69:221-224.;;Cooper, I.S. et al. (1974). ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" In The Cerebellum, Epilepsy, and Behavior. Cooper, I.S. et al., eds., Plenum Press:New York, pp. 119-171.;;Cooper, I.S. et al. (1977/1978). ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. 40: 124-134.;;Cooper, I.S. and Upton, A.R.M. (1978). ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992). ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. 58:200-208.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery 3(4):190-196.;;Gerlach, K.L. (1993). ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials 13:21-28.;;Gotman, J. (1999). ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology 16(2):130-140.;;Osario, I. et al (1995). ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia, 36(supplement 4):4, Abstract No. 1.04.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology 45:2250-2254.;;Sayler, K.E. et al. (1994). ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery 93(4):705-713.;;Schiff, S. et al. (1994). ""Controlling Chaos in the Brain,"" Nature 370:615-620.;;Thaller, S.R. et al. (1992). ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery 2(4):168-173.;;Velasco, F. et al. (1995). ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia 36(1):63-71.",EXPIRED
53,US,A1,US 2017/0266460 A1,159-561-963-127-802,2017-09-21,2017,US 201715613093 A,2017-06-02,US 201715613093 A;;US 201615137670 A;;US 201514688935 A;;US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,LOW FREQUENCY NEUROSTIMULATOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,UPTON ADRIAN R M;;FISCHELL DAVID R,NEUROPACE INC (2000-08-25),https://lens.org/159-561-963-127-802,Patent Application,yes,3,19,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/00;;A61N1/32;;A61N1/36;;A61N2/02;;A61N2/04,,0,0,,,,EXPIRED
54,AU,B2,AU 2008/326667 B2,115-973-925-589-672,2014-07-24,2014,AU 2008/326667 A,2008-10-29,US 24373308 A;;US 23429708 A;;US 92980107 A;;US 2008/0081655 W,2007-10-30,"Systems, methods and devices for a skull/brain interface","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,CHAO DANIEL;;TCHENG THOMAS;;PLESS BENJAMIN;;WINGELER BRETT,,https://lens.org/115-973-925-589-672,Granted Patent,no,2,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61B5/6864;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61B8/0808;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B2090/103;;A61N1/0539;;A61N1/36025;;A61B5/6864;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B8/0808;;A61B2090/103;;A61N1/0539;;A61N1/36025;;A61B90/10;;A61N1/0484;;A61N1/0492;;A61N1/205,A61N1/05,,0,0,,,,INACTIVE
55,CA,A1,CA 2702944 A1,184-821-520-147-964,2009-05-28,2009,CA 2702944 A,2008-10-29,US 92980107 A;;US 23429708 A;;US 24373308 A;;US 26095808 A;;US 2008/0081655 W,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,PLESS BENJAMIN;;CHAO DANIEL;;WINGELER BRETT;;TCHENG THOMAS,,https://lens.org/184-821-520-147-964,Patent Application,no,0,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05,,0,0,,,,ACTIVE
56,AU,A1,AU 2014/203524 A1,085-792-055-592-624,2014-07-17,2014,AU 2014/203524 A,2014-06-27,AU 2008/326667 A;;AU 2014/203524 A;;US 24373308 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain. -135-",NEUROPACE INC,PLESS BENJAMIN;;TCHENG THOMAS;;CHAO DANIEL;;WINGELER BRETT,,https://lens.org/085-792-055-592-624,Patent Application,no,0,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05,,0,0,,,,INACTIVE
57,US,B2,US 9352168 B2,086-607-447-296-268,2016-05-31,2016,US 201514688935 A,2015-04-16,US 201514688935 A;;US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,Low frequency neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-08-25),https://lens.org/086-607-447-296-268,Granted Patent,yes,57,5,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/04;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02,,53,47,049-764-006-876-782;;058-474-962-345-026;;100-329-685-384-712;;028-400-352-294-444;;000-907-476-829-590;;070-549-885-927-855;;117-280-426-177-420;;020-862-494-916-996;;021-307-591-737-010;;002-610-549-523-468;;063-749-422-355-89X;;003-567-098-113-528;;121-395-139-132-160;;068-670-171-691-134;;017-065-379-332-717;;013-545-706-354-946;;030-983-039-493-075;;003-490-521-438-037;;038-125-139-467-43X;;003-243-554-446-676;;045-313-415-627-674;;032-584-602-403-660;;091-138-016-549-341;;058-790-540-596-874;;021-657-845-715-349;;064-273-086-002-360;;070-826-749-769-613;;035-990-338-077-706;;143-828-927-516-199;;038-980-231-466-699;;134-661-542-323-873;;013-676-649-177-997;;058-990-110-607-410;;002-344-382-871-989;;031-445-476-481-273;;058-904-960-260-878;;143-398-932-451-548;;021-154-759-818-769;;041-461-559-713-466;;150-796-039-433-379;;024-657-104-096-682;;029-497-167-480-309;;042-629-324-644-008;;085-169-832-606-660;;025-992-119-710-993;;018-769-436-346-405;;034-215-008-256-505,10.1097/00001756-199511000-00018;;8595196;;9875279;;10.1006/exnr.1998.6932;;10.1016/s0168-5597(97)00096-8;;9474057;;7225959;;10.1017/s0317167100042864;;10482807;;10.1016/s0006-8993(99)01731-x;;3808255;;10.1097/00006123-198701000-00030;;10.1097/00019052-199806000-00003;;9642537;;10.1159/000125575;;402170;;1663448;;10.1016/0013-4694(85)91075-2;;2408867;;7250277;;10.1016/0014-4886(81)90057-1;;9448642;;10.1016/s0924-980x(97)00036-2;;10.1016/0013-4694(94)00249-k;;7530636;;10.1523/jneurosci.15-01-00604.1995;;pmc6578315;;7823167;;10.1016/0920-1211(95)00025-6;;8536671;;10.1111/j.1528-1157.1965.tb03782.x;;14337460;;9749744;;10.1046/j.1460-9568.1998.00090.x;;10.1016/s0006-8993(97)01118-9;;9439820;;10646759;;10.1016/s1361-8415(98)80008-x;;10.1111/j.1528-1157.1992.tb02192.x;;1396427;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;7284903;;10.1017/s0317167100043286;;6512714;;10.1080/00223980.1984.9712600;;2429284;;10.1111/j.1540-8159.1986.tb05426.x;;10.1016/0014-4886(69)90128-9;;4981856;;6970503;;10.1007/978-3-7091-8592-6_31;;10910346;;10.1038/35018000;;10.1111/j.1600-0404.1994.tb05195.x;;8155315;;10.1016/0896-6273(94)90205-4;;10.1152/jn.1998.79.3.1592;;9497437;;10.1212/wnl.53.7.1462;;10534252;;10590958;;10.1097/00006123-199505000-00025;;7540735;;10.1227/00006123-199505000-00025;;3770122;;10.1016/0014-4886(86)90105-6;;10.3171/jns.1970.32.5.0553;;5438095;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;8190292;;10.1212/wnl.44.5.884;;6603358;;10.1111/j.1528-1157.1983.tb04915.x;;1162603;;10.1016/0013-4694(67)90188-5;;4168976;;14439711;;10.3171/jns.1960.17.1.0055;;3321152;;10.1016/0278-5846(87)90018-2;;10.1007/s004150050482;;10552238;;10.1177/155005948801900404;;3060288;;10.1016/0920-1211(89)90029-6;;2731520;;8730820;;10.1097/00001756-199601310-00035,"Weiss et al., S.R.B., et al., ""Quenching: Inhibition of Development and Expression of Amygdala Kindled Seizures with Low Frequency Stimulation,"" NeuroReport (1995) 6: pp. 217-276.;;Weiss et al., S.R. et al., ""Quenching Revisited: Low Level Direct Current Inhibits Amygdala-Kindled Seizures,"" Experimental Neurology (1998) 154: pp. 185-192.;;Roland, V. et al., ""The Production of Brain Lesions With Electric Currents,"" J. Neurosurg. 14 (1957), pp. 302-328.;;E.M. Wasserman, ""Risk and Safety of Repetitive Transcranial Magnetic Stimulation: Report and Suggested Guidelines from the International Workshop on the Safety of Repetitive Transcranial Mag. Stim . . . ,"" Electroenceph. and Clin Neurophys. 108 (1998), pp. 1-16.;;J. Gaito et al., ""The Effect of Several Intertrial Intervals on the 1 Hz Interference Effect,"" Le Journal Canadian des Sciences Neurologiques 1981; 8(1): pp. 61-65.;;Adamec, R.E., ""Evidence that Limbic Neural Plasticity in the Right Hemisphere Mediates Partial Kindling Induced Increases in Anxiety-Like Behavior,"" Brain Research (1999); 839: pp. 133-152.;;Agnew, W.F., et al., ""Considerations for Safety in the Use of Extracranial Stimulation for Motor Evoked Potentials,"" (1987) 20: pp. 143-147.;;Aurora, S. K., et al., ""Brain Excitability in Migraine: Evidence from Transcranial Magnetic Stimulation Studies,"" Current Opinion in Neurology (1998) 11: pp. 205-209.;;Bartlett, J.R., et al., Deleterious Effects of Prolonged Electrical Excitation of Striate Cortex in macaques, Brain Behav. Evol. (1977) 14: pp. 46-66.;;Bridgers, S.L., ""The Safety of Transcranial Magnetic Stimulation Reconsidered: Evidence Regarding Cognitive and Other Cerebral Effects,"" Magnetic Motor Stimulation: Basic Principles and Clinical Experience (1991) EEG Suppl. 43: pp. 170-179.;;Buzsaki, G., et al., ""Depth Profiles of Hippocampal Rhythmic Slow Activity (theta rhythm') Depend on Behavior,"" Electroencephologr. Clin. Neurophysiol. (1985) 61: pp. 77-88.;;Cain, D. P., et al., ""Kindling with Low-Frequency Stimulation: Generality, Transfer and Recruiting Effects,"" Experimental Neurology (1981) 73: pp. 219-232.;;Chen, R. et al., ""Safety of Different Inter-Train Intervals for Repetitive Transcranial Magnetic Stimulation and Recommendations for Safe Ranges of Stimulation Parameters,"" Electroencephalograpy and Clinical Neurophysiology (1997) 105: pp. 415-421.;;Classen, J. et al., ""Epileptic Seizures Triggered Directly by Focal Transcranial Magnetic Stimulation,"" Electroencephalography and Clinical Neurophysiology (1995) 94: pp. 19-25.;;Contreras, D., et al., ""Cellular Basis of EEG Slow Rhythms: A Study of Dynamic Corticothalmic Relationships,"" J. Neurosci. (1995) 15: pp. 604-622.;;Dennison, Z. et al., ""Persistence of Kindling: Effect of Partial Kindling, Retention Interval, Kindling Site, and Stimulation Parameters,"" Epilepsy Research (1995) 21: pp. 171-182.;;Dow, R.S., ""Extrinsic Regulatory Mechanisms of Seizure Activity,"" Epilepsia (1965) 6: pp. 122-140.;;Elger, C., et al., ""Short Communication Seizure Prediction by Non-Linear Time Series Analysis of Brain Electrical Activity,"" European Journal of Neuroscience (1998) 10: pp. 786-789.;;Emori, K, et al., ""Changes in Paired-Pulse Depression During the Triggering of Seizures by 2 Hz Dentate Gyrus Stimulation: the Effect of the Kindling,"" Brain Research (1997) 776: pp. 250-254.;;Ettinger, G.J., et al., ""Experimentation with a Transcranial Magnetic Stimulation System for Functional Brain Mapping,"" Medical Image Analysis (1998) vol. 2, No. 2, pp. 133-142.;;Fischer, R.S., et al., ""Placebo-Controlled Pilot Study of CentromedianThalamic Stimulation in Treatment of Intractable Seizures,"" Epilepsia (1992) 33: pp. 841-851.;;Gaito, J., et al., ""Interference Effect of 3 Hz Brain Stimulation on Kindling Behavior Induced by 60 Hz Stimulation,"" Epilepsia (1980) 21: pp. 73-84.;;Gaito, J., ""The Effect of Variable Duration One Hertz Interference on Kindling,"" Le Journal Canadien des Sciences Neurologiques (1980): 7: pp. 59-64.;;Gaito, J., et al., ""The Effect of Low Frequency and Direct Current Stimulation on the Kindling Phenomenon in Rats,"" Le Journal Canadiens des Sciences Neurologiques (1981) 8(3): pp. 249-253.;;Gaito, J., ""Suppression of Kindling Behavior,"" J. Psychology (1984) 118: pp. 113-125.;;Girvin, J.P., ""Cerebral (Cortical) Biostimulation,"" PACE (1986) 9: pp. 764-771.;;Goddard, G. V., et al., ""A Permanent Change in Brain Function Resulting From Daily Electrical Stimulation,"" Experimental Neurology (1967) 25: pp. 295-330.;;Goodman, J.H., ""Experimental Models of Status Epilepticus,"" in S. L. Peterson et al., eds., Neuropharmacology Methods in Epilepsy Research, CRC Press (1998) pp. 95-125.;;Gybels, J., et al., ""Electrical Stimulation of the Central Gray for Pain Relief in Human: Autopsy Data,"" Acta Neurochirugica (1980) Suppl. 30: pp. 259-268.;;Hallet, M., ""Transcranial Magnetic Stimulation and the Human Brain,"" Nature (2000) 406: pp. 147-150.;;Jennum, P., et al., ""Transcranial Magnetic Stimulation. Its Role in the Evaluation of Patients with Partial Epilepsy,"" Acta Neurol. Scand. (1994) Suppl. 152: pp. 93-96.;;Krauss, G. L., et al., ""Cerebellar and Thalamic Stimulation for Epilepsy,"" in 0. Devinsky et al., eds., Electrical and Magnetic Stimulation of the Brain and Spinal Cord, New York: Raven Press, Ltd. (1993) pp. 231-245.;;Kreindler, A., ""Active Arrest Mechanisms of Epileptic Seizures,"" Epilepsia (1962) 2: pp. 329-337.;;Linden, D.J., ""Long-Term Synaptic Depression in the Mammalian Brain,"" Neuron (1994) 12: pp. 457-472.;;Leung, L.S., et al., ""Theta-Frequency Resonance in Hippocampal CA1 Neurons In Vitro Demonstrated by Sinusoidal Current Injection,"" J. Neurophysiol. (1998) 79: pp. 1592-1596.;;MacDonell, R.A.L., et al., ""Motor Cortex Localization Using Functional MRI and Transcranial Magnetic Stimulation,"" Neurology (1999) 53: pp. 1462-1467.;;Maertens De Noordhout, A., et al., ""Transcranial Magnetic Stiulation in Migraine,"" Transcranial Magnetic Stimulation (1999) EEG Suppl. 51: pp. 260-264.;;Migita, K., et al., ""Transcranial Magnetic Coil Stimulation of Motor Cortex in Patients with Central Pain,"" Neurosurgery (1995) vol. 36, No. 5, pp. 1037-1040.;;Minabe, Y. et al.,""Low-Frequency Kindling as a New Experimental Model of Epilepsy,"" Experimental Neurology (1986) 94: pp. 317-323.;;Mortimer, J.T., et al., ""Experimental Nondestructive Electrical Stimulation of the Brain and Spinal Cord,"" J. Neurosurg. (1970) 32: pp. 553-559.;;Ojemann, G.A., et al., ""Stereotactic and Other Procedures for Epilepsy,"" in D.P. Purpura et al., eds., Neurosurgical Management of the Epilepsies, Advances in Neurology (1975) 8: pp. 241-263.;;Osorio, L., et al., ""Real-Time Automated Dection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset,"" Epilepsia (1998) 39: pp. 615-627.;;Pascual-Leone, A., et al., ""Akinesia in Parkinson's Disease,"" Neurology (1994) 44: pp. 884-891.;;Psatta, D.M., ""Control of Chronic Experimental Focal Epilepsy by Feedback Caudatum Stimulations,"" Epilepsia (1983) 24: pp. 444-454.;;Pudenz, R.H., et al., ""Electrical Stimulation of the Brain. II. Effects on the Blood-Brain Barrier,"" Surg. Neurol. (1975) 4: pp. 265-270.;;Reimer, G. R., et al., ""Effects of Cerebellar Stimulation on Cobalt-Induced Epilepsy in the Cat,"" Electroenceph. Clin. Neurophysiol. (1967) 23: pp. 456-462.;;Rowland, V., et al., ""The Production of Brain Lesions With Electric Currents,"" J. Neurosurg. (1960) 17: pp. 55-69.;;Schmutz, M., ""Relevance of Kindling and Related Processes to Human Epileptogenesis,"" Prog. Neuro-Psychopharmacolog. & Biol. Psychiat. (1987) 11: pp. 5050-5525.;;Schulze-Bonhage, A., et al., ""Safety of Single and Repetitive focal Transcranial Magnetic Stimuli as Assessed by Intracranial EEG Recordings in Patients with Partial Epilepsy,"" J. Neurol. (1999) 246: pp. 914-919.;;Sramka, M., et al., ""Observation of Kindling Phenomenon in Treatment of Pain by Stimulation in Thalamus,"" in W.H. Sweet et al., eds., Neurosurgical Treatment in Psychiatry, Pain and Epilepsy, Baltimore: University Park Press (1977) pp. 651-654.;;Staton, R.D., et al., The Electroencephalographic Pattern During Electroconvulsive Therapy: V. Observations on the Origin of Phase III Delta Energy and the Mechanism of Action of ECT, Clin. Electroencephalogr. (1988) 10: pp. 176-198.;;Ullal, G.R., et al., ""Low Frequency Stimulation Induces an Increase in After-Discharge Thresholds in Hippocampal and Amygdaloid Kindling,"" Epilepsy Res. 3 (1989) pp. 232-235.;;Wang, H. et al., ""LTD and LTP Induced by Transcranial Magnetic Stimulation in Auditory Cortex,"" Neuroreport (1996) 7: pp. 521-525.",EXPIRED
58,US,A1,US 2010/0331762 A1,045-435-339-869-510,2010-12-30,2010,US 88117110 A,2010-09-13,US 88117110 A;;US 70453407 A,2007-02-08,Refillable Reservoir Lead Systems,"Medical electrical lead systems and related methods are described. The medical electrical lead systems may be configured to be at least partially implanted in a body of a subject. Some variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and a lumen extending at least partially therebetween, at least one electrode in the proximity of the distal end of the lead body, and a reservoir in fluid communication with the lumen, where the reservoir is located at a position removed from the distal end of the lead body. Certain variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and first and second lumens extending at least partially therebetween, and at least one electrode in the proximity of the distal end of the lead body.",NEUROPACE INC,WINGEIER BRETT M;;MORRELL MARTHA J;;BOLING C LANCE,NEUROPACE INC (2007-03-26),https://lens.org/045-435-339-869-510,Patent Application,yes,68,9,6,044-530-454-860-377;;178-537-703-735-106;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,6,178-537-703-735-106;;044-530-454-860-377;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,0,A61N1/0529;;A61N1/0536;;A61N1/0568;;A61N1/0529;;A61N1/0536;;A61N1/0568,A61M37/00;;A61N1/30,604/21;;604/66,0,0,,,,INACTIVE
59,US,A1,US 2014/0378807 A1,155-521-267-223-516,2014-12-25,2014,US 201414484605 A,2014-09-12,US 201414484605 A;;US 88013810 A;;US 97309104 A;;US 89609201 A,2001-06-28,SEIZURE SENSING AND DETECTION USING AN IMPLANTABLE DEVICE,"Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,PLESS BENJAMIN D;;ARCHER STEPHEN T;;BAYSINGER CRAIG M;;GIBB BARBARA;;GURUNATHAN SURESH;;TCHENG THOMAS K,NEUROPACE INC (2001-06-28),https://lens.org/155-521-267-223-516,Patent Application,yes,4,2,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/00;;A61B5/04;;A61B5/0476;;A61B5/0478,600/378,0,0,,,,EXPIRED
60,CA,C,CA 2702944 C,164-124-168-542-789,2016-11-15,2016,CA 2702944 A,2008-10-29,US 92980107 A;;US 23429708 A;;US 24373308 A;;US 26095808 A;;US 2008/0081655 W,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed arc methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,PLESS BENJAMIN;;CHAO DANIEL;;WINGEIER BRETT;;TCHENG THOMAS,,https://lens.org/164-124-168-542-789,Granted Patent,no,0,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61B5/6864;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61B8/0808;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B2090/103;;A61N1/0539;;A61N1/36025;;A61B5/6864;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B8/0808;;A61B2090/103;;A61N1/0539;;A61N1/36025;;A61B90/10;;A61N1/0484;;A61N1/0492;;A61N1/205,A61N1/00;;A61B5/0476;;A61F7/00;;A61L31/10;;A61L31/16;;A61M39/02;;A61N1/20;;A61N1/30;;A61N5/06,,0,0,,,,ACTIVE
61,AU,B2,AU 2014/203524 B2,069-404-211-987-648,2015-11-05,2015,AU 2014/203524 A,2014-06-27,AU 2008/326667 A;;AU 2014/203524 A;;US 24373308 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain. -135-",NEUROPACE INC,PLESS BENJAMIN;;TCHENG THOMAS;;CHAO DANIEL;;WINGEIER BRETT,,https://lens.org/069-404-211-987-648,Granted Patent,no,1,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61B5/6864;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61B8/0808;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B2090/103;;A61N1/0539;;A61N1/36025;;A61B5/6864;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B8/0808;;A61B2090/103;;A61N1/0539;;A61N1/36025;;A61B90/10;;A61N1/0484;;A61N1/0492;;A61N1/205,A61N1/05,,0,0,,,,INACTIVE
62,AU,B2,AU 2015/268576 B2,167-606-908-208-972,2017-02-02,2017,AU 2015/268576 A,2015-12-08,AU 2014/203524 A;;AU 2015/268576 A,2014-06-27,"Systems, methods and devices for a skull/brain interface","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain. -102-",NEUROPACE INC,WINGEIER BRETT;;TCHENG THOMAS;;CHAO DANIEL;;PLESS BENJAMIN,,https://lens.org/167-606-908-208-972,Granted Patent,no,2,0,2,067-954-416-708-722;;167-606-908-208-972,AU,2,067-954-416-708-722;;167-606-908-208-972,AU,0,,A61N1/05,,0,0,,,,INACTIVE
63,US,B1,US 6591138 B1,063-625-412-026-457,2003-07-08,2003,US 65296400 A,2000-08-31,US 65296400 A,2000-08-31,Low frequency neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC. A DELAWARE CORPORATION (2000-08-25),https://lens.org/063-625-412-026-457,Granted Patent,yes,47,266,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02;;A61N2/04,607/45;;607/76,47,41,013-545-706-354-946;;024-657-104-096-682;;064-273-086-002-360;;058-904-960-260-878;;150-796-039-433-379;;174-178-036-962-905;;020-862-494-916-996;;070-826-749-769-613;;063-749-422-355-89X;;041-461-559-713-466;;021-657-845-715-349;;031-445-476-481-273;;070-549-885-927-855;;042-629-324-644-008;;018-769-436-346-405;;003-243-554-446-676;;038-980-231-466-699;;017-065-379-332-717;;049-764-006-876-782;;058-474-962-345-026;;000-907-476-829-590;;021-307-591-737-010;;143-828-927-516-199;;021-154-759-818-769;;121-395-139-132-160;;002-344-382-871-989;;034-215-008-256-505;;003-567-098-113-528;;100-329-685-384-712;;117-280-426-177-420;;038-125-139-467-43X;;085-169-832-606-660;;058-990-110-607-410;;013-676-649-177-997;;035-990-338-077-706;;045-313-415-627-674;;032-584-602-403-660;;028-400-352-294-444;;091-138-016-549-341;;058-790-540-596-874;;003-490-521-438-037,10.1111/j.1528-1157.1965.tb03782.x;;14337460;;10.1016/0013-4694(67)90188-5;;4168976;;10.1016/0014-4886(69)90128-9;;4981856;;10.3171/jns.1970.32.5.0553;;5438095;;1162603;;804233;;10.1159/000125575;;402170;;6970503;;10.1007/978-3-7091-8592-6_31;;7250277;;10.1016/0014-4886(81)90057-1;;6603358;;10.1111/j.1528-1157.1983.tb04915.x;;2429284;;10.1111/j.1540-8159.1986.tb05426.x;;3770122;;10.1016/0014-4886(86)90105-6;;3808255;;10.1097/00006123-198701000-00030;;3321152;;10.1016/0278-5846(87)90018-2;;10.1016/0920-1211(89)90029-6;;2731520;;10.1111/j.1528-1157.1992.tb02192.x;;1396427;;8155315;;10.1016/0896-6273(94)90205-4;;10.1016/0920-1211(95)00025-6;;8536671;;10.1097/00001756-199511000-00018;;8595196;;9875279;;10.1006/exnr.1998.6932;;10482807;;10.1016/s0006-8993(99)01731-x;;1663448;;10.1111/j.1600-0404.1994.tb05195.x;;8190292;;10.1212/wnl.44.5.884;;10.1016/0013-4694(94)00249-k;;7530636;;10.1097/00006123-199505000-00025;;7540735;;10.1227/00006123-199505000-00025;;8730820;;10.1097/00001756-199601310-00035;;9448642;;10.1016/s0924-980x(97)00036-2;;10.1016/s0168-5597(97)00096-8;;9474057;;10.1097/00019052-199806000-00003;;9642537;;10646759;;10.1016/s1361-8415(98)80008-x;;10.1007/s004150050482;;10552238;;10590958;;10.1212/wnl.53.7.1462;;10534252;;10910346;;10.1038/35018000;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;7225959;;10.1017/s0317167100042864;;7284903;;10.1017/s0317167100043286;;6512714;;10.1080/00223980.1984.9712600;;10.1016/s0006-8993(97)01118-9;;9439820,"V. Rowland et al., ""The Production of Brain Lesions With Electric Currents,"" J. Neurosurg. 14 (1957), pp. 302-328.;;A. Kreindler, ""Active Arrest Mechanisms of Epileptic Seizures,"" Epilepsia 3 (1962), pp. 329-337.;;R.S. Dow, ""Extrinsic Regulatory Mechanisms of Seizure Activity,"" Epilepsia 6 (1995), pp. 122-140.;;G.R. Reimer et al., ""Effects of Cerebellar Stimulation on Cobalt-Induced Epilepsy in the Cat,"" Electroenceph. Clin. Neurophysiol. 23 (1967), pp. 456-462.;;G.V. Goddard et al., ""A Permanent Change in Brain Function Resulting from Daily Electrical Stimulation,"" Experimental Neurology 25 (1969), pp. 295-330.;;J.T. Mortimer et al., ""Experimental Nondestructive Electrical Stimulation of the Brain and Spinal Cord,"" J. Neurosurg. 32 (1970), pp. 553-559.;;R.H. Pudenz et al., ""Electrical Stimulation of the Brain. II. Effects on the Blood-Brain Barrier,"" Surg. Neurol. 4 (1975), pp. 265-270.;;G.A. Ojemann et al., ""Stereotactic and Other Procedures for Epilepsy,"" in D.P. Purpura et al., eds., Neurosurgical Management of the Epilepsies (1975), (Advances in Neurology, vol. 8), pp. 241-263.;;J.R. Bartlett et al., ""Deleterious Effects of Prolonged Electrical Excitation of Striate Cortex in Macaques,"" Brain Behav. Evol. 14 (1977), pp. 46-66.;;M. Sramka et al., ""Observation of Kindling Phenomenon in Treatment of Pain by Stimulation in Thalamus,"" in W.H. Sweet et al., eds., Neurosurgical Treatment in Psychiatry, Pain and Epilepsy, Baltimore: University Park Press (1977), pp. 651-654.;;J. Gybels et al., ""Electrical Stimulation of the Central Gray for Pain Relief in Human: Autopsy Data,"" Acta Neurochirurgica Suppl. 30 (1980), pp. 259-268.;;D.P. Cain et al., ""Kindling with Low-Frequency Stimulation: Generality, Transfer, and Recruiting Effects,"" Experimental Neurology 73 (1981), pp. 219-232.;;D.M. Psatta, ""Control of Chronic Experimental Focal Epilepsy by Feedback Caudatum Stimulations,"" Epilepsia 24 (1983), pp. 444-454.;;J.P. Girvin, ""Cerebral (Cortical) Biostimulation,"" PACE 9 (1986), pp. 764-771.;;Y. Minabe et al., ""Low-Frequency Kindling as a New Experimental Model of Epilepsy,"" Experimental Neurology 94 (1986), pp. 317-323.;;W.F. Agnew et al., ""Considerations for Safety in the Use of Extracranial Stimulation for Motor Evoked Potentials,"" Neurosurgery 20 (1987), pp. 143-147.;;M. Schmutz, ""Relevance of Kindling and Related Processes to Human Epileptogenesis,"" Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 11 (1987), pp. 505-525.;;G.R. Ullal et al., ""Low frequency stimulation induces an increase in after-discharge thresholds in hippocampal and amygdaloid kindling,"" Epilepsy Res. 3 (1989), pp. 232-235.;;R.S. Fisher et al., ""Placebo-Controlled Pilot Study of Centromedian Thalamic Stimulation in Treatment of Intractable Seizures,"" Epilepsia 35(5) (1992), pp. 841-851.;;G.L. Krauss et al., ""Cerebellar and Thalamic Stimulation for Epilepsy,"" in O. Devinsky et al., eds., Electrical and Magnetic Stimulation of the Brain and Spinal Cord, New York: Raven Press, Ltd. (1993), pp. 231-245.;;D.J. Linden, ""Long-Term Synaptic Depression in the Mammalian Brain,"" Neuron 12 (1994), pp. 457-472.;;Z. Dennison et al., ""Persistence of kindling: Effect of partial kindling, retention interval, kindling site, and stimulation parameters,"" Epilepsy Research 21 (1995), pp. 171-182.;;S.R.B. Weiss et al., ""Quenching: inhibition of development and expression of amygdala kindled seizures with low frequency stimulation,"" NeuroReport 6 (1995), pp. 2171-2176.;;S.R.B. Weiss et al., ""Quenching Revisited: Low Level Direct Current Inhibits Amygdala-Kindled Seizures,"" Experimental Neurology 154 (1998), pp. 185-192.;;J.H. Goodman, ""Experimental Models of Status Epilepticus,"" in S.L. Peterson et al., eds., Neuropharmacology Methods in Epilepsy Research, CRC Press (1998), pp. 95-125.;;R.E. Adamec, ""Evidence that limbic neural plasticity in the right hemisphere mediates partial kindling induced lasting increases in anxiety-like behavior,"" Brain Research 839 (1999), pp. 133-152.;;S.L. Bridgers, ""The Safety of Transcranial Magnetic Stimulation Reconsidered: Evidence Regarding Cognitive and Other Cerebral Effects,"" Magnetic Motor Stimulation: Basic Principles and Clinical Experience (EEG Suppl. 43) 1991, pp. 170-179.;;P. Jennum et al., ""Transcranial magnetic stimulation. Its role in the evaluation of patients with partial epilepsy,"" Acta Neurol. Scand. 1994: Suppl. 152, pp. 93-96.;;A. Pascual-Leone et al., ""Akinesia in Parkinson's Disease,"" Neurology 44, May 1994, pp. 884-891.;;J. Classen et al., ""Epileptic seizures triggered directly by focal transcranial magnetic stimulation,"" Electroencephalography and Clinical Neurophysiology 94 (1995), pp. 19-25.;;K. Migita et al., ""Transcranial Magnetic Coil Stimulation of Motor Cortex in Patients with Central Pain,"" Neurosurgery, vol. 36, No. 5, May 1995, pp. 1037-1040.;;H. Wang et al., ""LTD and LTP induced by transcranial magnetic stimulation in auditory cortex,"" Neuroreport 7 (1996), pp. 521-525.;;R. Chen et al., ""Safety of different inter-train intervals for repetetive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters,"" Electroencephalography and Clinical Neurophysiology 105 (1997), pp. 415-421.;;E.M. Wassermann, ""Risk and Safety of Repetitive Transcranial Magnetic Stimulation: Report and Suggested Guidelines from the International Workshop on the Safety of Repetitive Transcranial Mag. Stim . . . ,"" Electroenceph. and Clin. Neurophys. 108 (1998), pp. 1-16.;;S.K. Aurora et al., ""Brain excitability in migraine: evidence from transcranial magnetic stimulation studies,"" Current Opinion in Neurololgy, 1998, 11, pp. 205-209.;;G.J. Ettinger, et al., ""Experimentation with a transcranial magnetic stimulation system for functional brain mapping,"" Medical Image Analysis (1998) vol. 2, No. 2, pp. 133-142.;;A. Schulze-Bonhage et al., ""Safety of single and repetitive focal transcranial magnetic stimuli as assessed by intracranial EEG recordings in patients with partial epilepsy,"" J. Neurol. (1999) 246, pp. 914-919.;;A. Maertens de Noordhout et al., ""Transcranial magnetic stimulation in migraine,"" Transcranial Magnetic Stimulation (EEG Suppl. 51), 1999, pp. 260-264.;;R.A.L. Macdonell et al., ""Motor cortex localization using functional MRI and transcranial magnetic stimulation,"" Neurology 1999;53, pp. 1462-1467.;;M. Hallett, ""Transcranial magnetic stimulation and the human brain,"" Nature, vol. 406, Jul. 13, 2000, pp. 147-150.;;J. Gaito et al., ""Interference Effect of 3 Hz Brain Stimulation of Kindling Behavior Induced by 60 Hz Stimulation,"" Epilepsia, 21 (1980), pp. 73-84.;;J. Gaito, ""The Effect of Variable Duration One Hertz Interference on Kindling,"" Le Journal Canadien Des Sciences Neurologiques, vol. 7, No. 1, Feb. 1980, pp. 59-64.;;J. Gaito et al., ""The Effect of Several Intertrial Intervals on the 1 Hz Interference Effect,"" Le Journal Canadien des Sciences Neurologiques 1981; 8(1): pp. 61-65.;;J. Gaito, ""The Effect of Low Frequency and Direct Current Stimulation on The Kindling Phenomenon in Rats,"" Le Journal Canadien des Sciences Neurologiques 1981; 8(3): pp. 249-253.;;J. Gaito, ""Suppression of Kindling Behavior,"" J. Psychology 1984; 118: pp. 113-125.;;K. Emori et al., ""Changes in paired-pulse depression during the triggering of seizures by 2 Hz dentate gyrus stimulation: the effect of the kindling,"" Brain Research 776 (1997), pp. 250-254.;;R. Fischell et al., ""Means and Method for the Treatment of Migraine Headaches,"" Co-Pending U.S. Patent Application Ser. No. 09/629,210, filed Jul. 28, 2000.",EXPIRED
64,CA,C,CA 2251852 C,176-779-803-691-197,2012-12-18,2012,CA 2251852 A,1998-10-26,US 95786997 A,1997-10-27,MEANS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,,https://lens.org/176-779-803-691-197,Granted Patent,no,0,1,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/32;;A61N1/36,,0,0,,,,EXPIRED
65,US,A1,US 2021/0259607 A1,180-888-327-041-982,2021-08-26,2021,US 202117313866 A,2021-05-06,US 202117313866 A;;US 201916442424 A;;US 201715478168 A;;US 201213673312 A;;US 201161558382 P,2011-11-10,MULTIMODAL BRAIN SENSING LEAD,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/180-888-327-041-982,Patent Application,yes,24,0,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61B5/291;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/1455;;A61B5/16;;A61B5/316;;A61N1/02;;A61N1/05;;A61N1/36,,0,0,,,,ACTIVE
66,EP,A3,EP 1145736 A3,087-979-855-502-888,2004-04-14,2004,EP 01303246 A,2001-04-05,US 54345000 A,2000-04-05,Multimodal neurostimulator,"This is directed to an implantable multimodal neurostimulator having improved efficacy in treating epilepsy and other neurological disorders and to processes of using that neurostimulator. The neurostimulator itself generally has two modes of electrical stimulation: the first involves delivering a non-responsive electrical stimulation signal which is applied to the central nervous system to reduce the likelihood of a seizure or other undesirable neurological even from occurring, and a second mode that involves delivering electrical stimulation signal or signals when epileptiform waveforms are impending or extant. The responsive electrical stimulation signal or signals are intended to terminate epileptiform activity, e.g., to desynchronize abnormally synchronous brain electrical activity. Alternatively, the second mode may be used to deliver sensory stimulation, e.g., a scalp or sound stimulation, to the patient rather than deliver electrical stimulation to the patient. Finally, the implanted neurostimulator may be used by a physician to induce epileptiform activity and then verify the effectiveness of the parameters of the first and second neurostimulation signal or signals.",NEUROPACE INC,PLESS BENJAMIN D,,https://lens.org/087-979-855-502-888,Search Report,yes,4,0,7,024-096-457-615-102;;128-755-226-255-290;;017-686-610-075-111;;087-979-855-502-888;;158-501-983-099-369;;061-206-050-442-20X;;008-166-797-662-811,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36064,A61N1/36,,0,0,,,,DISCONTINUED
67,US,B2,US 10123717 B2,046-846-458-039-598,2018-11-13,2018,US 201213673312 A,2012-11-09,US 201213673312 A;;US 201161558382 P,2011-11-10,Multimodal brain sensing lead,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/046-846-458-039-598,Granted Patent,yes,43,7,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61N1/05;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/04;;A61B5/0478;;A61B5/1455;;A61B5/16;;A61N1/00;;A61N1/02;;A61N1/36,,0,0,,,,ACTIVE
68,US,B2,US 9694195 B2,183-117-468-610-273,2017-07-04,2017,US 201615137670 A,2016-04-25,US 201615137670 A;;US 201514688935 A;;US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,Low frequency neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-08-25),https://lens.org/183-117-468-610-273,Granted Patent,yes,58,1,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/04;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02,,53,48,025-992-119-710-993;;018-769-436-346-405;;034-215-008-256-505;;049-764-006-876-782;;058-474-962-345-026;;100-329-685-384-712;;028-400-352-294-444;;000-907-476-829-590;;070-549-885-927-855;;117-280-426-177-420;;020-862-494-916-996;;021-307-591-737-010;;002-610-549-523-468;;063-749-422-355-89X;;003-567-098-113-528;;121-395-139-132-160;;068-670-171-691-134;;017-065-379-332-717;;013-545-706-354-946;;030-983-039-493-075;;003-490-521-438-037;;038-125-139-467-43X;;003-243-554-446-676;;045-313-415-627-674;;032-584-602-403-660;;091-138-016-549-341;;058-790-540-596-874;;021-657-845-715-349;;064-273-086-002-360;;070-826-749-769-613;;035-990-338-077-706;;143-828-927-516-199;;038-980-231-466-699;;134-661-542-323-873;;013-676-649-177-997;;058-990-110-607-410;;002-344-382-871-989;;031-445-476-481-273;;058-904-960-260-878;;174-178-036-962-905;;143-398-932-451-548;;021-154-759-818-769;;041-461-559-713-466;;150-796-039-433-379;;024-657-104-096-682;;029-497-167-480-309;;042-629-324-644-008;;085-169-832-606-660,10.1177/155005948801900404;;3060288;;10.1016/0920-1211(89)90029-6;;2731520;;8730820;;10.1097/00001756-199601310-00035;;10.1097/00001756-199511000-00018;;8595196;;9875279;;10.1006/exnr.1998.6932;;10.1016/s0168-5597(97)00096-8;;9474057;;7225959;;10.1017/s0317167100042864;;10482807;;10.1016/s0006-8993(99)01731-x;;3808255;;10.1097/00006123-198701000-00030;;10.1097/00019052-199806000-00003;;9642537;;10.1159/000125575;;402170;;1663448;;10.1016/0013-4694(85)91075-2;;2408867;;7250277;;10.1016/0014-4886(81)90057-1;;9448642;;10.1016/s0924-980x(97)00036-2;;10.1016/0013-4694(94)00249-k;;7530636;;10.1523/jneurosci.15-01-00604.1995;;pmc6578315;;7823167;;10.1016/0920-1211(95)00025-6;;8536671;;10.1111/j.1528-1157.1965.tb03782.x;;14337460;;9749744;;10.1046/j.1460-9568.1998.00090.x;;10.1016/s0006-8993(97)01118-9;;9439820;;10646759;;10.1016/s1361-8415(98)80008-x;;10.1111/j.1528-1157.1992.tb02192.x;;1396427;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;7284903;;10.1017/s0317167100043286;;6512714;;10.1080/00223980.1984.9712600;;2429284;;10.1111/j.1540-8159.1986.tb05426.x;;10.1016/0014-4886(69)90128-9;;4981856;;6970503;;10.1007/978-3-7091-8592-6_31;;10910346;;10.1038/35018000;;10.1111/j.1600-0404.1994.tb05195.x;;8155315;;10.1016/0896-6273(94)90205-4;;10.1152/jn.1998.79.3.1592;;9497437;;10.1212/wnl.53.7.1462;;10534252;;10590958;;10.1097/00006123-199505000-00025;;7540735;;10.1227/00006123-199505000-00025;;3770122;;10.1016/0014-4886(86)90105-6;;10.3171/jns.1970.32.5.0553;;5438095;;804233;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;8190292;;10.1212/wnl.44.5.884;;6603358;;10.1111/j.1528-1157.1983.tb04915.x;;1162603;;10.1016/0013-4694(67)90188-5;;4168976;;14439711;;10.3171/jns.1960.17.1.0055;;3321152;;10.1016/0278-5846(87)90018-2;;10.1007/s004150050482;;10552238,"Staton, et al., “The electroencephalographic pattern during electroconvulsive therapy. V. Observations on the origin of phase III delta energy and the mechanism of action of ECT.” Clin. Electroencephalogry 10: 176-198 (1988).;;Ullal, et al., “Low frequency stimulation induces an increase in after-discharge thresholds in hippocampal and amygdaloid kindling.” Epilepsy Res. 3: 232-235 (1989).;;Wang et al., “LTD and LTP induced by transcranial magnetic stimulation in auditory cortex.” Neuroreport 7: 521-525 (1996).;;Weiss, et al., “Quenching: inhibition of development and expression of amygdala kindled seizures with low frequency stimulation.” NeuroReport 6: 217-276 (1995).;;Weiss, et al., “Quenching revisited: low level direct current inhibits amygdala-kindled seizures.” Experimental Neurology 154: 185-192 (1998).;;Roland et al., “The production of brain lesions with electric currents.” J. Neurosurg. 14: 302-328 (1957).;;Wasserman, “Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Mag Stim . . . ” Electroencehp. & Clin. Neurophys. 108: 1-16 (1998).;;Gaito et al., “The effect of several intertrial intervals on the 1 Hz interference effect.” Le J. Canadien des Sci. Neurol. 8: 61-65 (1981).;;Adamec, “Evidence that limbic neural plasticity in the right hemisphere mediates partial kindling induced increases in anxiety-like behavior.” Brain Res. 839: 133-152 (1999).;;Agnew et al., “Considerations for safety in the use of extracranial stimulation for motor evoked potentials.” Neurosurgery 20: 143-147 (1987).;;Aurora et al., “Brain excitability in migraine: evidence from transcranial magnetic stimulation studies.” Current Opinion in Neurology 11: 205-209 (1998).;;Bartlett et al., “Deleterious effects of prolonged electrical excitation of striate cortex in macaques.” Brain Behav. Evol. 14: 46-66 (1977).;;Bridgers, “The safety of transcranial magnetic stimulation reconsidered: evidence regarding cognitive and other cerebral effects. ”Magnetic Motor Stimulation: Basic Principles and Clinical Experience, EEG Suppl. 43: 170-179 (1991).;;Buzsaki et al., “Depth profiles of hippocampal rhythmic slow activity (theta rhythm) depend on behavior.” Electroencephologr Clin. Neurophys. 61: 77-88 (1985).;;Cain, et al., “Kindling with low-frequency stimulation: generality, transfer and recruiting effects.” Exper. Neurol. 73: 219-232 (1981).;;Chen et al., “Safety of different inter-train intervals for repetitive transcranial magnetic stimulation and recommendations for safe ranges of stimulation parameters.” Electroencephologr. Clin. Neurophys. 105: 415-421 (1997).;;Classen et al., “Epileptic seizures triggered directly by focal transcranial magnetic stimulation.” Electroencephologr Clin. Neurophys. 94: 19-25 (1995).;;Contreras et al., “Cellular basis of EEG rhythms: a study of dynamic corticothalmic relationships.” J. Neurosci. 15: 604-622 (1995).;;Dennison et al., “Persistence of kindling: effect of partial kindling, retention interval, kindling site and stimulation parameters.” Epilepsy Res. 21: 171-182 (1995).;;Dow, “Extrinsic regulatory mechanisms of seizure activity.” Epilepsia 6: 122-140 (1965).;;Elger et al., “Short communication seizure prediction by non-linear time series analysis of brain electrical activity.” European J. Neuroscience 10: 786-789 (1998).;;Emori et al., “Changes in paired-pulse depression during the triggering of seizures by 2 Hz dentate gyrus stimulation: the effect of kindling.” Brain Res. 776: 250-254 (1997).;;Ettinger et al., “Experimentation with a transcranial magnetic stimulation system for functional brain mapping.” Medical Image Analysis vol. 2, No. 2: 133-142 (1998).;;Fischer et al., “Placebo-controlled pilot study of centromedian thalamic stimulation in treatment of intractable seizures.” Epilepsia 33: 841-851 (1992).;;Gaito et al., “Interference effect of 3 Hz brain stimulation on kindling behavior induced by 60 Hz stimulation.” Epilepsia 21: 73-84 (1980).;;Gaito, “The effect of variable duration one Hertz interference on kindling.” Le J. Canadien des Sci. Neurol. 7: 59-64 (1980).;;Gaito et al., “The effect of low frequency and direct current stimulation on the kindling phenomenon in rats.” Le J. Canadien des Sci. Neurol. 8(3): 249-253 (1981).;;Gaito, “Suppression of kindling behavior” J. Psychology 118: 113-125 (1984).;;Girvin, “Cerebral (cortical) biostimulation.” PACE 9: 764-771 (1986).;;Goddard et al., “A permanent change in brain function resulting from daily electrical stimulation” Exper. Neurol. 25: 295-330 (1967).;;Goodman, “Experimental models of status epilepticus.” in S. L. Peterson et al. eds, Neuropharmacology Methods in Epilepsy Research. CRC Press, 95-125 (1998).;;Gybels et al., “Electrical stimulation of the central gray for pain relief in human autopsy data.” Acta Neurochirugica Supp. 30: 259-268 (1980).;;Hallett, “Transcranial magnetic stimulation and the human brain.” Nature 406: 147-150 (2000).;;Jennum et al., “Transcranial magnetic stimulation: its role in the evaluation of patients with partial epilepsy.” Acta Neurol. Scand. Suppl. 152: 93-96 (1994).;;Krauss et al., “Cerebellar and thalamic stimulation for epilepsy.” in O. Devinsky et al. eds, Electrical and Magnetic Stimulation of the Brain and Spinal Cord. New York: Raven Press, Ltd. 231-245 (1993).;;Kreindler, “Active arrest mechanisms of epileptic seizures.” Epilepsia 2: 329-337 (1962).;;Linden, “Long-term synaptic depression in the mammalian brain.” Neuron 12: 457-472 (1994).;;Leung et al., “Theta-frequency resonance in hippocampal CA1 neurons in vitro demonstrated by sinusoidal current injection.” J. Neurophysiol. 79: 1592-1596 (1998).;;MacDonnell et al., “Motor cortex localization using functional MRI and transcranial magnetic stimulation.” Neurology 53: 1462-1467 (1999).;;De Noordhout et al., “Transcranial magnetic stimulation in migraine.” Transcranial Magnetic Stimulation, EEG Suppl. 51: 260-264 (1999).;;Migita et al., “Transcranial magnetic coil stimulation of motor cortex in patients with central pain.” Neurosurgery vol. 36, No. 5: 1037-1040 (1995).;;Minabe et al., “Low-frequency kindling as a new experimental model of epilepsy.” Exper. Neurol. 94: 317-323 (1986).;;Mortimer et al., “Experimental nondestructive electrical stimulation of the brain and spinal cord.” J. Neurosurg. 32: 553-559 (1970).;;Ojemann et al., “Stereotactic and other procedures for epilepsy,” in D.P. Purpura et al. eds, Neurosurgical Management of the Epilepsies, Advances in Neurology 8: 241-263 (1975).;;Osorio et al., “Real-time automated detection and quantitative analysis of seizures and short-term prediction of clinical onset.” Epilepsia 39: 615-627 (1998).;;Pascual-Leone et al., “Akinesia in Parkinson's disease.” Neurology 44: 884-891 (1994).;;Psatta, “Control of chronic experimental focal epilepsy by feedback caudatum stimulations.” Epilepsia 24: 444-454 (1983).;;Pudenz et al., “Electrical stimulation of the brain. II. effects on the blood-brain barrier.” Surg. Neurol. 4: 265-270 (1975).;;Reimer et al., “Effects of cerebellar stimulation on cobalt-induced epilepsy in the cat.” Electroenceph. Clin. Neurophysiol. 23: 456-462 (1967).;;Rowland et al., “The production of brain lesions with electric currents.” J. Neurosurg. 17: 55-69 (1960).;;Schmutz, “Relevance of kindling and related processes to human epileptogenesis.” Prog. Neuro-Psychopharm. & Biol. Psychiat. 11: 505-525 (1987).;;Schulze-Bonhage et al., “Safety of single and repetitive focal transcranial magnetic stimuli as assessed by intracranial EEG recordings in patients with partial epilepsy.” J. Neurol. 246: 914-919 (1999).;;Sramka et al., “Observation of kindling phenomenon in treatment of pain by stimulation in thalamus,” in W.H. Sweet et al., eds. Neurosurgical Treatment in Psychiatry, Pain and Epilepsy. Baltimore: University Park Press 651-654 (1977).",EXPIRED
69,US,A1,US 2016/0236004 A1,185-299-912-241-367,2016-08-18,2016,US 201615137670 A,2016-04-25,US 201615137670 A;;US 201514688935 A;;US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,LOW FREQUENCY NEUROSTIMULATOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-08-25),https://lens.org/185-299-912-241-367,Patent Application,yes,3,19,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/00;;A61N1/32;;A61N1/36;;A61N2/02;;A61N2/04,,0,0,,,,EXPIRED
70,US,A1,US 2009/0318747 A1,143-139-684-274-733,2009-12-24,2009,US 54930309 A,2009-08-27,US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,Low Frequency Neurostimulator for the Treatment of Neurological Disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,FILTER-PUR LLC (2020-10-27);;ARUENE CORPORATION (2021-01-29);;NEUROPACE INC (2000-08-30),https://lens.org/143-139-684-274-733,Patent Application,yes,55,9,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/04;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02,600/14,0,0,,,,EXPIRED
71,EP,A3,EP 0911061 A3,155-444-696-051-568,1999-11-24,1999,EP 98308716 A,1998-10-26,US 95786997 A,1997-10-27,System for the treatment of neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,,https://lens.org/155-444-696-051-568,Search Report,yes,5,0,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,,0,0,,,,EXPIRED
72,US,A1,US 2007/0016094 A1,096-192-350-198-822,2007-01-18,2007,US 97309104 A,2004-10-25,US 97309104 A;;US 89609201 A,2001-06-28,Seizure sensing and detection using an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in an electrographic signal received from a patient's brain. The features and window-based characteristics are combinable in various ways according to the invention to detect and predict neurological events in real time, enabling responsive action by the implantable device.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2001-06-28),https://lens.org/096-192-350-198-822,Patent Application,yes,27,13,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/04;;A61B5/0476,600/544;;607/45,0,0,,,,EXPIRED
73,US,A1,US 2003/0028072 A1,145-905-524-298-499,2003-02-06,2003,US 24599202 A,2002-09-17,US 24599202 A;;US 65296400 A,2000-08-31,Low frequency magnetic neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-08-25),https://lens.org/145-905-524-298-499,Patent Application,yes,3,330,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02;;A61N2/04,600/13;;600/15,0,0,,,,DISCONTINUED
74,US,A1,US 2010/0331717 A1,151-016-225-329-950,2010-12-30,2010,US 88013810 A,2010-09-12,US 88013810 A;;US 97309104 A;;US 89609201 A,2001-06-28,Seizure Sensing and Detection Using an Implantable Device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in an electrographic signal received from a patient's brain. The features and window-based characteristics are combinable in various ways according to the invention to detect and predict neurological events in real time, enabling responsive action by the implantable device.",NEUROPACE INC,PLESS BENJAMIN D;;ARCHER STEPHEN T;;BAYSINGER CRAIG M;;GIBB BARBARA;;GURUNATHAN SURESH;;KIRKPATRICK BRUCE;;TCHENG THOMAS K,NEUROPACE INC (2001-06-28),https://lens.org/151-016-225-329-950,Patent Application,yes,29,5,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/0476,600/544,0,0,,,,DISCONTINUED
75,US,A1,US 2019/0298211 A1,092-067-892-515-417,2019-10-03,2019,US 201916442424 A,2019-06-14,US 201916442424 A;;US 201715478168 A;;US 201213673312 A;;US 201161558382 P,2011-11-10,MULTIMODAL BRAIN SENSING LEAD,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/092-067-892-515-417,Patent Application,yes,0,0,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61B5/0478;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/04;;A61B5/1455;;A61B5/16;;A61N1/02;;A61N1/05;;A61N1/36,,0,0,,,,ACTIVE
76,US,B2,US 7601116 B2,032-119-597-244-795,2009-10-13,2009,US 43667606 A,2006-05-16,US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,Low frequency magnetic neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,FILTER-PUR LLC (2020-10-27);;ARUENE CORPORATION (2021-01-29);;NEUROPACE INC (2000-08-30),https://lens.org/032-119-597-244-795,Granted Patent,yes,8,53,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/04;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02,600/14;;600/15,8,8,002-610-549-523-468;;068-670-171-691-134;;030-983-039-493-075;;035-990-338-077-706;;134-661-542-323-873;;143-398-932-451-548;;041-461-559-713-466;;025-992-119-710-993,10.1016/0013-4694(85)91075-2;;2408867;;10.1523/jneurosci.15-01-00604.1995;;pmc6578315;;7823167;;9749744;;10.1046/j.1460-9568.1998.00090.x;;10910346;;10.1038/35018000;;10.1152/jn.1998.79.3.1592;;9497437;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;6603358;;10.1111/j.1528-1157.1983.tb04915.x;;10.1177/155005948801900404;;3060288,"Buzsaki, G., et al., ""Depth Profiles of Hippocampal Rhythmic Slow Activity ('theta rhythm') Depend On Behavior,"" Electroencephalogr. Clin. Neurophysiol. 1985; 61: 77-88.;;Contreras, D., et al., ""Cellular Basis of EEG Slow Rhythms: A Study of Dynamic Corticothalamic Relationships,"" J. Neurosci. 1995: 15: 604-622.;;Elger, C., et al., ""Short Communication Seizure Prediction by Non-Linear Time Series Analysis of Brain Electrical Activity,"" European Journal of Neuroscience, vol. 10 (1998), pp. 786-789.;;Hallet, M., ""Transcranial Magnetic Stimulation and the Human Brain,"" Nature 2000; 406: 147-150.;;Leung, LS, et al., ""Theta-Frequency Resonance in Hippocampal CA1 Neurons In Vitro Demonstrated By Sinusoidal Current Injection,"" J. Neurophysiol. 1998; 79: 1592-1596.;;Osorio, I., et al., ""Real-Time Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset,"" Epilepsia 1998; 39: 615-627.;;Psatta, D.M., ""Control of Chronic Experimental Focal Epilepsy By Feedback Caudatum Stimulations,"" Epilepsia 1983; 24: 444-454.;;Staton, R.D., et al., ""The Electroencephalographic Pattern During Electroconvulsive Therapy: V. Observations on the Origin of Phase III Delta Energy and the Mechanism of Action of ECT,"" Clin. Electroencephalogr. 1988; 19: 176-198.",EXPIRED
77,US,B2,US 11026617 B2,010-316-728-368-128,2021-06-08,2021,US 201916442424 A,2019-06-14,US 201916442424 A;;US 201715478168 A;;US 201213673312 A;;US 201161558382 P,2011-11-10,Multimodal brain sensing lead,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/010-316-728-368-128,Granted Patent,yes,59,0,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61B5/291;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/1455;;A61B5/16;;A61B5/316;;A61N1/02;;A61N1/05;;A61N1/36,,0,0,,,,ACTIVE
78,US,A1,US 2015/0217127 A1,109-911-382-763-556,2015-08-06,2015,US 201514688935 A,2015-04-16,US 201514688935 A;;US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,LOW FREQUENCY NEUROSTIMULATOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-08-25),https://lens.org/109-911-382-763-556,Patent Application,yes,1,17,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/02;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/04,,0,0,,,,EXPIRED
79,US,A1,US 2018/0085015 A1,027-517-067-401-231,2018-03-29,2018,US 201715817160 A,2017-11-17,US 201715817160 A;;US 201213539301 A;;US 201161504164 P,2011-07-01,SYSTEMS AND METHODS FOR ASSESSING THE EFFECTIVENESS OF A THERAPY INCLUDING A DRUG REGIMEN USING AN IMPLANTABLE MEDICAL DEVICE,"Systems and methods rely on feedback from an active medical device or devices (e.g., neurostimulator coupled to sensing and stimulation elements such as electrodes) to assess the effectiveness of a patient's drug regimen. Such reliance may include analyzing characteristics in physiological data acquired by the medical device(s), for example, in the form of responses evoked from the patient by electrical stimulation waveforms. Systems and methods further involved adjusting one or more parameters according to which a combination therapy consisting of at least a drug regimen and an electrical stimulation therapy are delivered to a patient, in an effort to optimize the therapeutic effect of the combination. The adjustments may be automatically by one or more implanted or external hosts working together or alone, and/or with the input of a physician.",NEUROPACE INC,CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS,NEUROPACE INC (2012-07-02),https://lens.org/027-517-067-401-231,Patent Application,yes,6,9,6,013-543-225-511-569;;088-148-197-388-452;;027-517-067-401-231;;142-233-704-121-377;;086-034-979-357-994;;112-648-625-812-547,US,6,013-543-225-511-569;;027-517-067-401-231;;086-034-979-357-994;;142-233-704-121-377;;112-648-625-812-547;;088-148-197-388-452,US,0,A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;G16H20/10;;G16H40/63;;G16H50/20;;G16H20/40;;A61B5/24;;A61B5/377;;A61B5/0002;;A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;A61B5/24;;A61B5/377;;A61B5/0031,A61B5/04;;A61B5/00;;A61B5/0484;;A61B5/145;;A61B5/1455,,0,0,,,,ACTIVE
80,WO,A2,WO 2003/001996 A2,000-801-430-461-721,2003-01-09,2003,US 0220630 W,2002-06-28,US 89609201 A,2001-06-28,SEIZURE SENSING AND DETECTION USING AN IMPLANTABLE DEVICE,"A system and method for detecting and predicting neurological events with an implantable device (110) uses a relatively low-power central processing unit (428) in connection with signal processing circuitry (422) to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in an electrographic signal received from a patient's brain. The features and window-based characteristics are combinable in various ways according to the invention to detect and predict neurological events in real time, enabling responsive action by the implantable device.",NEUROPACE INC,PLESS BENJAMIN D;;ARCHER STEPHEN T;;BAYSINGER CRAIG M;;GIBB BARBARA;;GURUNATHAN SURESH K;;KIRKPATRICK BRUCE;;TCHENG THOMAS K,,https://lens.org/000-801-430-461-721,Patent Application,yes,0,0,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/0476,,0,0,,,,PENDING
81,US,B2,US 7813811 B2,044-530-454-860-377,2010-10-12,2010,US 70453407 A,2007-02-08,US 70453407 A,2007-02-08,Refillable reservoir lead systems,"Medical electrical lead systems and related methods are described. The medical electrical lead systems may be configured to be at least partially implanted in a body of a subject. Some variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and a lumen extending at least partially therebetween, at least one electrode in the proximity of the distal end of the lead body, and a reservoir in fluid communication with the lumen, where the reservoir is located at a position removed from the distal end of the lead body. Certain variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and first and second lumens extending at least partially therebetween, and at least one electrode in the proximity of the distal end of the lead body.",NEUROPACE INC,WINGEIER BRETT M;;MORRELL MARTHA J;;BOLING C LANCE,NEUROPACE INC (2007-03-26),https://lens.org/044-530-454-860-377,Granted Patent,yes,60,19,6,044-530-454-860-377;;178-537-703-735-106;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,6,178-537-703-735-106;;044-530-454-860-377;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,0,A61N1/0529;;A61N1/0536;;A61N1/0568;;A61N1/0529;;A61N1/0536;;A61N1/0568,A61N1/00,607/116,12,6,078-011-754-012-619;;125-373-393-924-516;;011-003-220-418-314;;035-504-916-619-225;;017-151-528-619-262;;033-799-424-376-448,10.1097/00007691-200110000-00006;;11591899;;10.1126/science.290.5496.1532;;11090343;;10.1149/1.1393450;;10.1016/0966-7822(94)90032-9;;10.1517/17425247.1.1.37;;16296719;;pmc1361256;;pmc6792642;;9547224;;10.1523/jneurosci.18-09-03158.1998,"Anonymous. (2006). ""Ommaya Reservoir,"" located at , last visited on Sep. 18, 2006, six pages.;;Cavuoto, J. (Jan. 2002). ""Biomaterials Key Factor in Next-Generation Electrodes,"" Neurotech Business Report 2(1):3-5.;;Christensen, J. et al. (Oct. 2001). ""Plasma Concentration of Topiramate Correlates with Cerebrospinal Fluid Concentration,"" Therapeutic Drug Monitoring 23(5):529-535.;;Craighead, H.G. (Nov. 24, 2000). ""Nanoelectromechanical Systems,"" Science 290:1532-1535.;;Doose, D.R. et al. (2002). ""Topiramate: Chemistry, Biotransformation, and Pharmacokinetics,"" Chapter 78, in Antiepileptic Drugs, 5th Edition, Levy, R.H. et al. eds., Lippincott Williams & Wilkins: Philadelphia, PA, pp. 727-734.;;Ghosh, S. et al. (May 2000). ""Electrochemical Characterization of Poly(3,4-ethylene dioxythiophene) Based Conducting Hydrogel Networks,"" J. of the Electrochem. Soc. 147(5):1872-1877.;;Gilmore, K. et al. (1994). ""Preparation of Hydrogel/Conducting Polymer Composites,"" Polymer Gels and Networks 2(2):135-143.;;Martin, D.C. et al. ""Bio-Electronic Implantable Device Coating Applications,"" in White Paper: Bioactive Conducting Polymer Coatings for Biomedical Devices, University of Michigan, four pages. (in internal database as of Aug. 30, 2006).;;Olsen, R.W. (2002). ""Phenobarbital and Other Barbiturates: Mechanisms of Action,"" Chapter 50, in Antiepileptic Drugs , 5th Edition, Levy, R.H. et al. eds., Lippincott Williams & Wilkins: Philadelphia, PA, pp. 489-495.;;Pitt, W.G. et al. (Nov. 2004). ""Ultrasonic Drug Delivery-A General Review,"" Expert Opinion on Drug Delivery 1(1):37-56.;;Rusakov, D.A. et al. (May 1, 1998). ""Extrasynaptic Glutamate Diffusion in the Hippocampus: Ultrastructural Constraints, Uptake, and Receptor Activation,"" The J. of Neurosci. 18(9):3158-3170.;;Non-Final Office Action mailed on Feb. 23, 2010, for U.S. Appl. No. 11/704,549, filed Feb. 8, 2007, fourteen pages.",INACTIVE
82,US,B2,US 7813793 B2,083-643-114-218-287,2010-10-12,2010,US 97309104 A,2004-10-25,US 97309104 A;;US 89609201 A,2001-06-28,Seizure sensing and detection using an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in an electrographic signal received from a patient's brain. The features and window-based characteristics are combinable in various ways according to the invention to detect and predict neurological events in real time, enabling responsive action by the implantable device.",NEUROPACE INC,PLESS BENJAMIN D;;ARCHER STEPHEN T;;BAYSINGER CRAIG M;;GIBB BARBARA;;GURUNATHAN SURESH;;KIRKPATRICK BRUCE;;TCHENG THOMAS K,NEUROPACE INC (2001-06-28),https://lens.org/083-643-114-218-287,Granted Patent,yes,27,2,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/00;;A61B5/0476,600/544,14,5,143-388-558-467-689;;124-403-369-942-149;;032-832-759-355-695;;066-655-225-086-020;;006-634-128-055-848,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;9214791;;10.1109/10.552241;;10.1212/wnl.45.12.2250;;8848202;;10.1109/iembs.2001.1020545,"Gotman, J., Automatic Seizure Detection: Improvements and Evaluation, Electroencephalogr. Clin. Neurophysiol. (1990) 76(4): 317-24.;;Wagner, H. R., et al., Suppression of Cortical Epileptiform Activity By Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol. (1975) 39(5): 499-506.;;H. Qu and J. Gotman, A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use as a Warning Device, IEEE Trans. Biomed. Eng. (1997); 44(2): 115-22.;;H. Qu and J. Gotman, A seizure warning system for long term epilepsy monitoring, Neurology 1995; 45: 2250-4.;;R. Esteller et al. ""Line length: an efficient feature for seizure onset detection"" Proceedings of the 23rd. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 2001 Conference Proceedings. (EMBS). Instanbul, Turkey, Oct. 25-28, 2001; [Annual International Conference of the IEEE Engineering in Medicine and Biology Society. EMBS], vol. 1., p. 1707-1710, XP010594759.;;C. Castellaro et al. ""Improvements in Automatic Detection of Events in Long Term EEG and Polygraphy"" Bollettino-Lega Italiana Contro L'Epilessia, May 13, 1993 Milan, IT vol: 84, pp. 291-301, XP008014892.;;Activa Therapy Overview, http://www.medtronic.com/physicianlactiva/index.html, Jun. 5, 2007.;;Tarver, T. et al., ""An Implantable Neurocybernetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007.;;PCT Application PCT/US02/20630, International Search Report Mailed Jun. 5, 2003.;;Article 96(2) Communication dated Jun. 4, 2004 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Applicant Response dated Mar. 16, 2005 to Article 96(2) Communication dated Jun. 4, 2004 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Article 96(2) Communication dated Oct. 2, 2006 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Applicant Response dated Apr. 26, 2007 to Article 96(2) Communication dated Oct. 2, 2006 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Summons to attend oral proceedings dated Jul. 30, 2008 for counterpart foreign application EP Patent Application No. 02748010.2-1526.",EXPIRED
83,US,A1,US 2016/0228705 A1,169-105-775-673-72X,2016-08-11,2016,US 201615040932 A,2016-02-10,US 201615040932 A;;US 201562114529 P;;US 201562114520 P,2015-02-10,SEIZURE ONSET CLASSIFICATION AND STIMULATION PARAMETER SELECTION,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/169-105-775-673-72X,Patent Application,yes,3,61,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/36;;A61B5/374;;A61N1/05;;A61N1/372,,0,0,,,,ACTIVE
84,CA,A1,CA 2251852 A1,074-009-695-618-339,1999-04-27,1999,CA 2251852 A,1998-10-26,US 95786997 A,1997-10-27,MEANS AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatm ent of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disea se. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that c an be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a respo nse to be generated for stopping the neurological event. The response could be an electric al signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurologica l event can originate from devices either internal or external to the patient. The system al so has the capability for multi-channel recording of EEG related signals that occur both be fore and after the detection of a neurological event. Programmability of many different operating p arameters of the system by means of external equipment provides adaptability for treating pat ients who manifest different symptoms and who respond differently to the response generate d by the system.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M;;FISCHELL ROBERT E,,https://lens.org/074-009-695-618-339,Patent Application,no,0,4,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,,0,0,,,,EXPIRED
85,US,B2,US 11690553 B2,175-675-620-671-158,2023-07-04,2023,US 202117313866 A,2021-05-06,US 202117313866 A;;US 201916442424 A;;US 201715478168 A;;US 201213673312 A;;US 201161558382 P,2011-11-10,Multimodal brain sensing lead,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/175-675-620-671-158,Granted Patent,yes,75,0,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61B5/291;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/1455;;A61B5/16;;A61B5/316;;A61N1/02;;A61N1/05;;A61N1/36,,0,0,,,,ACTIVE
86,US,B2,US 10321866 B2,188-590-973-357-868,2019-06-18,2019,US 201414484605 A,2014-09-12,US 201414484605 A;;US 88013810 A;;US 97309104 A;;US 89609201 A,2001-06-28,Seizure sensing and detection using an implantable device,"Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,PLESS BENJAMIN D;;ARCHER STEPHEN T;;BAYSINGER CRAIG M;;GIBB BARBARA;;GURUNATHAN SURESH;;KIRKPATRICK BRUCE;;TCHENG THOMAS K,NEUROPACE INC (2001-06-28),https://lens.org/188-590-973-357-868,Granted Patent,yes,28,0,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/04;;A61B5/00;;A61B5/0476;;A61B5/0478,,13,5,143-388-558-467-689;;124-403-369-942-149;;032-832-759-355-695;;066-655-225-086-020;;006-634-128-055-848,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;9214791;;10.1109/10.552241;;10.1212/wnl.45.12.2250;;8848202;;10.1109/iembs.2001.1020545,"Article 96(2) Communication dated Jun. 4, 2004 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Applicant Response dated Mar. 16, 2005 to Article 96(2) Communication dated Jun. 4, 2004 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Article 96(2) Communication dated Oct. 2, 2006 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Applicant Response dated Apr. 26, 2007 to Article 96(2) Communication dated Oct. 2, 2006 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Summons to attend oral proceedings dated Jul. 30, 2008 for counterpart foreign application EP Patent Application No. 02748010.2-1526.;;Gotman, J., Automatic Seizure Detection: Improvements and Evaluation, Electroencephalogr. Clin. Neurophysiol. (1990) 76(4): 317-24.;;Wagner, H. R., et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol. (1975) 39(5): 499-506.;;H. Qu and J. Gotman, A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use as a Warning Device, IEEE Trans. Biomed. Eng. (1997); 44(2): 115-22.;;H. Qu and J. Gotman, A seizure warning system for long term epilepsy monitoring, Neurology 1995; 45: 2250-4.;;ESTELLER R., ET AL: ""Line length: an efficient feature for seizure onset detection"", 2001 CONFERENCE PROCEEDINGS OF THE 23RD ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (CAT. NO.01CH37272) VOL.3, IEEE, IEEE PISCATAWAY, NJ, USA, vol. 2, 25 October 2001 (2001-10-25) - 28 October 2001 (2001-10-28), IEEE PISCATAWAY, NJ, USA,, pages 1707 - 1710, XP010594759, ISBN: 978-0-7803-7211-5;;CASTELLARO C, ET AL.: ""EVOLUZIONE DI UN PROGRAMMA PER IL RICONOSCIMENTO AUTOMATICO DEGLI EVENTI NELLE LUNGHE REGISTRAZIONI EEG E POLIGRAFICHE//IMPROVEMENTS IN AUTOMATIC DETECTION OF EVENTS IN LONG TERM EEG AND POLYGRAPHY"", BOLLETTINO - LEGA ITALIANA CONTRO L'EPILESSIA., MILAN., IT, vol. 84, 13 May 1993 (1993-05-13), IT, pages 291 - 301, XP008014892, ISSN: 0394-560X;;ACTIVA Therapy Overview, http:\\www.medtronic.com/physicianlactiva/index.html, Jun. 5, 2007.;;PCT Application PCT/US02/20630, International Search Report dated Jun. 5, 2003.",EXPIRED
87,US,B2,US 6810285 B2,087-193-376-549-772,2004-10-26,2004,US 89609201 A,2001-06-28,US 89609201 A,2001-06-28,Seizure sensing and detection using an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in an electrographic signal received from a patient's brain. The features and window-based characteristics are combinable in various ways according to the invention to detect and predict neurological events in real time, enabling responsive action by the implantable device.",NEUROPACE INC,PLESS BENJAMIN D;;ARCHER STEPHEN T;;BAYSINGER CRAIG M;;GIBB BARBARA;;GURUNATHAN SURESH K;;KIRKPATRICK BRUCE;;TCHENG THOMAS K,NEUROPACE INC. A CORP. OF DELAWARE (2001-06-28),https://lens.org/087-193-376-549-772,Granted Patent,yes,3,284,12,151-016-225-329-950;;140-505-690-223-578;;096-192-350-198-822;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;078-320-802-816-048;;155-521-267-223-516,WO;;EP;;CA;;US,12,155-521-267-223-516;;140-505-690-223-578;;151-016-225-329-950;;189-387-128-786-393;;188-590-973-357-868;;000-801-430-461-721;;087-193-376-549-772;;178-741-249-487-840;;010-508-207-237-663;;083-643-114-218-287;;096-192-350-198-822;;078-320-802-816-048,WO;;EP;;CA;;US,0,A61B5/7242;;A61B5/7275;;A61B5/4094;;A61N1/36064;;A61B5/369;;A61B5/7242;;A61B5/7275;;A61B5/372;;A61B5/293;;A61B5/4094;;A61B5/6868;;A61B5/7203;;A61B5/7246;;A61B5/7264,A61B5/0476,600/544,0,0,,,,EXPIRED
88,US,B2,US 10390721 B2,157-497-414-018-471,2019-08-27,2019,US 201715478168 A,2017-04-03,US 201715478168 A;;US 201213673312 A;;US 201161558382 P,2011-11-10,Multimodal brain sensing lead,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/157-497-414-018-471,Granted Patent,yes,46,1,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61N1/05;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/04;;A61B5/0478;;A61B5/1455;;A61B5/16;;A61N1/02;;A61N1/36,,0,0,,,,ACTIVE
89,US,B2,US 11478642 B2,044-625-297-583-717,2022-10-25,2022,US 201916706136 A,2019-12-06,US 201916706136 A;;US 201816152111 A;;US 201615040932 A;;US 201562114520 P;;US 201562114529 P,2015-02-10,Seizure onset classification and stimulation parameter selection,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/044-625-297-583-717,Granted Patent,yes,67,1,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/36;;A61B5/00;;A61B5/374;;A61N1/05;;A61N1/372,,45,41,057-567-246-168-045;;059-149-073-001-124;;082-274-054-270-018;;040-835-492-690-77X;;056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;011-361-025-719-111;;009-232-618-324-42X;;033-846-106-320-19X;;018-029-109-808-875;;018-206-279-918-107;;040-799-728-524-861;;104-825-678-110-383;;100-520-336-176-718;;023-530-194-293-895;;018-209-093-437-149;;055-646-286-233-553;;021-258-119-628-488;;005-086-907-620-34X;;052-004-551-432-446;;059-118-580-234-908;;024-669-744-597-90X;;021-215-488-132-648;;000-472-633-790-467;;115-843-510-470-535;;010-922-327-567-206;;143-398-932-451-548;;122-301-647-307-402;;036-765-169-783-989;;023-176-465-500-421;;066-816-734-785-465;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;076-895-870-263-38X;;044-097-080-269-237;;048-540-262-662-215;;058-656-369-991-112;;104-848-923-274-640,10.1007/s11263-015-0816-y;;26017442;;10.1038/nature14539;;15940994;;10.1109/tnn.2005.845141;;10.1109/taslp.2018.2798811;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1093/brain/awt299;;24176980;;23280797;;10.1002/ana.23663;;10.3389/fneng.2013.00005;;pmc3717521;;23885239;;10.1111/j.1471-4159.2005.03630.x;;16405497;;7805641;;10.1016/0920-1211(94)90040-x;;10.1016/s1388-2457(00)00402-8;;10996555;;10.1212/wnl.56.11.1453;;11402100;;12489898;;10.1093/sleep/25.8.56;;10.1111/j.1528-1167.2007.01400.x;;18047600;;pmc3703322;;10.1155/2013/932790;;23853720;;4070426;;10.1016/0031-9384(85)90136-2;;pmc6740994;;10.1523/jneurosci.23-34-10897.2003;;14645485;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1016/j.clinph.2008.08.025;;18993113;;pmc4524640;;10.1371/journal.pone.0133900;;26241907;;16099210;;10.1016/j.clinph.2005.06.017;;10.55782/ane-1996-1121;;8787174;;10.1111/j.1528-1167.2008.01881.x;;19054395;;pmc2773143;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;22476713;;10.1007/s11517-012-0904-x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/s0896-6273(01)00262-8;;11343644;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;10.1103/physreve.80.011902;;19658724;;pmc3308339;;22454622;;10.3389/fnhum.2012.00058;;10.1016/j.expneurol.2009.12.010;;pmc3167385;;20026111;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269,"Russakovsky et al., “ImageNet Large Scale Visual Recognition Challenge”, International Journal of Computer Vision, available online Apr. 11, 2015, published Dec. 2015; vol. 115, Issue 3, DOI 10.1007/s11263-015-0816-; pp. 211-252.;;Lecun et al., “Deep Learning”, Nature, May 27, 2015, vol. 521; DOI:10.1038/nature14539; pp. 436-444.;;Xu et al., “Survey of Clustering Algorithms”, IEEE Transactions on Neural Networks, vol. 16, No. 3, May 1, 2005; 35 pages.;;Krizhevsky et al., “ImageNet Classification with Deep Convolutional Neural Networks”, NIPS'12 Proceedings of the 25th International Conference on Neural Information Processing Systems—vol. 1, pp. 1097-1105, Dec. 3, 2012.;;Ling, Zhen-Huia et al. “Waveform Modeling and Generation Using Hierarchical Recurrent Neural Networks for Speech Bandwidth Extension”, IEEE/ACM Transactions on Audio, Speech, and Language Processing, vol. 26, No. 5, pp. 883-894, May 2018.;;Zeiler, Matthew D. et al. “Visualizing and Understanding Convolutional Networks”, ArXiv:1311.2901v3, Nov. 28, 2013, pp. 1-11.;;Ali Hossam Shoeb, and John GuttaAg: “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer, S. S., Guimaraes, P., Katz, A., Kim, J., and Spencer, D.: “Morphological patterns of seizures recorded intracranially,” Epilepsia, 33:537-545 (1992).;;Lee, S. A., Spencer, D. D., and Spencer, S. S.: “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” Epilepsia, 41:297-307 (2000).;;Langan, Y., Nashef, L., and Sander, J. W.: “Case-control study of SUDEP,” Neurology, 64:1131-1133 (2005).;;Bateman, L. M., Li, C. S., Lin, T. C., and Seyal, M.: “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” Epilepsia, 51:2211-2214 (2010).;;Schiller, Y., Cascino, G. D., Busacker, N. E., and Sharbrough, F. W.: “Characterization and comparison of local onset and remote propagated electrographic seizures recorded with intracranial electrodes,” Epilepsia,39:380-388 (1998).;;Perucca, P., Dubeau, F., and Gotman, J.: “Intracranial electroencephalographic seizure-onset patterns: effect of underlying pathology,” Brain Journal of Neurology, 137:183-196 (2014).;;Tass, P. A., Qin, L., Hauptmann, C., Dovero, S., Bezard, E., Boraud, T., and Meissner, W. G.: “Coordinated reset has sustained aftereffects in Parkinsonian monkeys,” Ann. Neurol, 72:816-820 (2012).;;Lysyansky, B., Popovych, O. V., and Tass, P. A.: “Optimal number of stimulation contacts for coordinated reset neuromodulation,” Front Neuroeng.,6:5 (2013).;;Colom, L. V.: “Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease,” J Neurochem., 96:609-623 (2006).;;Miller, J. W., Turner, G. M., and Gray, B. C.: “Anticonvulsant effects of the experimental induction of hippocampal theta activity,” Epilepsy Res., 18:195-204 (1994).;;Crespel, A., Coubes, P., and Baldy-Moulinier, M.: “Sleep influence on seizures and epilepsy effects on sleep in partial frontal and temporal lobe epilepsies,” M. Clin.Neurophysiol.,111 Suppl 2:S54-S59 (2000).;;Herman, S. T., Walczak, T. S., and Bazil, C. W.: “Distribution of partial seizures during the sleep-wake cycle: differences by seizure onset site,” Neurology,56:1453-1459 (2001).;;Minecan, D., Natarajan, A., Marzec, M., and Malow, B.: “Relationship of epileptic seizures to sleep stage and sleep depth,” Sleep,25:899-904 (2002).;;Malow, B. A.: “The interaction between sleep and epilepsy,” Epilepsia, 48 Suppl 9:36-38 (2007).;;Ng, M. and Pavlova: “Why are seizures rare in rapid eye movement sleep? Review of the frequency of seizures in different sleep stages,” M. Epilepsy Res.Treat.,2013:932790 (2013).;;Welsh, D. K., Richardson, G. S., and Dement, W. C.: “A circadian rhythm of hippocampal theta activity in the mouse,” Physiol.Behav, 35:533-538 (1985).;;Cantero, J. L., Atienza, M., Stickgold, R., Kahana, M. J., Madsen, J. R., and Kocsis, B.: “Sleep-dependent theta oscillations in the human hippocampus and neocortex,”, J Neurosci, 23:10897-10903 (2003).;;Soodman, J. H., Berger, R. E., and Tcheng, T. K.: “Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures,” Epilepsia, 46:1-7 (2005).;;Carrington, C. A., Gilby, K. L., and Mcintyre, D. C.: “Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains,” Epilepsia, 48:1604-1613 (2007).;;Chan, A. M., Sun, F. T., Boto, E. H., and Wingeier, B. M.: “Automated seizure onset detection for accurate onset time determination in intracranial EEG,” Clin.Neurophysiol., 119:2687-2696 (2008).;;Brinkmann, B. H., Patterson, E. E., Vite, C., Vasoli, V. M., Crepeau, D., Stead, M., Howbert, J. J., Cherkassky, V., Wagenaar, J. B., Litt, B., and Worrell, G. A.: “Forecasting Seizures Using Intracranial EEG Measures and SVM in Naturally Occurring Canine Epilepsy,” G. A. PLoS.One.,10:e0133900 (2015).;;Van Putten, M. J., Kind, T., Visser, F., and Lagerburg, V.: “Detecting temporal lobe seizures from scalp EEG recordings: a comparison of various features,” Clin.Neurophysiol.,116:2480-2489 (2005).;;Wackermann, J.: “Beyond mapping: estimating complexity of multichannel EEG recordings,” Acta Neurobiol.Exp. (Wars.), 56:197-208 (1996).;;Ogren, Jennifer A., Bragin, Anatol, Wilson, Charles L., Hoftman, Gil D., Lin, Jack J., Dutton, Rebecca A., Fields, Tony A., Toga, Arthur W., Thompson, Paul M., Engel, Jr., Jerome, Staba, Richard J.: “Three-dimensional hippocampal atrophy maps distinguish two common temporal lobe seizure-onset patterns,” Epilepsia, 50(6):1361-1370 (2009).;;Ivan Osorio, Mark G. Frei and Steven B. Wilkinson: “Real-Time Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset”, Epilepsia, 39(6):615-627 (1998).;;Lojini Logesparan, Alexander J. Casson and Esther Rodrigufz-Villegas: “Optimal features for online seizure detection”, Medical & Biological Engineering & Computing, 50.7 (2012): 659-669, and Supplementary Material relating to article.;;Ali Hossam Shoeb: Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard-MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;Maryann D'Alessandro, George Vachtsevanos, Rosana Esteller, Javier Echauz, Stephen Cranstoun, Greg Worrell, Landi Parish and Brian Litt: “A multi-feature and multi-channel univariate selection process for seizure prediction”, Clinical Neurophysiology 116 (2005) 506-516.;;Isa Conradsen, Student Member; IEEE, Sándor Beniczky, Karsten Hoppe, Peter Wolf and Helge B. D. Sorensen Member, IEEE: “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection based on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions@ieee.org.;;Brian Litt, Rosana Esteiler, Javier Echauz, Maryann D'Alessandro, Rachel Shor, Thomas Henry, Page Pennell, Charles Epstein, Roy Bakay, Marc Dichter, and George Vachtsevanos: “Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients”, Neuron, vol. 30, 51-64, Apr. 2001.;;Alaa Kharbouch, Ali Shoeb, John Guttag, and Sydney S. Cash: “An algorithm for seizure onset detection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Yusuf U Khan, Omar Farooq and Priyanka Sharma: “Automatic Detection of Seizure Onset in Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Yizhuo Zhang, Guanghua Xu, Jing Wang, Lin Liang: “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899.;;P. A. Tass, A. N. Silchenko, C. Hauptmann, U. B. Barnikol, and E.-J Speckmann: “Long-lasting desynchronization in rat hippocampal slice induced by coordinated reset stimulation”, Physical Review F 80, 011902 (2009).;;Oleksandr V. Popovych and Peter A. Tass: “Desynchronizing Electrical and Sensory Coordinated Reset Neuromodulation”, Frontiers in Human Neuroscience, Mar. 20, 2012, vol. 6, Article 58.;;Antonio García-Hernández, Brian H. Bland, Julio Facelli, and C. Luis V. Colom: “Septo-hippocampal networks in chronic epilepsy”, EAT Neurol. Mar. 2010; 222(1): 86-92.;;A.J. Gabor, R.R. Leach, and F.U. Dowla: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;A.J. Gabor: “Automated Seizure Detection Using a Self-Organizing Neural Network, Validation and Comparison with Other Detection Strategies”, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.",ACTIVE
90,US,B2,US 10130813 B2,195-657-317-579-881,2018-11-20,2018,US 201615040932 A,2016-02-10,US 201615040932 A;;US 201562114529 P;;US 201562114520 P,2015-02-10,Seizure onset classification and stimulation parameter selection,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/195-657-317-579-881,Granted Patent,yes,62,4,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/00;;A61B5/00;;A61B5/374;;A61N1/05;;A61N1/36;;A61N1/372,,39,37,056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;011-361-025-719-111;;009-232-618-324-42X;;033-846-106-320-19X;;018-029-109-808-875;;018-206-279-918-107;;040-799-728-524-861;;104-825-678-110-383;;100-520-336-176-718;;023-530-194-293-895;;018-209-093-437-149;;055-646-286-233-553;;021-258-119-628-488;;005-086-907-620-34X;;052-004-551-432-446;;059-118-580-234-908;;024-669-744-597-90X;;021-215-488-132-648;;000-472-633-790-467;;115-843-510-470-535;;010-922-327-567-206;;143-398-932-451-548;;122-301-647-307-402;;036-765-169-783-989;;023-176-465-500-421;;066-816-734-785-465;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;076-895-870-263-38X;;044-097-080-269-237;;048-540-262-662-215;;058-656-369-991-112;;104-848-923-274-640,1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1093/brain/awt299;;24176980;;23280797;;10.1002/ana.23663;;10.3389/fneng.2013.00005;;pmc3717521;;23885239;;10.1111/j.1471-4159.2005.03630.x;;16405497;;7805641;;10.1016/0920-1211(94)90040-x;;10.1016/s1388-2457(00)00402-8;;10996555;;10.1212/wnl.56.11.1453;;11402100;;12489898;;10.1093/sleep/25.8.56;;10.1111/j.1528-1167.2007.01400.x;;18047600;;pmc3703322;;10.1155/2013/932790;;23853720;;4070426;;10.1016/0031-9384(85)90136-2;;pmc6740994;;10.1523/jneurosci.23-34-10897.2003;;14645485;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1016/j.clinph.2008.08.025;;18993113;;pmc4524640;;10.1371/journal.pone.0133900;;26241907;;16099210;;10.1016/j.clinph.2005.06.017;;10.55782/ane-1996-1121;;8787174;;10.1111/j.1528-1167.2008.01881.x;;19054395;;pmc2773143;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;22476713;;10.1007/s11517-012-0904-x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/s0896-6273(01)00262-8;;11343644;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;10.1103/physreve.80.011902;;19658724;;pmc3308339;;22454622;;10.3389/fnhum.2012.00058;;10.1016/j.expneurol.2009.12.010;;pmc3167385;;20026111;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269,"Ali Hossam Shoeb, and John Guttag: “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer, S. S., Guimaraes, P., Katz, A., Kim, J., and Spencer, D: “Morphological patterns of seizures recorded intracranially,” Epilepsia, 33:537-545 (1992).;;Lee, S. A., Spencer, D. D., and Spencer, S. S.: “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” Epilepsia, 41:297-307 (2000).;;Langan, Y., Nashef, L., and Sander, J. W.: “Case-control study of SUDEP,” Neurology, 64:1131-1133 (2005).;;Bateman, L. M., Li, C. S., Lin, T. C., and Seyal, M: “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” Epilepsia, 51:2211-2214 (2010).;;Schiller, Y., Cascino, G. D., Busacker, N. E, and Sharbrough, F. W.: “Characterization and comparison of local onset and remote propagated electrographic seizures recorded with intracranial electrodes,” Epilepsia,39:380-388 (1998).;;Perucca, P., Dubeau, F., and Gotman, J: “Intracranial electroencephalographic seizure-onset patterns: effect of underlying pathology,” Brain Journal of Neurology, 137:183-196 (2014).;;Tass, P. A., Qin, L., Hauptmann, C., Dovero, S., Bezard, E., Boraud, T., and Meissner, W. G.: “Coordinated reset has sustained aftereffects in Parkinsonian monkeys,” Ann. Neural, 72:816-820 (2012).;;Lysyansky, B., Popovych, O. V., and Tass, P. A.: “Optimal number of stimulation contacts for coordinated reset neuromodulation,” Front Neuroeng.,6:5 (2013).;;Colom, L. V.: “Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease,” J Neurochem., 96:609-623 (2006).;;Miller, J. W., Turner, G. M., and Gray, B. C.: “Anticonvulsant effects of the experimental induction of hippocampal theta activity,” Epilepsy Res.,18:195-204 (1994).;;Crespel, A., Coubes, P., and Baldy-Moulinier, M.: “Sleep influence on seizures and epilepsy effects on sleep in partial frontal and temporal lobe epilepsies,” M. Clin.Neurophysiol.,111 Suppl 2:S54-S59 (2000).;;Herman, S. T., Walczak, T. S., and Bazil, C. W.: “Distribution of partial seizures during the sleep—wake cycle: differences by seizure onset site,” Neurology,56:1453-1459 (2001).;;Minecan, D., Natarajan, A., Marzec, M., and Malow, B.: “Relationship of epileptic seizures to sleep stage and sleep depth,” Sleep,25:899-904 (2002).;;Malow, B. A.: “The interaction between sleep and epilepsy,” Epilepsia, 48 Suppl 9:36-38 (2007).;;NG, M. and Pavlova: “Why are seizures rare in rapid eye movement sleep? Review of the frequency of seizures in different sleep stages,” M. Epilepsy Res. Treat.,2013:932790 (2013).;;Welsh, D. K., Richardson, G. S., and Dement, W. C.: “A circadian rhythm of hippocampal theta activity in the mouse,” Physiol.Behav, 35:533-538 (1985).;;Cantero, J. L., Atienza, M., Stickgold, R., Kahana, M. J., Madsen, J. R., and Kocsis, B.: “Sleep-dependent theta oscillations in the human hippocampus and neocortex,”, J Neurosci, 23:10897-10903 (2003).;;Goodman, J. H., Berger, R. E., and Tcheng, T. K.: “Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures,” Epilepsia, 46:1-7 (2005).;;Carrington, C. A., Gilby, K. L., and McIntyre, D. C.: “Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains,” Epilepsia, 48:1604-1613 (2007).;;Chan, A. M Sun, F. T., Boto, E. H., and Wingeier, B. M.: “Automated seizure onset detection for accurate onset time determination in intracranial EEG,” Clin.Neurophysiol.,119:2687-2696 (2008).;;Brinkmann, B. H., Patterson, E. E., Vite, C., Vasoli, V. M., Crepeau, D., Stead, M., Howbert, J. J., Cherkassky, V., Wagenaar, J. B., Litt, B., and Worrell, G. A.: “Forecasting Seizures Using Intracranial EEG Measures and SVM in Naturally Occurring Canine Epilepsy,” G. A. PLoS.One.,10:e0133900 (2015).;;Van Putten, M. J., Kind, T., Visser, F., and Lagerburg, V.: “Detecting temporal lobe seizures from scalp EEG recordings: a comparison of various features,” Clin.Neurophysiol.,116:2480-2489 (2005).;;Wackermann, J.: “Beyond mapping: estimating complexity of multichannel EEG recordings,” Acta Neurobiol.Exp. (Wars.), 56:197-208 (1996).;;Ogren, Jennifer A., Bragin, Anatol, Wilson, Charles L., Hoftman, Gil D., Lin, Jack J., Dutton, Rebecca A., Fields, Tony A., Toga, Arthur W., Thompson, Paul M., Engel, Jr., Jerome, Staba, Richard J.: “Three-dimensional hippocampal atrophy maps distinguish two common temporal lobe seizure—onset patterns,” Epilepsia, 50(6):1361-1370 (2009).;;Ivan Osorio, Mark G. Frei and Steven B. Wilkinson: “Real-Time Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset”, Epilepsia, 39(6):615-627 (1998).;;Lojini Logesparan, Alexander J. Casson and Esther Rodriguez-Villegas: “Optimal features for online seizure detection”, Medical & Biological Engineering & Computing, 50.7 (2012): 659-669, and Supplementary Material relating to article.;;Ali Hossam Shoeb: Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard-MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;Maryann D'Alessandro, George Vachtsevanos, Rosana Esteller, Javier Echauz, Stephen Cranstoun, Greg Worrell, Landi Parish and Brian Litt: “A multi-feature and multi-channel univariate selection process for seizure prediction”, Clinical Neurophysiology 116 (2005) 506-516.;;ISA Conradsen, Student Member; IEEE, Sándor Beniczky, Karsten Hoppe, Peter Wolf and Helge B. D. Sorensen Member, IEEE: “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection based on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions@ieee.org.;;Brian Litt, Rosana Esteiler, Javier Echauz, Maryann D'Alessandro, Rachel Shor, Thomas Henry,' Page Pennell, Charles Epstein, Roy Bakay, Marc Dichter, and George Vachtsevanos: “Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients”, Neuron, vol. 30, 51-64, Apr. 2001.;;Alaa Kharbouch, Ali Shoes, John Guttag, and Sydney S. Cash: “An algorithm for seizure onset Detection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Yusuf U Khan, Omar Farooq and Priyanka Sharma: “Automatic Detection of Seizure Onset in Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Yizhuo Zhang, Guanghua Xu, Jing Wang, Lin Liang: “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899.;;P. A. Tass, A. N. Silchenko, C. Hauptmann, U. B. Barnikol, and E.-J Speckmann: “Long-lasting desynchronization in rat hippocampal slice induced by coordinated reset stimulation”, Physical Review F 80, 011902 (2009).;;Oleksandr V. Popovych and Peter A. Tass: “Desynchronizing Electrical and Sensory Coordinated Reset Neuromodulation”, Frontiers in Human Neuroscience, Mar. 20, 2012, vol. 6, Article 58.;;Antonio García-Hernández, Brian H. Bland, Julio Facelli, and C. Luis V. Colom: “Septo-hippocampal networks in chronic epilepsy”, EAT Neurol. Mar. 2010; 222(1): 86-92.;;A.J. Gabor, R.R. Leach, and F.U. Dowla: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;A.J. Gabor: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Validation and Comparison with Other Detection Strategies, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.",ACTIVE
91,US,A1,US 2010/0210964 A1,020-336-202-344-288,2010-08-19,2010,US 77064310 A,2010-04-29,US 77064310 A;;US 37170106 A,2006-03-08,IMPLANTABLE SEIZURE MONITOR,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/020-336-202-344-288,Patent Application,yes,29,1,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544,0,0,,,,ACTIVE
92,US,B2,US 10543368 B2,163-939-465-406-83X,2020-01-28,2020,US 201816152111 A,2018-10-04,US 201816152111 A;;US 201615040932 A;;US 201562114529 P;;US 201562114520 P,2015-02-10,Seizure onset classification and stimulation parameter selection,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/163-939-465-406-83X,Granted Patent,yes,62,1,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/00;;A61B5/00;;A61B5/374;;A61N1/05;;A61N1/36;;A61N1/372,,39,37,056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;011-361-025-719-111;;009-232-618-324-42X;;033-846-106-320-19X;;018-029-109-808-875;;018-206-279-918-107;;040-799-728-524-861;;104-825-678-110-383;;100-520-336-176-718;;023-530-194-293-895;;018-209-093-437-149;;055-646-286-233-553;;021-258-119-628-488;;005-086-907-620-34X;;052-004-551-432-446;;059-118-580-234-908;;024-669-744-597-90X;;021-215-488-132-648;;000-472-633-790-467;;115-843-510-470-535;;010-922-327-567-206;;143-398-932-451-548;;122-301-647-307-402;;036-765-169-783-989;;023-176-465-500-421;;066-816-734-785-465;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;076-895-870-263-38X;;044-097-080-269-237;;048-540-262-662-215;;058-656-369-991-112;;104-848-923-274-640,1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1093/brain/awt299;;24176980;;23280797;;10.1002/ana.23663;;10.3389/fneng.2013.00005;;pmc3717521;;23885239;;10.1111/j.1471-4159.2005.03630.x;;16405497;;7805641;;10.1016/0920-1211(94)90040-x;;10.1016/s1388-2457(00)00402-8;;10996555;;10.1212/wnl.56.11.1453;;11402100;;12489898;;10.1093/sleep/25.8.56;;10.1111/j.1528-1167.2007.01400.x;;18047600;;pmc3703322;;10.1155/2013/932790;;23853720;;4070426;;10.1016/0031-9384(85)90136-2;;pmc6740994;;10.1523/jneurosci.23-34-10897.2003;;14645485;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1016/j.clinph.2008.08.025;;18993113;;pmc4524640;;10.1371/journal.pone.0133900;;26241907;;16099210;;10.1016/j.clinph.2005.06.017;;10.55782/ane-1996-1121;;8787174;;10.1111/j.1528-1167.2008.01881.x;;19054395;;pmc2773143;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;22476713;;10.1007/s11517-012-0904-x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/s0896-6273(01)00262-8;;11343644;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;10.1103/physreve.80.011902;;19658724;;pmc3308339;;22454622;;10.3389/fnhum.2012.00058;;10.1016/j.expneurol.2009.12.010;;pmc3167385;;20026111;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269,"Ali Hossam Shoeb, and John Guttag: “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer, S. S., Guimaraes, P., Katz, A., Kim, J., and Spencer, D.: “Morphological patterns of seizures recorded intracranially,” Epilepsia, 33:537-545 (1992).;;Lee, S. A., Spencer, D. D., and Spencer, S. S.: “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” Epilepsia, 41:297-307 (2000).;;Langan, Y., Nashef, L., and Sander, J. W.: “Case-control study of SUDEP,” Neurology, 64:1131-1133 (2005).;;Bateman, L. M., Li, C. S., Lin, T. C., and Seyal, M: “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” Epilepsia, 51:2211-2214 (2010).;;Schiller, Y., Cascino, G. D., Busacker, N. E., and Sharbrough, F. W.: “Characterization and comparison of local onset and remote propagated electrographic seizures recorded with intracranial electrodes,” Epilepsia,39:380-388 (1998).;;Perucca, P., Dubeau, F., and Gotman, J: “Intracranial electroencephalographic seizure-onset patterns: effect of underlying pathology,” Brain Journal of Neurology, 137:183-196 (2014).;;Tass, P. A., Qin, L., Hauptmann, C., Dovero, S., Bezard, E., Boraud, T., and Meissner, W. G.: “Coordinated reset has sustained aftereffects in Parkinsonian monkeys,” Ann. Neurol, 72:816-820 (2012).;;Lysyansky, B., Popovych, O. V., and Tass, P. A.: “Optimal number of stimulation contacts for coordinated reset neuromodulation,” Front Neuroeng.,6:5 (2013).;;Colom, L. V.: “Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease,” J Neurochem., 96:609-623 (2006).;;Miller, J. W., Turner, G. M., and Gray, B. C.: “Anticonvulsant effects of the experimental induction of hippocampal theta activity,” Epilepsy Res.,18:195-204 (1994).;;Crespel A. Coubes, P., and Baldy-Moulinier, M.: “Sleep influence on seizures and epilepsy effects on sleep in partial frontal and temporal lobe epilepsies,” M. Clin.Neurophysiol.,111 Suppl 2:S54-S59 (2000).;;Herman, S. T., Walczak, T. S., and Bazil, C. W.: “Distribution of partial seizures during the sleep—wake cycle: differences by seizure onset site,” Neurology,56:1453-1459 (2001).;;Minecan, D., Natarajan, A., Marzec, M., and Malow, B.: “Relationship of epileptic seizures to sleep stage and sleep depth,” Sleep,25:899-904 (2002).;;Malow, B. A.: “The interaction between sleep and epilepsy,” Epilepsia, 48 Suppl 9:36-38 (2007).;;Ng, M. and Pavlova: “Why are seizures rare in rapid eye movement sleep? Review of the frequency of seizures in different sleep stages,” M. Epilepsy Res.Treat.,2013:932790 (2013).;;Welsh, D. K., Richardson, G. S., and Dement, W. C.: “A circadian rhythm of hippocampal theta activity in the mouse,” Physiol.Behav, 35:533-538 (1985).;;Cantero, J. L., Atienza, M., Stickgold, R., Kahana, M. J., Madsen, J. R., and Kocsis, B.: “Sleep-dependent theta oscillations in the human hippocampus and neocortex,”, J Neurosci, 23:10897-10903 (2003).;;Goodman, J. H., Berger, R. E., and Tcheng, T. K.: “Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures,” Epilepsia, 46:1-7 (2005).;;Carrington, C. A., Gilby, K. L., and McIntyre, D. C.: “Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains,” Epilepsia, 48:1604-1613 (2007).;;Chan, A. M., Sun, F. T., Boto, E. H., and Wingeier, B. M.: “Automated seizure onset detection for accurate onset time determination in intracranial EEG,” Clin.Neurophysiol.,119:2687-2696 (2008).;;Brinkmann, B. H., Patterson, E. E., Vite, C., Vasoli, V. M., Crepeau, D., Stead, M., Howbert, J. J., Cherkassky, V., Wagenaar, J. B., Litt, B., and Worrell, G. A.: “Forecasting Seizures Using Intracranial EEG Measures and SVM in Naturally Occurring Canine Epilepsy,” G. A. PLoS.One.,10:e0133900 (2015).;;Van Putten, M. J., Kind, T., Visser, F., and Lagerburg, V.: “Detecting temporal lobe seizures from scalp EEG recordings: a comparison of various features,” Clin.Neurophysiol.,116:2480-2489 (2005).;;Wackermann, J.: “Beyond mapping: estimating complexity of multichannel EEG recordings,” Acta Neurobiol.Exp. (Wars.), 56:197-208 (1996).;;Ogren, Jennifer A., Bragin, Anatol, Wilson, Charles L., Hoftman, Gil D., Lin, Jack J., Dutton, Rebecca A., Fields, Tony A., Toga, Arthur W., Thompson, Paul M., Engel, Jr., Jerome, Staba, Richard J: “Three-dimensional hippocampal atrophy maps distinguish two common temporal lobe seizure—onset patterns,” Epilepsia, 50(6):1361-1370 (2009).;;Ivan Osorio, Mark G. Frei and Steven B. Wilkinson: “Real-Time Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset”, Epilepsia, 39(6):615-627 (1998).;;lojini Logesparan, Alexander J. Casson and Esther Rodriguez-Villegas: “Optimal features for online seizure detection”, Medical & Biological Engineering & Computing, 50.7 (2012): 659-669, and Supplementary Material relating to article.;;Ali Hossam Shoeb: Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard-MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;Maryann D'Alessandro, George Vachtsevanos, Rosana Esteller, Javier Echauz, Stephen Cranstoun, Greg Worrell, Landi Parish and Brian Litt: “A multi-feature and multi-channel univariate selection process for seizure prediction”, Clinical Neurophysiology 116 (2005) 506-516.;;Isa Conradsen, Student Member; IEEE, Sándor Beniczky, Karsten Hoppe, Peter Wolf and Helge B. D. Sorensen Member, IEEE: “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection based on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions@ieee.org.;;Brian Litt, Rosana Esteiler, Javier Echauz, Maryann D'Alessandro, Rachel Shor, Thomas Henry Page Pennell, Charles Epstein, Roy Bakay, Marc Dichter, and George Vachtsevanos: “Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients”, Neuron, vol. 30, 51-64, Apr. 2001.;;Alaa Kharbouch, Ali Shoeb, John Guttag, and Sydney S. Cash: “An algorithm for seizure onset detection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Yusuf U Khan, Omar Farooq and Priyanka Sharma: “Automatic Detection of Seizure Onset in Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Yizhuo Zhang, Guanghua Xu, Jing Wang, Lin Liang: “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899.;;P. A. Tass, A. N. Silchenko, C. Hauptmann, U. B. Barnikol, and E.-J Speckmann: “Long-lasting desynchronization in rat hippocampal slice induced by coordinated reset stimulation”, Physical Review F 80, 011902 (2009).;;Oleksandr V. Popovych and Peter A. Tass: “Desynchronizing Electrical and Sensory Coordinated Reset Neuromodulation”, Frontiers in Human Neuroscience, Mar. 20, 2012, vol. 6, Article 58.;;Antonio García-Hernández, Brian H. Bland, Julio Facelli, and C. Luis V. Colom: “Septo-hippocampal networks in chronic epilepsy”, EAT Neurol. Mar. 2010; 222(1): 86-92.;;A.J. Gabor, R.R. Leach, and F.U. Dowla: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;A.J. Gabor: “Automated Seizure Detection Using a Self-Organizing Neural Network, Validation and Comparison with Other Detection Strategies”, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.",ACTIVE
93,US,A1,US 2023/0019572 A1,152-057-332-365-006,2023-01-19,2023,US 202217946888 A,2022-09-16,US 202217946888 A;;US 201916706136 A;;US 201816152111 A;;US 201615040932 A;;US 201562114529 P;;US 201562114520 P,2015-02-10,SEIZURE ONSET CLASSIFICATION AND STIMULATION PARAMETER SELECTION,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/152-057-332-365-006,Patent Application,yes,0,0,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/36;;A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
94,US,B2,US 11064926 B2,086-034-979-357-994,2021-07-20,2021,US 201715817160 A,2017-11-17,US 201715817160 A;;US 201213539301 A;;US 201161504164 P,2011-07-01,Systems and methods for assessing the effectiveness of a therapy including a drug regimen using an implantable medical device,"Systems and methods rely on feedback from an active medical device or devices (e.g., neurostimulator coupled to sensing and stimulation elements such as electrodes) to assess the effectiveness of a patient's drug regimen. Such reliance may include analyzing characteristics in physiological data acquired by the medical device(s), for example, in the form of responses evoked from the patient by electrical stimulation waveforms. Systems and methods further involved adjusting one or more parameters according to which a combination therapy consisting of at least a drug regimen and an electrical stimulation therapy are delivered to a patient, in an effort to optimize the therapeutic effect of the combination. The adjustments may be automatically by one or more implanted or external hosts working together or alone, and/or with the input of a physician.",NEUROPACE INC,CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS,NEUROPACE INC (2012-07-02),https://lens.org/086-034-979-357-994,Granted Patent,yes,84,0,6,013-543-225-511-569;;088-148-197-388-452;;027-517-067-401-231;;142-233-704-121-377;;086-034-979-357-994;;112-648-625-812-547,US,6,013-543-225-511-569;;027-517-067-401-231;;086-034-979-357-994;;142-233-704-121-377;;112-648-625-812-547;;088-148-197-388-452,US,0,A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;G16H20/10;;G16H40/63;;G16H50/20;;G16H20/40;;A61B5/24;;A61B5/377;;A61B5/0002;;A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;A61B5/24;;A61B5/377;;A61B5/0031,A61B5/00;;A61B5/145;;A61B5/1455;;A61B5/24;;A61B5/377,,84,79,021-343-643-658-663;;089-141-020-769-019;;111-927-111-780-264;;063-265-586-811-555;;035-743-258-200-462;;033-926-973-714-322;;014-220-313-033-616;;050-079-405-736-293;;039-764-221-708-009;;082-777-980-851-860;;028-379-703-376-932;;032-459-228-604-768;;091-439-344-250-153;;003-840-997-893-470;;013-758-453-301-350;;088-470-528-825-06X;;068-271-385-421-027;;048-716-516-978-823;;180-907-315-878-217;;008-899-678-494-817;;058-507-299-973-568;;161-642-479-871-61X;;024-493-928-366-528;;098-836-301-361-033;;026-550-980-573-429;;018-769-436-346-405;;011-127-685-846-057;;086-189-746-679-569;;087-366-366-471-863;;108-413-138-372-248;;009-942-057-817-414;;054-935-153-904-493;;078-155-881-977-731;;054-199-899-081-726;;120-220-554-504-426;;009-508-767-594-137;;027-274-714-311-512;;009-801-313-950-996;;086-332-837-014-131;;045-057-161-610-230;;071-436-185-436-516;;037-450-223-496-711;;059-118-580-234-908;;114-829-580-772-11X;;055-543-632-831-264;;017-287-425-621-215;;028-133-278-688-002;;035-640-232-996-720;;014-048-491-459-642;;040-419-788-229-410;;037-778-125-628-978;;045-906-950-685-693;;024-701-648-275-81X;;079-153-022-224-958;;078-383-690-818-361;;113-491-096-155-820;;045-313-415-627-674;;032-584-602-403-660;;076-603-155-673-139;;001-076-554-468-404;;055-830-876-793-93X;;027-671-333-824-532;;071-923-571-385-057;;104-114-776-004-620;;009-531-689-113-806;;052-004-551-432-446;;043-434-594-857-202;;020-753-507-641-248;;100-592-562-354-327;;037-937-861-281-488;;091-346-342-395-751;;018-000-981-167-661;;034-048-504-919-763;;073-391-713-720-091;;007-199-691-580-812;;011-111-613-221-078;;009-489-023-634-262;;100-005-053-904-205;;104-457-091-225-177,17414976;;10.1097/wnp.0b013e31803991c3;;10.2165/11204490-000000000-00000;;21395360;;10.1111/j.1528-1157.1979.tb04846.x;;115675;;10.1016/j.eplepsyres.2007.05.003;;17576049;;10.1097/01.wco.0000218233.60217.84;;16538091;;10.1055/s-2002-36645;;12528050;;10.1212/wnl.0b013e3182302056;;21917777;;10.1046/j.1528-1157.2003.26302.x;;12558576;;10.1056/nejmp058102;;15901856;;15967089;;10.1007/s11940-005-0036-9;;10.1097/00004691-200111000-00004;;11779967;;10.1111/j.1528-1167.2009.02231.x;;19187291;;10.1111/j.1528-1167.2008.02007.x;;19702729;;19682045;;10.1111/j.1528-1167.2009.02213.x;;10.1142/s0129065711002730;;21442778;;14642995;;10.1016/j.eplepsyres.2003.10.001;;10.1212/wnl.35.10.1406;;3929158;;10.1016/j.apmr.2007.05.025;;18164349;;10.1006/exnr.2002.7869;;11922662;;pmc2169898;;9436738;;10.1136/jnnp.64.1.108;;10.1152/jn.00514.2006;;17151229;;10.1016/j.eplepsyres.2004.07.004;;10.1016/s0920-1211(04)00121-4;;15380563;;11045433;;10768292;;10.1111/j.1528-1157.2000.tb02163.x;;10.1016/s1474-4422(02)00163-1;;12849399;;10.1212/01.wnl.0000098937.35486.a3;;14694029;;2080382;;10.1159/000100190;;10.1212/01.wnl.0000209300.49308.8f;;16554495;;10.1016/0920-1211(89)90029-6;;2731520;;10.2176/nmc.50.355;;20505288;;10.1006/exnr.2001.7830;;11771947;;15987261;;10.1111/j.1528-1167.2005.01016.x;;10.1016/s0006-8993(98)00723-9;;9739139;;10.1111/j.1528-1167.2007.01038.x;;17381435;;12027909;;10.1046/j.1528-1157.2002.29001.x;;10.1016/j.neuroscience.2007.02.014;;17412517;;14725968;;10.1016/j.brainres.2003.11.010;;10.1016/0306-4522(91)90380-7;;1716744;;10.1523/jneurosci.17-23-09308.1997;;pmc6573610;;9364076;;10.1001/archneur.59.12.1905;;12470178;;10714408;;10.1111/j.1528-1157.2000.tb00166.x;;10.1111/j.1469-7793.2001.0181j.x;;pmc2278457;;11179402;;10.1111/j.1528-1167.2007.01005.x;;17726798;;10.1046/j.1528-1157.43.s.5.22.x;;12121300;;10.1056/nejm199601183340308;;8531974;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1111/j.1528-1157.1991.tb05533.x;;1743148;;13877492;;10.3171/jns.1962.19.2.0122;;10.1682/jrrd.2008.09.0130;;20104398;;10.1159/000099878;;9711758;;18550176;;pmc2518220;;10.1016/j.jneumeth.2008.04.019;;10.1093/brain/awh337;;pmc2696356;;15563512;;16898260;;11074793;;10.1001/archneur.57.11.1611;;pmc1573268;;10.1038/sj.bjp.0704606;;11906955;;10.1113/jphysiol.1994.sp020381;;7869266;;pmc1155826;;12790886;;10.1046/j.1528-1157.2003.48202.x;;20331461;;10.1111/j.1528-1167.2010.02536.x;;10489023;;10.1212/wnl.53.4.666;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;10899202;;10.1152/jn.2000.84.1.274;;10.1016/j.neulet.2007.08.023;;17868994;;15270763;;10.1111/j.0013-9580.2004.42203.x;;10.1046/j.1528-1157.2002.18101.x;;11952764;;10.1152/jn.1996.76.6.4202;;8985916;;10.1523/jneurosci.21-02-00590.2001;;pmc6763796;;11160438;;10.1007/978-1-4757-6376-8_17;;15250598;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1016/b978-012373961-2.00244-7;;14683557;;10.1227/01.neu.0000097552.31763.ae;;10.1016/j.eplepsyres.2007.09.010;;18083005;;10.1016/0006-8993(90)91601-c;;1705855;;114000;;7760143;;10.1152/jn.1995.73.2.876;;pmc1302649;;10.1016/s0006-3495(03)74888-7;;12524321;;10.1111/j.0013-9580.2004.60203.x;;15230703;;10.1016/j.clinph.2005.02.010;;15978492;;15571514;;10.1111/j.0013-9580.2004.26104.x;;10.1056/nejm200002033420503;;10660394;;10599784;;10.1212/wnl.53.9.2073;;18075945,"Li Y, Mogul DJ. “Electrical control of epileptic seizures”. J Clin Neurophysiol 2007; 24: 197-204.;;Lyseng-Williamson KA. “Levetiracetam: a review of its use in epilepsy”. Drugs 2011; 71: 489-514.;;Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. “Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals”. Epilepsia 1979; 20: 623-633.;;Mohammad-Zadeh M, Mirnajafi-Zadeh J, Fathollahi Y et al. “Effect of low frequency stimulation of perforant path on kindling rate and synaptic transmission in the dentate gyrus during kindling acquisition in rats”. Epilepsy Res. 2007; 75: 154-161.;;Morrell M. “Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures?”. Curr. Opin.Neurol. 2006; 19: 164-168.;;Morrell MJ. “Antiepileptic medications for the treatment of epilepsy”. Semin.Neurol. 2002; 22: 247-258.;;Morrell MJ. “Responsive cortical stimulation for the treatment of medically intractable partial epilepsy”. Neurology 2011; 77: 1295-1304.;;Motamedi M, Nguyen DK, Zaatreh M et al. “Levetiracetam efficacy in refractory partial-onset seizures, especially after failed epilepsy surgery”. Epilepsia 2003; 44: 211-214.;;Okie S. “Traumatic brain injury in the war zone”. N.Engl.J Med 2005; 352: 2043-2047.;;Oommen J, Morrell M, Fisher RS. “Experimental Electrical Stimulation Therapy for Epilepsy”. Curr.Treat. Options.Neurol. 2005; 7: 261-271.;;Penfield W, Jasper H. Electrocorticography. Epilepsy and the Functional Anatomy of the Human Brain. Boston: Little, Brown, 1954: 692-738.;;Peters TE, Bhavaraju NC, Frei MG, Osorio I. “Network system for automated seizure detection and contingent delivery of therapy”. J.Clin.Neurophysiol. 2001; 18: 545-549.;;Pitkanen A, Immonen RJ, Grohn OH, Kharatishvili I. “From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options”. Epilepsia 2009; 50 Suppl 2: 21-29.;;Rajdev P, Ward M, Irazoqui P. “Effect of stimulus parameters in the treatment of seizures by electrical stimulation in the kainate animal model”. Int J Neural Syst. 2011; 21: 151-162.;;Ryvlin P, Kahane P. “Does epilepsy surgery lower the mortality of drug-resistant epilepsy?”. Epilepsy Res. 2003; 56: 105-120.;;Salazar AM, Jabbari B, Vance SC, Grafman J, Amin D, Dillon JD. “Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study”. Neurology 1985; 35: 1406-1414.;;Sayer NA, Chiros CE, Sigford B et al. “Characteristics and rehabilitation outcomes among patients with blast and other injuries sustained during the Global War on Terror”. Arch Phys.Med Rehabil. 2008; 89: 163-170.;;Scharfman HE, Goodman JH, Sollas AL, Croll SD. “Spontaneous limbic seizures after intrahippocampal Infusion of brain-derived neurotrophic factor”. Exp.Neurol. 2002; 174: 201-214.;;Schierhout G, Roberts I. “Prophylactic antiepileptic agents after head injury: a systematic review”. J Neurol.Neurosurg.Psychiatry 1998; 64: 108-112.;;Schiller Y, Bankirer Y. “Cellular mechanisms underlying antiepileptic effects of low- and high-frequency electrical stimulation in acute epilepsy in neocortical brain slices in vitro”. J Neurophysiol. 2007; 97: 1887-1902.;;Schmidt D, Baumgartner C, Loscher W. “The chance of cure following surgery for drug-resistant temporal lobe epilepsy. What do we know and do we need to revise our expectations?”. Epilepsy Res. 2004; 60:187-201.;;Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. “An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action”. Epilepsia 2000; 41 Suppl 1: S3-S9.;;Spencer SS. “When should temporal-lobe epilepsy be treated surgically?”. Lancet Neurol. 2002; 1: 375-382.;;Spencer SS, Berg AT, Vickrey BG et al. “Initial outcomes in the Multicenter Study of Epilepsy Surgery”. Neurology 2003; 61: 1680-1685.;;Sramka M, Chkhenkeli SA. “Clinical experience in intraoperational determination of brain inhibitory structures and application of implanted neurostimulators in epilepsy”. Stereotact.Funct.Neurosurg 1990; 54-55: 56-59.;;Tellez-Zentano JF, McLachlan RS, Parrent A, Kubu CS, Wiebe S. “Hippocampal electrical stimulation in mesial temporal lobe epilepsy”. Neurology, Published online before print Mar. 22, 2006.;;Ullal GR, Ninchoji T, Uemura K. “Low frequency stimulation induces an increase in after-discharge thresholds in hippocampal and amygdaloid kindling”. Epilepsy Res. 1989; 3: 232-235.;;Urino T, Hashizume K, Maehara M et al. “Epileptic focus stimulation and seizure control in the rat model of kainic acid-induced limbic seizures”. Neurol.Med Chir (Tokyo) 2010; 50: 355-360.;;Velisek L, Veliskova J, Moshe SL. “Electrical stimulation of substantia nigra pars reticulata is anticonvulsant in adult and young male rats”. Exp.Neurol. 2002; 173: 145-152.;;Vonck K, Boon P, Claeys P, Dedeurwaerdere S, Achten R, Van Roost D. “Long-term deep brain stimulation for refractory temporal lobe epilepsy”. Epilepsia 2005; 46 Suppl 5: 98-99.;;Warren RJ, Durand DM. “Effects of applied currents on spontaneous epileptiform activity induced by low calcium in the rat hippocampus”. Brain Res. 1998; 806: 186-195.;;Wyckhuys T, De ST, Claeys P et al. “High frequency deep brain stimulation in the hippocampus modifies seizure characteristics in kindled rats”. Epilepsia 2007; 48: 1543-1550.;;Yamamoto J, Ikeda A, Satow T et al. “Low-frequency electric cortical stimulation has an inhibitory effect on epileptic focus in mesial temporal lobe epilepsy”. Epilepsia 2002; 43: 491-495.;;Zhu-Ge ZB, Zhu YY, Wu DC et al. “Unilateral low-frequency stimulation of central piriform cortex inhibits amygdaloid-kindled seizures in Sprague-Dawley rats”. Neuroscience 2007; 146: 901-906.;;Albensi BC, Ata G, Schmidt E, Waterman JD, Janigro D. “Activation of long-term synaptic plasticity causes suppression of epileptiform activity in rat hippocampal slices”. Brain Res. 2004; 998: 56-64.;;Babb TL, Kupfer WR, Pretorius JK, Crandall PH, Levesque MF. “Synaptic reorganization by mossy fibers in human epileptic fascia dentata”. Neuroscience 1991; 42: 351-363.;;Barbarosie M, Avoli M. “CA3-driven hippocampal-entorhinal loop controls rather than sustains in vitro limbic seizures”. J Neurosci. 1997; 17: 9308-9314.;;Bazil CW, Rose A, Resor S, Yapicular B, Hirsch LJ. “Levetiracetam may be more effective for late-onset partial epilepsy”. Arch Neurol. 2002; 59: 1905-1908.;;Begley CE, Famulari M, Annegers JF et al. “The cost of epilepsy in the United States: an estimate from population-based clinical and survey data”. Epilepsia 2000; 41: 342-351.;;Bikson M, Lian J, Hahn PJ, Stacey WC, Sciortino C, Durand DM. “Suppression of epileptiform activity by high frequency sinusoidal fields in rat hippocampal slices”. J Physiol 2001; 531: 181-191.;;Boon P, Vonck K, De Herdt, V et al. “Deep brain stimulation in patients with refractory temporal lobe epilepsy”. Epilepsia 2007; 48: 1551-1560.;;Bragin A, Wilson CL, Engel J, JR. “Rate of interictal events and spontaneous seizures in epileptic rats after electrical stimulation of hippocampus and its afferents”. Epilepsia 2002; 43 Suppl 5: 81-85.;;Brodie MJ, Dichter MA “Antiepileptic drugs”. N.Engl.J Med 1996; 334: 168-175.;;Carrington CA, Gilby KL, McIntyre DC. “Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains”. Epilepsia 2007; 48: 1604-1613.;;Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L. “Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures”. Epilepsia 1991; 32: 778-782.Brodie MJ, Dichter MA. “Antiepileptic drugs”. N.Engl.J Med 1996; 334: 168-175.;;Caveness WF, Walker AE, Ascroft PB. “Incidence of posttraumatic epilepsy in Korean veterans as compared with those from World War I and World War II”. J Neurosurg. 1962; 19: 122-129.;;Chen JW, Ruff RL, Eavey R, Wasterlain CG. “Posttraumatic epilepsy and treatment”. J Rehabil.Res.Dev. 2009; 46: 685-696.;;Chkhenkeli SA, Chkhenkeli IS. “Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy”. Stereotact.Funct.Neurosurg. 1997; 69: 221-224.;;Curia G, Longo D, Biagini G, Jones RS, Avoli M. “The pilocarpine model of temporal lobe epilepsy”. J Neurosci.Methods 2008; 172: 143-157.;;D'Ambrosio R, Fender JS, Fairbanks JP et al. “Progression from frontal-parietal to mesial-temporal epilepsy after fluid percussion injury in the rat”. Brain 2005; 128: 174-188.;;Dedeurwaerdere S, Vonck K, De Herdt, V et al. “Neuromodulation with levetiracetam and vagus nerve stimulationin experimental animal models of epilepsy”. Acta Neurol.Belg. 2006; 106: 91-97.;;Diaz-Arrastia R, Agostini MA, Frol AB et al. “Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults”. Arch Neurol. 2000; 57: 1611-1616.;;Doheny HC, Whittington MA, Jefferys JG, Patsalos PN. “A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy”. Br.J Pharmacol. 2002; 135: 1425-1434.;;Durand DM, Warman EN. “Desynchronization of epileptiform activity by extracellular current pulses in rat hippocampal slices”. J.Physiol 1994; 480 ( Pt 3): 527-537.;;Engel J, JR., Wiebe S, French J et al. “Practice parameter: temporal lobe and localized neocortical resections for epilepsy”. Epilepsia 2003; 44: 741-751.;;Fisher R, Salanova V, Witt T et al. “Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy”. Epilepsia 2010.;;Fisher RS, Handforth A. “Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology”. Neurology 1999; 53: 666-669.;;Gaito J, Nobrega JN, Gaito ST. “Interference effect of 3 Hz brain stimulation on kindling behavior induced by 60 Hz stimulation”. Epilepsia 1980; 21: 73-84.;;Gaito J. “The effect of variable duration one hertz interference on kindling”. Can.J.Neurol.Sci. 1980; 7: 59-64.;;Ghai RS, Bikson M, Durand DM. “Effects of applied electric fields on low-calcium epileptiform activity in the CA1 region of rat hippocampal slices”. J.Neurophysiol. 2000; 84: 274-280.;;Ghorbani P, Mohammad-Zadeh M, Mirnajafi-Zadeh J, Fathollahi Y. “Effect of different patterns of low-frequency stimulation on piriform cortex kindled seizures”. Neurosci.Lett. 2007; 425: 162-166.;;Gleissner U, Helmstaedter C, Schramm J, Elger CE “Memory outcome after selective amygdalohippocampectomy in patients with temporal lobe epilepsy: one-year follow-up”. Epilepsia 2004; 45: 960-962.;;Glien M, Brandt C, Potschka H, Loscher W. “Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe Epilepsy”. Epilepsia 2002; 43: 350-357.;;Gluckman BJ, Neel EJ, Netoff TI, Ditto WL, Spano ML, Schiff SJ. “Electric field suppression of epileptiform activity in hippocampal slices”. J.Neurophysiol. 1996; 76: 4202-4205.;;Gluckman BJ, Nguyen H, Weinstein SL, Schiff SJ. “Adaptive electric field control of epileptic seizures”. J. Neurosci. 2001; 21: 590-600.;;Goodman J. Experimental Models of Status Epilepticus. In: Peterson SL, Albertson TE, editors. Neuropharmacology Methods in Epilepsy Research. New York: CRC Press, 1998: 95-125.;;Goodman JH. “Brain stimulation as a therapy for epilepsy”. Adv.Exp.Med.Biol. 2004; 548: 239-247.;;Goodman JH, Berger RE, Tcheng TK. “Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures”. Epilepsia 2005; 46: 1-7.;;Goodman, J. H., Schon, J. P., Phani, S., and Zucker, J. R. Postictal Low Freqeunecy Sine Wave Stimulation Decreases the Incidence of Kindled Seizures. Epilepsia 2005; 46(s8): 104-105.;;Goodman JH. Deep Brain and Peripheral Nerve Stimulation as Potential Therapies for Epilepsy. In: Schwartzkroin PA, editor. Encyclopedia of Basic Epilepsy Research, vol. 3. Oxford: Academic Press, 2009: 1421-6.;;Hamani C, Ewerton FI, Bonilha SM, Ballester G, Mello LE, Lozano AM. “Bilateral anterior thalamic nucleus lesions and high-frequency stimulation are protective against pilocarpine-induced seizures and status epilepticus”. Neurosurgery 2004; 54: 191-195.;;Hamani C, Hodaie M, Chiang J et al. “Deep brain stimulation of the anterior nucleus of the thalamus: effects of electrical stimulation on pilocarpine-induced seizures and status epilepticus”. Epilepsy Res. 2008; 78: 117-123.;;Houser CR. “Granule cell dispersion in the dentate gyrus of humans with temporal lobe epilepsy”. Brain Res. 1990; 535: 195-204.;;Jennett B. “Posttraumatic epilepsy”. Adv.Neurol. 1979; 22: 137-147.;;Jerger K, Schiff SJ. “Periodic pacing an in vitro epileptic focus”. J.Neurophysiol. 1995; 73: 876-879.;;Kano, T., D'Antuono, M., De Guzman, P., Benini, R., and Avoli, M. Low-Frequency Stimulation of the Amygdala Inhibits Ictogenesis in the Perirhinal Cortex. Epilepsia 2002; 43(s7): 129-130.;;Khosravani H, Carlen PL, Velazquez JL. “The control of seizure-like activity in the rat hippocampal slice”. Biophys.J 2003; 84: 687-695.;;Kinoshita M, Ikeda A, Matsumoto R et al. “Electric stimulation on human cortex suppresses fast cortical activity and epileptic spikes”. Epilepsia 2004; 45: 787-791.;;Kinoshita M, Ikeda A, Matsuhashi M et al. “Electric cortical stimulation suppresses epileptic and background activities in neocortical epilepsy and mesial temporal lobe epilepsy”. Clin Neurophysiol 2005; 116: 1291-1299.;;Kossoff EH, Ritzl EK, Politsky JM et al. “Effect of an External Responsive Neurostimulator on Seizures and Electrographic Discharges during Subdural Electrode Monitoring”. Epilepsia 2004; 45: 1560-1567.;;Krauss GL, Fisher RS. Cerebellar and thalamic stimulation for epilepsy In: Devinsky O, Beric A, Dogali M, editors. Electrical and Magnetic Stimulation of the Brain and Spinal Cord. New York: Raven Press, 1993: 231-45.;;Kwan P, Brodie MJ. “Early identification of refractory epilepsy”. N.Engl.J.Med 2000; 342: 314-319.;;Lesser RP, Kim SH, Beyderman L et al. “Brief bursts of pulse stimulation terminate afterdischarges caused by cortical stimulation”. Neurology 1999; 53: 2073-2081.;;Lew HL, Cifu DX, Sigford B, Scott S, Sayer N, Jaffee MS. “Team approach to diagnosis and management of traumatic brain injury and its comorbidities”. J Rehabil.Res.Dev. 2007; 44: vii-vxi.",ACTIVE
95,US,A1,US 2017/0238832 A1,009-142-224-430-298,2017-08-24,2017,US 201715478168 A,2017-04-03,US 201715478168 A;;US 201213673312 A;;US 201161558382 P,2011-11-10,MULTIMODAL BRAIN SENSING LEAD,"A medical lead with at least a distal portion thereof implantable in the brain of a patient is described, together with methods and systems for using the lead. The lead is provided with at least two sensing modalities (e.g., two or more sensing modalities for measurements of field potential measurements, neuronal single unit activity, neuronal multi unit activity, optical blood volume, optical blood oxygenation, voltammetry and rheoencephalography). Acquisition of measurements and the lead components and other components for accomplishing a measurement in each modality are also described as are various applications for the multimodal brain sensing lead.",NEUROPACE INC,TCHENG THOMAS K,NEUROPACE INC (2012-11-12),https://lens.org/009-142-224-430-298,Patent Application,yes,0,3,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,8,092-067-892-515-417;;010-316-728-368-128;;175-675-620-671-158;;157-497-414-018-471;;014-819-362-714-574;;180-888-327-041-982;;009-142-224-430-298;;046-846-458-039-598,US,0,A61B5/6868;;A61B5/0031;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/291;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/7278;;A61B2562/046;;A61B2562/063;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36139;;A61B5/291;;A61B5/0006;;A61B5/0031;;A61B5/0205;;A61B5/0261;;A61B5/14553;;A61B5/165;;A61B5/316;;A61B5/4082;;A61B5/4094;;A61B5/4839;;A61B5/6868;;A61B5/7278;;A61B2562/0209;;A61B2562/028;;A61B2562/0285;;A61B2562/046;;A61B2562/063;;A61N1/025;;A61N1/0531;;A61N1/0534;;A61N1/36064;;A61N1/36067;;A61N1/36082;;A61N1/36132;;A61N1/36139,A61B5/0478;;A61B5/00;;A61B5/0205;;A61B5/026;;A61B5/04;;A61B5/1455;;A61B5/16;;A61N1/02;;A61N1/05;;A61N1/36,,0,0,,,,ACTIVE
96,US,B1,US 6529774 B1,164-775-950-940-866,2003-03-04,2003,US 71166300 A,2000-11-09,US 71166300 A,2000-11-09,"Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation","This is directed to a neurostimulator assembly that is preferably implantable and is suitable for treating epilepsy and other neurological disorders. The assembly includes inventive leads that are suitable both for providing electrical somatosensory stimulation, extradurally applied, as well as electrical stimulation that is applied to the central nervous system. The leads are preferably also suitable for sensing electrical signals in the brain. The invention includes processes of using the neurostimulator and its leads. The neurostimulator may independently provide a variety of different electrical stimulation, e.g., non-responsive electrical stimulation signals applied to the central nervous system to reduce the likelihood of a seizure or other undesirable neurological even from occurring, electrical stimulation signals applied to the central nervous system when the neurostimulator determines that epileptiform waveforms are impending or extant, and extradural electrical somatosensory stimulation signals. The responsive electrical stimulation signal or signals are intended to terminate epileptiform activity, e.g., to desynchronize abnormally synchronous brain electrical activity.",NEUROPACE INC,GREENE DAVID A,NEUROPACE INC (2001-03-30),https://lens.org/164-775-950-940-866,Granted Patent,yes,102,372,1,164-775-950-940-866,US,1,164-775-950-940-866,US,0,A61N1/0529;;A61N1/0534;;A61N1/0553;;A61B5/7217;;A61B5/4094;;A61B5/24;;A61B5/291;;A61N1/0529;;A61N1/0553;;A61N1/0534;;A61B5/7217;;A61B5/4094;;A61B5/293,A61B5/04;;A61B5/0478;;A61N1/05,600/545;;600/378;;607/45;;607/116,15,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"Andriano, K.P. et al. (1994). ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants,"" Journal of Applied Biomaterials 5: 133-140.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Acticity of Brain Activity o Brain in Patients woth Intractable Epilepsey,"" Stereotact Funct Neurosurg 69:221-224.;;Cooper, I.S. et al. (1974). ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" In The Cerebellum, Epilepsy, and Behavior. Cooper, I.S. et al., eds., Plenum Press:New York, pp.119-171.;;Cooper, I.S. et al. (1977/78). ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. 40:124-134.;;Cooper, I.S. and Upon, A.R.M. (1978). ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992). ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosung. 58:200-208.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery 3(4):190-196.;;Gerlach, K.L. (1993). ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials 13:21-28.;;Gotman, J. (1999). ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology 16(2):130-140.;;Osorio, I. et al (1995). ""Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia36(supplement 4):4, Abstract No. 1.04.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology 45:2250-2254.;;Salyer. K.E. et al. (1994). ""A Comparative Study of theEffects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Recostructive Surgery 93(4):705-713.;;Schiff, S.J. et al. (1994). ""Controlling Chaos in the Brain,"" Nature 370:615-620.;;Thaller, S.R. et al. (1992). ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery 2(4):168-173.;;Velasco, F. et al. (1995). ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia 36(1):63-71.",EXPIRED
97,US,A1,US 2011/0004116 A1,156-743-098-228-868,2011-01-06,2011,US 77069710 A,2010-04-29,US 77069710 A;;US 37170106 A,2006-03-08,Implantable Seizure Monitor,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/156-743-098-228-868,Patent Application,yes,29,0,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544,0,0,,,,ACTIVE
98,US,A1,US 2020/0108253 A1,115-712-516-132-131,2020-04-09,2020,US 201916706136 A,2019-12-06,US 201916706136 A;;US 201816152111 A;;US 201615040932 A;;US 201562114520 P;;US 201562114529 P,2015-02-10,SEIZURE ONSET CLASSIFICATION AND STIMULATION PARAMETER SELECTION,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/115-712-516-132-131,Patent Application,yes,0,6,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/36;;A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
99,US,A1,US 2019/0030337 A1,174-658-387-490-877,2019-01-31,2019,US 201816152111 A,2018-10-04,US 201816152111 A;;US 201615040932 A;;US 201562114529 P;;US 201562114520 P,2015-02-10,SEIZURE ONSET CLASSIFICATION AND STIMULATION PARAMETER SELECTION,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/174-658-387-490-877,Patent Application,yes,0,1,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/36;;A61B5/00;;A61B5/374;;A61N1/05;;A61N1/372,,0,0,,,,ACTIVE
100,US,B2,US 12029581 B2,013-543-225-511-569,2024-07-09,2024,US 202117346944 A,2021-06-14,US 202117346944 A;;US 201715817160 A;;US 201213539301 A;;US 201161504164 P,2011-07-01,Systems and methods for assessing the effectiveness of a therapy including a drug regimen using an implantable medical device,"Systems and methods rely on feedback from an active medical device or devices (e.g., neurostimulator coupled to sensing and stimulation elements such as electrodes) to assess the effectiveness of a patient's drug regimen. Such reliance may include analyzing characteristics in physiological data acquired by the medical device(s), for example, in the form of responses evoked from the patient by electrical stimulation waveforms. Systems and methods further involved adjusting one or more parameters according to which a combination therapy consisting of at least a drug regimen and an electrical stimulation therapy are delivered to a patient, in an effort to optimize the therapeutic effect of the combination. The adjustments may be automatically by one or more implanted or external hosts working together or alone, and/or with the input of a physician.",NEUROPACE INC,CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS,NEUROPACE INC (2012-07-02),https://lens.org/013-543-225-511-569,Granted Patent,yes,93,0,6,013-543-225-511-569;;088-148-197-388-452;;027-517-067-401-231;;142-233-704-121-377;;086-034-979-357-994;;112-648-625-812-547,US,6,013-543-225-511-569;;027-517-067-401-231;;086-034-979-357-994;;142-233-704-121-377;;112-648-625-812-547;;088-148-197-388-452,US,0,A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;G16H20/10;;G16H40/63;;G16H50/20;;G16H20/40;;A61B5/24;;A61B5/377;;A61B5/0002;;A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;A61B5/24;;A61B5/377;;A61B5/0031,A61B5/00;;A61B5/145;;A61B5/1455;;A61B5/24;;A61B5/377,,84,79,021-343-643-658-663;;089-141-020-769-019;;111-927-111-780-264;;063-265-586-811-555;;035-743-258-200-462;;033-926-973-714-322;;014-220-313-033-616;;050-079-405-736-293;;039-764-221-708-009;;082-777-980-851-860;;028-379-703-376-932;;032-459-228-604-768;;091-439-344-250-153;;003-840-997-893-470;;013-758-453-301-350;;088-470-528-825-06X;;068-271-385-421-027;;048-716-516-978-823;;180-907-315-878-217;;008-899-678-494-817;;058-507-299-973-568;;161-642-479-871-61X;;024-493-928-366-528;;098-836-301-361-033;;026-550-980-573-429;;018-769-436-346-405;;011-127-685-846-057;;086-189-746-679-569;;087-366-366-471-863;;108-413-138-372-248;;009-942-057-817-414;;054-935-153-904-493;;078-155-881-977-731;;054-199-899-081-726;;120-220-554-504-426;;009-508-767-594-137;;027-274-714-311-512;;009-801-313-950-996;;086-332-837-014-131;;045-057-161-610-230;;071-436-185-436-516;;037-450-223-496-711;;059-118-580-234-908;;114-829-580-772-11X;;055-543-632-831-264;;017-287-425-621-215;;028-133-278-688-002;;035-640-232-996-720;;014-048-491-459-642;;040-419-788-229-410;;037-778-125-628-978;;045-906-950-685-693;;024-701-648-275-81X;;079-153-022-224-958;;078-383-690-818-361;;113-491-096-155-820;;045-313-415-627-674;;032-584-602-403-660;;076-603-155-673-139;;001-076-554-468-404;;055-830-876-793-93X;;027-671-333-824-532;;071-923-571-385-057;;104-114-776-004-620;;009-531-689-113-806;;052-004-551-432-446;;043-434-594-857-202;;020-753-507-641-248;;100-592-562-354-327;;037-937-861-281-488;;091-346-342-395-751;;018-000-981-167-661;;034-048-504-919-763;;073-391-713-720-091;;007-199-691-580-812;;011-111-613-221-078;;009-489-023-634-262;;100-005-053-904-205;;104-457-091-225-177,17414976;;10.1097/wnp.0b013e31803991c3;;10.2165/11204490-000000000-00000;;21395360;;10.1111/j.1528-1157.1979.tb04846.x;;115675;;10.1016/j.eplepsyres.2007.05.003;;17576049;;10.1097/01.wco.0000218233.60217.84;;16538091;;10.1055/s-2002-36645;;12528050;;10.1212/wnl.0b013e3182302056;;21917777;;10.1046/j.1528-1157.2003.26302.x;;12558576;;10.1056/nejmp058102;;15901856;;15967089;;10.1007/s11940-005-0036-9;;10.1097/00004691-200111000-00004;;11779967;;10.1111/j.1528-1167.2009.02231.x;;19187291;;10.1111/j.1528-1167.2008.02007.x;;19702729;;19682045;;10.1111/j.1528-1167.2009.02213.x;;10.1142/s0129065711002730;;21442778;;14642995;;10.1016/j.eplepsyres.2003.10.001;;10.1212/wnl.35.10.1406;;3929158;;10.1016/j.apmr.2007.05.025;;18164349;;10.1006/exnr.2002.7869;;11922662;;pmc2169898;;9436738;;10.1136/jnnp.64.1.108;;10.1152/jn.00514.2006;;17151229;;10.1016/j.eplepsyres.2004.07.004;;10.1016/s0920-1211(04)00121-4;;15380563;;11045433;;10768292;;10.1111/j.1528-1157.2000.tb02163.x;;10.1016/s1474-4422(02)00163-1;;12849399;;10.1212/01.wnl.0000098937.35486.a3;;14694029;;2080382;;10.1159/000100190;;10.1212/01.wnl.0000209300.49308.8f;;16554495;;10.1016/0920-1211(89)90029-6;;2731520;;10.2176/nmc.50.355;;20505288;;10.1006/exnr.2001.7830;;11771947;;15987261;;10.1111/j.1528-1167.2005.01016.x;;10.1016/s0006-8993(98)00723-9;;9739139;;10.1111/j.1528-1167.2007.01038.x;;17381435;;12027909;;10.1046/j.1528-1157.2002.29001.x;;10.1016/j.neuroscience.2007.02.014;;17412517;;14725968;;10.1016/j.brainres.2003.11.010;;10.1016/0306-4522(91)90380-7;;1716744;;10.1523/jneurosci.17-23-09308.1997;;pmc6573610;;9364076;;10.1001/archneur.59.12.1905;;12470178;;10714408;;10.1111/j.1528-1157.2000.tb00166.x;;10.1111/j.1469-7793.2001.0181j.x;;pmc2278457;;11179402;;10.1111/j.1528-1167.2007.01005.x;;17726798;;10.1046/j.1528-1157.43.s.5.22.x;;12121300;;10.1056/nejm199601183340308;;8531974;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1111/j.1528-1157.1991.tb05533.x;;1743148;;13877492;;10.3171/jns.1962.19.2.0122;;10.1682/jrrd.2008.09.0130;;20104398;;10.1159/000099878;;9711758;;18550176;;pmc2518220;;10.1016/j.jneumeth.2008.04.019;;10.1093/brain/awh337;;pmc2696356;;15563512;;16898260;;11074793;;10.1001/archneur.57.11.1611;;pmc1573268;;10.1038/sj.bjp.0704606;;11906955;;10.1113/jphysiol.1994.sp020381;;7869266;;pmc1155826;;12790886;;10.1046/j.1528-1157.2003.48202.x;;20331461;;10.1111/j.1528-1167.2010.02536.x;;10489023;;10.1212/wnl.53.4.666;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;10899202;;10.1152/jn.2000.84.1.274;;10.1016/j.neulet.2007.08.023;;17868994;;15270763;;10.1111/j.0013-9580.2004.42203.x;;10.1046/j.1528-1157.2002.18101.x;;11952764;;10.1152/jn.1996.76.6.4202;;8985916;;10.1523/jneurosci.21-02-00590.2001;;pmc6763796;;11160438;;10.1007/978-1-4757-6376-8_17;;15250598;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1016/b978-012373961-2.00244-7;;14683557;;10.1227/01.neu.0000097552.31763.ae;;10.1016/j.eplepsyres.2007.09.010;;18083005;;10.1016/0006-8993(90)91601-c;;1705855;;114000;;7760143;;10.1152/jn.1995.73.2.876;;pmc1302649;;10.1016/s0006-3495(03)74888-7;;12524321;;10.1111/j.0013-9580.2004.60203.x;;15230703;;10.1016/j.clinph.2005.02.010;;15978492;;15571514;;10.1111/j.0013-9580.2004.26104.x;;10.1056/nejm200002033420503;;10660394;;10599784;;10.1212/wnl.53.9.2073;;18075945,"Li Y, Mogul DJ. “Electrical control of epileptic seizures”. J Clin Neurophysiol 2007; 24: 197-204.;;Lyseng-Williamson KA. “Levetiracetam: a review of its use in epilepsy”. Drugs 2011; 71: 489-514.;;Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. “Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals”. Epilepsia 1979; 20: 623-633.;;Mohammad-Zadeh M, Mirnajafi-Zadeh J, Fathollahi Y et al. “Effect of low frequency stimulation of perforant path on kindling rate and synaptic transmission in the dentate gyrus during kindling acquisition in rats”. Epilepsy Res. 2007; 75: 154-161.;;Morrell M. “Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures?”. Curr. Opin.Neurol. 2006; 19: 164-168.;;Morrell MJ. “Antiepileptic medications for the treatment of epilepsy”. Semin.Neurol. 2002; 22: 247-258.;;Morrell MJ. “Responsive cortical stimulation for the treatment of medically intractable partial epilepsy”. Neurology 2011; 77: 1295-1304.;;Motamedi M, Nguyen DK, Zaatreh M et al. “Levetiracetam efficacy in refractory partial-onset seizures, especially after failed epilepsy surgery”. Epilepsia 2003; 44: 211-214.;;Okie S. “Traumatic brain injury in the war zone”. N.Engl.J Med 2005; 352: 2043-2047.;;Oommen J, Morrell M, Fisher RS. “Experimental Electrical Stimulation Therapy for Epilepsy”. Curr.Treat. Options.Neurol. 2005; 7: 261-271.;;Penfield W, Jasper H. Electrocorticography. Epilepsy and the Functional Anatomy of the Human Brain. Boston: Little, Brown, 1954: 692-738.;;Peters TE, Bhavaraju NC, Frei MG, Osorio I. “Network system for automated seizure detection and contingent delivery of therapy”. J.Clin.Neurophysiol. 2001; 18: 545-549.;;Pitkanen A, Immonen RJ, Grohn OH, Kharatishvili I. “From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options”. Epilepsia 2009; 50 Suppl 2: 21-29.;;Rajdev P, Ward M, Irazoqui P. “Effect of stimulus parameters in the treatment of seizures by electrical stimulation in the kainate animal model”. Int J Neural Syst. 2011; 21: 151-162.;;Ryvlin P, Kahane P. “Does epilepsy surgery lower the mortality of drug-resistant epilepsy?”. Epilepsy Res. 2003; 56: 105-120.;;Salazar AM, Jabbari B, Vance SC, Grafman J, Amin D, Dillon JD. “Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study”. Neurology 1985; 35: 1406-1414.;;Sayer NA, Chiros CE, Sigford B et al. “Characteristics and rehabilitation outcomes among patients with blast and other injuries sustained during the Global War on Terror”. Arch Phys.Med Rehabil. 2008; 89: 163-170.;;Scharfman HE, Goodman JH, Sollas AL, Croll SD. “Spontaneous limbic seizures after intrahippocampal Infusion of brain-derived neurotrophic factor”. Exp.Neurol. 2002; 174: 201-214.;;Schierhout G, Roberts I. “Prophylactic antiepileptic agents after head injury: a systematic review”. J Neurol.Neurosurg.Psychiatry 1998; 64: 108-112.;;Schiller Y, Bankirer Y. “Cellular mechanisms underlying antiepileptic effects of low- and high-frequency electrical stimulation in acute epilepsy in neocortical brain slices in vitro”. J Neurophysiol. 2007; 97: 1887-1902.;;Schmidt D, Baumgartner C, Loscher W. “The chance of cure following surgery for drug-resistant temporal lobe epilepsy. What do we know and do we need to revise our expectations?”. Epilepsy Res. 2004; 60:187-201.;;Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. “An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action”. Epilepsia 2000; 41 Suppl 1: S3-S9.;;Spencer SS. “When should temporal-lobe epilepsy be treated surgically48 ”. Lancet Neurol. 2002; 1: 375-382.;;Spencer SS, Berg AT, Vickrey BG et al. “Initial outcomes in the Multicenter Study of Epilepsy Surgery”. Neurology 2003; 61: 1680-1685.;;Sramka M, Chkhenkeli SA. “Clinical experience in intraoperational determination of brain inhibitory structures and application of implanted neurostimulators in epilepsy”. Stereotact.Funct.Neurosurg 1990; 54-55: 56-59.;;Tellez-Zentano JF, McLachlan RS, Parrent A, Kubu CS, Wiebe S. “Hippocampal electrical stimulation in mesial temporal lobe epilepsy”. Neurology, Published online before print Mar. 22, 2006.;;Ullal GR, Ninchoji T, Uemura K. “Low frequency stimulation induces an increase in after-discharge thresholds in hippocampal and amygdaloid kindling”. Epilepsy Res. 1989; 3: 232-235.;;Urino T, Hashizume K, Maehara M et al. “Epileptic focus stimulation and seizure control in the rat model of kainic acid-induced limbic seizures”. Neurol.Med Chir (Tokyo) 2010; 50: 355-360.;;Velisek L, Veliskova J, Moshe SL. “Electrical stimulation of substantia nigra pars reticulata is anticonvulsant in adult and young male rats”. Exp.Neurol. 2002; 173: 145-152.;;Vonck K, Boon P, Claeys P, Dedeurwaerdere S, Achten R, Van Roost D. “Long-term deep brain stimulation for refractory temporal lobe epilepsy”. Epilepsia 2005; 46 Suppl 5: 98-99.;;Warren RJ, Durand DM. “Effects of applied currents on spontaneous epileptiform activity induced by low calcium in the rat hippocampus”. Brain Res. 1998; 806: 186-195.;;Wyckhuys T, De ST, Claeys P et al. “High frequency deep brain stimulation in the hippocampus modifies seizure characteristics in kindled rats”. Epilepsia 2007; 48: 1543-1550.;;Yamamoto J, Ikeda A, Satow T et al. “Low-frequency electric cortical stimulation has an inhibitory effect on epileptic focus in mesial temporal lobe epilepsy”. Epilepsia 2002; 43: 491-495.;;Zhu-Ge ZB, Zhu YY, Wu DC et al. “Unilateral low-frequency stimulation of central piriform cortex inhibits amygdaloid-kindled seizures in Sprague-Dawley rats”. Neuroscience 2007; 146: 901-906.;;Albensi BC, Ata G, Schmidt E, Waterman JD, Janigro D. “Activation of long-term synaptic plasticity causes suppression of epileptiform activity in rat hippocampal slices”. Brain Res. 2004; 998: 56-64.;;Babb TL, Kupfer WR, Pretorius JK, Crandall PH, Levesque MF. “Synaptic reorganization by mossy fibers in human epileptic fascia dentata”. Neuroscience 1991; 42: 351-363.;;Barbarosie M, Avoli M. “CA3-driven hippocampal-entorhinal loop controls rather than sustains in vitro limbic seizures”. J Neurosci. 1997; 17: 9308-9314.;;Bazil CW, Rose A, Resor S, Yapicular B, Hirsch LJ. “Levetiracetam may be more effective for late-onset partial epilepsy”. Arch Neurol. 2002; 59: 1905-1908.;;Begley CE, Famulari M, Annegers JF et al. “The cost of epilepsy in the United States: an estimate from population-based clinical and survey data”. Epilepsia 2000; 41: 342-351.;;Bikson M, Lian J, Hahn PJ, Stacey WC, Sciortino C, Durand DM. “Suppression of epileptiform activity by high frequency sinusoidal fields in rat hippocampal slices”. J Physiol 2001; 531: 181-191.;;Boon P, Vonck K, De Herdt, V et al. “Deep brain stimulation in patients with refractory temporal lobe epilepsy”. Epilepsia 2007; 48: 1551-1560.;;Bragin A, Wilson CL, Engel J, JR. “Rate of interictal events and spontaneous seizures in epileptic rats after electrical stimulation of hippocampus and its afferents”. Epilepsia 2002; 43 Suppl 5: 81-85.;;Brodie MJ, Dichter MA “Antiepileptic drugs”. N.Engl.J Med 1996; 334: 168-175.;;Carrington CA, Gilby KL, McIntyre DC. “Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains”. Epilepsia 2007; 48: 1604-1613.;;Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L. “Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures”. Epilepsia 1991; 32: 778-782.Brodie MJ, Dichter MA. “Antiepileptic drugs”. N.Engl.J Med 1996; 334: 168-175.;;Caveness WF, Walker AE, Ascroft PB. “Incidence of posttraumatic epilepsy in Korean veterans as compared with those from World War I and World War II”. J Neurosurg. 1962; 19: 122-129.;;Chen JW, Ruff RL, Eavey R, Wasterlain CG. “Posttraumatic epilepsy and treatment”. J Rehabil.Res.Dev. 2009; 46: 685-696.;;Chkhenkeli SA, Chkhenkeli IS. “Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy”. Stereotact.Funct.Neurosurg. 1997; 69: 221-224.;;Curia G, Longo D, Biagini G, Jones RS, Avoli M. “The pilocarpine model of temporal lobe epilepsy”. J Neurosci.Methods 2008; 172: 143-157.;;D'Ambrosio R, Fender JS, Fairbanks JP et al. “Progression from frontal-parietal to mesial-temporal epilepsy after fluid percussion injury in the rat”. Brain 2005; 128: 174-188.;;Dedeurwaerdere S, Vonck K, De Herdt, V et al. “Neuromodulation with levetiracetam and vagus nerve stimulationin experimental animal models of epilepsy”. Acta Neurol.Belg. 2006; 106: 91-97.;;Diaz-Arrastia R, Agostini MA, Frol AB et al. “Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults”. Arch Neurol. 2000; 57: 1611-1616.;;Doheny HC, Whittington MA, Jefferys JG, Patsalos PN. “A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy”. Br.J Pharmacol. 2002; 135: 1425-1434.;;Durand DM, Warman EN. “Desynchronization of epileptiform activity by extracellular current pulses in rat hippocampal slices”. J.Physiol 1994; 480 ( Pt 3): 527-537.;;Engel J, JR., Wiebe S, French J et al. “Practice parameter: temporal lobe and localized neocortical resections for epilepsy”. Epilepsia 2003; 44: 741-751.;;Fisher R, Salanova V, Witt T et al. “Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy”. Epilepsia 2010.;;Fisher RS, Handforth A. “Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology”. Neurology 1999; 53: 666-669.;;Gaito J, Nobrega JN, Gaito ST. “Interference effect of 3 Hz brain stimulation on kindling behavior induced by 60 Hz stimulation”. Epilepsia 1980; 21: 73-84.;;Gaito J. “The effect of variable duration one hertz interference on kindling”. Can.J.Neurol.Sci. 1980; 7: 59-64.;;Ghai RS, Bikson M, Durand DM. “Effects of applied electric fields on low-calcium epileptiform activity in the CA1 region of rat hippocampal slices”. J.Neurophysiol. 2000; 84: 274-280.;;Ghorbani P, Mohammad-Zadeh M, Mirnajafi-Zadeh J, Fathollahi Y. “Effect of different patterns of low-frequency stimulation on piriform cortex kindled seizures”. Neurosci.Lett. 2007; 425: 162-166.;;Gleissner U, Helmstaedter C, Schramm J, Elger CE “Memory outcome after selective amygdalohippocampectomy in patients with temporal lobe epilepsy: one-year follow-up”. Epilepsia 2004; 45: 960-962.;;Glien M, Brandt C, Potschka H, Loscher W. “Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe Epilepsy”. Epilepsia 2002; 43: 350-357.;;Gluckman BJ, Neel EJ, Netoff TI, Ditto WL, Spano ML, Schiff SJ. “Electric field suppression of epileptiform activity in hippocampal slices”. J.Neurophysiol. 1996; 76: 4202-4205.;;Gluckman BJ, Nguyen H, Weinstein SL, Schiff SJ. “Adaptive electric field control of epileptic seizures”. J. Neurosci. 2001; 21: 590-600.;;Goodman J. Experimental Models of Status Epilepticus. In: Peterson SL, Albertson TE, editors. Neuropharmacology Methods in Epilepsy Research. New York: CRC Press, 1998: 95-125.;;Goodman JH. “Brain stimulation as a therapy for epilepsy”. Adv.Exp.Med.Biol. 2004; 548: 239-247.;;Goodman JH, Berger RE, Tcheng TK. “Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures”. Epilepsia 2005; 46: 1-7.;;Goodman, J. H., Schon, J. P., Phani, S., and Zucker, J. R. Postictal Low Freqeunecy Sine Wave Stimulation Decreases the Incidence of Kindled Seizures. Epilepsia 2005; 46(s8): 104-105.;;Goodman JH. Deep Brain and Peripheral Nerve Stimulation as Potential Therapies for Epilepsy. In: Schwartzkroin PA, editor. Encyclopedia of Basic Epilepsy Research, vol. 3. Oxford: Academic Press, 2009: 1421-6.;;Hamani C, Ewerton FI, Bonilha SM, Ballester G, Mello LE, Lozano AM. “Bilateral anterior thalamic nucleus lesions and high-frequency stimulation are protective against pilocarpine-induced seizures and status epilepticus”. Neurosurgery 2004; 54: 191-195.;;Hamani C, Hodaie M, Chiang J et al. “Deep brain stimulation of the anterior nucleus of the thalamus: effects of electrical stimulation on pilocarpine-induced seizures and status epilepticus”. Epilepsy Res. 2008; 78: 117-123.;;Houser CR. “Granule cell dispersion in the dentate gyrus of humans with temporal lobe epilepsy”. Brain Res. 1990; 535: 195-204.;;Jennett B. “Posttraumatic epilepsy”. Adv.Neurol. 1979; 22: 137-147.;;Jerger K, Schiff SJ. “Periodic pacing an in vitro epileptic focus”. J.Neurophysiol. 1995; 73: 876-879.;;Kano, T., D'Antuono, M., De Guzman, P., Benini, R., and Avoli, M. Low-Frequency Stimulation of the Amygdala Inhibits Ictogenesis in the Perirhinal Cortex. Epilepsia 2002; 43(s7): 129-130.;;Khosravani H, Carlen PL, Velazquez JL. “The control of seizure-like activity in the rat hippocampal slice”. Biophys.J 2003; 84: 687-695.;;Kinoshita M, Ikeda A, Matsumoto R et al. “Electric stimulation on human cortex suppresses fast cortical activity and epileptic spikes”. Epilepsia 2004; 45: 787-791.;;Kinoshita M, Ikeda A, Matsuhashi M et al. “Electric cortical stimulation suppresses epileptic and background activities in neocortical epilepsy and mesial temporal lobe epilepsy”. Clin Neurophysiol 2005; 116: 1291-1299.;;Kossoff EH, Ritzl EK, Politsky JM et al. “Effect of an External Responsive Neurostimulator on Seizures and Electrographic Discharges during Subdural Electrode Monitoring”. Epilepsia 2004; 45: 1560-1567.;;Krauss GL, Fisher RS. Cerebellar and thalamic stimulation for epilepsy In: Devinsky O, Beric A, Dogali M, editors. Electrical and Magnetic Stimulation of the Brain and Spinal Cord. New York: Raven Press, 1993: 231-45.;;Kwan P, Brodie MJ. “Early identification of refractory epilepsy”. N.Engl.J.Med 2000; 342: 314-319;;Lesser RP, Kim SH, Beyderman L et al. “Brief bursts of pulse stimulation terminate afterdischarges caused by cortical stimulation”. Neurology 1999; 53: 2073-2081.;;Lew HL, Cifu DX, Sigford B, Scott S, Sayer N, Jaffee MS. “Team approach to diagnosis and management of traumatic brain injury and its comorbidities”. J Rehabil.Res.Dev. 2007; 44: vii-vxi.",ACTIVE
101,US,B2,US 11771898 B2,012-496-980-284-050,2023-10-03,2023,US 202217946888 A,2022-09-16,US 202217946888 A;;US 201916706136 A;;US 201816152111 A;;US 201615040932 A;;US 201562114529 P;;US 201562114520 P,2015-02-10,Seizure onset classification and stimulation parameter selection,"A neurostimulation system senses electrographic signals from the brain of a patient, extracts features from the electrographic signals, and when the extracted features satisfy certain criteria, detects a neurological event type. A mapping function relates the detected neurological event type to a stimulation parameter subspace and a default stimulation parameter set where the values of the stimulation parameters define an instance of stimulation therapy for the patient. The decision whether to implement a stimulation parameter subspace or a default stimulation parameter set may be informed by integrating other information about a state of the patient. A stimulation parameter subspace or stimulation parameter set may optimized by testing it against various thresholds until certain effectiveness criteria is satisfied. The neurological event type may be one of several electrographic seizure onset types.",NEUROPACE INC,CROWDER TARA LEIGH;;ARCOT DESAI SHARANYA;;MORRELL MARTHA JO;;TCHENG THOMAS KIM;;KAPUR RITU,NEUROPACE INC (2015-02-13),https://lens.org/012-496-980-284-050,Granted Patent,yes,69,0,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,8,169-105-775-673-72X;;115-712-516-132-131;;174-658-387-490-877;;163-939-465-406-83X;;195-657-317-579-881;;044-625-297-583-717;;152-057-332-365-006;;012-496-980-284-050,US,0,A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247;;A61N1/36064;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/7264;;A61B5/7282;;A61N1/0529;;A61N1/36139;;A61N1/37241;;A61N1/37247,A61N1/36;;A61B5/00;;A61B5/374;;A61N1/05;;A61N1/372,,46,42,056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;011-361-025-719-111;;009-232-618-324-42X;;033-846-106-320-19X;;018-029-109-808-875;;018-206-279-918-107;;040-799-728-524-861;;104-825-678-110-383;;100-520-336-176-718;;023-530-194-293-895;;018-209-093-437-149;;055-646-286-233-553;;021-258-119-628-488;;005-086-907-620-34X;;052-004-551-432-446;;059-118-580-234-908;;024-669-744-597-90X;;021-215-488-132-648;;000-472-633-790-467;;115-843-510-470-535;;010-922-327-567-206;;143-398-932-451-548;;122-301-647-307-402;;036-765-169-783-989;;023-176-465-500-421;;066-816-734-785-465;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;076-895-870-263-38X;;044-097-080-269-237;;048-540-262-662-215;;058-656-369-991-112;;104-848-923-274-640;;057-567-246-168-045;;059-149-073-001-124;;082-274-054-270-018;;040-835-492-690-77X;;007-726-754-998-709,1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1093/brain/awt299;;24176980;;23280797;;10.1002/ana.23663;;10.3389/fneng.2013.00005;;pmc3717521;;23885239;;10.1111/j.1471-4159.2005.03630.x;;16405497;;7805641;;10.1016/0920-1211(94)90040-x;;10.1016/s1388-2457(00)00402-8;;10996555;;10.1212/wnl.56.11.1453;;11402100;;12489898;;10.1093/sleep/25.8.56;;10.1111/j.1528-1167.2007.01400.x;;18047600;;pmc3703322;;10.1155/2013/932790;;23853720;;4070426;;10.1016/0031-9384(85)90136-2;;pmc6740994;;10.1523/jneurosci.23-34-10897.2003;;14645485;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1016/j.clinph.2008.08.025;;18993113;;pmc4524640;;10.1371/journal.pone.0133900;;26241907;;16099210;;10.1016/j.clinph.2005.06.017;;10.55782/ane-1996-1121;;8787174;;10.1111/j.1528-1167.2008.01881.x;;19054395;;pmc2773143;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;22476713;;10.1007/s11517-012-0904-x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/s0896-6273(01)00262-8;;11343644;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;10.1103/physreve.80.011902;;19658724;;pmc3308339;;22454622;;10.3389/fnhum.2012.00058;;10.1016/j.expneurol.2009.12.010;;pmc3167385;;20026111;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269;;10.1007/s11263-015-0816-y;;26017442;;10.1038/nature14539;;15940994;;10.1109/tnn.2005.845141;;10.1109/taslp.2018.2798811;;10.1007/978-3-319-46976-8_13,"Shoeb et al. “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer et al. “Morphological patterns of seizures recorded intracranially,” Epilepsia, 33:537-545 (1992).;;Lee et al. “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” Epilepsia, 41:297-307 (2000).;;Langan et al. “Case-control study of SUDEP,” Neurology, 64:1131-1133 (2005).;;Bateman et al. “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” Epilepsia, 51:2211-2214 (2010).;;Schiller et al. “Characterization and comparison of local onset and remote propagated electrographic seizures recorded with intracranial electrodes,” Epilepsia,39:380-388 (1998).;;Perucca, et al. “Intracranial electroencephalographic seizure-onset patterns: effect of underlying pathology,” Brain Journal of Neurology, 137:183-196 (2014).;;Tass et al. “Coordinated reset has sustained aftereffects in Parkinsonian monkeys,” Ann. Neurol, 72:816-820 (2012).;;Lysyansky et al. “Optimal number of stimulation contacts for coordinated reset neuromodulation,” Front Neuroeng.,6:5 (2013).;;Colom et al. “Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease,” J Neurochem., 96:609-623 (2006).;;Muller et al. “Anticonvulsant effects of the experimental induction of hippocampal theta activity,” Epilepsy Res., 18:195-204 (1994).;;Crespel et al. “Sleep influence on seizures and epilepsy effects on sleep in partial frontal and temporal lobe epilepsies,” M. Clin.Neurophysiol.,111 Suppl 2:S54-S59 (2000).;;Herman et al. “Distribution of partial seizures during the sleep-wake cycle: differences by seizure onset site,” Neurology,56:1453-1459 (2001).;;Minecan et al. “Relationship of epileptic seizures to sleep stage and sleep depth,” Sleep,25:899-904 (2002).;;Malow. “The interaction between sleep and epilepsy,” Epilepsia, 48 Suppl 9:36-38 (2007).;;Ng et al. “Why are seizures rare in rapid eye movement sleep? Review of the frequency of seizures in different sleep stages,” M. Epilepsy Res. Treat.,2013:932790 (2013).;;Welsh et al. “A circadian rhythm of hippocampal theta activity in the mouse,” Physiol.Behav, 35:533-538 (1985).;;Cantero et al. “Sleep-dependent theta oscillations in the human hippocampus and neocortex,”, J Neurosci, 23:10897-10903 (2003).;;Goodman et al. “Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures,” Epilepsia, 46:1-7 (2005).;;Carrington et al. “Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains,” Epilepsia, 48:1604-1613 (2007).;;Chan et al. “Automated seizure onset detection for accurate onset time determination in intracranial EEG,” Clin. Neurophysiol.,119:2687-2696 (2008).;;Brinkmann et al. “Forecasting Seizures Using Intracranial EEG Measures and SVM in Naturally Occurring Canine Epilepsy,” G. A. PLoS.One.,10:e0133900 (2015).;;Van Putten et al. “Detecting temporal lobe seizures from scalp EEG recordings: a comparison of various features,” Clin.Neurophysiol., 116:2480-2489 (2005).;;Wackermann. “Beyond mapping: estimating complexity of multichannel EEG recordings,” Acta Neurobiol.Exp. (Wars.), 56:197-208 (1996).;;Ogren et al. “Three-dimensional hippocampal atrophy maps distinguish two common temporal lobe seizure-onset patterns,” Epilepsia, 50(6):1361-1370 (2009).;;Osorio et al. “Real-Time Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset”, Epilepsia, 39(6):615-627 (1998).;;Logesparan et al. “Optimal features for online seizure detection”, Medical & Biological Engineering & Computing, 50.7 (2012): 659-669, and Supplementary Material relating to article.;;Shoeb. Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard—MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;D'Alessandro et al. “A multi-feature and multi-channel univariate selection process for seizure prediction”, Clinical Neurophysiology 116 (2005) 506-516.;;Conradsen et al. “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection based on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions@ieee.org.;;Litt et al. “Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients”, Neuron, vol. 30, 51-64, Apr. 2001.;;Kharbouch et al. “An algorithm for seizure onset detection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Khan et al. “Automatic Detection of Seizure Onset in Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Zhang et al. “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899.;;Tass et al. “Long-lasting desynchronization in rat hippocampal slice induced by coordinated reset stimulation”, Physical Review F 80, 011902 (2009).;;Popovych et al. “Desynchronizing Electrical and Sensory Coordinated Reset Neuromodulation”, Frontiers in Human Neuroscience, Mar. 20, 2012, vol. 6, Article 58.;;García-Hernández et al. “Septo-hippocampal networks in chronic epilepsy”, EAT Neurol. Mar. 2010; 222(1): 86-92.;;Gabor et al. “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;Gabor. “Automated Seizure Detection Using a Self-Organizing Neural Network”, Validation and Comparison with Other Detection Strategies, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.;;Russakovsky et al. “ImageNet Large Scale Visual Recognition Challenge”, International Journal of Computer Vision, available online Apr. 11, 2015, published Dec. 2015; vol. 115, Issue 3, DOI 10.1007/s11263-015-0816-; pp. 211-252.;;Lecun et al. “Deep Learning”, Nature, May 27, 2015, vol. 521; DOI:10.1038/nature14539; pp. 436-444.;;Xu et al. “Survey of Clustering Algorithms”, IEEE Transactions on Neural Networks, vol. 16, No. 3, May 1, 2005.;;Krizhevsky et al. “ImageNet Classification with Deep Convolutional Neural Networks”, NIPS'12 Proceedings of the 25th International Conference on Neural Information Processing Systems—vol. 1, pp. 1097-1105 Dec. 3, 2012.;;Ling et al. “Waveform Modeling and Generation Using Hierarchical Recurrent Neural Networks for Speech Bandwidth Extension”, IEEE/ACM Transactions on Audio, Speech, and Language Processing, vol. 26, No. 5, pp. 883-894, May 2018.;;Zeiler et al. “Visualizing and Understanding Convolutional Networks”, ArXiv:1311.2901v3, Nov. 28, 2013, pp. 1-11.;;Kisilev et al., “Medical Image Description Using Multi-task-loss CNN.” Deep Learning and Data Labeling for Medical Applications. DLMIA Labels 2016 2016. Lecture Notes in Computer Science( ), vol. 10008. Springer, Cham, https://doi.org/10.1007/978-3-319-46976-8_13.",ACTIVE
102,US,A1,US 2015/0374973 A1,158-064-384-387-77X,2015-12-31,2015,US 201514845153 A,2015-09-03,US 201514845153 A;;US 52558606 A,2006-09-21,"TREATMENT OF LANGUAGE, BEHAVIOR AND SOCIAL DISORDERS","Methods of treating language, behavioral and social disorders are described, including methods of treating language disorders associated with electrographic abnormalities in the primary or associative language cortex of persons with autism spectrum disorders, pervasive developmental delay or acquired epileptic aphasia. A language, behavioral and social disorder may be treated by detecting epileptiform activity or an electrographic seizure for a subject's brain and applying neurostimulation to a language cortical region of the subject's brain (e.g., a primary or associative language cortical region). Detection of epileptiform activity or an electrographic seizure and stimulation of language cortex may be performed by a sensing and/or stimulation electrode that is inserted into a subject's brain and connected to one or more neurostimulation devices for monitoring and/or stimulating the language cortex.",NEUROPACE INC,MORRELL MARTHA J,NEUROPACE INC (2006-11-16),https://lens.org/158-064-384-387-77X,Patent Application,yes,0,7,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,0,A61B5/165;;A61B5/4094;;A61N1/0539;;A61N1/0531;;A61N1/36082;;A61N1/36135;;A61B5/4836;;A61B5/369;;A61B5/165;;A61B5/4094;;A61N1/0539;;A61B5/372;;A61B5/37;;A61N1/0531;;A61N1/36082;;A61B5/4836;;A61B5/6868;;A61B5/7282;;A61N1/0529;;A61N1/36135,A61N1/05;;A61B5/00;;A61B5/04;;A61B5/0402;;A61N1/36,,0,0,,,,INACTIVE
103,US,B2,US 9026792 B2,124-091-852-253-482,2015-05-05,2015,US 201414192673 A,2014-02-27,US 201414192673 A;;US 201113286065 A,2011-10-31,Establishing secure communication between an implantable medical device and an external device,"Establishing secure communication between an implantable medical device and an external device includes: accessing, at the implantable medical device, biological data; utilizing the biological data, at the implantable medical device, to generate a public cryptographic key; and utilizing the public cryptographic key, at the implantable medical device, to generate a private cryptographic key.",NEUROPACE INC,ANDERSEN DEAN P,NEUROPACE INC (2011-11-03),https://lens.org/124-091-852-253-482,Granted Patent,yes,14,8,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,0,H04W12/06;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;A61N1/37254;;G06F7/588;;G06F21/606;;G16H40/63;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04W12/50;;H04L9/0869;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;G06F7/588;;G06F21/606;;G16H40/63;;H04L9/0816;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04L2209/24;;H04W12/04;;H04W12/06;;H04W12/50,H04L29/06;;A61B5/00;;G06F7/58;;G06F19/00;;G06F21/60;;H04L9/08;;H04L29/08;;H04W12/04;;H04W12/06,713/169,6,1,165-603-805-319-614,10.1109/sp.2008.31,"""Data Encryption Standard (DES)"", Federal Information Processing Standards Publication 46-2, (Dec. 30, 1993).;;Volkmer, Markus et al., ""Lightweight Key Exchange and Stream Cipher based solely on Tree Parity Machines"", European Network of Excellence for Cryptology Workshop on RFID and Lightweight Crypto, Graz University of Technology, Graz, Austria, (2005).;;""Announcing the Advanced Encryption Standard (AES)"", Federal Information Processing Standards Publication 197, (Nov. 26, 2001).;;Halperin, Daniel et al., ""Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses"", IEEE Symposium on Security and Privacy, (2008).;;Paar, Christof et al., ""Understanding Cryptography"", A Textbook for Students and Practitioners. Springer-Verlag Berlin Heidelberg, (2010).;;U.S. Appl. No. 12/554,959, filed Sep. 7, 2007, now Patent No. 8,543,208, date of issuance: Sep. 24, 2013.",ACTIVE
104,US,A1,US 2003/0074033 A1,021-882-845-098-695,2003-04-17,2003,US 97705201 A,2001-10-12,US 97705201 A,2001-10-12,Patient-specific template development for neurological event detection,"An epileptiform activity patient-specific template creation system permits a user to efficiently develop an optimized set of patient-specific parameters for epileptiform activity detection algorithms. The epileptiform activity patient template creation system is primarily directed for use with an implantable neurostimulator system having EEG storage capability, in conjunction with a computer software program operating within a computer workstation having a processor, disk storage and input/output facilities for storing, processing and displaying patient EEG signals. The implantable neurostimulator is operative to store records of EEG data when neurological events are detected, when it receives external commands to record, or at preset or random times. The computer workstation operates on stored and uploaded records of EEG data to derive the patient-specific templates.",NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K;;KISHAWI EYAD;;GIBB BARBARA;;ECHAUZ JAVIER;;ESTELLER ROSANA,NEUROPACE INC (2002-02-04),https://lens.org/021-882-845-098-695,Patent Application,yes,0,91,6,042-232-344-981-962;;116-166-548-931-844;;021-882-845-098-695;;184-086-742-865-090;;099-772-665-237-750;;036-806-023-187-20X,WO;;US,6,042-232-344-981-962;;116-166-548-931-844;;021-882-845-098-695;;184-086-742-865-090;;099-772-665-237-750;;036-806-023-187-20X,WO;;US,0,A61B5/7217;;A61B5/4094;;G16H40/60;;G16H20/30;;A61B5/369;;A61B5/7217;;A61B5/4094;;G16H20/30;;G16H40/60;;A61B5/372,A61B5/0476;;G16H20/30;;G16H40/60,607/48,0,0,,,,EXPIRED
105,US,B2,US 9314182 B2,089-776-054-750-753,2016-04-19,2016,US 201213679925 A,2012-11-16,US 201213679925 A;;US 81119007 A;;US 24409302 A,2002-09-13,Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in one or more electrographic signals received from a patient's brain. The features and window-based characteristics are employed within the framework of a programmable finite state machine to identify patterns and sequences in and across the electrographic signals, facilitating early and reliable detection and prediction of complex spatiotemporal neurological events in real time, and enabling responsive action by the implantable device.",NEUROPACE INC,WINGEIER BRETT M;;TCHENG THOMAS K,NEUROPACE INC (2003-01-31),https://lens.org/089-776-054-750-753,Granted Patent,yes,14,0,6,146-724-208-359-687;;196-087-925-463-182;;094-670-667-520-593;;001-478-838-231-224;;089-776-054-750-753;;162-237-890-566-997,US,6,146-724-208-359-687;;196-087-925-463-182;;001-478-838-231-224;;094-670-667-520-593;;089-776-054-750-753;;162-237-890-566-997,US,0,A61B5/0031;;A61B5/076;;A61B5/369;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/369;;A61B5/0031;;A61B5/076;;A61B5/165;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/7257,A61B5/00;;A61B5/07;;A61B5/16;;A61B5/374,,17,12,017-287-994-439-632;;143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;056-361-838-782-639;;064-968-594-730-904;;051-118-310-498-961;;080-476-358-354-096;;135-113-919-675-473;;011-361-025-719-111;;066-816-734-785-465;;124-403-369-942-149,10.1111/j.1528-1157.1990.tb05846.x;;2226364;;10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1016/s1388-2457(00)00259-5;;10825700;;10.1016/s1388-2457(00)00543-5;;11165525;;10.1155/np.2000.49;;10709214;;pmc2565365;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1016/s0896-6273(01)00262-8;;11343644;;52443;;10.1016/0013-4694(75)90051-6,"Terry, Reese et al., ""An Implantable Neurocybernetic Prothesis System"", Epilepsia, 31 (Suppl. 2): S33-S37, Cyberonics, Inc, (1990).;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;http://www.vnstherapy-com/epilepsylhcplvnstherapyldefaull.aspx (NeuroCybernetic Prosthesis (NCP)), Accessed Jun. 5, 2007.;;Tarver, T. et al, ""An Implantable Neurocybernetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007, abstract only.;;J. Gotman, Automatic Seizure Detection: Improvements and Evaluation, Electroencephalogr. Clin. Neurophysiol. 1990, 76(4): 317-24.;;H. Qu and J. Gotman, A Seizure Warning System for Long-Term Epilepsy Monitoring, Neurology 1995; 45: 2250-4.;;H. Qu and J. Gotman, A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use as a Warning Device 1997.;;Spencer S.S., Guimaraes P., Katz A., Kim J., Spencer D., Morphological Patterns of Seizures Recorded Intracranially, Epilepsia 1992; 33: 537-545.;;Lee S.A., Spencer D. D., Spencer S. S., Intracranial EEG Seizure-Onset Patterns in NeoCortical Epilepsy, Epilepsia 2000; 41: 297-307.;;Schiff S.J., Colella D., Jacyna G.M. et al., Brain Chirps: Spectrographic Signatures of Epileptic Seizures; Clin. Neurophysiol. 2000; 111: 953-958.;;Bergey G.K., Franaszczuk P.J., Epileptic Seizures are Characterized by Changing Signal Complexity, Clin. Neurophysiol. 2001; 112: 241-249.;;Velasco A.L., Wilson C.L., Babb T.L., Engel J. Jr., Functional and Anatomic Correlates of Two Frequently Observed Temporal Lobe Seizure-Onset Patterns, Neural Plasticity, 2000, 7: 49-63.;;Schiller Y., Cascino G.D., Busacker N.E., Sharbrough F. W., Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intra-cranial electrodes; Epilepsia 1998; 39; 380-388.;;Litt B., Esteller R., Echauz J. et al., Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients, Neuron, 2001: 30: 51-64.;;Wagner, H.R. et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol., 1975; 39(5): 499-506.;;http://www.vnstherapy.com/epilepsy/hcp/vnstherapy/default.aspx (NeuroCybernetic Prosthesis (NCP)), Jun. 5, 2007.;;http://www.medtronic.com/physician/activa/index.html (Medtronic Active), Jun. 5, 2007.",EXPIRED
106,US,A1,US 2024/0306989 A1,112-648-625-812-547,2024-09-19,2024,US 202418674684 A,2024-05-24,US 202418674684 A;;US 202117346944 A;;US 201715817160 A;;US 201213539301 A;;US 201161504164 P,2011-07-01,SYSTEMS AND METHODS FOR ASSESSING THE EFFECTIVENESS OF A THERAPY INCLUDING A DRUG REGIMEN USING AN IMPLANTABLE MEDICAL DEVICE,"Systems and methods rely on feedback from an active medical device or devices (e.g., neurostimulator coupled to sensing and stimulation elements such as electrodes) to assess the effectiveness of a patient's drug regimen. Such reliance may include analyzing characteristics in physiological data acquired by the medical device(s), for example, in the form of responses evoked from the patient by electrical stimulation waveforms. Systems and methods further involved adjusting one or more parameters according to which a combination therapy consisting of at least a drug regimen and an electrical stimulation therapy are delivered to a patient, in an effort to optimize the therapeutic effect of the combination. The adjustments may be automatically by one or more implanted or external hosts working together or alone, and/or with the input of a physician.",NEUROPACE INC,CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS,NEUROPACE INC (2012-07-02),https://lens.org/112-648-625-812-547,Patent Application,yes,0,0,6,013-543-225-511-569;;088-148-197-388-452;;027-517-067-401-231;;142-233-704-121-377;;086-034-979-357-994;;112-648-625-812-547,US,6,013-543-225-511-569;;027-517-067-401-231;;086-034-979-357-994;;142-233-704-121-377;;112-648-625-812-547;;088-148-197-388-452,US,0,A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;G16H20/10;;G16H40/63;;G16H50/20;;G16H20/40;;A61B5/24;;A61B5/377;;A61B5/0002;;A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;A61B5/24;;A61B5/377;;A61B5/0031,A61B5/00;;A61B5/145;;A61B5/1455;;A61B5/24;;A61B5/377,,0,0,,,,PENDING
107,US,A1,US 2007/0213784 A1,020-677-395-212-219,2007-09-13,2007,US 37437906 A,2006-03-13,US 37437906 A,2006-03-13,Seizure therapy and suppression using an implantable device,"A system and method for detecting neurological conditions, including periods of high ictal activity and periods of low ictal activity, uses a relatively low-power central processing unit in connection with signal processing circuitry to identify characteristics of an electrographic signal received from a patient's brain. Cerebral blood flow may also be monitored. Observed characteristics are used to drive targeted responsive therapy and suppressive responsive therapy, or the modulation of cerebral blood flow, to prevent or terminate imminent seizures and to reduce the likelihood of future seizures.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2006-05-05),https://lens.org/020-677-395-212-219,Patent Application,yes,8,37,1,020-677-395-212-219,US,1,020-677-395-212-219,US,0,A61N1/36082;;A61N1/36082,A61N1/00,607/45,0,0,,,,DISCONTINUED
108,US,A1,US 2015/0207622 A1,147-850-092-368-189,2015-07-23,2015,US 201514676759 A,2015-04-01,US 201514676759 A;;US 201414192673 A;;US 201113286065 A,2011-10-31,ESTABLISHING SECURE COMMUNICATION BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND AN EXTERNAL DEVICE,"Establishing secure communication between an implantable medical device and an external device includes: accessing, at the implantable medical device, biological data; utilizing the biological data, at the implantable medical device, to generate a public cryptographic key; and utilizing the public cryptographic key, at the implantable medical device, to generate a private cryptographic key.",NEUROPACE INC,ANDERSEN DEAN P,NEUROPACE INC (2011-11-03),https://lens.org/147-850-092-368-189,Patent Application,yes,0,8,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,0,H04W12/06;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;A61N1/37254;;G06F7/588;;G06F21/606;;G16H40/63;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04W12/50;;H04L9/0869;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;G06F7/588;;G06F21/606;;G16H40/63;;H04L9/0816;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04L2209/24;;H04W12/04;;H04W12/06;;H04W12/50,H04L9/08;;A61B5/0476;;A61N1/36;;G06F7/58,,0,0,,,,ACTIVE
109,US,B2,US 6690974 B2,017-686-610-075-111,2004-02-10,2004,US 95290101 A,2001-09-11,US 95290101 A;;US 54345000 A,2000-04-05,Stimulation signal generator for an implantable device,"An implantable multimodal neurostimulator having improved efficacy in treating epilepsy and other neurological disorders and processes of using that neurostimulator are described herein. The neurostimulator itself generally has two modes of electrical stimulation. The first involves delivering a non-responsive electrical stimulation signal that is applied to the central nervous system to reduce the likelihood of a seizure or other undesirable neurological even from occurring. Various waveform morphologies are described for non-responsive stimulation signals. A second mode involves delivering a responsive electrical stimulation signal when epileptiform waveforms are impending or extant. The responsive electrical stimulation signal is intended to terminate epileptiform activity, e.g., to desynchronize abnormally synchronous brain electrical activity.",NEUROPACE INC,ARCHER STEPHEN T;;PLESS BENJAMIN D,NEUROPACE INC (2001-09-11),https://lens.org/017-686-610-075-111,Granted Patent,yes,1,376,7,024-096-457-615-102;;128-755-226-255-290;;017-686-610-075-111;;087-979-855-502-888;;158-501-983-099-369;;061-206-050-442-20X;;008-166-797-662-811,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36064,A61N1/36,607/45,0,0,,,,EXPIRED
110,US,A1,US 2021/0298654 A1,142-233-704-121-377,2021-09-30,2021,US 202117346944 A,2021-06-14,US 202117346944 A;;US 201715817160 A;;US 201213539301 A;;US 201161504164 P,2011-07-01,SYSTEMS AND METHODS FOR ASSESSING THE EFFECTIVENESS OF A THERAPY INCLUDING A DRUG REGIMEN USING AN IMPLANTABLE MEDICAL DEVICE,"Systems and methods rely on feedback from an active medical device or devices (e.g., neurostimulator coupled to sensing and stimulation elements such as electrodes) to assess the effectiveness of a patient's drug regimen. Such reliance may include analyzing characteristics in physiological data acquired by the medical device(s), for example, in the form of responses evoked from the patient by electrical stimulation waveforms. Systems and methods further involved adjusting one or more parameters according to which a combination therapy consisting of at least a drug regimen and an electrical stimulation therapy are delivered to a patient, in an effort to optimize the therapeutic effect of the combination. The adjustments may be automatically by one or more implanted or external hosts working together or alone, and/or with the input of a physician.",NEUROPACE INC,CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS,NEUROPACE INC (2012-07-02),https://lens.org/142-233-704-121-377,Patent Application,yes,9,1,6,013-543-225-511-569;;088-148-197-388-452;;027-517-067-401-231;;142-233-704-121-377;;086-034-979-357-994;;112-648-625-812-547,US,6,013-543-225-511-569;;027-517-067-401-231;;086-034-979-357-994;;142-233-704-121-377;;112-648-625-812-547;;088-148-197-388-452,US,0,A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;G16H20/10;;G16H40/63;;G16H50/20;;G16H20/40;;A61B5/24;;A61B5/377;;A61B5/0002;;A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;A61B5/24;;A61B5/377;;A61B5/0031,A61B5/24;;A61B5/00;;A61B5/377,,0,0,,,,ACTIVE
111,US,B2,US 9237012 B2,004-325-428-944-16X,2016-01-12,2016,US 201514676759 A,2015-04-01,US 201514676759 A;;US 201414192673 A;;US 201113286065 A,2011-10-31,Establishing secure communication between an implantable medical device and an external device,"Establishing secure communication between an implantable medical device and an external device includes: accessing, at the implantable medical device, biological data; utilizing the biological data, at the implantable medical device, to generate a public cryptographic key; and utilizing the public cryptographic key, at the implantable medical device, to generate a private cryptographic key.",NEUROPACE INC,ANDERSEN DEAN P,NEUROPACE INC (2011-11-03),https://lens.org/004-325-428-944-16X,Granted Patent,yes,15,8,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,0,H04W12/06;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;A61N1/37254;;G06F7/588;;G06F21/606;;G16H40/63;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04W12/50;;H04L9/0869;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;G06F7/588;;G06F21/606;;G16H40/63;;H04L9/0816;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04L2209/24;;H04W12/04;;H04W12/06;;H04W12/50,H04L29/06;;A61B5/00;;A61B5/0476;;A61N1/36;;G06F7/58;;G06F19/00;;G06F21/60;;H04L9/08;;H04L29/08;;H04W12/04;;H04W12/06,,5,1,165-603-805-319-614,10.1109/sp.2008.31,"""Data Encryption Standard (DES)"", Federal Information Processing Standards Publication 46-2, (Dec. 30, 1993).;;Volkmer, Markus et al., ""Lightweight Key Exchange and Stream Cipher based solely on Tree Parity Machines"", European Network of Excellence for Cryptology Workshop on RFID and Lightweight Crypto, Graz University of Technology, Graz, Austria, (2005).;;""Announcing the Advanced Encryption Standard (AES)"", Federal Information Processing Standards Publication 197, (Nov. 26, 2001).;;Halperin, Daniel et al., ""Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses"", IEEE Symposium on Security and Privacy, (2008).;;Paar, Christof et al., ""Understanding Cryptography"", A Textbook for Students and Practitioners. Springer-Verlag Berlin Heidelberg, (2010).",ACTIVE
112,US,A1,US 2007/0244408 A1,162-237-890-566-997,2007-10-18,2007,US 81119007 A,2007-06-07,US 81119007 A;;US 24409302 A,2002-09-13,Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in one or more electrographic signals received from a patient's brain. The features and window-based characteristics are employed within the framework of a programmable finite state machine to identify patterns and sequences in and across the electrographic signals, facilitating early and reliable detection and prediction of complex spatiotemporal neurological events in real time, and enabling responsive action by the implantable device.",NEUROPACE INC,WINGEIER BRETT M;;TCHENG THOMAS K,NEUROPACE INC (2003-01-31),https://lens.org/162-237-890-566-997,Patent Application,yes,9,16,6,146-724-208-359-687;;196-087-925-463-182;;094-670-667-520-593;;001-478-838-231-224;;089-776-054-750-753;;162-237-890-566-997,US,6,146-724-208-359-687;;196-087-925-463-182;;001-478-838-231-224;;094-670-667-520-593;;089-776-054-750-753;;162-237-890-566-997,US,0,A61B5/0031;;A61B5/076;;A61B5/369;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/369;;A61B5/0031;;A61B5/076;;A61B5/165;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/7257,A61B5/00;;A61B5/07;;A61B5/374,600/544,0,0,,,,INACTIVE
113,US,A1,US 2011/0213265 A1,117-309-259-969-821,2011-09-01,2011,US 201113105717 A,2011-05-11,US 201113105717 A;;US 77064310 A;;US 37170106 A,2006-03-08,IMPLANTABLE SEIZURE MONITOR,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/117-309-259-969-821,Patent Application,yes,29,5,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544,0,0,,,,INACTIVE
114,US,A1,US 2014/0200477 A1,017-460-392-127-97X,2014-07-17,2014,US 201414192673 A,2014-02-27,US 201414192673 A;;US 201113286065 A,2011-10-31,ESTABLISHING SECURE COMMUNICATION BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND AN EXTERNAL DEVICE,"Establishing secure communication between an implantable medical device and an external device includes: accessing, at the implantable medical device, biological data; utilizing the biological data, at the implantable medical device, to generate a public cryptographic key; and utilizing the public cryptographic key, at the implantable medical device, to generate a private cryptographic key.",NEUROPACE INC,ANDERSEN DEAN P,NEUROPACE INC (2011-11-03),https://lens.org/017-460-392-127-97X,Patent Application,yes,4,13,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,0,H04W12/06;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;A61N1/37254;;G06F7/588;;G06F21/606;;G16H40/63;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04W12/50;;H04L9/0869;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;G06F7/588;;G06F21/606;;G16H40/63;;H04L9/0816;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04L2209/24;;H04W12/04;;H04W12/06;;H04W12/50,H04L9/08;;A61B5/00,600/544,0,0,,,,ACTIVE
115,US,A1,US 2004/0054297 A1,001-478-838-231-224,2004-03-18,2004,US 24409302 A,2002-09-13,US 24409302 A,2002-09-13,Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in one or more electrographic signals received from a patient's brain. The features and window-based characteristics are employed within the framework of a programmable finite state machine to identify patterns and sequences in and across the electrographic signals, facilitating early and reliable detection and prediction of complex spatiotemporal neurological events in real time, and enabling responsive action by the implantable device.",NEUROPACE INC,WINGEIER BRETT M;;TCHENG THOMAS K,NEUROPACE INC (2003-01-31),https://lens.org/001-478-838-231-224,Patent Application,yes,9,154,6,146-724-208-359-687;;196-087-925-463-182;;094-670-667-520-593;;001-478-838-231-224;;089-776-054-750-753;;162-237-890-566-997,US,6,146-724-208-359-687;;196-087-925-463-182;;001-478-838-231-224;;094-670-667-520-593;;089-776-054-750-753;;162-237-890-566-997,US,0,A61B5/0031;;A61B5/076;;A61B5/369;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/369;;A61B5/0031;;A61B5/076;;A61B5/165;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/7257,A61B5/00;;A61B5/07;;A61B5/374,600/544,0,0,,,,EXPIRED
116,US,B2,US 7277748 B2,094-670-667-520-593,2007-10-02,2007,US 24409302 A,2002-09-13,US 24409302 A,2002-09-13,Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in one or more electrographic signals received from a patient's brain. The features and window-based characteristics are employed within the framework of a programmable finite state machine to identify patterns and sequences in and across the electrographic signals, facilitating early and reliable detection and prediction of complex spatiotemporal neurological events in real time, and enabling responsive action by the implantable device.",NEUROPACE INC,WINGEIER BRETT M;;TCHENG THOMAS K,NEUROPACE INC (2003-01-31),https://lens.org/094-670-667-520-593,Granted Patent,yes,9,37,6,146-724-208-359-687;;196-087-925-463-182;;094-670-667-520-593;;001-478-838-231-224;;089-776-054-750-753;;162-237-890-566-997,US,6,146-724-208-359-687;;196-087-925-463-182;;001-478-838-231-224;;094-670-667-520-593;;089-776-054-750-753;;162-237-890-566-997,US,0,A61B5/0031;;A61B5/076;;A61B5/369;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/369;;A61B5/0031;;A61B5/076;;A61B5/165;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/7257,A61B5/00;;A61B5/07;;A61B5/374,600/544,14,11,143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;056-361-838-782-639;;064-968-594-730-904;;051-118-310-498-961;;080-476-358-354-096;;135-113-919-675-473;;011-361-025-719-111;;066-816-734-785-465;;124-403-369-942-149,10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1016/s1388-2457(00)00259-5;;10825700;;10.1016/s1388-2457(00)00543-5;;11165525;;10.1155/np.2000.49;;10709214;;pmc2565365;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1016/s0896-6273(01)00262-8;;11343644;;52443;;10.1016/0013-4694(75)90051-6,"U.S. Appl. No. 09/517,797, filed Mar. 2, 2000, Fischell et al.;;J. Gotman, Automatic Seizure Detection: Improvements and Evaluation, Electroencephalogr. Clin. Neurophysiol. 1990, 76(4): 317-24.;;H. Qu and J. Gotman, A Seizure Warning System for Long-Term Epilepsy Monitoring, Neurology 1995; 45: 2250-4.;;H. Qu and J. Gotman, A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use as a Warning Device, 1997.;;Spencer S.S., Guimaraes P., Katz A., Kim J., Spencer D., Morphological Patterns of Seizures Recorded Intracranially, Epilepsia 1992; 33: 537-545.;;Lee S.A., Spencer D. D., Spencer S. S., Intracranial EEG Seizure-Onset Patterns in NeoCortical Epilepsy, Epilepsia 2000; 41: 297-307.;;Schiff S.J., Colella D., Jacyna G.M. et al., Brain Chirps: Spectographic Signatures of Epileptic Seizures; Clin. Neurophysiol. 2000; 111: 953-958.;;Bergey G.K., Franaszczuk P.J., Epileptic Seizures are Characterized by Changing Signal Complexity, Clin. Neurophysiol. 2001; 112: 241-249.;;Velasco A.L., Wilson C.L., Babb T.L., Engel J. Jr., Functional and Anatomic Correlates of Two Frequently Observed Temporal Lobe Seizure-Onset Patterns, Neural Plasticity, 2000 7:49-63.;;Schiller Y., Cascino G.D., Busacker N.E., Sharbrough F. W., Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intra-cranial electrodes; Epilesia 1998; 39; 380-388.;;Litt B., Esteller R., Echauz J. et al., Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients, Neuron, 2001: 30: 51-64.;;Wagner, H.R. et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol., 1975; 39(5): 499-506.;;http://www.vnstherapy.com/epilepsy/hcp/vnstherapy/default.aspx (NeuroCybernetic Prosthesis (NCP)), Jun. 5, 2007.;;http://www.medtronic.com/physician/activa/index.html (Medtronic Activa), Jun. 5, 2007.",EXPIRED
117,US,B2,US 7787945 B2,161-535-870-570-066,2010-08-31,2010,US 37170106 A,2006-03-08,US 37170106 A,2006-03-08,Implantable seizure monitor,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/161-535-870-570-066,Granted Patent,yes,30,15,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544;;600/545,7,4,143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;124-403-369-942-149,10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;52443;;10.1016/0013-4694(75)90051-6,"Cyberonics, Inc., www.vnstherapy.com (Cyberonics NeuroCyberonic Prosthesis (NCP)).;;Medtronic, Inc., www.activadbs.com/about-activa.asp.;;Medtronic (2003) ""Your Activa (tm) Therapy (With a Kinetra (tm) or Soletra (tm) Neurostimulator,"" Patient Manual.;;Gotman, J, ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalogr. and Clinical Neurophysiol. (1990) 76(4): 317-24.;;Qu, H., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-4.;;Qu, H., et al., ""A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use As a Warning Device,"" IEEE Transactions on Biomedical Engineering (1997) 44(2): 115-22.;;Wagner, H.R., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. and Clinical Neurophysiol. (1975) 39(5): 499-506.",ACTIVE
118,US,A1,US 2022/0323019 A1,192-198-208-870-670,2022-10-13,2022,US 202217709159 A,2022-03-30,US 202217709159 A;;US 202163170018 P;;US 202263312429 P,2021-04-02,SYSTEMS AND METHODS FOR OBTAINING A CLINICAL RESPONSE ESTIMATE BIOMARKER USING MACHINE-LEARNED MODELS TRAINED ON IMPLANTED NEUROSTIMULATOR DATA,"A clinical response estimate (CRE) biomarker of a patient having an implanted neurostimulation system is monitored. To this end, an input dataset is derived from a subject-patient dataset that includes various different data types and different features of the patient. The data types are based on electrical activity the patient's brain sensed and stored by the implanted neurostimulation system. The input dataset is a subset of the larger subject-patient dataset, and the specific data types and patient features included in that subset are derived based on a plurality of key inputs of the subject-patient dataset. Once the input dataset is derived, it is processed by a clinical response estimator having machine-learned models. First and second machine-learned models of the clinical response estimator are applied to the input dataset to provide model inputs to an ensemble machine-learned model to determine the CRE biomarker.",NEUROPACE INC,ARCOT DESAI SHARANYA;;CROWDER TARA L;;TCHENG THOMAS K;;MORRELL MARTHA J;;JOHNSON DYHR LISE,NEUROPACE INC (2022-04-20),https://lens.org/192-198-208-870-670,Patent Application,yes,0,4,3,146-361-602-503-771;;192-198-208-870-670;;130-920-098-526-786,US,3,146-361-602-503-771;;192-198-208-870-670;;130-920-098-526-786,US,0,A61N1/36135;;A61N1/36064;;A61N1/37235;;A61N1/0531;;A61B5/4094;;G16H40/63;;G16H20/30;;G16H50/20;;G16H20/40;;G06N3/0464;;G06N3/045;;G06N3/0442;;G06N20/20;;G06N5/01;;A61N1/36139;;A61N1/0526;;A61N1/36064;;A61B5/4848;;A61N1/0529;;A61N1/37247;;G06N20/20;;A61B5/0006;;A61B5/0031;;A61B5/4064;;A61B5/4094;;A61B5/7267;;G06N3/044;;G06N3/045;;G16H50/20;;G06N3/047,A61B5/00;;G06N20/20,,0,0,,,,PENDING
119,US,A1,US 2020/0298007 A1,022-015-582-770-160,2020-09-24,2020,US 202016803945 A,2020-02-27,US 202016803945 A;;US 201962820753 P,2019-03-19,METHODS AND SYSTEMS FOR OPTIMIZING THERAPY USING STIMULATION MIMICKING NATURAL SEIZURES,"Systems, methods, and devices for automatic generation of a stimulation therapy that mimics electrographic activity in the brain at natural seizure termination define a stimulation therapy to be generated by an implanted component of a medical device system and delivered to a subject through identifying data characterizing a patient's seizures, especially at termination. A machine learning model identifies the seizures or seizure types from which to establish a canonical seizure or seizure type, and an algorithm translates the canonical seizure or seizure type into data that can be used to characterize a stimulation therapy. The systems, methods, and devices, include those configured to deliver the stimulation therapy that emulates the canonical seizure or seizure type when the seizure is detected, with the aim of terminating the seizure sooner than it would terminate without intervention.",NEUROPACE INC,JAROSIEWICZ BEATA,NEUROPACE INC (2020-03-12),https://lens.org/022-015-582-770-160,Patent Application,yes,1,3,3,018-526-567-303-273;;166-625-081-735-981;;022-015-582-770-160,US,3,018-526-567-303-273;;166-625-081-735-981;;022-015-582-770-160,US,0,G16H20/30;;A61B5/0022;;A61B5/0031;;A61B5/01;;A61B5/02;;A61B5/14542;;A61B5/293;;A61B5/296;;A61B5/4064;;A61B5/4082;;A61B5/4094;;A61B5/4812;;A61B5/4836;;A61B5/7214;;A61B5/7257;;A61B5/7267;;A61B2560/0219;;A61B2562/04;;A61B2562/046;;A61N1/0531;;A61N1/0534;;A61N1/36139;;A61N1/3615;;A61N1/36171;;A61N1/36175;;G06N3/044;;G06N3/045;;G06N3/047;;G06N3/08;;G06N7/01;;G16H40/63;;G16H50/20;;G16H50/50;;A61N1/36139;;A61B5/4094;;A61B5/7282;;A61N1/0531;;A61N1/0534;;A61N1/36175;;G06F16/2474;;G06N5/04;;G06N20/00;;G16H30/20;;G16H50/50,A61N1/36;;G06F16/2458;;G06N5/04;;G06N20/00;;G16H30/20;;G16H50/50,,0,0,,,,ACTIVE
120,US,B2,US 9265931 B2,001-475-642-475-186,2016-02-23,2016,US 201514845153 A,2015-09-03,US 201514845153 A;;US 52558606 A,2006-09-21,"Treatment of language, behavior and social disorders","Methods of treating language, behavioral and social disorders are described, including methods of treating language disorders associated with electrographic abnormalities in the primary or associative language cortex of persons with autism spectrum disorders, pervasive developmental delay or acquired epileptic aphasia. A language, behavioral and social disorder may be treated by detecting epileptiform activity or an electrographic seizure for a subject's brain and applying neurostimulation to a language cortical region of the subject's brain (e.g., a primary or associative language cortical region). Detection of epileptiform activity or an electrographic seizure and stimulation of language cortex may be performed by a sensing and/or stimulation electrode that is inserted into a subject's brain and connected to one or more neurostimulation devices for monitoring and/or stimulating the language cortex.",NEUROPACE INC,MORRELL MARTHA J,NEUROPACE INC (2006-11-16),https://lens.org/001-475-642-475-186,Granted Patent,yes,13,8,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,0,A61B5/165;;A61B5/4094;;A61N1/0539;;A61N1/0531;;A61N1/36082;;A61N1/36135;;A61B5/4836;;A61B5/369;;A61B5/165;;A61B5/4094;;A61N1/0539;;A61B5/372;;A61B5/37;;A61N1/0531;;A61N1/36082;;A61B5/4836;;A61B5/6868;;A61B5/7282;;A61N1/0529;;A61N1/36135,A61N1/05;;A61B5/00;;A61B5/04;;A61B5/0402;;A61N1/36,,9,9,033-409-029-479-221;;003-437-454-229-979;;029-335-233-748-077;;020-676-908-972-703;;039-096-134-013-54X;;055-989-827-587-296;;031-305-152-174-854;;010-443-289-341-901;;009-083-260-830-814,10.1007/s00787-004-0353-7;;15365890;;10.1177/155005940503600105;;15683193;;9090688;;10.1016/s0887-8994(96)00297-4;;10.1016/s1525-5050(03)00080-5;;12791330;;7573755;;10.1016/0387-7604(95)00019-8;;15362170;;10.1002/mrdd.20025;;15526970;;10.1177/088307380401900106;;10.1177/08830738040190010601;;10.1016/s1474-4422(02)00160-6;;12849396;;10916262;;10.1109/10.846685,"Hrdlicka, M. et al. ""Not EEG Abnormalities but Epilepsy is Associated with Autistic Regression and Mental Functioning in Childhood Autism,"" European Child & Adolescent Psychiatry (2004) 13(4):209-213.;;Hughes, J.R. et al. ""EEG and Seizures in Autistic Children and Adolescents: Further Findings with Therapeutic Implications,"" Clinical EEG Neuroscience (Jan. 2005) 36 (1):15-20.;;Neville, B.R.G., et al ""Surgical Treatment of Severe Autistic Regression in Childhood Epilepsy,"" Pediatric Neurology (Feb. 1997) 16(2):137-140.;;Park, Y.D. ""The Effects of Vagus Nerve Stimulation Therapy on Patients with Intractable Seizures and Either Landau-Kleffner Syndrome or Autism,"" Epilepsy & Behavior (2003) 4(3):286-290.;;Rossi, P.G. et al. ""EEG Features and Epilepsy in Patients with Autism,"" Brain and Development (Mar./Apr. 1995) 17(2):169-174.;;Tharp, B.R. ""Epileptic Encephalopathies and Their Relationship to Developmental Disorders: Do Spikes Cause Autism?"" Mental Retardation and Developmental Disabilities Research Reviews (2004) 10:132-134.;;Trevathan, E. ""Seizures and Epilepsy Among Children with Language Regression and Autistic Spectrum Disorders,"" Journal of Child Neurology (Aug. 2004) 19(S1):S49-57.;;Tuchman, R. et al., ""Epilepsy in Autism,"" The Lancet Neurology (Oct. 2002)1:352-358.;;Weiland, J.D. et al. ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering (Jul. 2000) 47(7):911-918.",INACTIVE
121,US,A1,US 2003/0195588 A1,162-173-710-206-178,2003-10-16,2003,US 12385702 A,2002-04-16,US 12385702 A,2002-04-16,External ear canal interface for the treatment of neurological disorders,"A system for treating various neurological, vestibular, and other disorders includes a stimulator device situated in an ear canal of the patient. The stimulator device is adapted to provide magnetic, electrical, audible, tactile, or caloric stimulation, and may be programmed to provide such stimulation in continuous, semi-continuous, periodic, programmed, or on-demand modes, or various combinations of the above.",NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,,https://lens.org/162-173-710-206-178,Patent Application,yes,0,346,1,162-173-710-206-178,US,1,162-173-710-206-178,US,0,A61N2/02;;A61N1/36036;;A61N2/02;;A61N1/36036,A61N1/36;;A61N2/02,607/55,0,0,,,,DISCONTINUED
122,US,B2,US 9265946 B2,059-122-939-353-404,2016-02-23,2016,US 201514846382 A,2015-09-04,US 201514846382 A;;US 55495409 A;;US 52558606 A,2006-09-21,"Treatment of language, behavior and social disorders","Methods of treating language, behavioral and social disorders are described, including methods of treating language disorders associated with electrographic abnormalities in the primary or associative language cortex of persons with autism spectrum disorders, pervasive developmental delay or acquired epileptic aphasia. A language, behavioral and social disorder may be treated by detecting epileptiform activity or an electrographic seizure for a subject's brain and applying neurostimulation to a language cortical region of the subject's brain (e.g., a primary or associative language cortical region). Detection of epileptiform activity or an electrographic seizure and stimulation of language cortex may be performed by a sensing and/or stimulation electrode that is inserted into a subject's brain and connected to one or more neurostimulation devices for monitoring and/or stimulating the language cortex.",NEUROPACE INC,MORRELL MARTHA J,NEUROPACE INC (2006-11-16),https://lens.org/059-122-939-353-404,Granted Patent,yes,13,8,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,0,A61B5/165;;A61B5/4094;;A61N1/0539;;A61N1/0531;;A61N1/36082;;A61N1/36135;;A61B5/4836;;A61B5/369;;A61B5/165;;A61B5/4094;;A61N1/0539;;A61B5/372;;A61B5/37;;A61N1/0531;;A61N1/36082;;A61B5/4836;;A61B5/6868;;A61B5/7282;;A61N1/0529;;A61N1/36135,A61N1/05;;A61N1/36,,9,9,033-409-029-479-221;;003-437-454-229-979;;029-335-233-748-077;;020-676-908-972-703;;039-096-134-013-54X;;055-989-827-587-296;;031-305-152-174-854;;010-443-289-341-901;;009-083-260-830-814,10.1007/s00787-004-0353-7;;15365890;;10.1177/155005940503600105;;15683193;;9090688;;10.1016/s0887-8994(96)00297-4;;10.1016/s1525-5050(03)00080-5;;12791330;;7573755;;10.1016/0387-7604(95)00019-8;;15362170;;10.1002/mrdd.20025;;15526970;;10.1177/088307380401900106;;10.1177/08830738040190010601;;10.1016/s1474-4422(02)00160-6;;12849396;;10916262;;10.1109/10.846685,"Hrdlicka, M. et al. ""Not EEG Abnormalities but Epilepsy is Associated with Autistic Regression and Mental Functioning in Childhood Autism,"" European Child & Adolescent Psychiatry (2004) 13(4):209-213.;;Hughes, J.R. et al. ""EEG and Seizures in Autistic Children and Adolescents: Further Findings with Therapeutic Implications,"" Clinical EEG Neuroscience (Jan. 2005) 36 (1):15-20.;;Neville, B.R.G., et al. ""Surgical Treatment of Severe Autistic Regression in Childhood Epilepsy,"" Pediatric Neurology (Feb. 1997) 16(2):137-140.;;Park, Y.D. ""The Effects of Vagus Nerve Stimulation Therapy on Patients with Intractable Seizures and Either Landau-Kleffner Syndrome or Autism,"" Epilepsy & Behavior (2003) 4(3):286-290.;;Rossi, P.G. et al. ""EEG Features and Epilepsy in Patients with Autism,"" Brain and Development (Mar./Apr. 1995) 17(2):169-174.;;Tharp, B.R. ""Epileptic Encephalopathies and Their Relationship to Developmental Disorders: Do Spikes Cause Autism?"" Mental Retardation and Developmental Disabilities Research Reviews (2004) 10:132-134.;;Trevathan, E. ""Seizures and Epilepsy Among Children with Language Regression and Autistic Spectrum Disorders,"" Journal of Child Neurology (Aug. 2004) 19(S1):S49-57.;;Tuchman, R. et al., ""Epilepsy in Autism,"" The Lancet Neurology (Oct. 2002)1:352-358.;;Weiland, J.D. et al. ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering (Jul. 2000) 47(7):911-918.",INACTIVE
123,US,A1,US 2022/0313159 A1,130-920-098-526-786,2022-10-06,2022,US 202217709195 A,2022-03-30,US 202217709195 A;;US 202163170018 P;;US 202263312429 P,2021-04-02,SYSTEMS AND METHODS FOR OBTAINING AND PRESENTING CLINICAL RESPONSE INFORMATION USING MACHINE-LEARNED MODELS TRAINED ON IMPLANTED NEUROSTIMULATOR DATA,An input dataset is processed to obtain a pre-event window of model inputs and a post-event window of model inputs. The input dataset is a subset of a larger subject-patient dataset that includes different data types and features of the patient. The data types are based on electrical activity of the patient's brain that is sensed and stored by an implanted neurostimulation system. A clinical response estimator (CRE) model is applied to the pre-event window of model inputs to derive pre-event CRE biomarkers. The CRE model is also applied to the post-event window of model inputs to derive post-event CRE biomarkers. The pre-event CRE biomarkers and post-event CRE biomarkers are displayed as a function of time together with the occurrence of the event of interest.,NEUROPACE INC,ARCOT DESAI SHARANYA;;CROWDER TARA L;;TCHENG THOMAS K;;MORRELL MARTHA J;;JOHNSON DYHR LISE,NEUROPACE INC (2022-04-20),https://lens.org/130-920-098-526-786,Patent Application,yes,13,2,3,146-361-602-503-771;;192-198-208-870-670;;130-920-098-526-786,US,3,146-361-602-503-771;;192-198-208-870-670;;130-920-098-526-786,US,0,A61N1/36135;;A61N1/36064;;A61N1/37235;;A61N1/0531;;A61B5/4094;;G16H40/63;;G16H20/30;;G16H50/20;;G16H20/40;;G06N3/0464;;G06N3/045;;G06N3/0442;;G06N20/20;;G06N5/01;;A61N1/36139;;A61N1/0526;;A61N1/36064;;A61B5/4848;;A61N1/0529;;A61N1/37247;;G06N20/20;;A61B5/0006;;A61B5/0031;;A61B5/4064;;A61B5/4094;;A61B5/7267;;G06N3/044;;G06N3/045;;G16H50/20;;G06N3/047,A61B5/00;;A61N1/05;;A61N1/36;;A61N1/372;;G06N3/04,,0,0,,,,PENDING
124,US,A1,US 2015/0374993 A1,042-208-686-617-343,2015-12-31,2015,US 201514846382 A,2015-09-04,US 201514846382 A;;US 55495409 A;;US 52558606 A,2006-09-21,"TREATMENT OF LANGUAGE, BEHAVIOR AND SOCIAL DISORDERS","Methods of treating language, behavioral and social disorders are described, including methods of treating language disorders associated with electrographic abnormalities in the primary or associative language cortex of persons with autism spectrum disorders, pervasive developmental delay or acquired epileptic aphasia. A language, behavioral and social disorder may be treated by detecting epileptiform activity or an electrographic seizure for a subject's brain and applying neurostimulation to a language cortical region of the subject's brain (e.g., a primary or associative language cortical region). Detection of epileptiform activity or an electrographic seizure and stimulation of language cortex may be performed by a sensing and/or stimulation electrode that is inserted into a subject's brain and connected to one or more neurostimulation devices for monitoring and/or stimulating the language cortex.",NEUROPACE INC,MORRELL MARTHA J,NEUROPACE INC (2006-11-16),https://lens.org/042-208-686-617-343,Patent Application,yes,0,9,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,0,A61B5/165;;A61B5/4094;;A61N1/0539;;A61N1/0531;;A61N1/36082;;A61N1/36135;;A61B5/4836;;A61B5/369;;A61B5/165;;A61B5/4094;;A61N1/0539;;A61B5/372;;A61B5/37;;A61N1/0531;;A61N1/36082;;A61B5/4836;;A61B5/6868;;A61B5/7282;;A61N1/0529;;A61N1/36135,A61N1/36;;A61N1/05,,0,0,,,,INACTIVE
125,US,A1,US 2003/0073917 A1,036-806-023-187-20X,2003-04-17,2003,US 14666302 A,2002-05-13,US 14666302 A;;US 97705201 A,2001-10-12,Patient-specific parameter selection for neurological event detection,"An epileptiform activity patient-specific template creation system permits a user to efficiently develop an optimized set of patient-specific parameters for epileptiform activity detection algorithms. The epileptiform activity patient template creation system is primarily directed for use with an implantable neurostimulator system having EEG storage capability, in conjunction with a computer software program operating within a computer workstation having a processor, disk storage and input/output facilities for storing, processing and displaying patient EEG signals. The implantable neurostimulator is operative to store records of EEG data when neurological events are detected, when it receives external commands to record, or at preset or arbitrary times. The computer workstation operates on stored and uploaded records of EEG data to derive the patient-specific templates via a single local minimum variant of a multidimensional greedy line search process and a feature overlay process.",NEUROPACE INC,ECHAUZ JAVIER;;ESTELLER ROSANA;;TCHENG THOMAS K;;PLESS BENJAMIN D,NEUROPACE INC (2002-08-07),https://lens.org/036-806-023-187-20X,Patent Application,yes,5,115,6,042-232-344-981-962;;116-166-548-931-844;;021-882-845-098-695;;184-086-742-865-090;;099-772-665-237-750;;036-806-023-187-20X,WO;;US,6,042-232-344-981-962;;116-166-548-931-844;;021-882-845-098-695;;184-086-742-865-090;;099-772-665-237-750;;036-806-023-187-20X,WO;;US,0,A61B5/7217;;A61B5/4094;;G16H40/60;;G16H20/30;;A61B5/369;;A61B5/7217;;A61B5/4094;;G16H20/30;;G16H40/60;;A61B5/372,A61B5/0476,60051,0,0,,,,EXPIRED
126,US,A1,US 2022/0314002 A1,146-361-602-503-771,2022-10-06,2022,US 202217709227 A,2022-03-30,US 202217709227 A;;US 202163170018 P;;US 202263312429 P,2021-04-02,SYSTEMS AND METHODS FOR CONTROLLING OPERATION OF AN IMPLANTED NEUROSTIMULATION SYSTEM BASED ON A MAPPING OF EPISODE DURATIONS AND SEIZURE PROBABILITY BIOMARKERS,An implanted neurostimulation system is configured to sense episodes of electrographic events and determine durations of episodes. Durations of electrographic events sensed by the implanted neurostimulation system are mapped with seizure probability biomarkers derived from records of the electrographic events to create a mapping function. A seizure probability biomarker that has a value desired for the operation of the implanted neurostimulation system is selected. The duration mapped to the selected seizure probability biomarker is identified and programmed into a control module of the implanted neurostimulation system as a programmed parameter that triggers the operation by the implanted neurostimulation system. The process may be repeated for other operations of the implanted neurostimulation system.,NEUROPACE INC,ARCOT DESAI SHARANYA;;GREENE DAVID A,NEUROPACE INC (2022-04-25),https://lens.org/146-361-602-503-771,Patent Application,yes,39,2,3,146-361-602-503-771;;192-198-208-870-670;;130-920-098-526-786,US,3,146-361-602-503-771;;192-198-208-870-670;;130-920-098-526-786,US,0,A61N1/36135;;A61N1/36064;;A61N1/37235;;A61N1/0531;;A61B5/4094;;G16H40/63;;G16H20/30;;G16H50/20;;G16H20/40;;G06N3/0464;;G06N3/045;;G06N3/0442;;G06N20/20;;G06N5/01;;A61N1/36139;;A61N1/0526;;A61N1/36064;;A61B5/4848;;A61N1/0529;;A61N1/37247;;G06N20/20;;A61B5/0006;;A61B5/0031;;A61B5/4064;;A61B5/4094;;A61B5/7267;;G06N3/044;;G06N3/045;;G16H50/20;;G06N3/047,A61N1/36;;A61N1/05,,0,0,,,,PENDING
127,WO,A2,WO 2003/030734 A2,042-232-344-981-962,2003-04-17,2003,US 0232735 W,2002-10-11,US 97705201 A,2001-10-12,PATIENT-SPECIFIC PARAMETER SELECTION FOR NEUROLOGICAL EVENT DETECTION,"An epileptiform activity patient-specific template creation system permits a user to efficiently develop an optimized set of patient-specific parameters for epileptiform activity detection algorithms. The epileptiform activity patient template creation system is primarily directed for use with an implantable neurostimulator (110) system having EEG storage capability, in conjunction with a computer software program operating within a computer workstation (212) having a processor, disk storage and input/output facilities for storing, processing and displaying patient EEG signals. The implantable neurostimulator is operative to store records of EEG data when neurological events are detected, when it receives external commands to record, or at preset or arbitrary times. The computer workstation operates on stored and uploaded records of EEG data to derive the patient-specific templates via a single local minimum variant of a multidimensional greedy line search process and a feature overlay process.",NEUROPACE INC,ECHAUZ JAVIER;;ESTELLER ROSANA;;TCHENG THOMAS K;;PLESS BENJAMIN D;;KISHAWI EYAD;;GIBB BARBARA,,https://lens.org/042-232-344-981-962,Patent Application,yes,4,0,6,042-232-344-981-962;;116-166-548-931-844;;021-882-845-098-695;;184-086-742-865-090;;099-772-665-237-750;;036-806-023-187-20X,WO;;US,6,042-232-344-981-962;;116-166-548-931-844;;021-882-845-098-695;;184-086-742-865-090;;099-772-665-237-750;;036-806-023-187-20X,WO;;US,0,A61B5/7217;;A61B5/4094;;G16H40/60;;G16H20/30;;A61B5/369;;A61B5/7217;;A61B5/4094;;G16H20/30;;G16H40/60;;A61B5/372,A61B5/0476;;G16H20/30;;G16H40/60,,0,0,,,,PENDING
128,US,A1,US 2023/0201599 A1,018-526-567-303-273,2023-06-29,2023,US 202318110676 A,2023-02-16,US 202318110676 A;;US 202016803945 A;;US 201962820753 P,2019-03-19,METHODS AND SYSTEMS FOR OPTIMIZING THERAPY USING STIMULATION MIMICKING NATURAL SEIZURES,"Systems, methods, and devices for automatic generation of a stimulation therapy that mimics electrographic activity in the brain at natural seizure termination define a stimulation therapy to be generated by an implanted component of a medical device system and delivered to a subject through identifying data characterizing a patient's seizures, especially at termination. A machine learning model identifies the seizures or seizure types from which to establish a canonical seizure or seizure type, and an algorithm translates the canonical seizure or seizure type into data that can be used to characterize a stimulation therapy. The systems, methods, and devices, include those configured to deliver the stimulation therapy that emulates the canonical seizure or seizure type when the seizure is detected, with the aim of terminating the seizure sooner than it would terminate without intervention.",NEUROPACE INC,JAROSIEWICZ BEATA,NEUROPACE INC (2020-03-12),https://lens.org/018-526-567-303-273,Patent Application,yes,1,0,3,018-526-567-303-273;;166-625-081-735-981;;022-015-582-770-160,US,3,018-526-567-303-273;;166-625-081-735-981;;022-015-582-770-160,US,0,A61B2562/04;;G16H20/30;;G16H50/20;;G16H50/50;;G16H40/63;;G06N3/08;;A61N1/0534;;A61N1/0531;;A61N1/36139;;A61N1/36175;;A61N1/36171;;A61N1/3615;;A61B5/4094;;A61B5/0031;;A61B5/4064;;A61B5/4836;;A61B5/293;;A61B5/296;;A61B5/4082;;A61B2560/0219;;A61B5/0022;;A61B2562/046;;A61B5/4812;;A61B5/7267;;A61B5/01;;A61B5/02;;A61B5/7257;;A61B5/7214;;A61B5/14542;;G06N3/047;;G06N7/01;;G06N3/045;;G06N3/044;;A61N1/36139;;A61N1/36175;;G16H30/20;;G16H50/50;;A61N1/0531;;G06N5/04;;G06F16/2474;;A61B5/4094;;A61N1/0534;;G06N20/00;;A61B5/7282,A61N1/36;;G06F16/2458;;G06N5/04;;G06N20/00;;G16H30/20;;G16H50/50,,0,0,,,,PENDING
129,US,B2,US 11612750 B2,166-625-081-735-981,2023-03-28,2023,US 202016803945 A,2020-02-27,US 202016803945 A;;US 201962820753 P,2019-03-19,Methods and systems for optimizing therapy using stimulation mimicking natural seizures,"Systems, methods, and devices for automatic generation of a stimulation therapy that mimics electrographic activity in the brain at natural seizure termination define a stimulation therapy to be generated by an implanted component of a medical device system and delivered to a subject through identifying data characterizing a patient's seizures, especially at termination. A machine learning model identifies the seizures or seizure types from which to establish a canonical seizure or seizure type, and an algorithm translates the canonical seizure or seizure type into data that can be used to characterize a stimulation therapy. The systems, methods, and devices, include those configured to deliver the stimulation therapy that emulates the canonical seizure or seizure type when the seizure is detected, with the aim of terminating the seizure sooner than it would terminate without intervention.",NEUROPACE INC,JAROSIEWICZ BEATA,NEUROPACE INC (2020-03-12),https://lens.org/166-625-081-735-981,Granted Patent,yes,72,0,3,018-526-567-303-273;;166-625-081-735-981;;022-015-582-770-160,US,3,018-526-567-303-273;;166-625-081-735-981;;022-015-582-770-160,US,0,G16H20/30;;A61B5/0022;;A61B5/0031;;A61B5/01;;A61B5/02;;A61B5/14542;;A61B5/293;;A61B5/296;;A61B5/4064;;A61B5/4082;;A61B5/4094;;A61B5/4812;;A61B5/4836;;A61B5/7214;;A61B5/7257;;A61B5/7267;;A61B2560/0219;;A61B2562/04;;A61B2562/046;;A61N1/0531;;A61N1/0534;;A61N1/36139;;A61N1/3615;;A61N1/36171;;A61N1/36175;;G06N3/044;;G06N3/045;;G06N3/047;;G06N3/08;;G06N7/01;;G16H40/63;;G16H50/20;;G16H50/50;;A61N1/36139;;A61B5/4094;;A61B5/7282;;A61N1/0531;;A61N1/0534;;A61N1/36175;;G06F16/2474;;G06N5/04;;G06N20/00;;G16H30/20;;G16H50/50,A61N1/36;;A61B5/00;;A61N1/05;;G06F16/2458;;G06N5/04;;G06N20/00;;G16H30/20;;G16H50/50,,62,51,059-149-073-001-124;;082-274-054-270-018;;028-375-151-725-525;;076-947-990-377-527;;040-835-492-690-77X;;056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;036-765-169-783-989;;023-176-465-500-421;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;058-656-369-991-112;;104-848-923-274-640;;096-532-070-721-701;;030-315-680-716-891;;027-365-942-045-854;;021-215-488-132-648;;005-086-907-620-34X;;059-118-580-234-908;;024-669-744-597-90X;;018-206-279-918-107;;104-825-678-110-383;;168-777-155-532-067;;048-540-262-662-215;;052-004-551-432-446;;100-520-336-176-718;;043-109-655-339-427;;007-726-754-998-709;;066-816-734-785-465;;122-301-647-307-402;;018-029-109-808-875;;018-209-093-437-149;;006-061-291-679-25X;;040-799-728-524-861;;023-530-194-293-895;;055-646-286-233-553;;010-922-327-567-206;;143-398-932-451-548;;009-232-618-324-42X;;044-097-080-269-237;;011-361-025-719-111;;083-311-330-735-958;;076-895-870-263-38X;;033-846-106-320-19X;;010-253-239-920-588;;000-472-633-790-467;;115-843-510-470-535;;021-258-119-628-488,26017442;;10.1038/nature14539;;15940994;;10.1109/tnn.2005.845141;;29807250;;10.1016/j.compbiomed.2018.05.019;;10.1088/1741-2552/aaf13f;;30524070;;10.1109/taslp.2018.2798811;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269;;pmc8382232;;10.1038/nature21056;;28117445;;10.1109/ner.2019.8717007;;29311566;;pmc5758806;;10.1038/s41467-017-02577-y;;pmc4524640;;10.1371/journal.pone.0133900;;26241907;;pmc6740994;;10.1523/jneurosci.23-34-10897.2003;;14645485;;10.1111/j.1528-1167.2007.01077.x;;17433055;;10.1016/j.clinph.2008.08.025;;18993113;;10.1111/j.1471-4159.2005.03630.x;;16405497;;10.1016/s1388-2457(00)00402-8;;10996555;;10.1016/j.clinph.2019.05.017;;31212202;;10.1016/j.expneurol.2009.12.010;;pmc3167385;;20026111;;15660762;;10.1111/j.0013-9580.2005.03804.x;;10.1212/wnl.56.11.1453;;11402100;;28899023;;10.1093/brain/awx173;;10.1007/978-3-319-46976-8_13;;10.1016/s0896-6273(01)00262-8;;11343644;;22476713;;10.1007/s11517-012-0904-x;;10.3389/fneng.2013.00005;;pmc3717521;;23885239;;10.1111/j.1528-1167.2007.01400.x;;18047600;;10.1073/pnas.1513716112;;pmc4664307;;26554021;;7805641;;10.1016/0920-1211(94)90040-x;;12489898;;10.1093/sleep/25.8.56;;pmc3703322;;10.1155/2013/932790;;23853720;;10.1111/j.1528-1167.2008.01881.x;;19054395;;pmc2773143;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;10.1093/brain/awt299;;24176980;;pmc3308339;;22454622;;10.3389/fnhum.2012.00058;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1016/j.yebeh.2018.04.003;;29719278;;10.1103/physreve.80.011902;;19658724;;23280797;;10.1002/ana.23663;;28922360;;pmc5602520;;10.1371/journal.pone.0184044;;16099210;;10.1016/j.clinph.2005.06.017;;10.55782/ane-1996-1121;;8787174;;4070426;;10.1016/0031-9384(85)90136-2,"Lecun et al., “Deep Learning”, Nature, May 27, 2015, vol. 521; DOI:10.1038/nature14539; pp. 436-444.;;Xu et al., “Survey of Clustering Algorithms”, IEEE Transactions on Neural Networks, vol. 16, No. 3, May 1, 2005; 35 pages.;;Hussein, Ramy et al. “Epileptic Seizure Detection: A Deep Learning Approach”, ArXiv:1803.09848v1, Mar. 27, 2018, pp. 1-12; 2018.;;Tsiouris, Kostas M. et al. “A Long Short-Term Memory deep learning network for the prediction of epileptic seizures using EEG signals”, Computers in Biology and Medicine, vol. 99, Aug. 1, 2018, pp. 24-37.;;Thodoroff, M. et al. “Learning Robust Features using Deep Learning for Automatic Seizure Detection”, ArXiv:1608.00220, Jul. 31, 2016, pp. 1-12.;;Pailla, Tejaswy et al. “Autoencoders for learning template spectrograms in electrocorticographic signals”, Journal of Neural Engineering, vol. 16, No. 1, Jan. 14, 2019.;;Ling, Zhen-Huia et al. “Waveform Modeling and Generation Using Hierarchical Recurrent Neural Networks for Speech Bandwidth Extension”, IEEE/ACM Transactions on Audio, Speech, and Language Processing, vol. 26, No. 5, pp. 883-894, May 2018.;;Zeiler, Matthew D. et al. “Visualizing and Understanding Convolutional Networks”, ArXiv:1311.2901v3, Nov. 28, 2013, pp. 1-11.;;Ali Hossam Shoeb, and John Guttag: “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer, S. S., Guimaraes, P., Katz, A., Kim, J., and Spencer, D. Epilepsia: “Morphological patterns of seizures recorded intracranially,” 33:537-545 (1992).;;Lee, S. A., Spencer, D. D., and Spencer, S. S. Epilepsia: “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” 41:297-307 (2000).;;Langan, Y., Nashef, L., and Sander, J. W.: “Case-control study of SUDEP,” Neurology,64:1131-1133 (2005).;;Bateman, L. M., Li, C. S., Lin, T. C., and Seyal, M. Epilepsia: “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” 51:2211-2214 (2010).;;Ali Hossam Shoeb: Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard-MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;Maryann D'Alessandro, George Vachtsevanos, Rosana Esteller, Javier Echauz, Stephen Cranstoun, Greg Worrell, Landi Parish and Brian Litt: “A multi-feature and multi-channel univariate selection process for seizure prediction”. Clinical Neurophysiology 116 (2005) 506-516.;;Isa Conradsen, Student Member; IEEE, Sándor Beniczky, Karsten Hoppe, Peter Wolf and Helge B. D. Sorensen Member, IEEE: “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection based on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions@ieee.org.;;Alaa Kharbouch, Ali Shoeb, John Guttag, and Sydney S. Cash: “An algorithm for seizure onset ietection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Yusuf U Khan, Omar Farooq and Priyanka Sharma: “Automatic Detection of Seizure Onset In Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Yizhuo Zhang, Guanghua Xu, Jing Wang, Lin Liang: “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899. Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset, Epilepsia, 39(6):615-627 (1998).;;A.J. Gabor, R.R. Leach, and F.U. Dowla: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;A.J. Gabor: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Validation and Comparison with Other Detection Strategies, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.;;Russakovsky et al., “ImageNet Large Scale Visual Recognition Challenge”, International Journal of Computer Mision, available online Apr. 11, 2015, published Dec. 2015; vol. 115, Issue 3, DOI 10.1007/s11263-015-0816-; pp. 211-252.;;Krizhevsky et al., “ImageNet Classification with Deep Convolutional Neural Networks”, NIPS'12 Proceedings of the 25th International Conference on Neural Information Processing Systems—vol. 1, pp. 1097-1105, Dec. 3, 2012.;;Desai, Sharanya, “Insights from mining large-scale human EcoG data”, ICTAL2017, The Penumbra Conference, presented Aug. 21, 2017; 9 pages.;;Desai et al., “Deep Learning for seizure classification and potential seizure biomarker discovery”, Abstract, published online at www.aesnet.org on Nov. 20, 2017; 2 pages.;;Esteva et al. “Dermatologist level classification of skin cancer with deep neural networks”, Nature, vol. 542, published Feb. 2, 2017, pp. 115-118.;;Desai et al., “Transfer-learning for differentiating epileptic patients who respond to treatment based on chronic ambulatory ECoG data,” in 2019 9th International IEEE/EMBS Conference on Neural Engineering (NER), 2019: IEEE, pp. 1-4.;;Baud et al., “Multi-day rhythms modulate seizure risk in epilepsy.” Nat Commun 9, 88, (2018).;;Brinkmann et al., “Forecasting Seizures Using Intracranial EEG Measures and SVM in Naturally Occurring Canine Epilepsy,” G. A. PLoS.One., 10:e0133900 (2015).;;Cantero et al., “Sleep-dependent theta oscillations in the human hippocampus and neocortex,”, J Neurosci,23:10897-10903 (2003).;;Carrington et al.,“Effect of focal low-frequency stimulation on amygdala-kindled afterdischarge thresholds and seizure profiles in fast- and slow-kindling rat strains,” Epilepsia,48:1604-1613 (2007).;;Chan et al. “Automated seizure onset detection for accurate onset time determination in intracranial EEG,” Clin. Neurophysiol., 119:2687-2696 (2008).;;Colom, “Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease,” J Neurochem., 96:609-623 (2006).;;Crespel et al. “Sleep influence on seizures and epilepsy effects on sleep in partial frontal and temporal lobe epilepsies,” M. Clin.Neurophysiol., 111 Suppl 2:S54-S59 (2000).;;Desai et al., “Quantitative electrocorticographic biomarkers of clinical outcomes in mesial temporal lobe epileptic patients treated with the RNS system”, Clinical Neurophysiology 130, 1364-1374, (2019).;;García-Hernández et al., “Septo-hippocampal networks in chronic epilepsy”, EAT Neurol. Mar. 2010; 222(1): 86-92.;;Goodman et al., “Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures,” Epilepsia,46:1-7 (2005).;;Herman et al., “Distribution of partial seizures during the sleep-wake cycle: differences by seizure onset site,” Neurology,56:1453-1459 (2001).;;Karoly et al., “The circadian profile of epilepsy improves seizure forecasting.” Brain 140, 2169-2182, (2017).;;Kisilev et al., “Medical Image Description Using Multi-task-loss CNN.” Deep Learning and Data Labeling for Medical Applications. DLMIA Labels 2016 2016. Lecture Notes in Computer Science(), vol. 10008. Springer, Cham. https://doi.org/10.1007/978-3-319-46976-8_13.;;Litt et al., “Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients”, Neuron, vol. 30, 51-64, Apr. 2001.;;Logesparan et al., “Optimal features for online seizure detection”, Medical & Biological Engineering & Computing, 50.7 (2012): 659-669, and Supplementary Material relating to article.;;Lysyansky et al., “Optimal number of stimulation contacts for coordinated reset neuromodulation,” Front Neuroeng.,6:5 (2013).;;Malow, “The interaction between sleep and epilepsy,” Epilepsia,48 Suppl 9:36-38 (2007).;;Meisel et al., “Intrinsic excitability measures track antiepileptic drug action and uncover increasing/ decreasing excitability over the wake/sleep cycle”. Proc Natl Acad Sci U S A 112, 14694-14699, (Nov. 6, 2015).;;Miller et al., “Anticonvulsant effects of the experimental induction of hippocampal theta activity,” Epilepsy Res., 18:195-204 (1994).;;Minecan et al., “Relationship of epileptic seizures to sleep stage and sleep depth,” Sleep,25:899-904 (2002).;;Ng et al., “Why are seizures rare in rapid eye movement sleep? Review of the frequency of seizures in different sleep stages,” M. Epilepsy Res Treat.,2013:932790 (2013).;;Ogren et al., “Three-dimensional hippocampal atrophy maps distinguish two common temporal lobe seizure-onset patterns,” Epilepsia, 50(6):1361-1370 (2009).;;Osorio et al., “Real-Time Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset”, Epilepsia, 39(6):615-627 (1998).;;Perucca et al., “Intracranial electroencephalographic seizure-onset patterns: effect of underlying pathology,” J. Brain: 137:183-196 (2014).;;Popovych et al., “Desynchronizing electrical and sensory coordinated reset neuromodulation”, Frontiers in Human Neuroscience, Mar. 20, 2012, vol. 6, Article 58.;;Schiller et al., “Characterization and comparison of local onset and remote propagated electrographic seizures recorded with intracranial electrodes,” Epilepsia,39:380-388 (1998).;;Skarpaas et al., “Clinical and electrocorticographic response to antiepileptic drugs in patients treated with responsive stimulation”, Epilepsy & Behavior 83, 192-200, (2018).;;Tass et al., “Long-lasting desynchronization in rat hippocampal slice induced by coordinated reset stimulation”, Physical Review F 80, 011902 (2009).;;Tass et al., “Coordinated reset has sustained aftereffects in Parkinsonian monkeys,” Ann.Neurol,72:816-820 (2012).;;Uriguen et al., “Comparison of background EEG activity of different groups of patients with idiopathic epilepsy using Shannon spectral entropy and cluster-based permutation statistical testing”. PLoS One 12, (Sep. 18, 2017).;;Van Putten et al., “Detecting temporal lobe seizures from scalp EEG recordings: a comparison of various features,” Clin.Neurophysiol.,116:2480-2489 (2005).;;Vaswani et al., “Attention is all you need”. Advances in Neural Information Processing Systems 30 (2017).;;Wackermann, “Beyond mapping: estimating complexity of multichannel EEG recordings,” Acta Neurobiol.Exp. (Wars.),56:197-208 (1996).;;Welsh et al., “A circadian rhythm of hippocampal theta activity in the mouse,” Physiol.Behav,35:533-538 (1985).;;Zeiler et al., “Visualizing and Understanding Convolutional Networks”, ArXiv:1311.2901v3, Nov. 28, 2013, pp. 1-11.",ACTIVE
130,US,B2,US 7801618 B2,153-895-849-109-127,2010-09-21,2010,US 76743207 A,2007-06-22,US 76743207 A,2007-06-22,Auto adjusting system for brain tissue stimulator,"An implantable neurostimulator for treating disorders such as epilepsy, pain, movement disorders and depression includes a detection subsystem capable of detecting a physiological condition and a therapy subsystem capable of providing a course of therapy in response to the condition. The therapy subsystem includes an auto-adjust module for automatically adjusting one or more parameters of the therapy so that the therapy subsystem can provide an adjusted parameter to the patient and solicit the patient's feedback concerning the adjustment without requiring the presence of, or immediate involvement with, a clinician or physician. The patient feedback can be analyzed by computer, clinician or a combination of both to determine an optimal range of parameters for subsequent courses of therapy. In this manner, information useful in tuning the neurostimulator therapy parameters to optimize them for individual patient can be acquired automatically outside of the traditional clinical setting, saving time and minimizing patient fatigue that otherwise would be experience in marathon, in-clinic tuning sessions. The auto-adjust module also can be configured to prompt the patient to provide feedback even when parameters are not being adjusted, so as to acquire information for a baseline or about any placebo effect when the patient is otherwise expecting changes to the therapy to be made.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2007-06-22),https://lens.org/153-895-849-109-127,Granted Patent,yes,66,15,2,153-895-849-109-127;;168-772-275-939-221,US,2,153-895-849-109-127;;168-772-275-939-221,US,0,A61N1/37247;;A61B5/0008;;A61B5/0031;;A61B5/021;;A61B5/11;;A61B5/369;;A61B5/4094;;A61B2562/0219;;A61N1/36071;;A61N1/37247;;A61B5/0008;;A61B5/0031;;A61B5/021;;A61B5/11;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2562/0219;;A61N1/36071,A61N1/36,607/59;;607/45;;607/63,1,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Gotman, J., ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalogr. Clin. Neurophysiol. (1990); 76(4): 317-24.",ACTIVE
131,US,A1,US 2008/0125830 A1,159-108-203-802-486,2008-05-29,2008,US 2862508 A,2008-02-08,US 2862508 A;;US 94175904 A,2004-09-14,Responsive Therapy for Psychiatric Disorders,"An implantable medical device is capable of delivering a form of therapy (e.g., electrical stimulation) to a region of the cingulate cortex of a patient's brain to treat a neurological event, condition or disorder, especially an event, condition, or disorder that is psychiatric in nature, such as depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders. The apparatus is also capable of detecting a signal corresponding to a characteristic of the psychiatric disorder. Methods of using the apparatus are also disclosed.",NEUROPACE INC,MORRELL MARTHA,NEUROPACE INC (2005-05-25),https://lens.org/159-108-203-802-486,Patent Application,yes,25,8,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,0,A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082;;A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082,A61N1/05,607/45,0,0,,,,DISCONTINUED
132,US,A1,US 2006/0058856 A1,009-161-362-856-039,2006-03-16,2006,US 94175904 A,2004-09-14,US 94175904 A,2004-09-14,Responsive therapy for psychiatric disorders,"An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.",NEUROPACE INC,MORRELL MARTHA,NEUROPACE INC (2005-05-25),https://lens.org/009-161-362-856-039,Patent Application,yes,20,58,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,0,A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082;;A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082,A61N1/34,607/46,0,0,,,,EXPIRED
133,US,A1,US 2008/0125831 A1,077-354-290-588-756,2008-05-29,2008,US 2869908 A,2008-02-08,US 2869908 A;;US 94175904 A,2004-09-14,Responsive Therapy for Psychiatric Disorders,"A medical device is capable of delivering a form of stimulation (e.g., electrical stimulation) to a region of the cingulate cortex of the human brain to treat a neurological event, condition or disorder, especially an event, condition, or disorder that is psychiatric in nature, such as depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders. The device additionally or alternatively may be capable of detecting a biological marker or changes in a biological marker corresponding to the neurological event, condition or disorder. Methods of using the device are also disclosed.",NEUROPACE INC,MORRELL MARTHA,NEUROPACE INC (2005-05-25),https://lens.org/077-354-290-588-756,Patent Application,yes,25,13,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,0,A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082;;A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082,A61N1/05,607/45,0,0,,,,DISCONTINUED
134,US,A1,US 2005/0228249 A1,121-788-413-509-555,2005-10-13,2005,US 82178904 A,2004-04-09,US 82178904 A,2004-04-09,Implantable lead system with seed electrodes,"A medical electrical lead system for neurological applications has a distal portion having a plurality of independently positionable seed electrodes, each of which may be connected via an interface to an implantable medical device. The interface allows the seed electrodes to be positioned, then excess wire trimmed, facilitating simplified connection of multiple independent electrodes to a single device. Seed electrodes according to the invention are small, have relatively low mass, and are minimally destructive of surrounding tissue.",NEUROPACE INC,BOLING C L,NEUROPACE INC (2004-12-16),https://lens.org/121-788-413-509-555,Patent Application,yes,8,42,2,121-788-413-509-555;;198-852-525-187-770,US,2,121-788-413-509-555;;198-852-525-187-770,US,0,A61N1/0529;;A61B5/291;;A61N1/0539;;A61N1/0529;;A61N1/0539,A61B5/04;;A61B5/0478;;A61N1/05,600/378;;607/116,0,0,,,,EXPIRED
135,US,B2,US 6459936 B2,025-746-519-808-224,2002-10-01,2002,US 93217501 A,2001-08-17,US 93217501 A;;US 62897700 A;;US 45030399 A;;US 95786997 A,1997-10-27,Methods for responsively treating neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-11-09),https://lens.org/025-746-519-808-224,Granted Patent,yes,5,240,2,082-643-935-874-509;;025-746-519-808-224,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36135;;A61N1/36017;;A61N1/36025;;A61N1/36064;;A61N1/36067;;A61N1/36075;;A61N1/37252;;A61N1/36135;;A61N1/36017;;A61N1/36025;;A61N1/36064;;A61N1/36067;;A61N1/36075;;A61N1/37252,A61N1/36,607/45,0,0,,,,EXPIRED
136,US,B2,US 7353065 B2,093-143-588-364-149,2008-04-01,2008,US 94175904 A,2004-09-14,US 94175904 A,2004-09-14,Responsive therapy for psychiatric disorders,"An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.",NEUROPACE INC,MORRELL MARTHA,NEUROPACE INC (2005-05-25),https://lens.org/093-143-588-364-149,Granted Patent,yes,20,148,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,4,093-143-588-364-149;;077-354-290-588-756;;159-108-203-802-486;;009-161-362-856-039,US,0,A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082;;A61N1/36071;;A61N1/0531;;A61N1/0539;;A61N1/36082,A61N1/05,607/45,1,1,009-083-260-830-814,10916262;;10.1109/10.846685,"Weiland and Anderson, ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",EXPIRED
137,US,A1,US 2008/0319511 A1,168-772-275-939-221,2008-12-25,2008,US 76743207 A,2007-06-22,US 76743207 A,2007-06-22,AUTO ADJUSTING SYSTEM FOR BRAIN TISSUE STIMULATOR,"An implantable neurostimulator for treating disorders such as epilepsy, pain, movement disorders and depression includes a detection subsystem capable of detecting a physiological condition and a therapy subsystem capable of providing a course of therapy in response to the condition. The therapy subsystem includes an auto-adjust module for automatically adjusting one or more parameters of the therapy so that the therapy subsystem can provide an adjusted parameter to the patient and solicit the patient's feedback concerning the adjustment without requiring the presence of, or immediate involvement with, a clinician or physician. The patient feedback can be analyzed by computer, clinician or a combination of both to determine an optimal range of parameters for subsequent courses of therapy. In this manner, information useful in tuning the neurostimulator therapy parameters to optimize them for individual patient can be acquired automatically outside of the traditional clinical setting, saving time and minimizing patient fatigue that otherwise would be experience in marathon, in-clinic tuning sessions. The auto-adjust module also can be configured to prompt the patient to provide feedback even when parameters are not being adjusted, so as to acquire information for a baseline or about any placebo effect when the patient is otherwise expecting changes to the therapy to be made.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2007-06-22),https://lens.org/168-772-275-939-221,Patent Application,yes,66,95,2,153-895-849-109-127;;168-772-275-939-221,US,2,153-895-849-109-127;;168-772-275-939-221,US,0,A61N1/37247;;A61B5/0008;;A61B5/0031;;A61B5/021;;A61B5/11;;A61B5/369;;A61B5/4094;;A61B2562/0219;;A61N1/36071;;A61N1/37247;;A61B5/0008;;A61B5/0031;;A61B5/021;;A61B5/11;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2562/0219;;A61N1/36071,A61N1/36;;A61B5/04,607/59;;600/544,0,0,,,,ACTIVE
138,US,B2,US 8412333 B2,144-608-584-800-922,2013-04-02,2013,US 201113106747 A,2011-05-12,US 201113106747 A;;US 14206305 A;;US 54326400 A,2000-04-05,Neurostimulator involving stimulation strategies and process for using it,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",PLESS BENJAMIN D;;NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/144-608-584-800-922,Granted Patent,yes,102,0,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/00;;A61B5/04;;A61N1/36,607/45;;607/62;;607/72;;600/544,32,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"U.S. Appl. No. 13/106,729 Office Action mailed Jul. 25, 2011.;;U.S. Appl. No. 13/106,729 Office Action mailed Nov. 14, 2011.;;U.S. Appl. No. 13/106,729 Office Action mailed Apr. 25, 2012.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Andriano, K.P., et al., ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical implants,"" Journal of Applied Biornaterials (1994) 5: 133-140.;;Chkhenkeli, S., et al., ""Effects of Therapeutic Stimulation of Nucleus Caudate on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact. Funct. Neurosurg., 1997, 69: 221-224.;;Cooper, I.S., et al., ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" in the Cerebellum, Epilepsy and Behavior, Cooper, I.S., et al., eds. Pleman Press: New York (1974) pp. 119-171.;;Cooper, I.S., et al., ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. (1977/1978) 40: 124-134.;;Cooper, I.S., et al., ""Effects of Cerebellar Stimulation on Epilepsy, the EEG, and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, 1978; 349-354.;;Davis, R. et al ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. (1992) 58: 200-208.;;Eppley, B.L., et al., ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery (1992) 3(4): 190-196.;;Gerlach, K. L., ""In-Vivo and Clinical Evaluations of Poly(L-Lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials (1993) 13: 21-28.;;Gotman, J., ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology (1999) 16(2): 130-140.;;Osario, I., et al., ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia (1995) 36 (Suppl. 4): 4, Abstract No. 1.04.;;Qu, H., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-2254.;;Sayler, K.E., et al., ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery (1994) 93(4): 705-713.;;Schiff, S., et al., ""Controlling Chaos in the Brain,"" Nature (1994) 370: 615-620.;;Thaller, S.R., at al., ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery (1992) 2(4): 168-173.;;Velasco, F., et al., ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia (1995) 36(1): 63-71.;;Communication Dated Mar. 1, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246.1.;;Applicant Response dated Apr. 13, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication Dated Mar. 8, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303245.3.;;Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245.3.;;Applicant Response dated Apr. 20, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245.3.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303245.3.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.",EXPIRED
139,US,B2,US 8326417 B2,047-800-269-701-709,2012-12-04,2012,US 201113106729 A,2011-05-12,US 201113106729 A;;US 14206305 A;;US 54326400 A,2000-04-05,Neurostimulator involving stimulation strategies and process for using it,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",PLESS BENJAMIN D;;NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/047-800-269-701-709,Granted Patent,yes,103,0,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/00;;A61B5/04;;A61N1/36,607/2;;607/3;;607/45;;607/62;;600/544,32,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"U.S. Appl. No. 13/106,747 Office Action mailed Jul. 26, 2011.;;U.S. Appl. No. 13/106,747 Office action mailed Oct. 20, 2011.;;U.S. Appl. No. 13/106,747 Office Action mailed Apr. 9, 2012.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Andriano, K.P., et al., ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical implants,"" Journal of Applied Biornaterials (1994) 5: 133-140.;;Chkhenkeli, S., et al., ""Effects of Therapeutic Stimulation of Nucleus Caudate on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact. Funct. Neurosurg., 1997, 69: 221-224.;;Cooper, I.S., et al., ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" in the Cerebellum, Epilepsy and Behavior, Cooper, I.S., et al., eds. Pleman Press: New York (1974) pp. 119-171.;;Cooper, I.S., et al., ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. (1977/1978) 40: 124-134.;;Cooper, I.S., et al., ""Effects of Cerebellar Stimulation on Epilepsy, the EEG, and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, 1978; 349-354.;;Davis, R. et al., ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. (1992) 58: 200-208.;;Eppley, B.L., et al., ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery (1992) 3(4): 190-196.;;Gerlach, K. L., ""In-Vivo and Clinical Evaluations of Poly(L-Lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials (1993) 13: 21-28.;;Gotman, J., ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology (1999) 16(2): 130-140.;;Osario, I., et al., ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia (1995) 36 (Suppl. 4): 4, Abstract No. 1.04.;;Qu, H., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-2254.;;Sayler, K.E., et al., ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery (1994) 93(4): 705-713.;;Schiff, S., et al., ""Controlling Chaos in the Brain,"" Nature (1994) 370: 615-620.;;Thaller, S.R., at al., ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery (1992) 2(4): 168-173.;;Velasco, F., et al., ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia (1995) 36(1): 63-71.;;Communication Dated Mar. 1, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246.1.;;Applicant Response dated Apr. 13, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication Dated Mar. 8, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303245.3.;;Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245.3.;;Applicant Response dated Apr. 20, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245.3.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303245.3.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.",EXPIRED
140,US,B2,US 8073544 B2,108-973-638-535-045,2011-12-06,2011,US 14206305 A,2005-05-31,US 14206305 A;;US 54326400 A,2000-04-05,Neurostimulator involving stimulation strategies and process for using it,"This is a neurostimulator that is configured to treat epilepsy and other neurological disorders using certain stimulation strategies, particularly changing various pulse parameters, during the imposition of a burst of those pulses. The invention includes the processes embodying those stimulation strategies.",PLESS BENJAMIN D;;NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2000-11-13),https://lens.org/108-973-638-535-045,Granted Patent,yes,112,25,11,108-973-638-535-045;;047-800-269-701-709;;089-133-065-882-20X;;088-366-887-252-89X;;040-390-197-256-947;;074-475-978-353-041;;124-510-298-765-088;;144-608-584-800-922;;129-800-313-548-338;;017-566-714-168-420;;109-215-788-779-911,EP;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178;;A61N1/36064;;A61N1/36082;;A61N1/36135;;A61N1/36178,A61N1/00;;A61B5/05;;A61N1/36,607/45;;607/62;;607/72;;600/544,25,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Communication Dated Mar. 1, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246.1.;;Applicant Response dated Apr. 13, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 18, 2005 for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303246.1.;;Communication Dated Mar. 8, 2004 European Search Report for counterpart foreign application EP Patent Application No. 01303245.3.;;Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245.3.;;Applicant Response dated Apr. 20, 2006 to Communication pursuant to Article 96(2) EPC dated Oct. 14, 2005 for counterpart foreign application EP Patent Application No. 01303245.3.;;Communication pursuant to Article 96(2) EPC dated Mar. 9, 2007 for counterpart foreign application EP Patent Application No. 01303245.3.;;Andriano, K.P. et al. (1994). ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants,"" Journal of Applied Biomaterials 5:133-140.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patents with Intractable Epilepsy,"" Stereotact Funct Neurosurg 69:221-224.;;Cooper, I.S. et al. (1974). ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" InThe Cerebellum, Epilepsy, and Behavior. Cooper, I.S. et al., eds., Pleman Press:New York, pp. 119-171.;;Cooper, I.S. et al. (1977/78). ""Saftey and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. 40: 124-134.;;Cooper, I.S. and Upton, A.R.M. (1978). ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992). ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. 58:200-208.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery 3(4):190-196.;;Gerlach, K.L. (1993). ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials 13:21-28.;;Gotman, J. (1999). ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology 16(2):130-140.;;Osario, I. et al (1995). ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia, 36(supplement 4):4.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology 45:2250-2254.;;Sayler, K.E. et al. (1994). ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery 93(4):705-713.;;Schiff, S. et al. (1994). ""Controlling Chaos in the Brain,"" Nature 370:615-620.;;Thaller, S.R. et al. (1992). ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery 2(4):168-173.;;Velasco, F. et al. (1995). ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia 36(1):63-71.;;U.S. Appl. No. 13/106,729 Office action mailed Jul. 25, 2011.",EXPIRED
141,US,A,US 6161045 A,196-467-262-751-929,2000-12-12,2000,US 32340799 A,1999-06-01,US 32340799 A,1999-06-01,Method for determining stimulation parameters for the treatment of epileptic seizures,Disclosed is a method for determining the optimal electrical stimulation parameters for intracranial stimulation therapy before implantation of a device for electrical stimulation therapy for epilepsy. This method would be used during intracranial electrical stimulation and monitoring procedures which are currently used to identify an epileptic region and map regional brain function prior to resective surgery. This method is used to determine therapeutic stimulation parameters during an evaluation procedure that can be carried out prior to the implantation of a closed-loop electrical stimulation device that is responsive to the onset of an epileptic seizure.,NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;MORELL MARTHA J;;GIBB BARBARA,NEUROPACE INC (2000-08-22),https://lens.org/196-467-262-751-929,Granted Patent,yes,3,231,1,196-467-262-751-929,US,1,196-467-262-751-929,US,0,A61N1/3615;;A61B5/378;;A61B5/4094;;A61N1/36064;;A61N1/36167;;A61N1/3615;;A61B5/378;;A61B5/4094;;A61N1/36064;;A61N1/36167,A61B5/0484;;A61N1/36,607/45,0,0,,,,EXPIRED
142,US,A1,US 2009/0112280 A1,072-952-591-612-789,2009-04-30,2009,US 26214608 A,2008-10-30,US 26214608 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/072-952-591-612-789,Patent Application,yes,47,60,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05,607/45,0,0,,,,ACTIVE
143,US,A1,US 2015/0039066 A1,066-559-342-073-544,2015-02-05,2015,US 201414506815 A,2014-10-06,US 201414506815 A;;US 26095808 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/066-559-342-073-544,Patent Application,yes,3,8,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05,607/116,0,0,,,,ACTIVE
144,US,A1,US 2015/0025610 A1,155-840-077-313-770,2015-01-22,2015,US 201414506817 A,2014-10-06,US 201414506817 A;;US 26214608 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/155-840-077-313-770,Patent Application,yes,3,8,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05,607/116,0,0,,,,ACTIVE
145,US,A1,US 2016/0339243 A1,161-945-437-443-949,2016-11-24,2016,US 201615225741 A,2016-08-01,US 201615225741 A;;US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Methods, devices, and systems induce neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Methods, devices, and systems identify where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces include diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/161-945-437-443-949,Patent Application,yes,2,11,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/36;;A61B90/10;;A61N1/04;;A61N1/05;;A61N1/20;;A61N1/30;;A61N5/06,,0,0,,,,ACTIVE
146,US,A1,US 2009/0112278 A1,042-262-060-172-466,2009-04-30,2009,US 24373308 A,2008-10-01,US 24373308 A;;US 92980107 A,2007-10-30,"Systems, Methods and Devices for a Skull/Brain Interface","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2008-10-02),https://lens.org/042-262-060-172-466,Patent Application,yes,37,208,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/00,607/45,0,0,,,,DISCONTINUED
147,US,B2,US 6597953 B2,111-807-146-929-878,2003-07-22,2003,US 78917101 A,2001-02-20,US 78917101 A,2001-02-20,Furcated sensing and stimulation lead,"A furcated medical electrical lead for neurological applications has a distal portion having a plurality of distal end segments, each of which bears at least one distal electrode for electrographic sensing or electrical stimulation. The furcated configuration allows each distal end segment to be implanted in a different site in the patient's brain. In contrast to surface strip or grid electrodes, shallow implantation reduces the probability that any of the electrodes will move away from the surface of the brain due to atrophy or other phenomena.",NEUROPACE INC,BOLING C LANCE,NEUROPACE INC. A DELAWARE CORPORATION (2001-02-20),https://lens.org/111-807-146-929-878,Granted Patent,yes,8,106,2,111-807-146-929-878;;006-724-357-094-911,US,2,111-807-146-929-878;;006-724-357-094-911,US,0,A61N1/0534;;A61N1/0531;;A61N1/0539;;A61N1/0534;;A61N1/0531;;A61N1/0539,A61N1/05,607/45;;607/122,0,0,,,,EXPIRED
148,US,A1,US 2022/0379118 A1,070-724-445-045-598,2022-12-01,2022,US 202217882482 A,2022-08-05,US 202217882482 A;;US 202016906914 A;;US 201715849492 A;;US 201762575351 P,2017-10-20,SYSTEMS AND METHODS FOR CLINICAL DECISION MAKING FOR A PATIENT RECEIVING A NEUROMODULATION THERAPY BASED ON DEEP LEARNING,"Information relevant to making clinical decisions for a patient is identified based on electrical activity records of the patient's brain and electrical activity records of other patients' brains. A deep learning algorithm is applied to an electrical activity record of the patient, i.e., an input record, and to a set of electrical activity records of other patients, i.e., a set of search records, to obtain an input feature vector of the patient and a set of search feature vectors, each including features extracted by the deep learning algorithm. A similarities algorithm is applied to the input feature vector and the set of search feature vectors to identify a subset of search records most like the input record. Clinical information associated with one or more search records in the identified subset of search records is extracted from a database and used to make decisions regarding the patient's neuromodulation therapies.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K,NEUROPACE INC (2018-01-10),https://lens.org/070-724-445-045-598,Patent Application,yes,0,0,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,0,A61N1/36139;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/40;;G16H50/20;;G16H50/70;;A61N1/36139;;A61N1/0534;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/70,A61N1/36;;A61N1/05;;A61N1/372,,0,0,,,,DISCONTINUED
149,US,B2,US 11439826 B2,173-947-234-281-155,2022-09-13,2022,US 202016906914 A,2020-06-19,US 202016906914 A;;US 201715849492 A;;US 201762575351 P,2017-10-20,Systems and methods for clinical decision making for a patient receiving a neuromodulation therapy based on deep learning,"Information relevant to making clinical decisions for a patient is identified based on electrical activity records of the patient's brain and electrical activity records of other patients' brains. A deep learning algorithm is applied to an electrical activity record of the patient, i.e., an input record, and to a set of electrical activity records of other patients, i.e., a set of search records, to obtain an input feature vector of the patient and a set of search feature vectors, each including features extracted by the deep learning algorithm. A similarities algorithm is applied to the input feature vector and the set of search feature vectors to identify a subset of search records most like the input record. Clinical information associated with one or more search records in the identified subset of search records is extracted from a database and used to make decisions regarding the patient's neuromodulation therapies.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K,NEUROPACE INC (2018-01-10),https://lens.org/173-947-234-281-155,Granted Patent,yes,68,0,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,0,A61N1/36139;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/40;;G16H50/20;;G16H50/70;;A61N1/36139;;A61N1/0534;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/70,A61N1/36;;A61N1/05;;A61N1/372;;G16H20/70,,23,16,056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;036-765-169-783-989;;023-176-465-500-421;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;058-656-369-991-112;;104-848-923-274-640;;096-532-070-721-701;;040-835-492-690-77X;;057-567-246-168-045;;059-149-073-001-124;;082-274-054-270-018,1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269;;pmc8382232;;10.1038/nature21056;;28117445;;10.1109/taslp.2018.2798811;;10.1007/s11263-015-0816-y;;26017442;;10.1038/nature14539;;15940994;;10.1109/tnn.2005.845141,"Ali Hossam Shoeb et al. “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer, S. S., Guimaraes, P., Katz, A., Kim, J., and Spencer, D. Epilepsia: “Morphological patterns of seizures recorded intracranially,” 33:537-545 (1992).;;Lee, S. A., Spencer, D. D., and Spencer, S. S. Epilepsia: “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” 41:297-307 (2000).;;Langan, Y., Nashef, L., and Sander, J. W.: “Case-control study of SUDEP,” Neurology,64:1131-1133 (2005).;;Bateman, L. M., Li, C. S., Lin, T. C., and Seyal, M. Epilepsia: “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” 51:2211-2214 (2010).;;Ali Hossam Shoeb: Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard—MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;Maryann D'Alessandro, George Vachtsevanos, Rosana Esteller, Javier Echauz, Stephen Cranstoun, Greg Worrell, Landi Parish and Brian Litt: “A multi-feature and multi-channel univariate selection process for seizure prediction”, Clinical Neurophysiology 116 (2005) 506-516.;;Isaa Conradsen, Student Member; IEEE, Sándor Beniczky, Karsten Hoppe, Peter Wolf and Helge B. D. Sorensen Member, IEEE: “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection based on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions@ieee.org.;;Alaa Kharbouch, Ali Shoeb, John Guttag, and Sydney S. Cash: “An algorithm for seizure onset detection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Yusuf U Khan, Omar Farooq and Priyanka Sharma: “Automatic Detection of Seizure Onset in Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Yizhuo Zhang, Guanghua Xu, Jing Wang, Lin Liang: “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899. Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset, Epilepsia, 39(6):615-627 (1998).;;A.J. Gabor, R.R. Leach, and F.U. Dowla: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;A.J. Gabor: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Validation and Comparison with Other Detection Strategies, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.;;Esteva et al. “Dermatologist level classification of skin cancer with deep neural networks”, Nature, vol. 542, published Feb. 2, 2017, pp. 115-118.;;Thodoro, M. et al. “Learning Robust Features using Deep Learning for Automatic Seizure Detection”, ArXiv:1608.00220, Jul. 31, 2016, pp. 1-12.;;Ling, Zhen-Huia et al. “Waveform Modeling and Generation Using Hierarchical Recurrent Neural Networks for Speech Bandwidth Extension”, IEEE/ACM Transactions on Audio, Speech, and Language Processing, vol. 26, No. 5, pp. 883-894, May 2018.;;Zeiler, Matthew D. et al. “Visualizing and Understanding Convolutional Networks”, ArXiv:1311.2901v3, Nov. 28, 2013, pp. 1-11.;;Russakovsky et al., “ImageNet Large Scale Visual Recognition Challenge”, International Journal of Computer Vision, available online Apr. 11, 2015, published Dec. 2015; vol. 115, Issue 3, DOI 10.1007/s11263-015-0816-; pp. 211-252.;;Lecun et al., “Deep Learning”, Nature, May 27, 2015, vol. 521; DOI:10.1038/nature14539; pp. 436-444.;;Xu et al., “Survey of Clustering Algorithms”, IEEE Transactions on Neural Networks, vol. 16, No. 3, May 1, 2005; 35 pages.;;Krizhevsky et al., “ImageNet Classification with Deep Convolutional Neural Networks”, NIPS'12 Proceedings of the 25th International Conference on Neural Information Processing Systems—vol. 1, pp. 1097-1105, Dec. 3, 2012.;;Desai, Sharanya, “Insights from mining large-scale human EcoG data”, ICTAL2017, The Penumbra Conference, presented Aug. 21, 2017.;;Desai et al., “Deep Learning for seizure classification and potential seizure biomarker discovery”, Abstract, published online at www.aesnet.org on Nov. 20, 2017.",ACTIVE
150,US,B2,US 9167976 B2,066-216-291-032-392,2015-10-27,2015,US 201414506811 A,2014-10-06,US 201414506811 A;;US 26095808 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/066-216-291-032-392,Granted Patent,yes,53,11,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61B5/0478;;A61B5/04;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008, comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci. 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol Number: 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
151,US,A1,US 2022/0347473 A1,029-698-356-065-877,2022-11-03,2022,US 202217853675 A,2022-06-29,US 202217853675 A;;US 201816218373 A;;US 201615225741 A;;US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Methods, devices, and systems induce neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Methods, devices, and systems identify where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces include diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/029-698-356-065-877,Patent Application,yes,0,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/36;;A61B5/00;;A61B8/08;;A61B90/10;;A61N1/04;;A61N1/05;;A61N1/20;;A61N1/30;;A61N5/06,,0,0,,,,DISCONTINUED
152,US,B2,US 9289143 B2,158-594-060-630-516,2016-03-22,2016,US 201414506817 A,2014-10-06,US 201414506817 A;;US 26214608 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/158-594-060-630-516,Granted Patent,yes,53,11,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05;;A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/U52008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
153,US,A1,US 2020/0316383 A1,091-123-378-888-082,2020-10-08,2020,US 202016906914 A,2020-06-19,US 202016906914 A;;US 201715849492 A;;US 201762575351 P,2017-10-20,SYSTEMS AND METHODS FOR CLINICAL DECISION MAKING FOR A PATIENT RECEIVING A NEUROMODULATION THERAPY BASED ON DEEP LEARNING,"Information relevant to making clinical decisions for a patient is identified based on electrical activity records of the patient's brain and electrical activity records of other patients' brains. A deep learning algorithm is applied to an electrical activity record of the patient, i.e., an input record, and to a set of electrical activity records of other patients, i.e., a set of search records, to obtain an input feature vector of the patient and a set of search feature vectors, each including features extracted by the deep learning algorithm. A similarities algorithm is applied to the input feature vector and the set of search feature vectors to identify a subset of search records most like the input record. Clinical information associated with one or more search records in the identified subset of search records is extracted from a database and used to make decisions regarding the patient's neuromodulation therapies.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K,NEUROPACE INC (2018-01-10),https://lens.org/091-123-378-888-082,Patent Application,yes,0,1,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,0,A61N1/36139;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/40;;G16H50/20;;G16H50/70;;A61N1/36139;;A61N1/0534;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/70,A61N1/36;;A61N1/05;;A61N1/372,,0,0,,,,ACTIVE
154,US,B1,US 6618623 B1,082-848-745-631-804,2003-09-09,2003,US 72493600 A,2000-11-28,US 72493600 A,2000-11-28,Ferrule for cranial implant,"A ferrule for retaining an implantable device within a cranial opening of a patient is set forth. The ferrule includes a shelf portion, a wall portion, and at least one supporting tab connected to the wall portion. The shelf portion has an inner surface and an outer surface. The inner surface of the shelf portion substantially conforms to an implantable device. The wall portion has an inner surface and an outer surface and encompasses the shelf portion. The inner surface of the wall portion substantially conforms to the implantable device and the outer surface of the wall portion substantially conforms to the cranial opening.",NEUROPACE INC,PLESS BENJAMIN D;;POTTS DENNIS,NEUROPACE INC (2001-06-01),https://lens.org/082-848-745-631-804,Granted Patent,yes,15,156,1,082-848-745-631-804,US,3,161-540-775-455-058;;049-643-719-595-162;;082-848-745-631-804,US,0,A61M39/0247;;A61N1/0539;;A61B2090/103;;A61N1/37514;;A61N1/37518;;A61M39/0247;;A61N1/0539;;A61B2090/103;;A61N1/37514;;A61N1/37518,A61M1/00;;A61N1/05,607/45;;607/116,9,0,,,"U.S. patent application Ser. No. 09/517,797, David R. Fischell, filed Mar. 2, 2000.;;U.S. patent application Ser. No. 09/543,264, Benjamin D. Pless, filed Apr. 5, 2000.;;U.S. patent application Ser. No. 09/543,450, Benjamin D. Pless, filed Apr. 5, 2000.;;U.S. patent application Ser. No. 09/711,663, David Greene, filed Nov. 9, 2000.;;U.S. patent application Ser. No. 09/373,676, Fischell et al., filed Aug. 13, 1999.;;U.S. patent application Ser. No. 09/557,168, Fischell et al., filed Apr. 19, 2000.;;U.S. patent application Ser. No. 09/609,086, Fischell et al., filed Jun. 30, 2000.;;U.S. patent application Ser. No. 09/706,322, Pless, filed Nov. 3, 2000.;;U.S. patent application Ser. No. 09/724,805, Pless et al., filed Nov. 28, 2000.",EXPIRED
155,US,A1,US 2014/0296646 A1,192-731-136-866-068,2014-10-02,2014,US 201414223478 A,2014-03-24,US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/192-731-136-866-068,Patent Application,yes,4,27,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05,600/202;;600/235,0,0,,,,INACTIVE
156,US,B2,US 10188860 B2,162-044-130-570-562,2019-01-29,2019,US 201615225741 A,2016-08-01,US 201615225741 A;;US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Methods, devices, and systems induce neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Methods, devices, and systems identify where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces include diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/162-044-130-570-562,Granted Patent,yes,59,9,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05;;A61B5/00;;A61B8/08;;A61B18/02;;A61B18/14;;A61B18/18;;A61B90/10;;A61N1/04;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,,41,31,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028,"Cappa, S. F. “Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients”, (Sep. 26, 2008), comment on Monti et al., “Improved Naming After Transcranial Direct Current Stimulation in Aphasia” (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (dated Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (dated May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor thresold, 2002, Epilepsia 43:932-935.;;Kennedy et al., “Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,” The Phoenix, Feb. 7, 2007, www.thephoenix.com/article_ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A_2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, the New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.",ACTIVE
157,US,B2,US 8140150 B2,136-395-653-456-306,2012-03-20,2012,US 77064310 A,2010-04-29,US 77064310 A;;US 37170106 A,2006-03-08,Implantable seizure monitor,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",GREENE DAVID;;NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/136-395-653-456-306,Granted Patent,yes,30,4,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544;;600/545,7,4,143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;124-403-369-942-149,10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;52443;;10.1016/0013-4694(75)90051-6,"Cyberonics, Inc., www.vnstherapy.com NeuroCyberonic Prosthesis (NCP)).;;Medtronic, Inc., www.activadbs.com|about-activa.asp.;;Medtronic (2003) ""Your Activa (tm) Therapy (With a Kinetra (trn) or Soletra (trn) Neurostimulator,"" Patient Manual.;;Gotrnan, J, ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalogr. and Clinical Neurophysiol. (1990) 76(4):317-24.;;Qu, R., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-4.;;Qu, R., et al., ""A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use As a Warning Device,"" IEEE Transactions on Biomedical Engineering (1997) 44(2): II5-22.;;Wagner, R.R., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. and Clinical Neurophysiol. (1975) 39(5): 499-506.",ACTIVE
158,US,A1,US 2019/0111258 A1,024-906-001-418-962,2019-04-18,2019,US 201816218373 A,2018-12-12,US 201816218373 A;;US 201615225741 A;;US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Methods, devices, and systems induce neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Methods, devices, and systems identify where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces include diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/024-906-001-418-962,Patent Application,yes,0,3,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/36;;A61B5/00;;A61B8/08;;A61B90/10;;A61N1/04;;A61N1/05;;A61N1/20;;A61N1/30;;A61N5/06,,0,0,,,,ACTIVE
159,US,B2,US 8249712 B2,181-858-323-032-148,2012-08-21,2012,US 201113293476 A,2011-11-10,US 201113293476 A;;US 49081806 A,2006-07-21,Treatment and warning of recurring therapy and other events using an implantable device,"An implantable neurostimulator system is capable of responsively treating epileptiform activity with electrical stimulation and other therapies and is further configured to detect periods of increased susceptibility to clinical seizures. The event densities of therapy applications (or detections or other events) in time are observed and calculated, and if high enough, measures are taken to warn the patient or provide additional therapy.",PLESS BENJAMIN D;;NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2006-08-28),https://lens.org/181-858-323-032-148,Granted Patent,yes,11,0,4,031-694-601-230-826;;177-098-343-393-123;;066-182-066-272-856;;181-858-323-032-148,US,4,031-694-601-230-826;;177-098-343-393-123;;066-182-066-272-856;;181-858-323-032-148,US,0,A61N1/36082;;A61B5/24;;A61B5/30;;A61B5/369;;A61B5/4094;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36082;;A61B5/24;;A61B5/30;;A61B5/369;;A61B5/4094;;A61N1/0529;;A61N1/0531;;A61N1/0539,A61N1/372,607/45;;607/46,4,2,124-403-369-942-149;;009-083-260-830-814,52443;;10.1016/0013-4694(75)90051-6;;10916262;;10.1109/10.846685,"http://www.siumed.edu/neuro/epilepsy/news/pressreleases/VNSpress.html (NeuroCybernetic Prosthesis (NCP) from Cyberonics, Inc.).;;http://www.medtronic.com/physician/activa/; http://www.medtronic.com/physician/activa/surg-components.html.;;Wagner, H.R., et al. ""Suppression of Cortical Eplieptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. 1975: 39(5): 499-506.;;Weiland, J. D., et al., ""Chronic Neural Stimulation With Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 74: 911-918 (2000).",INACTIVE
160,US,B2,US 8073545 B2,066-182-066-272-856,2011-12-06,2011,US 49081806 A,2006-07-21,US 49081806 A,2006-07-21,Treatment and warning of recurring therapy and other events using an implantable device,"An implantable neurostimulator system is capable of responsively treating epileptiform activity with electrical stimulation and other therapies and is further configured to detect periods of increased susceptibility to clinical seizures. The event densities of therapy applications (or detections or other events) in time are observed and calculated, and if high enough, measures are taken to warn the patient or provide additional therapy.",PLESS BENJAMIN D;;NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2006-08-28),https://lens.org/066-182-066-272-856,Granted Patent,yes,11,0,4,031-694-601-230-826;;177-098-343-393-123;;066-182-066-272-856;;181-858-323-032-148,US,4,031-694-601-230-826;;177-098-343-393-123;;066-182-066-272-856;;181-858-323-032-148,US,0,A61N1/36082;;A61B5/24;;A61B5/30;;A61B5/369;;A61B5/4094;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36082;;A61B5/24;;A61B5/30;;A61B5/369;;A61B5/4094;;A61N1/0529;;A61N1/0531;;A61N1/0539,A61N1/372,607/45;;607/46,4,2,124-403-369-942-149;;009-083-260-830-814,52443;;10.1016/0013-4694(75)90051-6;;10916262;;10.1109/10.846685,"http://www.siumed.edu/neuro/epilepsy/news/pressreleases/VNSpress.html (NeuroCybernetic Prosthesis (NCP) from Cyberonics, Inc.).;;http://www.medtronic.com/physician/activa/; http://www.medtronic.com/physician/activa/surg-components.html.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. 1975: 39(5): 499-506.;;Weiland, J. D., et al., ""Chronic Neural Stimulation With Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",ACTIVE
161,US,B2,US 9387320 B2,105-495-511-338-180,2016-07-12,2016,US 201514853858 A,2015-09-14,US 201514853858 A;;US 201414506819 A;;US 26214608 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/105-495-511-338-180,Granted Patent,yes,55,13,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N7/02;;A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61F7/00;;A61F7/12;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06;;A61N7/00,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",INACTIVE
162,US,B2,US 9167977 B2,179-924-638-786-13X,2015-10-27,2015,US 201414506815 A,2014-10-06,US 201414506815 A;;US 26095808 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/179-924-638-786-13X,Granted Patent,yes,53,12,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., a sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
163,US,A1,US 2009/0112277 A1,038-175-035-286-453,2009-04-30,2009,US 92980107 A,2007-10-30,US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","A method is disclosed for conveying a form of neuromodulation (e.g., electrical, chemical, optical, or thermal) from an external neuromodulation source interiorly of the skull to modulate neural activity. The method involves forming one or more apertures through or partially through the skull to provide an interface for delivering the neuromodulation. A method is disclosed for sensing one or more parameters characteristic of one or more states of the brain through an interface formed with one or more apertures extending all the way or part of the way through the skull. A device is disclosed that is implantable in the skull of a human patient to provide an interface between the exterior of the skull and the brain that includes a channel of a length sufficient to traverse the entire thickness of the skull or at least a part of the thickness of the skull. The channels may be provided in a wide variety of shapes and sizes with or without inner lumens. The channels may be configured for ion conduction of electrical signals, enabling DC or near DC stimulation of target neurons. Methods and devices for transferring energy (e.g., thermal energy) generated inside the skull to the outside of the skull and vice versa are also disclosed.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/038-175-035-286-453,Patent Application,yes,48,35,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05;;A61B18/00,607/45;;607/113,0,0,,,,ACTIVE
164,US,B2,US 11406824 B2,191-986-122-665-001,2022-08-09,2022,US 201816218373 A,2018-12-12,US 201816218373 A;;US 201615225741 A;;US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Methods, devices, and systems induce neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Methods, devices, and systems identify where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces include diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/191-986-122-665-001,Granted Patent,yes,71,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/36;;A61B5/00;;A61B8/08;;A61B18/02;;A61B18/14;;A61B18/18;;A61B90/10;;A61N1/04;;A61N1/05;;A61N1/20;;A61N1/30;;A61N5/06,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. “Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients”, (Sep. 26, 2008), comment on Monti et al., “Improved Naming After Transcranial Direct Current Stimulation in Aphasia” (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (dated Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (dated May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629¬-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., “Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,” The Phoenix, Feb. 7, 2007, www.thephoenix.com/article_ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A_2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006 Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., “Improved Naming After Transcranial Direct Current Stimulation in Aphasia,” Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., “Improved Naming After Transcranial Direct Current Stimulation in Aphasia,” Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
165,US,B2,US 9375564 B2,023-398-524-770-901,2016-06-28,2016,US 201514856475 A,2015-09-16,US 201514856475 A;;US 201414506815 A;;US 26095808 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/023-398-524-770-901,Granted Patent,yes,55,11,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61F7/00;;A61F7/12;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06;;A61N7/00;;A61N7/02,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",INACTIVE
166,US,B2,US 9167978 B2,163-779-370-904-22X,2015-10-27,2015,US 201414506819 A,2014-10-06,US 201414506819 A;;US 26214608 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/163-779-370-904-22X,Granted Patent,yes,53,11,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05;;A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/04;;A61N5/06,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-1422.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-453.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
167,US,A1,US 2016/0296746 A1,119-200-191-559-618,2016-10-13,2016,US 201615177311 A,2016-06-08,US 201615177311 A;;US 201514856475 A;;US 201414506815 A;;US 26095808 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/119-200-191-559-618,Patent Application,yes,0,9,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05;;A61F7/12;;A61N1/20;;A61N1/30;;A61N1/36;;A61N2/00;;A61N5/06;;A61N7/02,,0,0,,,,ACTIVE
168,US,A1,US 2016/0001065 A1,141-823-174-236-188,2016-01-07,2016,US 201514856475 A,2015-09-16,US 201514856475 A;;US 201414506815 A;;US 26095808 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/141-823-174-236-188,Patent Application,yes,1,8,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05,,0,0,,,,INACTIVE
169,US,A1,US 2015/0025408 A1,100-933-931-266-238,2015-01-22,2015,US 201414506811 A,2014-10-06,US 201414506811 A;;US 26095808 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/100-933-931-266-238,Patent Application,yes,0,9,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61B5/0478,600/544,0,0,,,,ACTIVE
170,US,B2,US 9597493 B2,117-795-738-878-878,2017-03-21,2017,US 201615177311 A,2016-06-08,US 201615177311 A;;US 201514856475 A;;US 201414506815 A;;US 26095808 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/117-795-738-878-878,Granted Patent,yes,63,8,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05;;A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61F7/00;;A61F7/12;;A61N1/20;;A61N1/30;;A61N1/36;;A61N2/00;;A61N5/06;;A61N7/00;;A61N7/02,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 17:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical maging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
171,US,B2,US 9440064 B2,101-671-075-442-727,2016-09-13,2016,US 201414223478 A,2014-03-24,US 201414223478 A;;US 24373308 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Methods, devices, and systems induce neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Methods, devices, and systems identify where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces include diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC,WINGEIER BRETT;;CHAO DANIEL;;PLESS BENJAMIN;;TCHENG THOMAS,NEUROPACE INC (2008-10-02),https://lens.org/101-671-075-442-727,Granted Patent,yes,55,27,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61B5/00;;A61B8/08;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/05;;A61N1/30;;A61N1/36;;A61N5/06,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Simulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al, Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neurol. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/articie-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current simulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol Number: 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04-14/1573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",INACTIVE
172,US,B2,US 10729907 B2,068-761-717-360-825,2020-08-04,2020,US 201715849492 A,2017-12-20,US 201715849492 A;;US 201762575351 P,2017-10-20,Systems and methods for clinical decision making for a patient receiving a neuromodulation therapy based on deep learning,"Information relevant to making clinical decisions for a patient is identified based on electrical activity records of the patient's brain and electrical activity records of other patients' brains. A deep learning algorithm is applied to an electrical activity record of the patient, i.e., an input record, and to a set of electrical activity records of other patients, i.e., a set of search records, to obtain an input feature vector of the patient and a set of search feature vectors, each including features extracted by the deep learning algorithm. A similarities algorithm is applied to the input feature vector and the set of search feature vectors to identify a subset of search records most like the input record. Clinical information associated with one or more search records in the identified subset of search records is extracted from a database and used to make decisions regarding the patient's neuromodulation therapies.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K,NEUROPACE INC (2018-01-10),https://lens.org/068-761-717-360-825,Granted Patent,yes,67,1,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,0,A61N1/36139;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/40;;G16H50/20;;G16H50/70;;A61N1/36139;;A61N1/0534;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/70,A61N1/36;;A61N1/05;;A61N1/372;;G16H20/70,,23,16,057-567-246-168-045;;059-149-073-001-124;;082-274-054-270-018;;056-361-838-782-639;;064-968-594-730-904;;001-853-941-824-214;;121-702-832-392-419;;036-765-169-783-989;;023-176-465-500-421;;001-518-342-987-312;;020-314-878-137-978;;088-688-985-375-086;;058-656-369-991-112;;104-848-923-274-640;;096-532-070-721-701;;040-835-492-690-77X,10.1007/s11263-015-0816-y;;26017442;;10.1038/nature14539;;15940994;;10.1109/tnn.2005.845141;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1212/01.wnl.0000156352.61328.cb;;15824334;;20491872;;10.1111/j.1528-1167.2010.02594.x;;10.1016/j.clinph.2004.11.014;;15721064;;10.1109/tbme.2011.2178094;;22156944;;10.1016/j.yebeh.2012.04.118;;10.5121/ijesa.2012.2309;;10.1016/j.compbiomed.2010.09.010;;20951372;;8862115;;10.1016/s0921-884x(96)96001-4;;10.1016/0013-4694(96)96001-0;;10.1016/s0013-4694(98)00043-1;;9743269;;pmc8382232;;10.1038/nature21056;;28117445;;10.1109/taslp.2018.2798811,"Russakovsky et al., “ImageNet Large Scale Visual Recognition Challenge”, International Journal of Computer Vision, available online Apr. 11, 2015, published Dec. 2015; vol. 115, Issue 3, DOI 10.1007/s11263-015-0816-; pp. 211-252.;;Lecun et al., “Deep Learning”, Nature, May 27, 2015, vol. 521; DOI:10.1038/nature14539; pp. 436-444.;;Xu et al., “Survey of Clustering Algorithms”, IEEE Transactions on Neural Networks, vol. 16, No. 3, May 1, 2005; 35 pages.;;Krizhevsky et al., “ImageNet Classification with Deep Convolutional Neural Networks”, NIPS'12 Proceedings of the 25th International Conference on Neural Information Processing Systems—vol. 1, pp. 1097-1105, Dec. 3, 2012.;;Desai, Sharanya, “Insights from mining large-scale human EcoG data”, ICTAL2017, The Penumbra Conference, presented Aug. 21, 2017; 9 pages.;;Desai et al., “Deep Learning for seizure classification and potential seizure biomarker discovery”, Abstract, published online at www.aesnet.org on Nov. 20, 2017; 2 pages.;;Ali Hossam Shoeb, and John Guttag: “Application of Machine Learning to Epileptic Seizure Detection”, Appearing in the Proceedings of the 27th International Conference on Machine Learning, Haifa, Israel 2010, Copyright 2010.;;Spencer, S. S., Guimaraes, P., Katz, A., Kim, J., and Spencer, D. Epilepsia: “Morphological patterns of seizures recorded intracranially,” 33:537-545 (1992).;;Lee, S. A., Spencer, D. D., and Spencer, S. S. Epilepsia: “Intracranial EEG seizure-onset patterns in neocortical epilepsy,” 41:297-307 (2000).;;Langan, Y., Nashef, L., and Sander, J. W.: “Case-control study of SUDEP,” Neurology,64:1131-1133 (2005).;;Bateman, L. M., Li, C. S., Lin, T. C., and Seyal, M. Epilepsia: “Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsy,” 51:2211-2214 (2010).;;Ali Hossam Shoeb: Thesis “Application of Machine Learning to Epileptic Seizure Onset Detection and Treatment”, Submitted to Harvard—MIT Div. of Health Sciences re Dr. of Philosophy in EE and Med Engineering at MIT, Sep. 2009.;;Maryann D'Alessandro, George Vachtsevanos, Rosana Esteller, Javier Echauz, Stephen Cranstoun, Greg Worrell, Landi Parish and Brian Litt: “A multi-feature and multi-channel univariate selection process for seizure prediction”, Clinical Neurophysiology 116 (2005) 506-516.;;Isa Conradsen, Student Member; IEEE, Sándor Beniczky, Karsten Hoppe, Peter Wolf and Helge B.D. Sorensen Member, IEEE: “Automated algorithm for generalised tonic-clonic epileptic seizure onset detection used on sEMG zero-crossing rate”, IEEE Transactions on Biomedical Engineering, Copyright IEEE 2011, pubs-permissions©ieee.org.;;Alaa Kharbouch, Ali Shoeb, John Guttag, and Sydney S. Cash: “An algorithm for seizure onset detection using intracranial EEG,” Epilepsy Balmy. Dec. 2011; 22(01): S29-S35.;;Yusuf U Khan, Omar Farooq and Priyanka Sharma: “Automatic Detection of Seizure Onset in Pediatric EEG”, International Journal of Embedded Systems and Applications (IJESA) vol. 2, No. 3, Sep. 2012.;;Yizhuo Zhang, Guanghua Xu, Jing Wang, Lin Liang: “An automatic patient-specific seizure onset detection method in intracranial EEG based on incremental nonlinear dimensionality reduction”, Computers in Biology and Medicine 40 (2010) 889-899. Automated Detection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset, Epilepsia, 39(6):615-627 (1998).;;A.J. Gabor, R.R. Leach, and F.U. Dowla: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Dept. of Neurology, University of CA, Davis Medical Center, Jan. 5, 1996; Published Apr. 15, 1996, Electroencephalography and Clinical Neurophysiology 99 (1996) 257-266.;;A.J. Gabor: “Automated Seizure Detection Using a Self-Organizing Neural Network”, Validation and Comparison with Other Detection Strategies, Dept. of Neurology, University of CA, Davis Medical Center, Accepted for Publication Feb. 28, 1998, Electroencephalography and Clinical Neurophysiology 107 (1998) 27-32.;;Esteva et al. “Dermatologist level classification of skin cancer with deep neural networks”, Nature, vol. 542, published Feb. 2, 2017, pp. 115-118.;;Thodoro, M. et al. “Learning Robust Features using Deep Learning for Automatic Seizure Detection”, ArXiv:1608.00220, Jul. 31, 2016, pp. 1-12.;;Ling, Zhen-Huia et al. “Waveform Modeling and Generation Using Hierarchical Recurrent Neural Networks for Speech Bandwidth Extension”, IEEE/ACM Transactions on Audio, Speech, and Language Processing, vol. 26, No. 5, pp. 883-894, May 2018.;;Zeiler, Matthew D. et al. “Visualizing and Understanding Convolutional Networks”, ArXiv:1311.2901v3, Nov. 28, 2013, pp. 1-11.",ACTIVE
173,US,A1,US 2019/0117978 A1,185-292-461-384-593,2019-04-25,2019,US 201715849492 A,2017-12-20,US 201715849492 A;;US 201762575351 P,2017-10-20,SYSTEMS AND METHODS FOR CLINICAL DECISION MAKING FOR A PATIENT RECEIVING A NEUROMODULATION THERAPY BASED ON DEEP LEARNING,"Information relevant to making clinical decisions for a subject patient is identified based on electrical activity records of the subject patient's brain and electrical activity records of other patients' brains. A deep learning algorithm is applied to an electrical activity record of the subject patient, i.e., an input record, and to a set of electrical activity records of other patients, i.e., a set of search records, to obtain an input feature vector of the patient and a set of search feature vectors, each including features extracted by the deep learning algorithm. A similarities algorithm is applied to the input feature vector and the set of search feature vectors to identify a subset of search records most like the input record. Clinical information associated with one or more search records in the identified subset of search records is extracted from a database and used to make decisions regarding the patient's neuromodulation therapies, or to make autonomous adjustments to therapies.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K,NEUROPACE INC (2018-01-10),https://lens.org/185-292-461-384-593,Patent Application,yes,1,13,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,5,173-947-234-281-155;;091-123-378-888-082;;185-292-461-384-593;;068-761-717-360-825;;070-724-445-045-598,US,0,A61N1/36139;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/40;;G16H50/20;;G16H50/70;;A61N1/36139;;A61N1/0534;;A61N1/36064;;A61N1/36171;;A61N1/36175;;A61N1/36178;;A61N1/37247;;G16H20/70,A61N1/36;;A61N1/05;;A61N1/372,,0,0,,,,ACTIVE
174,US,B2,US 9597494 B2,075-940-935-855-639,2017-03-21,2017,US 201615178525 A,2016-06-09,US 201615178525 A;;US 201514853858 A;;US 201414506819 A;;US 26214608 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/075-940-935-855-639,Granted Patent,yes,62,9,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N7/02;;A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61F7/00;;A61F7/12;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N2/00;;A61N5/06;;A61N7/00,,47,36,003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323,17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;International Preliminary Examination Report (IPER) for counterpart International Application No. PCT/US2008/081655 (May 14, 2010).;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal trans cranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21: 1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential ofrTMS and tDCS, 2007, Nat. Clin. Pract. Neuroi. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46: 1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;K.Arkar et al., Focal cooling suppresses spontaneous epileptifonn activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, 1. Neurosci. 24:9985-9992, as corrected in J. Neurosci . 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-36.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04 14/1 573554.html, updated 2006.;;Medtronic Sofamor Danek, The METRx X-Tube Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html, updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
175,US,A1,US 2015/0038822 A1,119-376-235-425-689,2015-02-05,2015,US 201414506819 A,2014-10-06,US 201414506819 A;;US 26214608 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/119-376-235-425-689,Patent Application,yes,0,8,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61B5/0478,600/378,0,0,,,,ACTIVE
176,US,A1,US 2009/0112273 A1,156-507-297-866-390,2009-04-30,2009,US 23429708 A,2008-09-19,US 23429708 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","A method is disclosed for conveying a form of neuromodulation (e.g., electrical, chemical, optical, or thermal) from an external neuromodulation source interiorly of the skull to modulate neural activity. The method involves forming one or more apertures through or partially through the skull to provide an interface for delivering the neuromodulation. A method is disclosed for sensing one or more parameters characteristic of one or more states of the brain through an interface formed with one or more apertures extending all the way or part of the way through the skull. A device is disclosed that is implantable in the skull of a human patient to provide an interface between the exterior of the skull and the brain that includes a channel of a length sufficient to traverse the entire thickness of the skull or at least a part of the thickness of the skull. The channels may be provided in a wide variety of shapes and sizes with or without inner lumens. The channels may be configured for ion conduction of electrical signals, enabling DC or near DC stimulation of target neurons. Methods and devices for transferring energy (e.g., thermal energy) generated inside the skull to the outside of the skull and vice versa are also disclosed.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/156-507-297-866-390,Patent Application,yes,26,51,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/00,607/3,0,0,,,,ACTIVE
177,US,A1,US 2016/0287436 A1,195-365-374-612-110,2016-10-06,2016,US 201615178525 A,2016-06-09,US 201615178525 A;;US 201514853858 A;;US 201414506819 A;;US 26214608 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/195-365-374-612-110,Patent Application,yes,0,11,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61F7/12;;A61B5/0478;;A61B90/98;;A61F7/00;;A61N1/05;;A61N1/30;;A61N1/36;;A61N5/06;;A61N7/02,,0,0,,,,ACTIVE
178,US,B2,US 7158833 B2,049-643-719-595-162,2007-01-02,2007,US 63984203 A,2003-08-12,US 63984203 A;;US 72493600 A,2000-11-28,Ferrule for cranial implant,"A ferrule for removably retaining a self-contained implantable device within a cranial opening of a patient is set forth. The ferrule includes a shelf portion, a wall portion, and at least one supporting tab connected to the wall portion. The shelf portion has an inner surface and an outer surface. The inner surface of the shelf portion substantially conforms to an implantable device. The wall portion has an inner surface and an outer surface and encompasses the shelf portion. The inner surface of the wall portion substantially conforms to the implantable device and the outer surface of the wall portion substantially conforms to the cranial opening.",NEUROPACE INC,PLESS BENJAMIN D;;POTTS DENNIS,NEUROPACE INC (2006-06-09),https://lens.org/049-643-719-595-162,Granted Patent,yes,19,12,2,161-540-775-455-058;;049-643-719-595-162,US,3,161-540-775-455-058;;049-643-719-595-162;;082-848-745-631-804,US,0,A61N1/37518;;A61B2090/103;;A61M39/0247;;A61N1/0539;;A61N1/37514;;A61N1/37518;;A61B2090/103;;A61M39/0247;;A61N1/0539;;A61N1/37514,A61N1/36;;A61M1/00;;A61N1/05,607/45;;607/139,9,0,,,"U.S. Appl. No. 09/373,676, filed Aug. 13, 1999, Fischell et al.;;U.S. Appl. No. 09/517,797, filed Mar. 2, 2000, David R. Fischell.;;U.S. Appl. No. 09/543,264, filed Apr. 5, 2000, Benjamin D. Pless.;;U.S. Appl. No. 09/543,450, filed Apr. 5, 2000, Benjamin D. Pless.;;U.S. Appl. No. 09/557,168, filed Apr. 19, 2000, Fischell et al.;;U.S. Appl. No. 09/609,086, filed Jun. 30, 2000, Fischell et al.;;U.S. Appl. No. 09/706,322, filed Nov. 3, 2000, Pless.;;U.S. Appl. No. 09/711,663, filed Nov. 9, 2000, David Greene.;;U.S. Appl. No. 09/724,805, filed Nov. 28, 2000, Pless et al.",EXPIRED
179,US,A1,US 2016/0001098 A1,146-400-257-108-672,2016-01-07,2016,US 201514853858 A,2015-09-14,US 201514853858 A;;US 201414506819 A;;US 26214608 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/146-400-257-108-672,Patent Application,yes,0,8,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N7/02;;A61F7/00;;A61F7/12,,0,0,,,,INACTIVE
180,US,A1,US 2019/0167101 A1,173-896-263-529-554,2019-06-06,2019,US 201916256966 A,2019-01-24,US 201916256966 A;;US 201414270212 A,2014-05-05,USE OF A PROGRESSIVE COMPRESSION ENCODING OF PHYSIOLOGIC WAVEFORM DATA IN AN IMPLANTABLE DEVICE TO SUPPORT DISCONTINUING TRANSMISSION OF LOW-VALUE DATA,"An external data retrieval apparatus receives a low resolution version of a physiological signal from an active implantable medical device and determines if the physiological signal represents a clinically significant event. The apparatus provides an indication of such determination to the implantable medical device. If the physiological signal does represent a clinically significant event, the apparatus receives a full download of the physiological signal from the implantable device.",NEUROPACE INC,ARCHER STEPHEN T;;MULLIGAN PATRICK GERARD;;GREENE DAVID A,NEUROPACE INC (2014-05-07),https://lens.org/173-896-263-529-554,Patent Application,yes,0,0,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,0,A61B5/316;;A61B5/00;;A61B5/0031;;A61B5/24;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63;;A61B5/00;;A61B5/0002;;A61B5/0031;;A61B5/24;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63,A61B5/00;;A61B5/04,,0,0,,,,ACTIVE
181,US,B2,US 8224434 B2,067-044-407-272-477,2012-07-17,2012,US 201113105717 A,2011-05-11,US 201113105717 A;;US 77064310 A;;US 37170106 A,2006-03-08,Implantable seizure monitor,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",GREENE DAVID;;NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/067-044-407-272-477,Granted Patent,yes,30,5,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544;;600/545,7,4,143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;124-403-369-942-149,10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;52443;;10.1016/0013-4694(75)90051-6,"Cyberonics, Inc., www.vnstherapy.com NeuroCyberonic Prosthesis (NCP)).;;Medtronic, Inc., www.activadbs.comlabout-activa.asp.;;Medtronic (2003) ""Your Activa (tm) Therapy (With a Kinetra (trn) or Soletra (trn) Neurostimulator,"" Patient Manual.;;Gotrnan, J, ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalogr. and Clinical Neurophysiol. (1990) 76(4):317-24.;;Qu, R., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-4.;;Qu, R., et al., ""A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use As a Warning Device,"" IEEE Transactions on Biomedical Engineering (1997) 44(2): 115-22.;;Wagner, R.R., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. and Clinical Neurophysiol. (1975) 39(5): 499-506.",INACTIVE
182,US,B2,US 8140151 B2,017-526-388-740-789,2012-03-20,2012,US 77069710 A,2010-04-29,US 77069710 A;;US 37170106 A,2006-03-08,Implantable seizure monitor,"An implantable seizure monitor can include at least one sensing electrode and an electronics module configured to detect, record and/or log neurological events. For example, the electronics module can be configured to detect brainwaves indicative of seizures, such as, for example, epileptic seizures, and to create a log indicating when such seizures occur. The implantable seizure monitor can include a cushioning member made of a soft material and configured to be implantable between the epidermis and cranium of a patient.",GREENE DAVID;;NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2007-07-10),https://lens.org/017-526-388-740-789,Granted Patent,yes,30,2,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,8,020-336-202-344-288;;117-309-259-969-821;;156-743-098-228-868;;161-535-870-570-066;;079-326-629-319-155;;136-395-653-456-306;;017-526-388-740-789;;067-044-407-272-477,US,0,A61B5/4094;;A61B5/291;;A61B5/4094,A61B5/374,600/544;;600/545,7,4,143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;124-403-369-942-149,10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;52443;;10.1016/0013-4694(75)90051-6,"Cyberonics, Inc., www.vnstherapy.com NeuroCyberonic Prosthesis (NCP)).;;Medtronic, Inc., www.activadbs.comlabout-activa.asp.;;Medtronic (2003) ""Your Activa (tm) Therapy (With a Kinetra (trn) or Soletra (trn) Neurostimulator,"" Patient Manual.;;Gotrnan, J, ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalogr. and Clinical Neurophysiol. (1990) 76(4):317-24.;;Qu, R., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-4.;;Qu, R., et al., ""A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use As a Warning Device,"" IEEE Transactions on Biomedical Engineering (1997) 44(2): II5-22.;;Wagner, R.R., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. and Clinical Neurophysiol. (1975) 39(5): 499-506.",ACTIVE
183,US,A1,US 2009/0112279 A1,124-789-452-223-326,2009-04-30,2009,US 26095808 A,2008-10-29,US 26095808 A;;US 92980107 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-20),https://lens.org/124-789-452-223-326,Patent Application,yes,47,26,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05,607/45,0,0,,,,ACTIVE
184,EP,B1,EP 2205313 B1,135-949-388-289-951,2016-11-30,2016,EP 08851167 A,2008-10-29,US 2008/0081655 W;;US 92980107 A;;US 23429708 A;;US 24373308 A,2007-10-30,SYSTEMS AND DEVICES FOR A SKULL/BRAIN INTERFACE,,NEUROPACE INC,PLESS BENJAMIN;;CHAO DANIEL;;WINGEIER BRETT;;TCHENG THOMAS,,https://lens.org/135-949-388-289-951,Granted Patent,yes,10,12,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05;;A61B5/00,,0,0,,,,ACTIVE
185,US,A1,US 2020/0315487 A1,066-866-561-129-691,2020-10-08,2020,US 202016905644 A,2020-06-18,US 202016905644 A;;US 201514828409 A,2015-08-17,NEUROLOGICAL EVENT DETECTION TOOLS FOR IMPLANTABLE MEDICAL DEVICES,An implantable device includes one or more electrodes to sense an electrical signal from a brain and a waveform analyzer to identify a half wave in the electrical signal; determine an amplitude and a duration of the half wave; determine if the amplitude satisfies a half wave amplitude criterion defined by a set of amplitude parameters comprising a minimum half wave amplitude and a maximum half wave amplitude; determine if the duration satisfies a half wave duration criterion defined by a set of duration parameters comprising a minimum half wave duration and a maximum half wave duration; and identify the half wave as a qualified half wave when the half wave amplitude criterion and the half wave duration criterion is satisfied. A neurological event may be detected based on one or more qualified half waves and electrical stimulation therapy may be delivered to the brain in response to the detection.,NEUROPACE INC,ESTELLER ROSANA,NEUROPACE INC (2015-10-30),https://lens.org/066-866-561-129-691,Patent Application,yes,1,0,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,0,A61B5/7282;;A61B5/0006;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0031;;A61B5/24;;A61B5/291;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0006;;A61B5/7282;;A61B5/291;;A61B5/24,A61B5/0478;;A61B5/00;;A61B5/04,,0,0,,,,ACTIVE
186,US,B2,US 11206979 B2,185-404-521-267-676,2021-12-28,2021,US 201916256966 A,2019-01-24,US 201916256966 A;;US 201414270212 A,2014-05-05,Use of a progressive compression encoding of physiologic waveform data in an implantable device to support discontinuing transmission of low-value data,"An external data retrieval apparatus receives a low resolution version of a physiological signal from an active implantable medical device and determines if the physiological signal represents a clinically significant event. The apparatus provides an indication of such determination to the implantable medical device. If the physiological signal does represent a clinically significant event, the apparatus receives a full download of the physiological signal from the implantable device.",NEUROPACE INC,ARCHER STEPHEN T;;MULLIGAN PATRICK GERARD;;GREENE DAVID A,NEUROPACE INC (2014-05-07),https://lens.org/185-404-521-267-676,Granted Patent,yes,13,0,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,0,A61B5/316;;A61B5/00;;A61B5/0031;;A61B5/24;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63;;A61B5/00;;A61B5/0002;;A61B5/0031;;A61B5/24;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63,A61B5/00;;A61B5/24;;A61B5/316;;A61B5/369;;G16H10/60;;G16H10/65;;G16H40/63,,0,0,,,,ACTIVE
187,US,A1,US 2019/0029551 A1,016-814-664-070-153,2019-01-31,2019,US 201816152152 A,2018-10-04,US 201816152152 A;;US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/016-814-664-070-153,Patent Application,yes,0,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
188,US,B2,US 11963779 B2,019-191-553-991-41X,2024-04-23,2024,US 202016905644 A,2020-06-18,US 202016905644 A;;US 201514828409 A,2015-08-17,Neurological event detection tools for implantable medical devices,An implantable device includes one or more electrodes to sense an electrical signal from a brain and a waveform analyzer to identify a half wave in the electrical signal; determine an amplitude and a duration of the half wave; determine if the amplitude satisfies a half wave amplitude criterion defined by a set of amplitude parameters comprising a minimum half wave amplitude and a maximum half wave amplitude; determine if the duration satisfies a half wave duration criterion defined by a set of duration parameters comprising a minimum half wave duration and a maximum half wave duration; and identify the half wave as a qualified half wave when the half wave amplitude criterion and the half wave duration criterion is satisfied. A neurological event may be detected based on one or more qualified half waves and electrical stimulation therapy may be delivered to the brain in response to the detection.,NEUROPACE INC,ESTELLER ROSANA,NEUROPACE INC (2015-10-30),https://lens.org/019-191-553-991-41X,Granted Patent,yes,29,0,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,0,A61B5/7282;;A61B5/0006;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0031;;A61B5/24;;A61B5/291;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0006;;A61B5/7282;;A61B5/291;;A61B5/24,A61B5/00;;A61B5/24;;A61B5/291,,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A.C., “Textbook of Medical Physiology”, 8th ed., Wonsiewicz M.J. ed., pp. wii-xli (Table of Contents only), 1991).;;Gotman, J. “Automatic Seizure Detection: Improvements and Evaluation”, Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",ACTIVE
189,US,A1,US 2016/0287120 A1,054-535-057-848-126,2016-10-06,2016,US 201615183325 A,2016-06-15,US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/054-535-057-848-126,Patent Application,yes,0,9,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
190,US,A1,US 2022/0061663 A1,083-165-814-802-552,2022-03-03,2022,US 202117521652 A,2021-11-08,US 202117521652 A;;US 201916256966 A;;US 201414270212 A,2014-05-05,USE OF A PROGRESSIVE COMPRESSION ENCODING OF PHYSIOLOGIC WAVEFORM DATA IN AN IMPLANTABLE DEVICE TO SUPPORT DISCONTINUING TRANSMISSION OF LOW-VALUE DATA,"An external data retrieval apparatus receives a low resolution version of a physiological signal from an active implantable medical device and determines if the physiological signal represents a clinically significant event. The apparatus provides an indication of such determination to the implantable medical device. If the physiological signal does represent a clinically significant event, the apparatus receives a full download of the physiological signal from the implantable device.",NEUROPACE INC,ARCHER STEPHEN T;;MULLIGAN PATRICK GERARD;;GREENE DAVID A,NEUROPACE INC (2014-05-07),https://lens.org/083-165-814-802-552,Patent Application,yes,1,0,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,0,A61B5/316;;A61B5/00;;A61B5/0031;;A61B5/24;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63;;A61B5/00;;A61B5/0002;;A61B5/0031;;A61B5/24;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63,A61B5/00;;A61B5/24;;A61B5/316;;G16H10/60;;G16H10/65;;G16H40/63,,0,0,,,,ACTIVE
191,US,B2,US 8478419 B2,171-621-506-522-002,2013-07-02,2013,US 92566807 A,2007-10-26,US 92566807 A;;US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",PLESS BENJAMIN D;;WINGEIER BRETT;;NEUROPACE INC,PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2007-05-16),https://lens.org/171-621-506-522-002,Granted Patent,yes,15,4,6,002-251-031-096-201;;069-686-345-844-480;;011-310-459-968-81X;;107-377-055-316-476;;105-617-775-657-09X;;171-621-506-522-002,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082;;A61B5/14553;;A61B5/0031;;A61B5/1459;;A61B5/372;;A61B5/4094;;A61B5/7217;;A61N1/36064;;A61N1/36082,A61N1/365,607/62;;607/3;;607/45,10,4,143-388-558-467-689;;124-403-369-942-149;;026-889-963-495-548;;122-023-235-058-123,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;10.1016/s1095-6433(99)00086-0;;10605067;;10.1152/jn.1995.74.6.2767;;8747234,"Gotman, J., ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalog. Clin. Neurophysiol. (1990) 76(4): 317-24.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. (1975): 39(5): 499-506.;;Matsuura, T., et al., ""Hennodynamics Evoked by Microelectrical Direct Stimulation in Rat Somatosensroy Cortex,"" Comp. Biochem. Physiol. A. Mo. I.. Integr. Physiol. (1999) Spet: 124(1): 47-52.;;Bahar, S et al., ""The Relationship Between Cerebral Blood Volume and Oxygenation Following Bipolar Stimulation of the Human Cortex: Evidence for an Initial Dip,"" American Epilepsy Society, Dec. 2004, New Orleans Poster Session.;;Tarver, T. et al, ""An Implantable Neurocybernetic Prosthesis System,"" http://www.ncbi.nlm.nih.gov, Jun. 12, 2007.;;ACTIVA Therapy Overview, http://www.medtronic.com/physician/activa/index.html, Jun. 5, 2007.;;Tavalin, S.J., et al., ""Mechanical Perturbation of Cultured Cortical Neurons Reveals a Stretch-Induced Delayed Depolarization,"" J. Neurophysiol. (1995).;;U.S. Appl. No. 11/925,655 Office Action mailed Jun. 28, 2010.;;Notice of Allowance mailed on Dec. 16, 2010 for U.S. Appl. No. 11/925,655.;;Office Action (Non-Final Rejection) mailed Apr. 27, 2012 for U.S. Appl. No. 12/700,692.",ACTIVE
192,US,B2,US 12138064 B2,031-730-642-861-582,2024-11-12,2024,US 202117191175 A,2021-03-03,US 202117191175 A;;US 201715838383 A,2017-12-12,"Systems, devices and methods using phase-amplitude coupling measures in implantable medical devices","A sensor of an implantable medical device senses electrical activity of the brain. A data analyzer of the device monitors an electrographic signal corresponding to the electrical activity of the sensed brain signal, and processes the brain signal to obtain a measure of phase-amplitude coupling. For a selected portion of the electrographic signal, the data analyzer detects first features and second features of the electrographic signal. The first features represent oscillations in a low frequency range, while the second features represent oscillations in a frequency range higher than the low frequency range. For example, the low frequency range may correspond to theta frequency and the higher frequency range may correspond to gamma frequency. The data analyzer determines a measure of phase-amplitude coupling between oscillations in the low frequency range and oscillations in the higher frequency range based on occurrences of second features which coincide with first features.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K;;ARCHER STEPHEN T,NEUROPACE INC (2017-12-13),https://lens.org/031-730-642-861-582,Granted Patent,yes,12,0,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,0,A61N1/36139;;A61N1/36171;;A61B5/686;;A61B5/6868;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61M5/1723;;A61N1/36064;;A61B5/316;;A61B5/291;;A61B5/374;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61N1/37229;;A61M5/1723;;A61M2210/0693;;A61M2230/10;;A61N1/36064;;A61N1/36171;;A61B5/686;;A61N1/36139;;A61B5/6868;;A61B5/374;;A61B5/291;;A61B5/316,A61N1/372;;A61B5/00;;A61B5/291;;A61B5/316;;A61B5/374;;A61M5/172;;A61N1/05;;A61N1/36,,10,10,042-771-578-838-803;;045-060-995-335-105;;056-740-695-873-516;;029-752-315-800-251;;052-601-223-633-332;;019-645-788-016-014;;038-753-862-994-084;;097-110-490-323-917;;062-869-544-021-417;;035-230-274-131-352,29060344;;10.1109/embc.2017.8037302;;24686330;;10.1038/srep04545;;pmc3971396;;pmc2840289;;20133762;;10.1073/pnas.0911531107;;10.1126/science.1128115;;16973878;;pmc2628289;;pmc3359652;;20932795;;10.1016/j.tics.2010.09.001;;23471992;;10.1073/pnas.1214546110;;pmc3606991;;10.1016/j.tics.2013.10.010;;24268290;;pmc2872428;;20351262;;10.1073/pnas.0911184107;;pmc2791641;;10.1073/pnas.0911331106;;19934062;;pmc2941206;;20463205;;10.1152/jn.00106.2010,"O'Leary et al., “Low-latency VLSI architecture for neural cross-frequency coupling analysis,” 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Seogwipo, 2017, pp. 2247-2250 , doi: 10.1109/EMBC.2017.8037302. (2017).;;Avarado-Rojas et al. “Slow modulations of high-frequency activity (40-140-Hz) discriminate preictal changes in human focal epilepsy.” Sci Rep 4:4545 (2014).;;Axmacher et al., “Cross-frequency coupling supports multi-item working memory in the human hippocampus.” Proc Natl.Acad Sci U.S.A. 107 (7):3228-3233 (2010.).;;Canolty et al. “High Gamma Power Is Phase-Locked to Theta Oscillations in Human Neocortex.” Science, vol. 313 (Sep. 15, 2006).;;Canolty et al. “The functional role of cross-frequency coupling.” Trends Cogn Sci 14 (11):506-515 (2010).;;Hemptinne et al., “Exaggerated phase-amplitude coupling in the primary motor cortex in Parkinson disease. ” Proc Natl.Acad Sci U.S.A. 110 (12):4780-4785 (2013).;;Roux et al. “Working memory and neural oscillations: alpha-gamma versus theta-gamma codes for distinct WM Information ?. ” Trends Cogn Sci 18 (1):16-25 (2014).;;Shirvalkar et al., Bidirectional changes to hippocampal theta-gamma comodulation predict memory for recent spatial episodes. Proc Natl.Acad Sci U.S.A. 107 (15):7054-7059 (2010).;;Tort et al. Theta-gamma coupling increases during the learning of item-context associations. Proc Natl.Acad Sci U.S.A. 106 (49):20942-20947 (2009).;;Tort et al. “Measuring Phase-Amplitude Coupling Between Neuronal Oscillations of Different Frequencies.” J Neurophysiol 104: 1195-1210 (May 12, 2010).",ACTIVE
193,US,A1,US 2015/0313490 A1,003-728-699-907-272,2015-11-05,2015,US 201414270212 A,2014-05-05,US 201414270212 A,2014-05-05,USE OF A PROGRESSIVE COMPRESSION ENCODING OF PHYSIOLOGIC WAVEFORM DATA IN AN IMPLANTABLE DEVICE TO SUPPORT DISCONTINUING TRANSMISSION OF LOW-VALUE DATA,"An external data retrieval apparatus receives a low resolution version of a physiological signal from an active implantable medical device and determines if the physiological signal represents a clinically significant event. The apparatus provides an indication of such determination to the implantable medical device. If the physiological signal does represent a clinically significant event, the apparatus receives a full download of the physiological signal from the implantable device.",NEUROPACE INC,ARCHER STEPHEN T;;MULLIGAN PATRICK GERARD;;GREENE DAVID A,NEUROPACE INC (2014-05-07),https://lens.org/003-728-699-907-272,Patent Application,yes,22,8,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,0,A61B5/316;;A61B5/00;;A61B5/0031;;A61B5/24;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63;;A61B5/00;;A61B5/0002;;A61B5/0031;;A61B5/24;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63,A61B5/04;;A61B5/00;;A61B5/0476,,0,0,,,,ACTIVE
194,US,A1,US 2008/0319335 A1,113-215-911-780-104,2008-12-25,2008,US 76557407 A,2007-06-20,US 76557407 A,2007-06-20,SYSTEM AND METHOD FOR AUTOMATICALLY ADJUSTING DETECTION THRESHOLDS IN A FEEDBACK-CONTROLLED NEUROLOGICAL EVENT DETECTOR,"Methods and systems for detecting neurological events and approximating a target detection rate are disclosed. A target detection rate may be identified for the neurological event. Electrographic signals incident on a neurological event detector may be monitored. Each signal may be compared to a threshold value for a parameter. As the threshold value varies, it has a predictable effect on a detection rate of the neurological event. A rate at which the electrographic signals exceed the threshold value may be measured and compared to the target detection rate. The threshold value may be adjusted to minimize the difference between the measured detection rate and the target detection rate.",NEUROPACE INC,GREENE DAVID A,NEUROPACE INC (2007-06-15),https://lens.org/113-215-911-780-104,Patent Application,yes,24,25,2,165-987-529-594-438;;113-215-911-780-104,US,2,165-987-529-594-438;;113-215-911-780-104,US,0,A61B5/4094;;A61B5/369;;A61B5/369;;A61B5/4094,A61B5/0476,600/544,0,0,,,,ACTIVE
195,US,A1,US 2021/0407678 A1,185-672-963-727-028,2021-12-30,2021,US 202117356342 A,2021-06-23,US 202117356342 A;;US 202063043514 P,2020-06-24,SYSTEMS AND METHODS FOR USING FEDERATED LEARNING FOR TRAINING CENTRALIZED SEIZURE DETECTION AND PREDICTION MODELS ON DECENTRALIZED DATASETS,"A server for updating a current version of a machine learning model resident in implanted medical devices includes an interface, a memory, and a processor. The interface is configured to receive a plurality of updated versions of the machine learning model from a plurality of remote sources remote from the server. The remote source may be, e.g., implanted medical devices and/or subservers. The processor is coupled to the memory and the interface and is configured to aggregate the plurality of updated versions to derive a server-updated version of the machine learning model, and to transmit the server-updated version of the machine learning model to one or more of the plurality of remote sources as a replacement for the current version of the machine learning model.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K,,https://lens.org/185-672-963-727-028,Patent Application,yes,0,9,1,185-672-963-727-028,US,1,185-672-963-727-028,US,0,G16H40/40;;G16H40/67;;G16H50/20;;G06N20/00;;G06N3/08;;G06N3/04;;G16H50/20;;G06F8/65;;G06N3/098,G16H50/20;;G06F8/65;;G06N3/04;;G06N3/08;;G16H20/30,,10,4,001-713-610-414-953;;100-266-361-390-74X;;015-711-236-108-903;;082-365-121-214-408,30790780;;10.1088/1741-2552/ab094a;;10.1186/1471-2105-10-25;;19154573;;pmc2660303;;10.1100/2012/278352;;pmc3361225;;22654582;;10.1155/2018/2724692,"Hard, A., Federated Learning for Mobile Keyboard Prediction, [received 9/3/2024]. Retrieved from Internet:<https://arxiv.org/abs/1811.03604> (Year: 2019);;Dumpelmann, M., Early seizure detection for closed loop direct neurostimulation devices in epilepsy, [received 9/3/2024]. Retrieved from Internet:<https://iopscience.iop.org/article/10.1088/1741-2552/ab094a/meta> (Year: 2019);;Smith, V., et al, Federated Multi-Task Learning, [received 9/3/20924]. Retrieved from Internet:<https://proceedings.neurips.cc/paper/2017/hash/6211080fa89981f66b1a0c9d55c61d0f-Abstract.html> (Year: 2017);;Brown, J., Identification of novel DNA repair proteins via primary sequence, secondary structure, and homology, [received 9/3/2024]. Retrieved from Internet:<https://link.springer.com/article/10.1186/1471-2105-10-25> (Year: 2009);;Camara, et al, Resting tremor classification and detection in Parkinson's disease patients, [received 9/6/2024]. Retrieved from Internet:<https://www.sciencedirect.com/science/article/pii/S1746809414001414> (Year: 2015);;Eirich, T., Beam: A Tool for Flexible Software Update, [received 9/6/2024]. Retrieved from Internet:<https://scholar.google.com/scholar?cluster=2104970323893850914&hl=en&as_sdt=0,47> (Year: 1994);;Kusonmano, et al, Effects of Pooling Samples on the Performance of Classification Algorithms: A Comparative Study, [received 9/6/2024]. Retrieved from Internet:<https://onlinelibrary.wiley.com/doi/full/10.1100/2012/278352> (Year: 2012);;McMahan, et al, Communication-Efficient Learning of Deep Networks from Decentralized Data, [received 9/6/2024]. Retrieved from Internet:<https://proceedings.mlr.press/v54/mcmahan17a?ref=https://githubhelp.com> (Year: 2017);;Thalij, et al, Multiobjective Glowworm Swarm Optimization-Based Dynamic Replication Algorithm for Real-Time Distributed Databases, [received 9/6/2024]. Retrieved from Internet:<https://onlinelibrary.wiley.com/doi/full/10.1155/2018/2724692> (Year: 2018);;Wang, et al, Federated Learning with Matched Averaging, [received 9/6/2024]. Retrieved from Internet:<https://arxiv.org/abs/2002.06440> (Year: 2020)",PENDING
196,US,A1,US 2017/0049351 A1,155-800-189-714-775,2017-02-23,2017,US 201514828409 A,2015-08-17,US 201514828409 A,2015-08-17,NEUROLOGICAL EVENT DETECTION TOOLS FOR IMPLANTABLE MEDICAL DEVICES,An implantable device includes one or more electrodes to sense an electrical signal from a brain and a waveform analyzer to identify a half wave in the electrical signal; determine an amplitude and a duration of the half wave; determine if the amplitude satisfies a half wave amplitude criterion defined by a set of amplitude parameters comprising a minimum half wave amplitude and a maximum half wave amplitude; determine if the duration satisfies a half wave duration criterion defined by a set of duration parameters comprising a minimum half wave duration and a maximum half wave duration; and identify the half wave as a qualified half wave when the half wave amplitude criterion and the half wave duration criterion is satisfied. A neurological event may be detected based on one or more qualified half waves and electrical stimulation therapy may be delivered to the brain in response to the detection.,NEUROPACE INC,ESTELLER ROSANA,NEUROPACE INC (2015-10-30),https://lens.org/155-800-189-714-775,Patent Application,yes,4,11,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,0,A61B5/7282;;A61B5/0006;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0031;;A61B5/24;;A61B5/291;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0006;;A61B5/7282;;A61B5/291;;A61B5/24,A61B5/0478;;A61B5/00;;A61B5/04,,1,1,013-962-774-946-721,15651562;;10.1109/tbme.2004.839630,"N. Acir, I. Oztura, M. Kuntalp, B. Baklan and C. Guzelis, ""Automatic detection of epileptiform events in EEG by a three-stage procedure based on artificial neural networks,"" in IEEE Transactions on Biomedical Engineering, vol. 52, no. 1, pp. 30-40, Jan. 2005.",ACTIVE
197,US,B2,US 10729352 B2,184-265-362-080-21X,2020-08-04,2020,US 201514828409 A,2015-08-17,US 201514828409 A,2015-08-17,Neurological event detection tools for implantable medical devices,An implantable device includes one or more electrodes to sense an electrical signal from a brain and a waveform analyzer to identify a half wave in the electrical signal; determine an amplitude and a duration of the half wave; determine if the amplitude satisfies a half wave amplitude criterion defined by a set of amplitude parameters comprising a minimum half wave amplitude and a maximum half wave amplitude; determine if the duration satisfies a half wave duration criterion defined by a set of duration parameters comprising a minimum half wave duration and a maximum half wave duration; and identify the half wave as a qualified half wave when the half wave amplitude criterion and the half wave duration criterion is satisfied. A neurological event may be detected based on one or more qualified half waves and electrical stimulation therapy may be delivered to the brain in response to the detection.,NEUROPACE INC,ESTELLER ROSANA,NEUROPACE INC (2015-10-30),https://lens.org/184-265-362-080-21X,Granted Patent,yes,28,0,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,4,155-800-189-714-775;;066-866-561-129-691;;184-265-362-080-21X;;019-191-553-991-41X,US,0,A61B5/7282;;A61B5/0006;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0031;;A61B5/24;;A61B5/291;;A61B5/4064;;A61B5/4094;;A61B5/6868;;A61B5/0006;;A61B5/7282;;A61B5/291;;A61B5/24,A61B5/0476;;A61B5/00;;A61B5/04;;A61B5/0478,,3,2,013-962-774-946-721;;143-388-558-467-689,15651562;;10.1109/tbme.2004.839630;;10.1016/0013-4694(90)90032-f;;1699724,"N. Acir, I. Oztura, M. Kuntalp, B. Baklan and C. Guzelis, “Automatic detection of epileptiform events in EEG by a three-stage procedure based on artificial neural networks,” in IEEE Transactions on Biomedical Engineering, vol. 52, No. 1, pp. 30-40, Jan. 2005.;;Guyton, A.C., “Textbook of Medical Physiology”, 8th ed., Wonsiewicz M.J. ed., pp. wii-xli (Table of Contents only), 1991).;;Gotman, J. “Automatic Seizure Detection: Improvements and Evaluation”, Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",ACTIVE
198,US,A1,US 2021/0244356 A1,055-689-639-717-255,2021-08-12,2021,US 202117244897 A,2021-04-29,US 202117244897 A;;US 201816152152 A;;US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/055-689-639-717-255,Patent Application,yes,0,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/316;;A61B5/369;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
199,US,B2,US 11813087 B2,182-456-388-756-766,2023-11-14,2023,US 202117244897 A,2021-04-29,US 202117244897 A;;US 201816152152 A;;US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/182-456-388-756-766,Granted Patent,yes,5,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/316;;A61B5/369;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
200,US,B2,US 11813035 B2,089-541-244-304-467,2023-11-14,2023,US 202117521652 A,2021-11-08,US 202117521652 A;;US 201916256966 A;;US 201414270212 A,2014-05-05,Use of a progressive compression encoding of physiologic waveform data in an implantable device to support discontinuing transmission of low-value data,"An external data retrieval apparatus receives a low resolution version of a physiological signal from an active implantable medical device and determines if the physiological signal represents a clinically significant event. The apparatus provides an indication of such determination to the implantable medical device. If the physiological signal does represent a clinically significant event, the apparatus receives a full download of the physiological signal from the implantable device.",NEUROPACE INC,ARCHER STEPHEN T;;MULLIGAN PATRICK GERARD;;GREENE DAVID A,NEUROPACE INC (2014-05-07),https://lens.org/089-541-244-304-467,Granted Patent,yes,14,0,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,0,A61B5/316;;A61B5/00;;A61B5/0031;;A61B5/24;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63;;A61B5/00;;A61B5/0002;;A61B5/0031;;A61B5/24;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63,A61B5/00;;A61B5/24;;A61B5/316;;A61B5/369;;G16H10/60;;G16H10/65;;G16H40/63,,0,0,,,,ACTIVE
201,US,B2,US 10231621 B2,130-910-254-609-956,2019-03-19,2019,US 201414270212 A,2014-05-05,US 201414270212 A,2014-05-05,Use of a progressive compression encoding of physiologic waveform data in an implantable device to support discontinuing transmission of low-value data,"An external data retrieval apparatus receives a low resolution version of a physiological signal from an active implantable medical device and determines if the physiological signal represents a clinically significant event. The apparatus provides an indication of such determination to the implantable medical device. If the physiological signal does represent a clinically significant event, the apparatus receives a full download of the physiological signal from the implantable device.",NEUROPACE INC,ARCHER STEPHEN T;;MULLIGAN PATRICK GERARD;;GREENE DAVID A,NEUROPACE INC (2014-05-07),https://lens.org/130-910-254-609-956,Granted Patent,yes,11,0,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,6,083-165-814-802-552;;130-910-254-609-956;;089-541-244-304-467;;185-404-521-267-676;;003-728-699-907-272;;173-896-263-529-554,US,0,A61B5/316;;A61B5/00;;A61B5/0031;;A61B5/24;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63;;A61B5/00;;A61B5/0002;;A61B5/0031;;A61B5/24;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7282;;A61B2560/0209;;G16H10/60;;G16H10/65;;G16H40/63,A61B5/00;;A61B5/04;;A61B5/0476,,0,0,,,,ACTIVE
202,US,A1,US 2024/0032870 A1,013-684-924-544-895,2024-02-01,2024,US 202318480239 A,2023-10-03,US 202318480239 A;;US 202117244897 A;;US 201816152152 A;;US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/013-684-924-544-895,Patent Application,yes,0,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/316;;A61B5/369;;A61B5/374;;A61N1/36,,0,0,,,,PENDING
203,US,B2,US 11026631 B2,086-380-648-977-330,2021-06-08,2021,US 201816152152 A,2018-10-04,US 201816152152 A;;US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/086-380-648-977-330,Granted Patent,yes,5,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/369;;A61B5/00;;A61B5/316;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
204,US,B2,US 9392972 B2,099-314-604-941-164,2016-07-19,2016,US 201313802456 A,2013-03-13,US 201313802456 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/099-314-604-941-164,Granted Patent,yes,3,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
205,US,B2,US 10966625 B2,036-785-113-344-061,2021-04-06,2021,US 201715838383 A,2017-12-12,US 201715838383 A,2017-12-12,"Systems, devices and methods using phase-amplitude coupling measures in implantable medical devices","A sensor of an implantable medical device senses electrical activity of the brain. A data analyzer of the device monitors an electrographic signal corresponding to the electrical activity of the sensed brain signal, and processes the brain signal to obtain a measure of phase-amplitude coupling. For a selected portion of the electrographic signal, the data analyzer detects first features and second features of the electrographic signal. The first features represent oscillations in a low frequency range, while the second features represent oscillations in a frequency range higher than the low frequency range. For example, the low frequency range may correspond to theta frequency and the higher frequency range may correspond to gamma frequency. The data analyzer determines a measure of phase-amplitude coupling between oscillations in the low frequency range and oscillations in the higher frequency range based on occurrences of second features which coincide with first features.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K;;ARCHER STEPHEN T,NEUROPACE INC (2017-12-13),https://lens.org/036-785-113-344-061,Granted Patent,yes,9,0,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,0,A61N1/36139;;A61N1/36171;;A61B5/686;;A61B5/6868;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61M5/1723;;A61N1/36064;;A61B5/316;;A61B5/291;;A61B5/374;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61N1/37229;;A61M5/1723;;A61M2210/0693;;A61M2230/10;;A61N1/36064;;A61N1/36171;;A61B5/686;;A61N1/36139;;A61B5/6868;;A61B5/374;;A61B5/291;;A61B5/316,A61B5/374;;A61B5/00;;A61M5/172;;A61N1/05;;A61N1/36;;A61N1/372,,10,10,042-771-578-838-803;;045-060-995-335-105;;056-740-695-873-516;;029-752-315-800-251;;052-601-223-633-332;;019-645-788-016-014;;038-753-862-994-084;;097-110-490-323-917;;062-869-544-021-417;;035-230-274-131-352,29060344;;10.1109/embc.2017.8037302;;24686330;;10.1038/srep04545;;pmc3971396;;pmc2840289;;20133762;;10.1073/pnas.0911531107;;10.1126/science.1128115;;16973878;;pmc2628289;;pmc3359652;;20932795;;10.1016/j.tics.2010.09.001;;23471992;;10.1073/pnas.1214546110;;pmc3606991;;10.1016/j.tics.2013.10.010;;24268290;;pmc2872428;;20351262;;10.1073/pnas.0911184107;;pmc2791641;;10.1073/pnas.0911331106;;19934062;;pmc2941206;;20463205;;10.1152/jn.00106.2010,"G. O'Leary, T. A. Valiante and R. Genov, “Low-latency VLSI architecture for neural cross-frequency coupling analysis,” 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Seogwipo, 2017, pp. 2247-2250 , doi: 10.1109/EMBC.2017.8037302. (Year: 2017).;;Avarado-Rojas et al. “Slow modulations of high-frequency activity (40-140-Hz) discriminate preictal changes in human focal epilepsy.” Sci Rep 4:4545 (2014).;;Axmacher et al., “Cross-frequency coupling supports multi-item working memory in the human hippocampus.” Proc Natl.Acad Sci U.S.A. 107 (7):3228-3233 (2010.).;;Canolty et al. “High Gamma Power Is Phase-Locked to Theta Oscillations in Human Neocortex.” Science, vol. 313 (Sep. 15, 2006).;;Canolty et al. “The functional role of cross-frequency coupling.” Trends Cogn Sci 14 (11):506-515 (2010).;;Hemptinne et al., “Exaggerated phase-amplitude coupling in the primary motor cortex in Parkinson disease.” Proc Natl.Acad Sci U.S.A. 110 (12):4780-4785 (2013).;;Roux et al. “Working memory and neural oscillations: alpha-gamma versus theta-gamma codes for distinct WM Information?.” Trends Cogn Sci 18 (1):16-25 (2014).;;Shirvalkar et al., Bidirectional changes to hippocampal theta-gamma comodulation predict memory for recent spatial episodes. Proc Natl.Acad Sci U.S.A. 107 (15):7054-7059 (2010).;;Tort et al. Theta-gamma coupling increases during the learning of item-context associations. Proc Natl.Acad Sci U.S.A. 106 (49):20942-20947 (2009).;;Tort et al. “Measuring Phase-Amplitude Coupling Between Neuronal Oscillations of Different Frequencies.” J Neurophysiol 104: 1195-1210 (May 12, 2010).",ACTIVE
206,US,B1,US 6473639 B1,131-110-760-202-543,2002-10-29,2002,US 51779700 A,2000-03-02,US 51779700 A,2000-03-02,Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures,This invention relates generally to information processing techniques used in the treatment of epilepsy and to devices for using these techniques.,NEUROPACE INC,FISCHELL DAVID R;;HARWOOD JONATHAN;;PLESS BENJAMIN D,NEUROPACE INC (2000-11-09),https://lens.org/131-110-760-202-543,Granted Patent,yes,87,414,1,131-110-760-202-543,US,1,131-110-760-202-543,US,0,A61B5/4094;;A61N1/36017;;A61N1/36064;;A61N1/37235;;A61B5/369;;A61B5/4094;;A61N1/37235;;A61N1/36064;;A61N1/36017;;A61B5/37;;A61B5/372;;A61B5/384,A61B5/0476;;A61N1/36,600/544,15,14,067-378-905-911-956;;028-133-278-688-002;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1002/jab.770050206;;10172072;;10.1159/000099878;;9711758;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"Andriano, K.P. et al. (1994). ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants,"" Journal of Applied Biomaterials 5:133-140.;;Chkhenkeli, S.A. and Chkhenkeli, I.S. (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact Funct Neurosurg 69:221-224.;;Cooper, I.S. et al. (1974). ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" In The Cerebellum, Epilepsy, and Behavior. Cooper, I.S. et al., eds., Pleman Press:New York, pp. 119-171.;;Cooper, I.S. et al. (1977/78). ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. 40: 124-134.;;Cooper, I.S. and Upton, A.R.M. (1978). ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992). ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. 58:200-208.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery 3(4):190-196.;;Gerlach, K.L. (1993). ""In-vivo and Clinical Evaluations of Poly(L-lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials 13:21-28.;;Gotman, J. (1999). ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology 16(2):130-140.;;Osario, I. et al. (1995). ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia, 36(supplement 4):4.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology 45:2250-2254.;;Sayler, K.E. et al. (1994). ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery 93(4):705-713.;;Schiff, S. et al. (1994). ""Controlling Chaos in the Brain,"" Nature 370:615-620.;;Thaller, S.R. et al. (1992). ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery 2(4):168-173.;;Velasco, F. et al. (1995). ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia 36(1):63-71.",EXPIRED
207,US,A1,US 2014/0276181 A1,139-542-633-557-819,2014-09-18,2014,US 201313802456 A,2013-03-13,US 201313802456 A;;US 201261730498 P,2012-11-27,Methods and Systems for Automatically Identifying Detection Parameters for an Implantable Medical Device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/139-542-633-557-819,Patent Application,yes,3,49,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374,600/544,0,0,,,,ACTIVE
208,US,B2,US 9955921 B2,034-615-322-226-307,2018-05-01,2018,US 201715654656 A,2017-07-19,US 201715654656 A;;US 201414341089 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spike activity, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2016-06-23),https://lens.org/034-615-322-226-307,Granted Patent,yes,5,3,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,G08B23/00;;A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
209,US,B2,US 10123715 B2,096-963-156-017-20X,2018-11-13,2018,US 201615183325 A,2016-06-15,US 201615183325 A;;US 201313802456 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,SUN FELICE;;ESTELLER ROSANA;;LEE ADAM,NEUROPACE INC (2013-04-16),https://lens.org/096-963-156-017-20X,Granted Patent,yes,5,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
210,US,A1,US 2025/0025091 A1,022-402-098-476-920,2025-01-23,2025,US 202418906685 A,2024-10-04,US 202418906685 A;;US 202117191175 A;;US 201715838383 A,2017-12-12,"SYSTEMS, DEVICES AND METHODS USING PHASE-AMPLITUDE COUPLING MEASURES IN IMPLANTABLE MEDICAL DEVICES","A sensor of an implantable medical device senses electrical activity of the brain. A data analyzer of the device monitors an electrographic signal corresponding to the electrical activity of the sensed brain signal, and processes the brain signal to obtain a measure of phase-amplitude coupling. For a selected portion of the electrographic signal, the data analyzer detects first features and second features of the electrographic signal. The first features represent oscillations in a low frequency range, while the second features represent oscillations in a frequency range higher than the low frequency range. For example, the low frequency range may correspond to theta frequency and the higher frequency range may correspond to gamma frequency. The data analyzer determines a measure of phase-amplitude coupling between oscillations in the low frequency range and oscillations in the higher frequency range based on occurrences of second features which coincide with first features.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K;;ARCHER STEPHEN T,NEUROPACE INC (2017-12-13),https://lens.org/022-402-098-476-920,Patent Application,yes,0,0,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,0,A61N1/36139;;A61N1/36171;;A61B5/686;;A61B5/6868;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61M5/1723;;A61N1/36064;;A61B5/316;;A61B5/291;;A61B5/374;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61N1/37229;;A61M5/1723;;A61M2210/0693;;A61M2230/10;;A61N1/36064;;A61N1/36171;;A61B5/686;;A61N1/36139;;A61B5/6868;;A61B5/374;;A61B5/291;;A61B5/316,A61B5/374;;A61B5/00;;A61B5/291;;A61B5/316;;A61M5/172;;A61N1/05;;A61N1/36;;A61N1/372,,0,0,,,,PENDING
211,US,B2,US 10722176 B2,033-831-120-590-194,2020-07-28,2020,US 201916374366 A,2019-04-03,US 201916374366 A;;US 201815928005 A;;US 201715654656 A;;US 201414341089 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spike activity, and power changes in the sensed signals, etc. A detection tool may be selected, and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2016-06-23),https://lens.org/033-831-120-590-194,Granted Patent,yes,8,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,G08B23/00;;A61B5/00;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
212,US,A1,US 2019/0175040 A1,084-933-586-536-584,2019-06-13,2019,US 201715838383 A,2017-12-12,US 201715838383 A,2017-12-12,"SYSTEMS, DEVICES AND METHODS USING PHASE-AMPLITUDE COUPLING MEASURES IN IMPLANTABLE MEDICAL DEVICES","A sensor of an implantable medical device senses electrical activity of the brain. A data analyzer of the device monitors an electrographic signal corresponding to the electrical activity of the sensed brain signal, and processes the brain signal to obtain a measure of phase-amplitude coupling. For a selected portion of the electrographic signal, the data analyzer detects first features and second features of the electrographic signal. The first features represent oscillations in a low frequency range, while the second features represent oscillations in a frequency range higher than the low frequency range. For example, the low frequency range may correspond to theta frequency and the higher frequency range may correspond to gamma frequency. The data analyzer determines a measure of phase-amplitude coupling between oscillations in the low frequency range and oscillations in the higher frequency range based on occurrences of second features which coincide with first features.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K;;ARCHER STEPHEN T,NEUROPACE INC (2017-12-13),https://lens.org/084-933-586-536-584,Patent Application,yes,0,8,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,0,A61N1/36139;;A61N1/36171;;A61B5/686;;A61B5/6868;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61M5/1723;;A61N1/36064;;A61B5/316;;A61B5/291;;A61B5/374;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61N1/37229;;A61M5/1723;;A61M2210/0693;;A61M2230/10;;A61N1/36064;;A61N1/36171;;A61B5/686;;A61N1/36139;;A61B5/6868;;A61B5/374;;A61B5/291;;A61B5/316,A61B5/374;;A61B5/00;;A61M5/172;;A61N1/05;;A61N1/36;;A61N1/372,,0,0,,,,ACTIVE
213,US,B2,US 8707040 B2,025-244-948-869-711,2014-04-22,2014,US 201113286065 A,2011-10-31,US 201113286065 A,2011-10-31,Establishing secure communication between an implantable medical device and an external device,"Establishing secure communication between an implantable medical device and an external device includes: accessing, at the implantable medical device, biological data; utilizing the biological data, at the implantable medical device, to generate a public cryptographic key; and utilizing the public cryptographic key, at the implantable medical device, to generate a private cryptographic key.",ANDERSEN DEAN P;;NEUROPACE INC,ANDERSEN DEAN P,NEUROPACE INC (2011-11-03),https://lens.org/025-244-948-869-711,Granted Patent,yes,12,14,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,6,004-325-428-944-16X;;106-904-703-537-804;;017-460-392-127-97X;;025-244-948-869-711;;124-091-852-253-482;;147-850-092-368-189,US,0,H04W12/06;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;A61N1/37254;;G06F7/588;;G06F21/606;;G16H40/63;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04W12/50;;H04L9/0869;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/24;;A61B5/369;;A61B5/6868;;A61N1/36064;;G06F7/588;;G06F21/606;;G16H40/63;;H04L9/0816;;H04L63/0442;;H04L63/0823;;H04L63/0861;;H04L67/12;;H04L2209/24;;H04W12/04;;H04W12/06;;H04W12/50,H04L29/06,713/169,6,1,165-603-805-319-614,10.1109/sp.2008.31,"U.S. Appl. No. 12/554,959, filed Sep. 7, 2007.;;""Data Encryption Standard (DES)"", Federal Information Processing Standards Publication 46-2, (Dec. 30, 1993).;;Volkmer, Markus et al., ""Lightweight Key Exchange and Stream Cipher based solely on Tree Parity Machines"", European Network of Excellence for Cryptology Workshop on RFID and Lightweight Crypto, Graz University of Technology, Graz, Austria, (2005).;;""Announcing the Advanced Encryption Standard (AES)"", Federal Information Processing Standards Publication 197,(Nov. 26, 2001).;;Halperin, Daniel et al., ""Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses"", IEEE Symposium on Security and Privacy, (2008).;;Paar, Christof et al., ""Understanding Cryptography"", A Textbook for Students and Practitioners. Springer-Verlag Berlin Heidelberg, (2010).",ACTIVE
214,US,A1,US 2016/0375247 A1,193-796-187-966-61X,2016-12-29,2016,US 201615257890 A,2016-09-06,US 201615257890 A;;US 201615135247 A;;US 201213631820 A,2012-09-28,METHODS AND SYSTEMS FOR CONTROLLING A STATE OF A NEUROSTIMULATOR,"A method and system is described for ensuring a state of an active implantable medical device based on the presence and persistence of a magnetic field. The output of a magnetic field sensor is monitored. The active implantable medical device is maintained in a first state, for so long as the presence of a magnetic field is detected by the magnetic field sensor, until a first interval is surpassed. If the first interval is surpassed, then a determination is made as to whether a second interval has been surpassed. If it is determined that the second interval has not been surpassed, then the active implantable medical device is transitioned into a second state. If it is determined that the second interval has been surpassed, then it is ensured that the active implantable medical device is in a predetermined one of the first and second states.",NEUROPACE INC,WINGEIER BRETT;;GIBB BARBARA;;BAYSINGER CRAIG;;TCHENG THOMAS;;GURUNATHAN SURESH,NEUROPACE INC (2012-10-05),https://lens.org/193-796-187-966-61X,Patent Application,yes,0,0,6,181-340-200-650-222;;193-796-187-966-61X;;073-935-585-828-905;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,6,181-340-200-650-222;;073-935-585-828-905;;193-796-187-966-61X;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,0,A61B5/0031;;A61B5/369;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36142;;A61N1/3718;;A61N1/36128;;A61B5/0031;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36067;;A61N1/36142;;A61N1/3718,A61N1/36;;A61B5/00;;A61B5/0476,,0,0,,,,ACTIVE
215,EP,B1,EP 1307260 B1,017-594-098-512-918,2006-11-02,2006,EP 01959350 A,2001-07-31,US 0123958 W;;US 62921000 A,2000-07-31,MIGRAINE HEADACHE TREATMENT APPARATUS,,NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,"NEUROPACE, INC. (2006-06-28)",https://lens.org/017-594-098-512-918,Granted Patent,yes,4,1,8,189-044-284-405-13X;;065-046-951-418-456;;017-594-098-512-918;;165-405-457-127-116;;107-267-318-347-470;;007-048-723-243-717;;075-155-970-554-90X;;125-802-401-205-523,WO;;EP;;CA;;DE;;US,8,189-044-284-405-13X;;065-046-951-418-456;;017-594-098-512-918;;125-802-401-205-523;;107-267-318-347-470;;007-048-723-243-717;;075-155-970-554-90X;;165-405-457-127-116,WO;;EP;;CA;;DE;;US,0,A61N2/02;;A61N2/02,A61N2/02;;A61N2/04,,0,0,,,,EXPIRED
216,US,B1,US 6353754 B1,043-855-387-830-643,2002-03-05,2002,US 55641500 A,2000-04-24,US 55641500 A,2000-04-24,System for the creation of patient specific templates for epileptiform activity detection,"An epileptiform activity patient template creation system is provided which permits the user to efficiently develop an optimized set of patient specific parameters for epileptiform activity detection algorithms. The epileptiform activity patient template creation system is primarily directed to a computer software package which operates within a computer workstation having a processor, disk storage and display for storing, processing and displaying patient EEG signals. The computer processor in conjunction with the software package allows for the marking of the initiation/termination of electrographic seizures within the patient's displayed EEG signals. Epileptiform activity segments are extracted from at least one of the EEG signals with the activity segments including a marked initiation of a seizure. Subsequently, a seizure data set simultaneously displaying a number of the epileptiform activity segments is shown on the display monitor. Epileptiform activity is then detected from the displayed segments by an epileptiform activity detection algorithm having at least one programmable epileptiform activity detection parameter. The template is then created and modified to optimize epileptiform activity detection. The final template can then be downloaded to an implantable neuropacemaker for epileptic seizure control through responsive stimulation.",NEUROPACE INC,FISCHELL DAVID R;;HARWOOD JONATHAN P,NEUROPACE INC (2000-04-18),https://lens.org/043-855-387-830-643,Granted Patent,yes,3,312,1,043-855-387-830-643,US,1,043-855-387-830-643,US,0,A61B5/4094;;A61B5/369;;A61B5/4094;;A61B5/372,A61B5/0476,600/544,0,0,,,,EXPIRED
217,US,A1,US 2019/0223796 A1,137-827-169-246-887,2019-07-25,2019,US 201916374366 A,2019-04-03,US 201916374366 A;;US 201815928005 A;;US 201715654656 A;;US 201414341089 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spike activity, and power changes in the sensed signals, etc. A detection tool may be selected, and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2016-06-23),https://lens.org/137-827-169-246-887,Patent Application,yes,4,1,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
218,US,A1,US 2021/0186407 A1,171-252-395-893-730,2021-06-24,2021,US 202117191175 A,2021-03-03,US 202117191175 A;;US 201715838383 A,2017-12-12,"SYSTEMS, DEVICES AND METHODS USING PHASE-AMPLITUDE COUPLING MEASURES IN IMPLANTABLE MEDICAL DEVICES","A sensor of an implantable medical device senses electrical activity of the brain. A data analyzer of the device monitors an electrographic signal corresponding to the electrical activity of the sensed brain signal, and processes the brain signal to obtain a measure of phase-amplitude coupling. For a selected portion of the electrographic signal, the data analyzer detects first features and second features of the electrographic signal. The first features represent oscillations in a low frequency range, while the second features represent oscillations in a frequency range higher than the low frequency range. For example, the low frequency range may correspond to theta frequency and the higher frequency range may correspond to gamma frequency. The data analyzer determines a measure of phase-amplitude coupling between oscillations in the low frequency range and oscillations in the higher frequency range based on occurrences of second features which coincide with first features.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K;;ARCHER STEPHEN T,NEUROPACE INC (2017-12-13),https://lens.org/171-252-395-893-730,Patent Application,yes,3,0,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,5,036-785-113-344-061;;031-730-642-861-582;;084-933-586-536-584;;171-252-395-893-730;;022-402-098-476-920,US,0,A61N1/36139;;A61N1/36171;;A61B5/686;;A61B5/6868;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61M5/1723;;A61N1/36064;;A61B5/316;;A61B5/291;;A61B5/374;;A61B5/4094;;A61N1/0534;;A61N1/36067;;A61N1/37229;;A61M5/1723;;A61M2210/0693;;A61M2230/10;;A61N1/36064;;A61N1/36171;;A61B5/686;;A61N1/36139;;A61B5/6868;;A61B5/374;;A61B5/291;;A61B5/316,A61B5/374;;A61B5/00;;A61B5/291;;A61B5/316;;A61M5/172;;A61N1/36;;A61N1/372,,0,0,,,,ACTIVE
219,US,B2,US 6662035 B2,147-139-216-831-004,2003-12-09,2003,US 95123401 A,2001-09-13,US 95123401 A,2001-09-13,Implantable lead connector assembly for implantable devices and methods of using it,"This is an implantable lead connector assembly for connecting electrode leads implanted into the brain to implantable devices. The lead connector assembly preferably includes at least one interposer for holding a lead electrode, a connector housing, a fastener, and electrical connection members that electrically link the electrode lead connections to the to pins projecting from the lead connector assembly. Electrical contact between the electrode lead and the external pins of the connector assembly is accomplished by closing the connector housing. Multiple electrical leads may be connected in this way and the electrical contacts between the connector and the electrode lead are sealed from each other and from external fluids. A method for connecting an implantable electrode lead to an implantable device using such an implantable connector is also provided.",NEUROPACE INC,SOCHOR JERZY,NEUROPACE INC (2001-11-26),https://lens.org/147-139-216-831-004,Granted Patent,yes,34,201,2,147-139-216-831-004;;016-022-883-048-719,US,2,147-139-216-831-004;;016-022-883-048-719,US,0,A61N1/0529;;A61B5/287;;A61B2562/227;;H01R13/5224;;H01R24/58;;H01R2107/00;;H01R2201/12;;Y10S439/909;;A61N1/0529;;A61B5/287;;A61B2562/227;;H01R13/5224;;H01R24/58;;H01R2107/00;;H01R2201/12;;Y10S439/909,A61B5/042;;A61N1/05;;H01R13/52;;H01R24/58,600/378;;607/116;;439/909,0,0,,,,EXPIRED
220,US,B2,US 9162052 B2,027-392-541-378-555,2015-10-20,2015,US 55495409 A,2009-09-07,US 55495409 A;;US 52558606 A,2006-09-21,"Treatment of language, behavior and social disorders","Methods of treating language, behavioral and social disorders are described, including methods of treating language disorders associated with electrographic abnormalities in the primary or associative language cortex of persons with autism spectrum disorders, pervasive developmental delay or acquired epileptic aphasia. A language, behavioral and social disorder may be treated by detecting epileptiform activity or an electrographic seizure for a subject's brain and applying neurostimulation to a language cortical region of the subject's brain (e.g., a primary or associative language cortical region). Detection of epileptiform activity or an electrographic seizure and stimulation of language cortex may be performed by a sensing and/or stimulation electrode that is inserted into a subject's brain and connected to one or more neurostimulation devices for monitoring and/or stimulating the language cortex.",MORRELL MARTHA J;;NEUROPACE INC,MORRELL MARTHA J,NEUROPACE INC (2006-11-16),https://lens.org/027-392-541-378-555,Granted Patent,yes,13,7,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,0,A61B5/165;;A61B5/4094;;A61N1/0539;;A61N1/0531;;A61N1/36082;;A61N1/36135;;A61B5/4836;;A61B5/369;;A61B5/165;;A61B5/4094;;A61N1/0539;;A61B5/372;;A61B5/37;;A61N1/0531;;A61N1/36082;;A61B5/4836;;A61B5/6868;;A61B5/7282;;A61N1/0529;;A61N1/36135,A61N1/00;;A61B5/00;;A61B5/0476;;A61B5/16;;A61N1/05;;A61N1/36,,9,9,033-409-029-479-221;;003-437-454-229-979;;029-335-233-748-077;;020-676-908-972-703;;039-096-134-013-54X;;055-989-827-587-296;;031-305-152-174-854;;010-443-289-341-901;;009-083-260-830-814,10.1007/s00787-004-0353-7;;15365890;;10.1177/155005940503600105;;15683193;;9090688;;10.1016/s0887-8994(96)00297-4;;10.1016/s1525-5050(03)00080-5;;12791330;;7573755;;10.1016/0387-7604(95)00019-8;;15362170;;10.1002/mrdd.20025;;15526970;;10.1177/088307380401900106;;10.1177/08830738040190010601;;10.1016/s1474-4422(02)00160-6;;12849396;;10916262;;10.1109/10.846685,"Hrdlicka, M. et al., ""Not EEG Abnormalities but Epilepsy is Associated with Autistic Regression and Mental Functioning in Childhood Autism"", European Child & Adolescent Psychiatry 13(4), (2004),209-213.;;Hughes, J. R. et al., ""EEG and Seizures in Autistic Children and Adolescents: Further Findings with Therapeutic Implications"", Clinical EEG Neuroscience 36(1), (Jan. 2005), 15-20.;;Neville, B. R. G. et al., ""Surgical Treatment of Severe Autistic Regression in Childhood Epilepsy"", Pediatric Neurology 16(2), (Feb. 1997), 137-140.;;Park, Y. D. ""The Effects of Vagus Nerve Stimulation Therapy on Patients with Intractable Seizures and Either Landau-Kleffner Syndrome or Autism"", Epilepsy & Behavior 4(3), (2003),286-290.;;Rossi, P. G. et al., ""EEG Features and Epilepsy in Patients with Autism"", Brain and Development 17(2), (Mar./Apr. 1995),169-174.;;Tharp, B. R. ""Epileptic Encephalopathies and Their Relationship to Developmental Disorders: Do Spikes Cause Autism?"", Mental Retardation and Developmental Disabilities Research Reviews 10, (2004),132-134.;;Trevathan, E. ""Seizures and Epilepsy Among Children with Language Regression and Autistic Spectrum Disorders"", Journal of Child Neurology 19(S1), (Aug. 2004),S49-57.;;Tuchman, R. et al., ""Epilepsy in Autism"", The Lancet Neurology 1, (Oct. 2002),352-358.;;Weiland, J. D. et al., ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes"", IEEE Transactions on Biomedical Engineering 47(7), (Jul. 2000),911-918.",ACTIVE
221,US,A1,US 2016/0027293 A1,064-722-045-771-877,2016-01-28,2016,US 201414341089 A,2014-07-25,US 201313802457 A;;US 201261730498 P;;US 201414341089 A,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2013-04-16),https://lens.org/064-722-045-771-877,Patent Application,yes,2,28,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,G08B29/00;;A61B5/374,,0,0,,,,ACTIVE
222,US,A1,US 2018/0220963 A1,098-909-634-107-476,2018-08-09,2018,US 201815928005 A,2018-03-21,US 201815928005 A;;US 201715654656 A;;US 201414341089 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spike activity, and power changes in the sensed signals, etc. A detection tool may be selected, and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2016-06-23),https://lens.org/098-909-634-107-476,Patent Application,yes,0,1,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
223,WO,A1,WO 2002/009811 A1,125-802-401-205-523,2002-02-07,2002,US 0123958 W,2001-07-31,US 62921000 A,2000-07-31,MIGRAINE HEADACHE TREATMENT APPARATUS,"A system and method for treating migraine headaches employs a readily portable and easy-to-operate head-mounted magnetic depolarizer (10) to generate a transient or alternating high-intensity magnetic field in and around the user's occipital lobe or other portion of the brain (1), thereby terminating the spreading depression phenomenon characterizing a migraine headache and its aura.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,,https://lens.org/125-802-401-205-523,Patent Application,yes,4,34,8,189-044-284-405-13X;;065-046-951-418-456;;017-594-098-512-918;;165-405-457-127-116;;107-267-318-347-470;;007-048-723-243-717;;075-155-970-554-90X;;125-802-401-205-523,WO;;EP;;CA;;DE;;US,8,189-044-284-405-13X;;065-046-951-418-456;;017-594-098-512-918;;125-802-401-205-523;;107-267-318-347-470;;007-048-723-243-717;;075-155-970-554-90X;;165-405-457-127-116,WO;;EP;;CA;;DE;;US,0,A61N2/02;;A61N2/02,A61N2/02;;A61N2/04,,0,0,,,,PATENTED
224,US,A1,US 2014/0185805 A1,083-210-531-048-772,2014-07-03,2014,US 201313804721 A,2013-03-14,US 201313804721 A;;US 201361748639 P,2013-01-03,Securely Exchanging Cipher Keys,"Methods and systems for securely exchanging cipher keys between an implantable device and an external device are described. An example method includes: receiving an authorization request from the external device, wherein the authorization request is a request to receive a first cipher key of a cipher key exchange; receiving an indication that a magnet is detected relative to the implantable device, wherein the indication signifies a secure environment for communication between the implantable device and the external device; and after receiving the authorization request and the indication of a detected magnet, generating a first cipher key transmittal instruction, wherein the first cipher key transmittal instruction instructs the first cipher key to be transmitted to the external device by the implantable device.",NEUROPACE INC,ANDERSEN DEAN P,NEUROPACE INC (2014-01-14),https://lens.org/083-210-531-048-772,Patent Application,yes,3,36,1,083-210-531-048-772,US,1,083-210-531-048-772,US,0,H04W12/04;;H04L67/12;;H04W12/02;;H04W12/35;;H04W12/04;;H04L67/12;;H04W12/02;;H04W12/35,H04W12/04,380/270,0,0,,,,DISCONTINUED
225,US,B2,US 8423145 B2,091-933-047-228-332,2013-04-16,2013,US 201213523855 A,2012-06-14,US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",PLESS BENJAMIN D;;TCHENG THOMAS K;;NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-09),https://lens.org/091-933-047-228-332,Granted Patent,yes,101,26,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61M5/142;;A61N1/36,607/45;;607/62,36,21,028-133-278-688-002;;067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;132-849-338-722-860;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;059-959-153-435-269;;030-458-658-036-396;;056-361-838-782-639;;124-403-369-942-149,10.1159/000099878;;9711758;;10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;312191;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10563620;;10.1212/wnl.53.8.1731;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;52443;;10.1016/0013-4694(75)90051-6,"Chkhenkeli, S.A. and, Chkhenkeli, I.S. et al., (1997). ""Effects of Therapeutic Stimulation of Nucleus Caudatus on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact Funct Neurosurg 69:221-224.;;Adriano, K.P. et al., (1994). ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical Implants,"" Journal of Applied Biomaterials 5: 133-140.;;Cooper, I.S. et al., (1974). ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" In The Cerebellum, Epilepsy, and Behavior. Cooper, I.S. et al., eds., Plenum Press:New York, pp. 119-171.;;Cooper, I.S. et al., (1977/1978). ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. 40:124-134.;;Cooper, I.S. and Upton, A.R.M. (1978). ""Effects of Cerebellar Stimulation on Epilepsy, the EEG and Cerebral Palsy in Man,"" In Contemporary Clinical Neurophysiology (EEG Suppl. No. 34). Cobb, W.A. et al., eds., Elsevier Scientific Publishing: Amsterdam, pp. 349-354.;;Davis, R. and Emmonds, S.E. (1992). ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. 58:200-208.;;Eppley, B.L. and Sadove, A.M. (1992). ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery 3(4):190-196.;;Gerlach, K.L. (1993). ""In-vivo and Clinical Evaluations of Poly(L-Lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials 13:21-28.;;Gotman, J. (1999). ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology 16(2): 130-140.;;Osario, I. et al., (1995). ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia, 36(supplement 4):4, Abstract No. 1.04.;;Qu, H. and Gotman, J. (1995). ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology 45:2250-2254.;;Sayler, K.E. et al., (1994). ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery 93(4):705-713.;;Schiff, S. et al., (1994). ""Controlling Chaos in the Brain,"" Nature 370:615-620.;;Thaller, S.R. et al., (1992). ""Use of Biodegradable Plates and Screws in a Rabbit Model,"" Journal of Craniofacial Surgery 2(4):168-173.;;Velasco, F. et al., (1995). ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia 36(1):63-71.;;Lee, S.A. et al., (2000). ""Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy"", Epilepsia, 41 (3): 297-307.;;Lesser, R.P. et al., ""Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation"", Neurologogy 1999; 53 (December): 2073-81.;;Schiller, Y et al., ""Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes"", Epilepsia, 1998; 39(4): 380-88.;;Morris III, G.L. et al., ""Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy"". Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).;;Limousin, P. ""Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor"", J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Activa).;;Spencer, S.S. et al., ""Morphological Patterns of Seizures Recorded Intracranially"", Epilepsia, 1992,33(3): 537-45.;;Wagner, H.R. et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization"", Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 8, 2004).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Oct. 14, 2005).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Apr. 20, 2006).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 9, 2007).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 1, 2004).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450)(Oct. 18, 2005).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Apr. 13, 2006).;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 9, 2007).;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.",EXPIRED
226,US,A1,US 2012/0253417 A1,115-468-682-997-403,2012-10-04,2012,US 201213523855 A,2012-06-14,US 201213523855 A;;US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54326400 A;;US 54345000 A,2000-04-05,DIFFERENTIAL NEUROSTIMULATION THERAPY DRIVEN BY PHYSIOLOGICAL THERAPY,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",PLESS BENJAMIN D;;TCHENG THOMAS K;;NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-09),https://lens.org/115-468-682-997-403,Patent Application,yes,0,0,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/36;;A61F7/00;;A61M5/142;;A61M37/00,607/3;;607/45,0,0,,,,EXPIRED
227,US,B2,US 9162051 B2,060-018-768-027-967,2015-10-20,2015,US 52558606 A,2006-09-21,US 52558606 A,2006-09-21,"Treatment of language, behavior and social disorders","Methods of treating language, behavioral and social disorders are described, including methods of treating language disorders associated with electrographic abnormalities in the primary or associative language cortex of persons with autism spectrum disorders, pervasive developmental delay or acquired epileptic aphasia. A language, behavioral and social disorder may be treated by detecting epileptiform activity or an electrographic seizure for a subject's brain and applying neurostimulation to a language cortical region of the subject's brain (e.g., a primary or associative language cortical region). Detection of epileptiform activity or an electrographic seizure and stimulation of language cortex may be performed by a sensing and/or stimulation electrode that is inserted into a subject's brain and connected to one or more neurostimulation devices for monitoring and/or stimulating the language cortex.",MORRELL MARTHA J;;NEUROPACE INC,MORRELL MARTHA J,NEUROPACE INC (2006-11-16),https://lens.org/060-018-768-027-967,Granted Patent,yes,13,7,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,8,059-122-939-353-404;;001-477-170-871-541;;060-018-768-027-967;;001-475-642-475-186;;027-392-541-378-555;;042-208-686-617-343;;008-845-511-738-038;;158-064-384-387-77X,US,0,A61B5/165;;A61B5/4094;;A61N1/0539;;A61N1/0531;;A61N1/36082;;A61N1/36135;;A61B5/4836;;A61B5/369;;A61B5/165;;A61B5/4094;;A61N1/0539;;A61B5/372;;A61B5/37;;A61N1/0531;;A61N1/36082;;A61B5/4836;;A61B5/6868;;A61B5/7282;;A61N1/0529;;A61N1/36135,A61N1/05;;A61B5/00;;A61B5/0476;;A61B5/16;;A61N1/36,,9,9,033-409-029-479-221;;003-437-454-229-979;;029-335-233-748-077;;020-676-908-972-703;;039-096-134-013-54X;;055-989-827-587-296;;031-305-152-174-854;;010-443-289-341-901;;009-083-260-830-814,10.1007/s00787-004-0353-7;;15365890;;10.1177/155005940503600105;;15683193;;9090688;;10.1016/s0887-8994(96)00297-4;;10.1016/s1525-5050(03)00080-5;;12791330;;7573755;;10.1016/0387-7604(95)00019-8;;15362170;;10.1002/mrdd.20025;;15526970;;10.1177/088307380401900106;;10.1177/08830738040190010601;;10.1016/s1474-4422(02)00160-6;;12849396;;10916262;;10.1109/10.846685,"Hrdlicka, M. et al. (2004). ""Not EEG Abnormalities but Epilepsy is Associated with Autistic Regression and Mental Functioning in Childhood Autism,"" European Child & Adolescent Psychiatry 13(4):209-213.;;Hughes, J. R. et al. (Jan. 2005). ""EEG and Seizures in Autistic Children and Adolescents: Further Findings with Therapeutic Implications,"" Clinical EEG Neuroscience 36(1):15-20.;;Neville, B. R. G. et al. (Feb. 1997). ""Surgical Treatment of Severe Autistic Regression in Childhood Epilepsy,"" Pediatric Neurology 16(2):137-140.;;Park, Y. D. (2003). ""The Effects of Vagus Nerve Stimulation Therapy on Patients with Intractable Seizures and Either Landau-Kleffner Syndrome or Autism,"" Epilepsy & Behavior 4(3):286-290.;;Rossi, P. G. et al. (Mar./Apr. 1995). ""EEG Features and Epilepsy in Patients with Autism,"" Brain and Development 17(2):169-174.;;Tharp, B. R. (2004). ""Epileptic Encephalopathies and Their Relationship to Developmental Disorders: Do Spikes Cause Autism?"" Mental Retardation and Developmental Disabilities Research Reviews 10:132-134.;;Trevathan, E. (Aug. 2004). ""Seizures and Epilepsy Among Children with Language Regression and Autistic Spectrum Disorders,"" Journal of Child Neurology 19(S1):S49-57.;;Tuchman, R. et al. (Oct. 2002). ""Epilepsy in Autism,"" The Lancet Neurology 1:352-358.;;Weiland, J. D. et al. (Jul. 2000). ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering 47(7):911-918.",ACTIVE
228,US,A,US 6061593 A,074-732-904-610-695,2000-05-09,2000,US 6573998 A,1998-04-24,US 6573998 A;;US 95786997 A,1997-10-27,EEG d-c voltage shift as a means for detecting the onset of a neurological event,"Disclosed herein is a multiple electrode, closed-loop system for the treatment of certain neurological disorders such as epilepsy, migraine headaches and Parkinson's disease. Specifically, the present invention combines a multi-electrode array with sophisticated signal processing techniques to achieve reliable detection of the onset of a neurological event (such as an epileptic seizure or migraine headache) typically originating from a focus of limited spatial extent within the brain. It is highly desirable to detect an epileptic seizure at least 5 seconds before the onset of clinical symptoms. Since there is often a d-c shift in the EEG voltage more than 5 seconds before the seizure, disclosed herein is a means for utilizing the d-c shift of the EEG for early detection of the seizure.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-03-27),https://lens.org/074-732-904-610-695,Granted Patent,yes,3,486,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,600/544,0,0,,,,EXPIRED
229,US,A1,US 2017/0311890 A1,082-094-363-670-498,2017-11-02,2017,US 201715654656 A,2017-07-19,US 201715654656 A;;US 201414341089 A;;US 201261730498 P,2012-11-27,METHODS AND SYSTEMS FOR AUTOMATICALLY IDENTIFYING DETECTION PARAMETERS FOR AN IMPLANTABLE MEDICAL DEVICE,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spike activity, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2016-06-23),https://lens.org/082-094-363-670-498,Patent Application,yes,2,3,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
230,US,A1,US 2014/0094876 A1,163-541-989-089-644,2014-04-03,2014,US 201213631820 A,2012-09-28,US 201213631820 A,2012-09-28,METHODS AND SYSTEMS FOR CONTROLLING A STATE OF A NEUROSTIMULATOR,"A method and system is described for ensuring a state of an active implantable medical device based on the presence and persistence of a magnetic field. The output of a magnetic field sensor is monitored. The active implantable medical device is maintained in a first state, for so long as the presence of a magnetic field is detected by the magnetic field sensor, until a first interval is surpassed. If the first interval is surpassed, then a determination is made as to whether a second interval has been surpassed. If it is determined that the second interval has not been surpassed, then the active implantable medical device is transitioned into a second state. If it is determined that the second interval has been surpassed, then it is ensured that the active implantable medical device is in a predetermined one of the first and second states.",NEUROPACE INC,WINGEIER BRETT;;GIBB BARBARA;;BAYSINGER CRAIG;;TCHENG THOMAS;;GURUNATHAN SURESH,NEUROPACE INC (2012-10-05),https://lens.org/163-541-989-089-644,Patent Application,yes,4,15,6,181-340-200-650-222;;193-796-187-966-61X;;073-935-585-828-905;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,6,181-340-200-650-222;;073-935-585-828-905;;193-796-187-966-61X;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,0,A61B5/0031;;A61B5/369;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36142;;A61N1/3718;;A61N1/36128;;A61B5/0031;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36067;;A61N1/36142;;A61N1/3718,A61N1/36,607/62,0,0,,,,INACTIVE
231,US,A,US 5938689 A,198-919-702-268-349,1999-08-17,1999,US 7097498 A,1998-05-01,US 7097498 A,1998-05-01,Electrode configuration for a brain neuropacemaker,"Disclosed herein are several unique configurations of electrodes for stimulation of brain tissue. Specifically, a configuration of electrodes is disclosed that has at least one electrode on the brain's surface and at least one additional electrode located deep within the tissue of the brain. It is envisioned that all such electrodes would be located in close proximity to a particular region of the brain such as an epileptic focus. It is further envisioned that several brain surface electrodes would be used in conjunction with several deep brain electrodes. Specifically, it is envisioned that all surface electrodes would be electrically joined together and all deep electrodes would be electrically joined together. In this way, when a source of electrical current is connected to those electrodes, a particular region of the brain could be surrounded by a ""curtain"" of electrical current that can be used to depolarize neurons at the perimeter of the region so as to prevent any electrical signal originating in that region from being transmitted beyond that region to the rest of the brain. Sub-surface electrodes placed between 1 and 10 mm below the brain's surface could also be used with either brain surface electrodes or deep brain electrodes.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R,NEUROPACE INC (1999-04-28),https://lens.org/198-919-702-268-349,Granted Patent,yes,9,202,1,198-919-702-268-349,US,1,198-919-702-268-349,US,0,A61N1/0529;;A61N1/0534;;A61N1/36064;;A61N1/36075;;A61N1/36185;;A61N1/0529;;A61N1/0534;;A61N1/36064;;A61N1/36075;;A61N1/36185,A61N1/05;;A61N1/36,607/45;;607/2;;607/116;;607/148;;600/378;;600/544,0,0,,,,EXPIRED
232,US,B2,US 10299728 B2,020-186-425-101-370,2019-05-28,2019,US 201815928005 A,2018-03-21,US 201815928005 A;;US 201715654656 A;;US 201414341089 A;;US 201261730498 P,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spike activity, and power changes in the sensed signals, etc. A detection tool may be selected, and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2016-06-23),https://lens.org/020-186-425-101-370,Granted Patent,yes,5,0,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,A61B5/00;;A61B5/374;;G08B23/00,,0,0,,,,ACTIVE
233,US,B1,US 6360122 B1,053-805-145-710-590,2002-03-19,2002,US 62897700 A,2000-08-02,US 62897700 A;;US 45030399 A;;US 95786997 A,1997-10-27,Data recording methods for an implantable device,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-11-09),https://lens.org/053-805-145-710-590,Granted Patent,yes,3,455,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,600/544,0,0,,,,EXPIRED
234,US,B2,US 9743886 B2,051-948-261-532-993,2017-08-29,2017,US 201414341089 A,2014-07-25,US 201313802457 A;;US 201261730498 P;;US 201414341089 A,2012-11-27,Methods and systems for automatically identifying detection parameters for an implantable medical device,"An initial set of parameters for operating one or more detection tools is automatically derived and subsequently adjusted so that each detection tool is more or less sensitive to signal characteristics in a region of interest. Detection tool(s) may be applied to physiological signals sensed from a patient (such as EEG signals) and may be configured to run in an implanted medical device that is programmable with the parameters to look for rhythmic activity, spiking, and power changes in the sensed signals, etc. A detection tool may be selected and parameter values derived in a logical sequence and/or in pairs based on a graphical representation of an activity type which may be selected by a user, for example, by clicking and dragging on the graphic via a GUI. Displayed simulations allow a user to assess what will be detected with a derived parameter set and then to adjust the sensitivity of the set or start over as desired.",NEUROPACE INC,ESTELLER ROSANA;;SUN FELICE,NEUROPACE INC (2013-04-16),https://lens.org/051-948-261-532-993,Granted Patent,yes,5,1,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,17,013-684-924-544-895;;051-948-261-532-993;;098-909-634-107-476;;034-615-322-226-307;;054-535-057-848-126;;137-827-169-246-887;;086-380-648-977-330;;099-314-604-941-164;;096-963-156-017-20X;;182-456-388-756-766;;139-542-633-557-819;;082-094-363-670-498;;055-689-639-717-255;;020-186-425-101-370;;064-722-045-771-877;;016-814-664-070-153;;033-831-120-590-194,US,0,A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/686;;A61B5/4094;;A61B5/374;;A61B5/369;;A61B5/4836;;A61B5/6868;;A61B5/7278;;A61B5/7282;;A61B5/7435;;A61B5/748;;A61N1/36135;;A61B5/374;;A61B5/37;;A61B5/686;;A61B5/4094;;A61N1/36064,G08B23/00;;A61B5/00;;A61B5/374,,0,0,,,,ACTIVE
235,US,A,US 6128538 A,024-030-376-301-273,2000-10-03,2000,US 45030399 A,1999-11-29,US 45030399 A;;US 95786997 A,1997-10-27,Means and method for the treatment of neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-07-31),https://lens.org/024-030-376-301-273,Granted Patent,yes,7,424,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,607/45,0,0,,,,EXPIRED
236,US,B2,US 10188862 B2,181-340-200-650-222,2019-01-29,2019,US 201615257890 A,2016-09-06,US 201615257890 A;;US 201615135247 A;;US 201213631820 A,2012-09-28,Methods and systems for controlling a state of a neurostimulator,"A method and system is described for ensuring a state of an active implantable medical device based on the presence and persistence of a magnetic field. The output of a magnetic field sensor is monitored. The active implantable medical device is maintained in a first state, for so long as the presence of a magnetic field is detected by the magnetic field sensor, until a first interval is surpassed. If the first interval is surpassed, then a determination is made as to whether a second interval has been surpassed. If it is determined that the second interval has not been surpassed, then the active implantable medical device is transitioned into a second state. If it is determined that the second interval has been surpassed, then it is ensured that the active implantable medical device is in a predetermined one of the first and second states.",NEUROPACE INC,WINGEIER BRETT;;GIBB BARBARA;;BAYSINGER CRAIG;;TCHENG THOMAS;;GURUNATHAN SURESH,NEUROPACE INC (2012-10-05),https://lens.org/181-340-200-650-222,Granted Patent,yes,17,0,6,181-340-200-650-222;;193-796-187-966-61X;;073-935-585-828-905;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,6,181-340-200-650-222;;073-935-585-828-905;;193-796-187-966-61X;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,0,A61B5/0031;;A61B5/369;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36142;;A61N1/3718;;A61N1/36128;;A61B5/0031;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36067;;A61N1/36142;;A61N1/3718,A61N1/36;;A61B5/00;;A61B5/0476;;A61N1/37,,0,0,,,,ACTIVE
237,US,A1,US 2016/0235991 A1,138-629-605-215-77X,2016-08-18,2016,US 201615135247 A,2016-04-21,US 201615135247 A;;US 201213631820 A,2012-09-28,METHODS AND SYSTEMS FOR CONTROLLING A STATE OF A NEUROSTIMULATOR,"A method and system is described for ensuring a state of an active implantable medical device based on the presence and persistence of a magnetic field. The output of a magnetic field sensor is monitored. The active implantable medical device is maintained in a first state, for so long as the presence of a magnetic field is detected by the magnetic field sensor, until a first interval is surpassed. If the first interval is surpassed, then a determination is made as to whether a second interval has been surpassed. If it is determined that the second interval has not been surpassed, then the active implantable medical device is transitioned into a second state. If it is determined that the second interval has been surpassed, then it is ensured that the active implantable medical device is in a predetermined one of the first and second states.",NEUROPACE INC,WINGEIER BRETT;;GIBB BARBARA;;BAYSINGER CRAIG;;TCHENG THOMAS;;GURUNATHAN SURESH,NEUROPACE INC (2012-10-05),https://lens.org/138-629-605-215-77X,Patent Application,yes,0,0,6,181-340-200-650-222;;193-796-187-966-61X;;073-935-585-828-905;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,6,181-340-200-650-222;;073-935-585-828-905;;193-796-187-966-61X;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,0,A61B5/0031;;A61B5/369;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36142;;A61N1/3718;;A61N1/36128;;A61B5/0031;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36067;;A61N1/36142;;A61N1/3718,A61N1/36;;A61B5/0476,,0,0,,,,INACTIVE
238,US,B2,US 9463322 B2,161-751-992-399-769,2016-10-11,2016,US 201615135247 A,2016-04-21,US 201615135247 A;;US 201213631820 A,2012-09-28,Methods and systems for controlling a state of a neurostimulator,"A method and system is described for ensuring a state of an active implantable medical device based on the presence and persistence of a magnetic field. The output of a magnetic field sensor is monitored. The active implantable medical device is maintained in a first state, for so long as the presence of a magnetic field is detected by the magnetic field sensor, until a first interval is surpassed. If the first interval is surpassed, then a determination is made as to whether a second interval has been surpassed. If it is determined that the second interval has not been surpassed, then the active implantable medical device is transitioned into a second state. If it is determined that the second interval has been surpassed, then it is ensured that the active implantable medical device is in a predetermined one of the first and second states.",NEUROPACE INC,WINGEIER BRETT;;GIBB BARBARA;;BAYSINGER CRAIG;;TCHENG THOMAS;;GURUNATHAN SURESH,NEUROPACE INC (2012-10-05),https://lens.org/161-751-992-399-769,Granted Patent,yes,18,8,6,181-340-200-650-222;;193-796-187-966-61X;;073-935-585-828-905;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,6,181-340-200-650-222;;073-935-585-828-905;;193-796-187-966-61X;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,0,A61B5/0031;;A61B5/369;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36142;;A61N1/3718;;A61N1/36128;;A61B5/0031;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36067;;A61N1/36142;;A61N1/3718,A61N1/36;;A61B5/00,,0,0,,,,INACTIVE
239,US,B2,US 8224452 B2,146-913-054-079-190,2012-07-17,2012,US 201113109970 A,2011-05-17,US 201113109970 A;;US 43619106 A;;US 12193302 A;;US 96294001 A;;US 54345000 A;;US 54326400 A,2000-04-05,Differential neurostimulation therapy driven by physiological therapy,"An implantable neurostimulator system adapted to provide therapy for various neurological disorders is capable of varying therapy delivery strategies based on the context, physiological or otherwise, into which the therapy is to be delivered. Responsive and scheduled therapies can be varied depending on various sensor measurements, calculations, inferences, and device states (including elapsed times and times of day) to deliver an appropriate course of therapy under the circumstances.",PLESS BENJAMIN D;;TCHENG THOMAS K;;NEUROPACE INC,PLESS BENJAMIN D;;TCHENG THOMAS K,NEUROPACE INC (2002-07-08),https://lens.org/146-913-054-079-190,Granted Patent,yes,103,14,15,145-713-618-912-297;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;091-933-047-228-332;;048-861-529-805-092;;061-631-376-949-809;;047-380-325-824-394;;115-468-682-997-403;;146-913-054-079-190;;145-269-019-951-00X;;143-164-892-494-217;;011-624-965-053-462;;044-511-791-743-100,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61N1/36135;;A61B5/4836;;A61M5/14276;;A61N1/0529;;A61N1/0531;;A61N1/0539;;A61N1/36064;;A61N1/36067;;A61N1/36078;;A61B5/372;;A61B5/37;;A61N1/36135;;A61B5/0006;;A61B5/0022;;A61B5/0031;;A61B5/076;;A61B5/4836;;A61B5/686;;A61B5/743;;A61B5/021;;A61B5/026;;A61B5/14542;;A61B5/14546;;A61B5/4812;;A61N1/36139,A61N1/00;;A61M5/142;;A61N1/36,607/45,36,21,028-133-278-688-002;;132-849-338-722-860;;064-968-594-730-904;;100-005-053-904-205;;011-361-025-719-111;;059-959-153-435-269;;030-458-658-036-396;;056-361-838-782-639;;124-403-369-942-149;;067-378-905-911-956;;002-815-208-266-669;;002-243-534-231-348;;093-237-262-514-757;;112-917-826-767-538;;009-758-570-877-426;;048-972-669-828-271;;066-655-225-086-020;;018-508-980-173-266;;059-752-522-673-716;;007-919-147-709-849;;009-347-841-916-604,10.1159/000099878;;9711758;;312191;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10599784;;10.1212/wnl.53.9.2073;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10563620;;10.1212/wnl.53.8.1731;;10.1136/jnnp.66.3.289;;pmc1736277;;10084526;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;52443;;10.1016/0013-4694(75)90051-6;;10.1002/jab.770050206;;10172072;;10.1007/978-1-4613-4508-4_6;;309307;;10.1159/000102438;;1439341;;10.1159/000098996;;1298420;;10.1097/00001665-199212000-00003;;10.1016/0267-6605(93)90085-l;;10146240;;10.1097/00004691-199903000-00005;;10359498;;10.1212/wnl.45.12.2250;;8848202;;8134429;;10.1097/00006534-199404000-00008;;8065447;;10.1038/370615a0;;10.1097/00001665-199203000-00002;;1391237;;10.1111/j.1528-1157.1995.tb01667.x;;8001511,"Chkhenkeli, S., et al., ""Effects of Therapeutic Stimulation of Nucleus Caudate on Epileptic Electrical Activity of Brain in Patients with Intractable Epilepsy,"" Stereotact. Funct. Neurosurg., 1997, 69: 221-224.;;Cooper, I.S., et al., ""Effects of Cerebellar Stimulation on Epilepsy, the EEG, and Cerebral Palsy in Man,"" Electroencephalogr. Clin. Neurophysiol. 1978; 34: 349-54.;;Lee, S.A., et al. ""Intracranial EEG Seizure-Onset Patterns in Neocortical Epilepsy,"" Epilepsia, 2000, 41(3): 297-307.;;Lesser, R.P. et al., ""Brief Bursts of Pulse Stimulation Terminate Afterdischarges Caused by Cortical Stimulation,"" Neurologogy 1999; 53 (December): 2073-81.;;Schiller, Y, et al., ""Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intracranial Electrodes,"" Epilepsia, 1998; 39(4): 380-88.;;Morris III, G.L., et al. ""Long Term Treatment with Vagal Nerve Stimulation in Patients with Refractory Epilepsy,""Neurology (Nov. 1999); 53(7): 1731-38 (Cyberonics NCP).;;Limousin, P., ""Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor,"" J. Neurol. Neurosurg. Psychiatry 1999; 66: 289-296 (Medtronic Activa).;;Spencer, S.S., et al., ""Morphological Patterns of Seizures Recorded Intracranially,"" Epilepsia, 1992, 33(3): 537-45.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. 1975; 39(5).;;Andriano, K.P., et al., ""Processing and Characterization of Absorbable Polyactide Polymers for Use in Surgical implants,"" Journal of Applied Biomaterials (1994) 5: 133-140.;;Cooper, I.S., et al., ""The Effect of Chronic Stimulation of Cerebellar Cortex on Epilepsy in Man,"" in the Cerebellum, Epilepsy and Behavior, Cooper, I.S., et al., eds. Pleman Press: New York (1974) pp. 119-171.;;Cooper, I.S., et al., ""Safety and Efficacy of Chronic Cerebellar Stimulation,"" Appl. Neurophysiol. (1977/1978) 40: 124-134.;;Davis, R. et al., ""Cerebellar Stimulation for Seizure Control: 17-Year Study,"" Stereotact. Funct. Neurosurg. (1992) 58: 200-208.;;Eppley, B.L., et al., ""Effects of Resorbable Fixation on Craniofacial Skeletal Growth: A Pilot Experimental Study,"" Journal of Craniofacial Surgery (1992) 3(4): 190-196.;;Gerlach, K. L., ""In-Vivo and Clinical Evaluations of Poly(L-Lactide) Plates and Screws for Use in Maxillofacial Traumatology,"" Clinical Materials (1993) 13: 21-28.;;Gotman, J., ""Automatic Detection of Seizures and Spikes,"" Journal of Clinical Neurophysiology (1999) 16(2): 130-140.;;Osario, I., et al., ""A Method for Accurate Automated Real-Time Seizure Detection,"" Epilepsia (1995) 36 (Suppl. 4): 4, Abstract No. 1.04.;;Qu, H., et al., ""A Seizure Warning System for Long-Term Epilepsy Monitoring,"" Neurology (1995) 45: 2250-2254.;;Sayler, K.E., et al., ""A Comparative Study of the Effects of Biodegradable and Titanium Plating Systems on Cranial Growth and Structure: Experimental Study in Beagles,"" Plastic and Reconstructive Surgery (1994) 93(4): 705-713.;;Schiff, S., et al., ""Controlling Chaos in the Brain,"" Nature (1994) 370: 615-620.;;Thaller, S.R., at al., ""Use of Biodegradable Plates and Screws in a Rabbit Model,""Journal of Craniofacial Surgery (1992) 2(4): 168-173.;;Velasco, F., et al., ""Electrical Stimulation of the Centromedian Thalamic Nucleus in Control of Seizures: Long Term Studies,"" Epilepsia (1995) 36(1): 63-71.;;European Search Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 8, 2004).;;First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Oct. 14, 2005).;;Response to First Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Apr. 20, 2006).;;Second Examination Report for European Application No. 01303245.3 (corresponding to U.S. Appl. No. 09/543,264) (Mar. 9, 2007).;;European Search Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 1, 2004).;;First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Oct. 18, 2005).;;Response to First Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Apr. 13, 2006).;;Second Examination Report for European Application No. 01303246.1 (corresponding to U.S. Appl. No. 09/543,450) (Mar. 9, 2007).;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;U.S. Appl. No. 60/427,699, filed Nov. 20, 2002.;;U.S. Appl. No. 60/436,792, filed Dec. 27, 2002.;;U.S. Appl. No. 60/438,286, filed Jan. 6, 2003.;;U.S. Appl. No. 60/460,140, filed Apr. 3, 2003.;;U.S. Appl. No. 60/562,487, filed Apr. 14, 2004.",EXPIRED
240,US,B2,US 9345884 B2,073-935-585-828-905,2016-05-24,2016,US 201213631820 A,2012-09-28,US 201213631820 A,2012-09-28,Methods and systems for controlling a state of a neurostimulator,"A method and system is described for ensuring a state of an active implantable medical device based on the presence and persistence of a magnetic field. The output of a magnetic field sensor is monitored. The active implantable medical device is maintained in a first state, for so long as the presence of a magnetic field is detected by the magnetic field sensor, until a first interval is surpassed. If the first interval is surpassed, then a determination is made as to whether a second interval has been surpassed. If it is determined that the second interval has not been surpassed, then the active implantable medical device is transitioned into a second state. If it is determined that the second interval has been surpassed, then it is ensured that the active implantable medical device is in a predetermined one of the first and second states.",NEUROPACE INC,WINGEIER BRETT;;GIBB BARBARA;;BAYSINGER CRAIG;;TCHENG THOMAS;;GURUNATHAN SURESH,NEUROPACE INC (2012-10-05),https://lens.org/073-935-585-828-905,Granted Patent,yes,17,1,6,181-340-200-650-222;;193-796-187-966-61X;;073-935-585-828-905;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,6,181-340-200-650-222;;073-935-585-828-905;;193-796-187-966-61X;;161-751-992-399-769;;163-541-989-089-644;;138-629-605-215-77X,US,0,A61B5/0031;;A61B5/369;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36142;;A61N1/3718;;A61N1/36128;;A61B5/0031;;A61B5/37;;A61B5/372;;A61B5/384;;A61B5/4094;;A61B2560/0242;;A61B2560/0266;;A61N1/36067;;A61N1/36142;;A61N1/3718,A61N1/36;;A61B5/00;;A61B5/0476;;A61N1/37,,0,0,,,,INACTIVE
241,US,A,US 6016449 A,085-009-395-322-703,2000-01-18,2000,US 95786997 A,1997-10-27,US 95786997 A,1997-10-27,System for treatment of neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE (1997-12-17);;CATHCO INCORPORATED (1997-11-30);;NEUROPACE INC (1997-12-17),https://lens.org/085-009-395-322-703,Granted Patent,yes,13,1293,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,607/45,1,0,,,"The novel by Michael Crichton Terminal Man , 1972, Ballantine Books, N.Y.C. pp 21 25,32,33,70,71,74 81.",EXPIRED
242,US,B2,US 6647296 B2,094-493-934-267-402,2003-11-11,2003,US 93253501 A,2001-08-17,US 93253501 A;;US 62897700 A;;US 45030399 A;;US 95786997 A,1997-10-27,Implantable apparatus for treating neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-11-09),https://lens.org/094-493-934-267-402,Granted Patent,yes,7,341,2,066-154-698-708-824;;094-493-934-267-402,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/3605;;A61N1/36017;;A61N1/36064;;A61N1/36082;;A61N1/37235;;A61N1/3605;;A61N1/36017;;A61N1/36064;;A61N1/36082;;A61N1/37235,A61N1/36,607/45;;600/544,0,0,,,,EXPIRED
243,US,B1,US 6354299 B1,123-089-701-744-314,2002-03-12,2002,US 60908600 A,2000-06-30,US 60908600 A;;US 48380600 A;;US 95786997 A,1997-10-27,Implantable device for patient communication,"An implantable device incorporating an acoustic transducer allows information and alerts to be communicated from the device to a patient. Sounds, including but not limited to buzzes, tones, sequences of tones, combinations of tones, complex sounds, and segments of reproduced or simulated human speech, are transmitted from an intracranially implanted portion of the device via bone conduction to the patient's ears, particularly the inner ears. In the disclosed embodiment, the acoustic transducer is used in cooperation with an implantable closed-loop system for the treatment of certain neurological disorders such as epilepsy, migraine headaches and Parkinson's disease, to warn the patient of an imminent seizure or other episode, to provide information to the patient on the state of the implantable apparatus, and to provide reminders and other information to the patient.",NEUROPACE INC,FISCHELL DAVID R;;ARCHER STEPHEN T;;FISCHELL ROBERT E;;UPTON ADRIAN R M,NEUROPACE INC. A DELAWARE CORPORATION (2000-11-09),https://lens.org/123-089-701-744-314,Granted Patent,yes,30,442,2,123-089-701-744-314;;081-500-670-537-835,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/37217;;A61N1/36025;;A61N1/36082;;A61N1/36135;;A61N1/37217;;A61N1/36025;;A61N1/36082;;A61N1/36135,A61N1/36,128/899,1,1,031-207-519-257-420,805584,"H. Fernandez et al., ""New System for a Two-Speed Electroencephalograph with an Auditory Device for Diminishing the Length of Seizures,"" Aviation, Space, and Environ. Medicine, May 1975, pp. 743-744.",EXPIRED
244,US,A,US 6134474 A,000-404-621-139-410,2000-10-17,2000,US 48380600 A,2000-01-15,US 48380600 A;;US 95786997 A,1997-10-27,Responsive implantable system for the treatment of neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,NEUROPACE INC (2000-07-31),https://lens.org/000-404-621-139-410,Granted Patent,yes,1,454,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,607/45,0,0,,,,EXPIRED
245,US,A1,US 2013/0123584 A1,161-942-618-164-830,2013-05-16,2013,US 201313733055 A,2013-01-02,US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,DEVICES AND METHODS FOR MONITORING PHYSIOLOGICAL INFORMATION RELATING TO SLEEP WITH AN IMPLANTABLE DEVICE,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC;;NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/161-942-618-164-830,Patent Application,yes,0,19,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/00;;A61B5/374;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/11;;A61B5/1455,600/301;;600/300;;600/509;;600/323;;600/549;;600/505;;600/595,0,0,,,,ACTIVE
246,US,A1,US 2014/0081348 A1,160-571-257-488-12X,2014-03-20,2014,US 201313781602 A,2013-02-28,US 201313781602 A;;US 201261618570 P,2012-03-30,LOW-FREQUENCY STIMULATION SYSTEMS AND METHODS,"Described here are devices and methods for delivering a low-frequency stimulation signal to tissue. In some variations, the low-frequency stimulation signal is delivered using one or more stimulation sequences, in which the low-frequency stimulation is sequentially delivered to a plurality of stimulation pathways. The stimulation pathways may comprise one or more monopolar stimulation pathways and/or one or more bipolar stimulation pathways.",NEUROPACE INC,FISCHELL DAVID R,NEUROPACE INC (2013-05-14),https://lens.org/160-571-257-488-12X,Patent Application,yes,3,23,1,160-571-257-488-12X,US,1,160-571-257-488-12X,US,0,A61N1/36064;;A61N1/36067;;A61N1/36071;;A61N1/36082;;A61N1/36171;;A61N1/3655;;A61N1/36564;;A61N1/37247;;A61N1/37258;;A61N1/36064;;A61N1/0529;;A61N1/36067;;A61N1/36071;;A61N1/36082;;A61N1/36171;;A61N1/3655;;A61N1/36564;;A61N1/37247;;A61N1/37258,A61N1/36;;A61N1/05,607/45,0,0,,,,DISCONTINUED
247,US,B2,US 9788952 B2,061-948-864-921-114,2017-10-17,2017,US 201313792119 A,2013-03-10,US 201313792119 A;;US 201261645593 P,2012-05-10,Burr hole covers and methods for using same,A burr hole cover includes a cap or cap assembly and a retainer and is configured to be partially positioned within a burr hole formed in a patient. The retainer has a cap-receiving aperture; a plurality of grooves provided in the retainer and a plurality of cut-outs wherein each cut-out is provided at an end of each groove towards the outer perimeter of the retainer. A channel may be provided at an opposite end of each groove vertically-extending from the top to the bottom of the retainer to encourage a medical device segment to remain in a groove during installation of the burr hole cover. The burr hole cover may be used to secure segments of medical devices relative to a burr hole and to allow a range of lateral motion for the portion(s) of the medical device(s) extending proximally out of the corresponding groove.,NEUROPACE INC,PASPA PAUL;;SANDOVAL GREG;;CHAVEZ ALFONSO;;POTTS DENNIS;;PEARSON JOHN DUNAGAN,NEUROPACE INC (2013-03-13),https://lens.org/061-948-864-921-114,Granted Patent,yes,50,0,4,161-344-237-751-302;;166-944-865-607-468;;114-166-939-121-408;;061-948-864-921-114,US,4,161-344-237-751-302;;061-948-864-921-114;;114-166-939-121-408;;166-944-865-607-468,US,0,A61N1/0539;;A61F2/2875;;A61N1/0539,A61F2/02;;A61F2/28;;A61N1/05,,0,0,,,,ACTIVE
248,US,A1,US 2014/0266774 A1,041-128-493-892-027,2014-09-18,2014,US 201313830021 A,2013-03-14,US 201313830021 A,2013-03-14,OPTIMIZING DATA RETRIEVAL FROM AN ACTIVE IMPLANTABLE MEDICAL DEVICE,"An external data retrieval apparatus includes a transceiver, and a processing system coupled to the transceiver. The processing system obtains a plurality of measures over a period of time. The measures relate to a quality of a communications channel between the data retrieval apparatus and an active implantable medical device. The processing system determines a trend in the plurality of measures over the period of time, and then determines a preferred time during which to retrieve data based on the trend.",NEUROPACE INC;;NEUROPACE INC,GREENE DAVID A;;ARCHER STEVE T;;MULLIGAN IV PATRICK G,NEUROPACE INC (2013-04-10),https://lens.org/041-128-493-892-027,Patent Application,yes,8,12,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;009-784-087-984-140;;190-321-968-016-483;;154-825-651-991-68X,US,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;154-825-651-991-68X;;190-321-968-016-483;;009-784-087-984-140,US,0,A61N1/37252;;A61N1/36128;;A61N1/37276;;A61N1/37252;;A61N1/37276,A61N1/372;;G08C17/02;;H04Q9/00,340/870.01,0,0,,,,ACTIVE
249,US,A1,US 2013/0304216 A1,166-944-865-607-468,2013-11-14,2013,US 201313792119 A,2013-03-10,US 201313792119 A;;US 201261645593 P,2012-05-10,Burr Hole Covers and Methods for Using Same,A burr hole cover includes a cap or cap assembly and a retainer and is configured to be partially positioned within a burr hole formed in a patient. The retainer has a cap-receiving aperture; a plurality of grooves provided in the retainer and a plurality of cut-outs wherein each cut-out is provided at an end of each groove towards the outer perimeter of the retainer. A channel may be provided at an opposite end of each groove vertically-extending from the top to the bottom of the retainer to encourage a medical device segment to remain in a groove during installation of the burr hole cover. The burr hole cover may be used to secure segments of medical devices relative to a burr hole and to allow a range of lateral motion for the portion(s) of the medical device(s) extending proximally out of the corresponding groove.,NEUROPACE INC,PASPA PAUL;;SANDOVAL GREG;;CHAVEZ ALFONSO;;POTTS DENNIS;;PEARSON JOHN DUNAGAN,NEUROPACE INC (2013-03-13),https://lens.org/166-944-865-607-468,Patent Application,yes,3,22,4,161-344-237-751-302;;166-944-865-607-468;;114-166-939-121-408;;061-948-864-921-114,US,4,161-344-237-751-302;;061-948-864-921-114;;114-166-939-121-408;;166-944-865-607-468,US,0,A61N1/0539;;A61F2/2875;;A61N1/0539,A61F2/28,623/17.19,0,0,,,,ACTIVE
250,US,A1,US 2002/0099412 A1,081-500-670-537-835,2002-07-25,2002,US 9589202 A,2002-03-12,US 9589202 A;;US 60908600 A;;US 48380600 A;;US 95786997 A,1997-10-27,Methods for using an implantable device for patient communication,"An implantable device incorporating an acoustic transducer allows information and alerts to be communicated from the device to a patient. Sounds, including but not limited to buzzes, tones, sequences of tones, combinations of tones, complex sounds, and segments of reproduced or simulated human speech, are transmitted from an intracranially implanted portion of the device via bone conduction to the patient's ears, particularly the inner ears. In the disclosed embodiment, the acoustic transducer is used in cooperation with an implantable closed-loop system for the treatment of certain neurological disorders such as epilepsy, migraine headaches and Parkinson's disease, to warn the patient of an imminent seizure or other episode, to provide information to the patient on the state of the implantable apparatus, and to provide reminders and other information to the patient.",NEUROPACE INC,FISCHELL DAVID R;;ARCHER STEPHEN T;;FISCHELL ROBERT E;;UPTON ADRIAN R M,,https://lens.org/081-500-670-537-835,Patent Application,yes,5,216,2,123-089-701-744-314;;081-500-670-537-835,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61N1/37217;;A61N1/36025;;A61N1/36082;;A61N1/36135;;A61N1/37217;;A61N1/36025;;A61N1/36082;;A61N1/36135,A61N1/36,607/3,0,0,,,,DISCONTINUED
251,US,B2,US 7294101 B2,171-705-167-558-85X,2007-11-13,2007,US 32716302 A,2002-12-21,US 32716302 A,2002-12-21,Means and methods for treating headaches,"Disclosed is a system and method for treating headaches. The system employs a self-contained, battery operated, readily portable and easy-to-operate head-mounted magnetic depolarizer to generate a transient or time-varying high-intensity magnetic field into and around the user's head or neck. The magnetic depolarizer system can be used to depolarize the neurons of the brain and/or the trigeminal nerve. This type of neuronal depolarization has the capability for terminating migraine or other types of headaches.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,FILTER-PUR LLC (2020-10-27);;ARUENE CORPORATION (2021-01-29);;NEUROPACE INC (2007-07-10),https://lens.org/171-705-167-558-85X,Granted Patent,yes,6,55,4,171-705-167-558-85X;;091-385-553-353-166;;032-112-388-204-04X;;145-620-405-822-033,US,4,171-705-167-558-85X;;091-385-553-353-166;;032-112-388-204-04X;;145-620-405-822-033,US,0,A61N2/02;;A61N2/02,A61N2/04;;A61N2/02,600/13,3,3,146-284-830-710-784;;017-482-530-306-421;;035-990-338-077-706,10.1016/s0140-6736(85)92413-4;;10.1212/wnl.54.7.1529;;10751273;;10910346;;10.1038/35018000,"Barker, A.T. et al., ""Non-Invasive Magnetic Stimulation of Human Motor Cortex,"" The Lancet, May 11, 1985, pp. 1106-1107.;;Boroojerdi, M.D. et al., ""Reduction of Human Visual Cortex Excitability Using 1-Hz Transcranial Magnetic Stimulation,"" Neurology, Apr. 2000, pp. 1529-1531.;;Hallet, M., ""Transcranial Magnetic Stimulation and the Human Brain,"" Nature, Jul. 13, 2000, vol. 406, pp. 147-150.",EXPIRED
252,EP,A2,EP 0911061 A2,154-884-036-186-662,1999-04-28,1999,EP 98308716 A,1998-10-26,US 95786997 A,1997-10-27,System for the treatment of neurological disorders,"Disclosed is a multiple electrode, closed-loop, responsive system for the treatment of certain neurological diseases such as epilepsy, migraine headaches and Parkinson's disease. Brain electrodes would be placed in close proximity to the brain or deep within brain tissue. When a neurological event such as the onset of an epileptic seizure occurs, EEG signals from the electrodes are processed by signal conditioning means in a control module that can be placed beneath the patient's scalp, within the patient's chest, or situated externally on the patient. Neurological event detection means in the control module will then cause a response to be generated for stopping the neurological event. The response could be an electrical signal to brain electrodes or to electrodes located remotely in the patient's body. The response could also be the release of medication or the application of a sensory input such as sound, light or mechanical vibration or electrical stimulation of the skin. The response to the neurological event can originate from devices either internal or external to the patient. The system also has the capability for multi-channel recording of EEG related signals that occur both before and after the detection of a neurological event. Programmability of many different operating parameters of the system by means of external equipment provides adaptability for treating patients who manifest different symptoms and who respond differently to the response generated by the system. <IMAGE>",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,,https://lens.org/154-884-036-186-662,Patent Application,yes,4,39,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,,0,0,,,,EXPIRED
253,US,A1,US 2014/0163659 A1,112-833-646-095-801,2014-06-12,2014,US 201414181562 A,2014-02-14,US 201414181562 A;;US 68881410 A;;US 46785306 A;;US 12389102 A,2002-04-15,REINFORCED SENSING AND STIMULATION LEADS AND USE IN DETECTION SYSTEMS,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING C LANCE,NEUROPACE INC (2012-06-28),https://lens.org/112-833-646-095-801,Patent Application,yes,19,15,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61N1/05;;A61B5/308;;A61N1/08,607/116,0,0,,,,EXPIRED
254,US,A1,US 2018/0021137 A1,114-166-939-121-408,2018-01-25,2018,US 201715702626 A,2017-09-12,US 201715702626 A;;US 201313792119 A;;US 201261645593 P,2012-05-10,BURR HOLE COVERS AND METHODS FOR USING SAME,A burr hole cover includes a cap or cap assembly and a retainer and is configured to be partially positioned within a burr hole formed in a patient. The retainer has a cap-receiving aperture; a plurality of grooves provided in the retainer and a plurality of cut-outs wherein each cut-out is provided at an end of each groove towards the outer perimeter of the retainer. A channel may be provided at an opposite end of each groove vertically-extending from the top to the bottom of the retainer to encourage a medical device segment to remain in a groove during installation of the burr hole cover. The burr hole cover may be used to secure segments of medical devices relative to a burr hole and to allow a range of lateral motion for the portion(s) of the medical device(s) extending proximally out of the corresponding groove.,NEUROPACE INC,SANDOVAL GREG;;CHAVEZ ALFONSO;;POTTS DENNIS;;PEARSON JOHN DUNAGAN;;PASPA PAUL,NEUROPACE INC (2013-03-13),https://lens.org/114-166-939-121-408,Patent Application,yes,7,1,4,161-344-237-751-302;;166-944-865-607-468;;114-166-939-121-408;;061-948-864-921-114,US,4,161-344-237-751-302;;061-948-864-921-114;;114-166-939-121-408;;166-944-865-607-468,US,0,A61N1/0539;;A61F2/2875;;A61N1/0539,A61F2/28;;A61N1/05,,0,0,,,,ACTIVE
255,US,B2,US 11458302 B2,065-301-426-371-421,2022-10-04,2022,US 202017096773 A,2020-11-12,US 202017096773 A;;US 201962943698 P,2019-12-04,Hinged lead fixation devices for securing a lead to a cranium,"A lead fixation device for securing a portion of a lead relative to a surface of a skull includes a skull attachment member having an upper surface and a lower surface, a locking member having an upper surface and a lower surface and associated with the skull attachment member, and a passageway associated with the locking member and configured to receive the portion of the lead. The skull attachment member and the locking member are configured to rotate relative to each other to transition the lead fixation device between a closed state wherein the lower surface of the skull attachment member and the lower surface of the locking member are generally aligned in a common plane, and an opened state wherein the lower surface of the skull attachment member and the lower surface of the locking member are not aligned in a common plane.",NEUROPACE INC,CHAVEZ ALFONSO,NEUROPACE INC (2020-11-18),https://lens.org/065-301-426-371-421,Granted Patent,yes,57,0,2,065-301-426-371-421;;056-929-957-001-080,US,2,065-301-426-371-421;;056-929-957-001-080,US,0,A61N1/0534;;A61N1/0539;;A61N1/37518;;A61N1/0539;;A61N1/0534;;A61N1/37518,A61N1/05;;A61N1/375,,4,1,038-757-509-977-927,pmc4852184;;10.7759/cureus.549;;27158578,"Biomet Microfixation. Neuroimplant System. Product Brochure (2013).;;Aesculap Inc. Cranial Fixation Systems. Product Brochure (2014).;;Miller et al. “Stereotactic bony trajectory preservation for responsive neurostimulator lead placement following depth EEG recording.” Cureus 8(3):3549. DOI 10.7759/cureus.549 (Mar. 30, 2016).;;Synthes CMF. “MatrixNEURO. The next generation cranial plating system.” Product Brochure (2006).",ACTIVE
256,US,B2,US 7672736 B2,029-437-336-020-000,2010-03-02,2010,US 46785306 A,2006-08-28,US 46785306 A;;US 12389102 A,2002-04-15,Reinforced sensing and stimulation leads and use in detection systems,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING LANCE,NEUROPACE INC (2002-06-28),https://lens.org/029-437-336-020-000,Granted Patent,yes,6,12,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61N1/05;;A61B5/308;;A61N1/08,607/122;;607/116,0,0,,,,EXPIRED
257,US,B2,US 10517732 B2,161-344-237-751-302,2019-12-31,2019,US 201715702626 A,2017-09-12,US 201715702626 A;;US 201313792119 A;;US 201261645593 P,2012-05-10,Burr hole covers and methods for using same,A burr hole cover includes a cap or cap assembly and a retainer and is configured to be partially positioned within a burr hole formed in a patient. The retainer has a cap-receiving aperture; a plurality of grooves provided in the retainer and a plurality of cut-outs wherein each cut-out is provided at an end of each groove towards the outer perimeter of the retainer. A channel may be provided at an opposite end of each groove vertically-extending from the top to the bottom of the retainer to encourage a medical device segment to remain in a groove during installation of the burr hole cover. The burr hole cover may be used to secure segments of medical devices relative to a burr hole and to allow a range of lateral motion for the portion(s) of the medical device(s) extending proximally out of the corresponding groove.,NEUROPACE INC,PASPA PAUL;;SANDOVAL GREG;;CHAVEZ ALFONSO;;POTTS DENNIS;;PEARSON JOHN DUNAGAN,NEUROPACE INC (2013-03-13),https://lens.org/161-344-237-751-302,Granted Patent,yes,52,0,4,161-344-237-751-302;;166-944-865-607-468;;114-166-939-121-408;;061-948-864-921-114,US,4,161-344-237-751-302;;061-948-864-921-114;;114-166-939-121-408;;166-944-865-607-468,US,0,A61N1/0539;;A61F2/2875;;A61N1/0539,A61F2/28;;A61N1/05,,0,0,,,,ACTIVE
258,US,A1,US 2023/0172529 A1,149-360-236-698-736,2023-06-08,2023,US 202218070902 A,2022-11-29,US 202218070902 A;;US 202163285416 P,2021-12-02,SYSTEM AND METHODS FOR FACILITATING NEUROMODULATION THERAPY BY AUTOMATICALLY CLASSIFYING ELECTROGRAPHIC RECORDS BASED ON LOCATION AND PATTERN OF ELECTROGRAPHIC SEIZURES,"A method of assessing electrical activity of a brain includes, for each of a plurality of electrical-activity records of the brain, applying a machine-learned ESC model to the record to classify the record as one of a seizure record or a non-seizure record, wherein each of record is sensed by a corresponding one of a plurality of sensing channels of an implanted medical device; for each seizure record in a set of seizure records, applying the machine-learned ESC model to the seizure record to classify the seizure record as one of a local-seizure record or a spread-seizure record, wherein the seizure record comprises a first seizure record captured by a first sensing channel and a second seizure record captured by a second sensing channel; and for each spread-seizure record in a set of spread-seizure records, applying a machine-learned SSC model to the spread-seizure record to classify the spread-seizure record as a type of seizure spread pattern.",NEUROPACE INC,ARCOT DESAI SHARANYA;;TCHENG THOMAS K;;SEALE CAIRN G;;MORRELL MARTHA J;;GREENE DAVID A,NEUROPACE INC (2022-11-29),https://lens.org/149-360-236-698-736,Patent Application,yes,0,0,1,149-360-236-698-736,US,1,149-360-236-698-736,US,0,A61B5/316;;A61B5/369;;A61B5/374;;A61B5/4094;;A61B5/4836;;A61B5/6868;;A61B5/7264;;A61B5/7267;;A61B5/7275;;G16H50/20;;G16H50/30;;A61B5/4094;;A61B5/6868;;A61B5/7264;;G16H20/40,A61B5/00;;G16H20/40,,0,0,,,,PENDING
259,US,B2,US 8353837 B2,118-522-020-206-151,2013-01-15,2013,US 70069210 A,2010-02-04,US 70069210 A;;US 40457906 A;;US 1462804 A,2004-12-15,Modulation and analysis of cerebral perfusion in epilepsy and other neurological disorders,"A system including an implantable neurostimulator device capable of modulating cerebral blood flow to treat epilepsy and other neurological disorders. In one embodiment, the system is capable of modulating cerebral blood flow (also referred to as cerebral perfusion) in response to measurements and other observed conditions. Perfusion may be increased or decreased by systems and methods according to the invention as clinically required.",NEUROPACE INC;;JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,JOHN MICHAEL SASHA;;PLESS BENJAMIN D;;WINGEIER BRETT,NEUROPACE INC (2009-04-24),https://lens.org/118-522-020-206-151,Granted Patent,yes,18,11,8,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;183-832-713-296-293;;120-494-017-174-394;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,14,118-522-020-206-151;;168-437-865-717-989;;055-445-056-422-200;;120-494-017-174-394;;011-310-459-968-81X;;107-377-055-316-476;;171-621-506-522-002;;105-617-775-657-09X;;002-251-031-096-201;;183-832-713-296-293;;069-686-345-844-480;;131-059-343-374-765;;128-620-827-527-919;;027-397-593-075-735,US,0,A61N1/36139;;A61B5/0031;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00;;A61N2007/0043;;A61N1/36139;;A61B5/0031;;A61B5/02;;A61B5/14553;;A61B5/1459;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/7217;;A61B8/06;;A61B8/12;;A61B8/488;;A61F7/00;;A61F7/12;;A61N1/36057;;A61N1/36064;;A61N1/36082;;A61N1/3614;;A61N2/006;;A61N2/02;;A61N5/0622;;A61N7/00,A61B8/06,600/454;;607/62;;607/45;;600/378,14,4,143-388-558-467-689;;124-403-369-942-149;;122-023-235-058-123;;026-889-963-495-548,10.1016/0013-4694(90)90032-f;;1699724;;52443;;10.1016/0013-4694(75)90051-6;;10.1152/jn.1995.74.6.2767;;8747234;;10.1016/s1095-6433(99)00086-0;;10605067,"U.S. Appl. No. 11/925,655 Office Action mailed Jun. 28, 2010.;;Gotman, J., Automatic Seizure Detection: Improvements and Evaluation, Electroencephalogr. Clin. Neurophysiol. (1990) 76(4): 317-24.;;Wagner, H. R., et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol. (1975) 39(5): 499-506.;;Tavalin, S.J., et al., Mechanical Perturbation of Cultured Cortical Neurons Reveals a Stretch-Induced Delayed Depolarization, J. Neurophysiol. (1995) 74(6): 2767-2773.;;Bahar, S. et al., The Relationship Between Cerebral Blood Volume And Oxygenation Following BiPolar Stimulation of the Human Cortex: Evidence for an Initial Dip, Epilepsia 2004; 45 Suppl 7, 107-108.;;Matsuura, T, et. al., Hemodynamics Evoked by Microelectrical Direct Stimulation in Rat somatosensory Cortex, Comp. Biochem. Physiol. A. Mo. 1 Integr. Physiol. Sep. 1999; 124(1): 47-52.;;U.S. Appl. No. 11/925,668, filed May 26, 2010.;;U.S. Appl. No. 11/925,668 Amendment filed May 26, 2010.;;Tarver, T. et al., ""An Implantable Neurocybernetic Prosthesis System,"" http://www.ncbi.nlm.nlh.gov, Jun. 12, 2007.;;Activa Therapy Overview, http://www.medtronic.com/physician/activa/index.html, Jun. 5, 2007.;;U.S. Appl. No. 11/925,668, Office action mailed Mar. 1, 2010.;;Office Action (Final Rejection) mailed Aug. 19, 2010 for U.S. Appl. No. 11/925,668.;;Amendment Filed on Dec. 20, 2010 for U.S. Appl. No. 11/925,668.;;Notice of Allowance mailed on Dec. 16, 2010 for U.S. Appl. No. 11/925,655.",INACTIVE
260,EP,B1,EP 0911061 B1,107-889-693-697-508,2005-10-26,2005,EP 98308716 A,1998-10-26,US 95786997 A,1997-10-27,System for the treatment of neurological disorders,,NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,,https://lens.org/107-889-693-697-508,Granted Patent,yes,1,6,14,138-444-676-931-852;;107-889-693-697-508;;151-357-101-805-287;;155-444-696-051-568;;000-404-621-139-410;;166-475-924-560-550;;003-362-109-147-602;;176-779-803-691-197;;074-009-695-618-339;;154-884-036-186-662;;085-009-395-322-703;;024-030-376-301-273;;053-805-145-710-590;;074-732-904-610-695,AT;;EP;;CA;;DE;;US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/4094;;A61B5/6814;;A61N1/36025;;A61N1/3605;;A61N1/36082;;A61N1/37211;;G16H20/40;;A61B5/369;;A61B5/6814;;A61N1/3605;;A61N1/36082;;A61N1/36025;;A61B5/4094;;A61N1/37211;;A61B5/37,A61N1/36,,0,0,,,,EXPIRED
261,US,A1,US 2008/0045776 A1,091-385-553-353-166,2008-02-21,2008,US 97471207 A,2007-10-15,US 97471207 A;;US 32716302 A,2002-12-21,Means and methods for treating headaches,"Disclosed is a system and method for treating headaches. The system employs a self-contained, battery operated, readily portable and easy-to-operate head-mounted magnetic depolarizer to generate a transient or time-varying high-intensity magnetic field into and around the user's head or neck. The magnetic depolarizer system can be used to depolarize the neurons of the brain and/or the trigeminal nerve. This type of neuronal depolarization has the capability for terminating migraine or other types of headaches.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R,FILTER-PUR LLC (2020-10-27);;ARUENE CORPORATION (2021-01-29);;NEUROPACE INC (2007-07-10),https://lens.org/091-385-553-353-166,Patent Application,yes,7,122,4,171-705-167-558-85X;;091-385-553-353-166;;032-112-388-204-04X;;145-620-405-822-033,US,4,171-705-167-558-85X;;091-385-553-353-166;;032-112-388-204-04X;;145-620-405-822-033,US,0,A61N2/02;;A61N2/02,A61N2/04;;A61N2/02,600/14,0,0,,,,EXPIRED
262,US,B1,US 6427086 B1,004-804-748-407-003,2002-07-30,2002,US 55716800 A,2000-04-21,US 55716800 A;;US 48380600 A;;US 95786997 A,1997-10-27,Means and method for the intracranial placement of a neurostimulator,"Disclosed is a means and method for placing an implantable neurostimulator control module into a place in the cranium where cranial bone has been removed. The method for accomplishing this cranial implantation is by first removing a patient's hair over the site of the implant, then cutting the scalp at that site and pulling it back to expose the cranium. A neurosurgeon would then remove a portion of the cranial bone to accept a control module to be implanted within that hole. The control module would then be placed into that hole. It is also conceived that the control module would be fixed in place by the use of one or more attachment devices such as a multiplicity of bone screws placed through holes in one or more flanges that extend over the cranium beyond the control module. The implantation could also include a fairing placed around the control module to provide a smooth contour under the patient's scalp. Also described is a spacer shim placed under the flange(s) to adjust the position of the control module so that its bottom surface does not put pressure on the dura mater lying directly over the brain tissue at the bottom of the hole. It is also envisioned that a resorbable disk could be placed under the bottom surface of the control module to further protect the brain and/or to elute an anti-biotic or anti-inflammatory substance to reduce the possibility of infection and/or inflammation.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M;;POTTS DENNIS R;;PLESS BENJAMIN D,NEUROPACE INC (2001-07-13),https://lens.org/004-804-748-407-003,Granted Patent,yes,9,395,1,004-804-748-407-003,US,59,074-732-904-610-695;;145-713-618-912-297;;089-133-065-882-20X;;017-686-610-075-111;;087-979-855-502-888;;129-800-313-548-338;;124-510-298-765-088;;164-607-216-081-54X;;144-608-584-800-922;;047-380-325-824-394;;061-206-050-442-20X;;109-215-788-779-911;;000-404-621-139-410;;011-624-965-053-462;;040-390-197-256-947;;044-511-791-743-100;;176-779-803-691-197;;154-884-036-186-662;;094-493-934-267-402;;047-800-269-701-709;;024-096-457-615-102;;174-318-359-062-890;;146-812-252-066-128;;188-537-368-246-024;;153-973-094-235-643;;088-366-887-252-89X;;048-861-529-805-092;;082-643-935-874-509;;145-269-019-951-00X;;151-357-101-805-287;;143-164-892-494-217;;166-475-924-560-550;;003-362-109-147-602;;074-009-695-618-339;;123-089-701-744-314;;024-030-376-301-273;;138-444-676-931-852;;091-933-047-228-332;;081-500-670-537-835;;061-631-376-949-809;;025-746-519-808-224;;115-468-682-997-403;;017-566-714-168-420;;118-644-614-747-786;;155-444-696-051-568;;158-501-983-099-369;;082-001-738-439-925;;108-973-638-535-045;;107-889-693-697-508;;146-913-054-079-190;;008-166-797-662-811;;066-154-698-708-824;;128-755-226-255-290;;079-411-409-996-070;;074-475-978-353-041;;053-805-145-710-590;;004-804-748-407-003;;085-009-395-322-703;;164-537-068-876-648,AT;;EP;;CA;;DE;;US,0,A61B5/6814;;A61B5/369;;A61B5/4094;;A61N1/36017;;A61N1/36025;;A61N1/3605;;A61N1/36064;;A61N1/37235;;A61B5/6814;;A61B5/369;;A61B5/4094;;A61N1/36017;;A61N1/36025;;A61N1/3605;;A61N1/36064;;A61N1/37235,A61N1/36,607/45,1,1,169-126-282-198-193,10.1177/00034894991080s406,"T.J. Balkany et al., ""Surgical Technique for the Clarion Cochlear Implant,"" Ann. Otol. Rhinol. Laryngol., 1999 Apr., 108(Suppl. 177, No. 4, Part 2):27-30.",EXPIRED
263,US,A1,US 2021/0170166 A1,056-929-957-001-080,2021-06-10,2021,US 202017096773 A,2020-11-12,US 202017096773 A;;US 201962943698 P,2019-12-04,HINGED LEAD FIXATION DEVICES FOR SECURING A LEAD TO A CRANIUM,"A lead fixation device for securing a portion of a lead relative to a surface of a skull includes a skull attachment member having an upper surface and a lower surface, a locking member having an upper surface and a lower surface and associated with the skull attachment member, and a passageway associated with the locking member and configured to receive the portion of the lead. The skull attachment member and the locking member are configured to rotate relative to each other to transition the lead fixation device between a closed state wherein the lower surface of the skull attachment member and the lower surface of the locking member are generally aligned in a common plane, and an opened state wherein the lower surface of the skull attachment member and the lower surface of the locking member are not aligned in a common plane.",NEUROPACE INC,CHAVEZ ALFONSO,NEUROPACE INC (2020-11-18),https://lens.org/056-929-957-001-080,Patent Application,yes,0,0,2,065-301-426-371-421;;056-929-957-001-080,US,2,065-301-426-371-421;;056-929-957-001-080,US,0,A61N1/0534;;A61N1/0539;;A61N1/37518;;A61N1/0539;;A61N1/0534;;A61N1/37518,A61N1/05;;A61N1/375,,0,0,,,,ACTIVE
264,US,A1,US 2010/0107408 A1,100-438-243-348-346,2010-05-06,2010,US 68881410 A,2010-01-15,US 68881410 A;;US 46785306 A;;US 12389102 A,2002-04-15,Reinforced Sensing and Stimulation Leads and Use in Detection Systems,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING C LANCE,NEUROPACE INC (2002-06-28),https://lens.org/100-438-243-348-346,Patent Application,yes,9,5,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,H01R43/00;;A61B5/308;;A61N1/05;;A61N1/08,29/825,0,0,,,,ACTIVE
265,US,B2,US 10368994 B2,142-646-396-690-820,2019-08-06,2019,US 201715402047 A,2017-01-09,US 201715402047 A;;US 201313792165 A,2013-03-10,Recessed burr hole covers and methods for using the same,"A burr hole cover is configured to be recessed in a burr hole formed in a patient and includes a base and a cap provided with complementary features to allow a portion of a medical device, such as a brain lead, to be situated in the burr hole cover and then secured by rotation of the cap relative to the base. The features include channels on the base and matching cut-outs on the cap, and slots and locking pockets on the base that are configured to be aligned with locking tabs and locking protrusions on the cap. Because the burr hole cover is recessed in the burr hole, the medical device can extend proximally of the burr hole at the level of the cranium. A bottom surface of the cap may be provided with guides for the lead extending distally in towards the brain.",NEUROPACE INC,CHAVEZ ALFONSO;;WEBER PETER B,NEUROPACE INC (2013-03-11),https://lens.org/142-646-396-690-820,Granted Patent,yes,50,0,4,139-582-858-403-139;;089-515-786-584-185;;142-646-396-690-820;;056-897-730-348-860,US,4,089-515-786-584-185;;139-582-858-403-139;;142-646-396-690-820;;056-897-730-348-860,US,0,A61N1/0539;;A61N1/0534;;A61F2/2875;;A61N1/0534;;A61N1/0539,A61F2/28;;A61N1/05,,0,0,,,,ACTIVE
266,US,B2,US 9162050 B2,118-491-744-333-982,2015-10-20,2015,US 201414181562 A,2014-02-14,US 201414181562 A;;US 68881410 A;;US 46785306 A;;US 12389102 A,2002-04-15,Reinforced sensing and stimulation leads and use in detection systems,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING C LANCE,NEUROPACE INC (2012-06-28),https://lens.org/118-491-744-333-982,Granted Patent,yes,28,4,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61N1/05;;A61B5/308;;A61N1/08,,3,3,129-566-571-935-311;;068-676-618-067-23X;;132-849-338-722-860,9949771;;10.1227/00006123-198706000-00016;;3614572;;312191,"Ajmone-Marsan, C., ""Electrocorticography: Historical Comments on its Development and the Evolution of its Applications,"" Electroencephalogr. Clin. Neurophysiol. Suppl. (1998) 48: 10-16.;;Black, P.M. et al., ""Cortical Mapping for Defining the Limits of Tumor Resection,"" Neurosurgery (1987) 20: 914-919.;;Cooper, I.S., et al., ""Effects of Cerebellar Stimulation of Epilepsy, the EEG and Cerebral Palsy in Man,"" Electroencephalogr. Clin. Neurophysiol. Suppl. (1978) 34: 349-354.",EXPIRED
267,US,A1,US 2010/0217341 A1,192-590-653-695-141,2010-08-26,2010,US 77470710 A,2010-05-05,US 77470710 A;;US 63588506 A,2006-12-07,Functional Ferrule,"Described here are intracranial ferrules, systems, and methods for sensing and stimulating neural tissues. The ferrules are generally designed to include a holding area for retaining an implantable device. In some variations, the ferrule itself may perform the sensing and stimulating functions. In other variations, the ferrule may function to sense data from neural tissues and the implantable device may function to stimulate neural tissues. In yet other variations, the ferrule may function to stimulate, and the implantable device may function to sense data from, the neural tissues. The sensing and stimulating functions may be used to detect and/or treat various neurological conditions.",NEUROPACE INC,JOHN MICHAEL S;;WINGEIER BRETT;;TCHENG THOMAS K;;PLESS BENJAMIN D,NEUROPACE INC (2007-02-27),https://lens.org/192-590-653-695-141,Patent Application,yes,24,40,4,065-378-302-648-260;;192-590-653-695-141;;052-340-018-918-782;;187-965-876-513-162,US,4,192-590-653-695-141;;065-378-302-648-260;;052-340-018-918-782;;187-965-876-513-162,US,0,A61N1/0529;;A61B8/0808;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0529;;A61B8/0808;;A61N1/0531;;A61N1/0534;;A61N1/0539,A61N1/00;;A61B5/00,607/2;;600/301,0,0,,,,INACTIVE
268,US,B2,US 8903483 B2,112-206-073-723-125,2014-12-02,2014,US 201313966899 A,2013-08-14,US 201313966899 A;;US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/112-206-073-723-125,Granted Patent,yes,18,10,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374;;A61B5/00;;A61B5/01;;A61B5/0205;;A61B5/024;;A61B5/026;;A61B5/11;;A61B5/1455;;A61N1/36,600/544;;600/545,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A.C., ""Textbook of Medical Physiology"", 8th ed., Wonsiewicz M.J. ed., pp. wii-xli (Table of Contents only), 1991).;;Gotman, J. ""Automatic Seizure Detection: Improvements and Evaluation"", Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",ACTIVE
269,US,B2,US 7494458 B2,032-112-388-204-04X,2009-02-24,2009,US 97471207 A,2007-10-15,US 97471207 A;;US 32716302 A,2002-12-21,Means and methods for treating headaches,"Disclosed is a system and method for treating headaches. The system employs a self-contained, battery operated, readily portable and easy-to-operate head-mounted magnetic depolarizer to generate a transient or time-varying high-intensity magnetic field into and around the user's head or neck. The magnetic depolarizer system can be used to depolarize the neurons of the brain and/or the trigeminal nerve. This type of neuronal depolarization has the capability for terminating migraine or other types of headaches.",NEUROPACE INC,FISCHELL ROBERT E;;FISCHELL DAVID R;;UPTON ADRIAN R M,FILTER-PUR LLC (2020-10-27);;ARUENE CORPORATION (2021-01-29);;NEUROPACE INC (2007-07-10),https://lens.org/032-112-388-204-04X,Granted Patent,yes,7,38,4,171-705-167-558-85X;;091-385-553-353-166;;032-112-388-204-04X;;145-620-405-822-033,US,4,171-705-167-558-85X;;091-385-553-353-166;;032-112-388-204-04X;;145-620-405-822-033,US,0,A61N2/02;;A61N2/02,A61N2/04;;A61N2/02,600/13,3,3,146-284-830-710-784;;017-482-530-306-421;;035-990-338-077-706,10.1016/s0140-6736(85)92413-4;;10.1212/wnl.54.7.1529;;10751273;;10910346;;10.1038/35018000,"Barker, A.T. et al., ""Non-Invasive Magnetic Stimulation of Human Motor Cortex,"" The Lancet, May 11, 1985, pp. 1106-1107.;;Boroojerdi, M.D. et al., ""Reduction of Human Visual Cortex Excitability Using 1-Hz Transcranial Magnetic Stimulation,"" Neurology, Apr. 2000, pp. 1529-1531.;;Hallet, M., ""Transcranial Magnetic Stimulation and the Human Brain,"" Nature, Jul. 13, 2000, vol. 406, pp. 147-150.",EXPIRED
270,US,A1,US 2007/0043410 A1,099-857-122-133-253,2007-02-22,2007,US 46785306 A,2006-08-28,US 46785306 A;;US 12389102 A,2002-04-15,REINFORCED SENSING AND STIMULATION LEADS AND USE IN DETECTION SYSTEMS,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING C L,NEUROPACE INC (2002-06-28),https://lens.org/099-857-122-133-253,Patent Application,yes,6,12,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61N1/04;;A61B5/308;;A61N1/05;;A61N1/08,607/116,0,0,,,,EXPIRED
271,US,A1,US 2003/0195602 A1,143-130-584-397-954,2003-10-16,2003,US 12389102 A,2002-04-15,US 12389102 A,2002-04-15,Reinforced sensing and stimulation leads and use in detection systems,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING C LANCE,NEUROPACE INC (2002-06-28),https://lens.org/143-130-584-397-954,Patent Application,yes,6,99,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61B5/308;;A61N1/05;;A61N1/08,607/122,0,0,,,,EXPIRED
272,US,B2,US 10188855 B2,011-612-369-392-603,2019-01-29,2019,US 201615340869 A,2016-11-01,US 201615340869 A;;US 201113310695 A;;US 41975510 P,2010-12-03,Lead fixation device for securing a medical lead in a human patient,"A lead fixation device for securing a medical lead in a human patient includes: a single-piece structure comprising: a top surface; a bottom surface; an outer perimeter; and an inner perimeter, the inner perimeter comprising: a diameter approximately equal to or smaller than a diameter of a burr hole into which the lead fixation device is designed to be deployed; a central bore extending longitudinally from the top surface through to the bottom surface, a portion of the central bore being located in approximately a center of the lead fixation device and comprising a central bore diameter; and at least one retention tract formed in the top surface of a cap of the lead fixation device, the retention tract configured for retaining, with an interference fit, a portion of a body of the medical lead in the lead fixation device.",NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2012-03-05),https://lens.org/011-612-369-392-603,Granted Patent,yes,49,0,4,070-230-048-005-55X;;159-132-276-049-827;;011-612-369-392-603;;053-124-776-924-751,US,4,070-230-048-005-55X;;159-132-276-049-827;;011-612-369-392-603;;053-124-776-924-751,US,0,A61N1/0539;;A61N1/0539;;A61N1/05;;A61N1/0526;;A61N1/0529;;A61N1/0534;;A61N1/0558,A61N1/05;;A61N1/375,,0,0,,,,ACTIVE
273,US,A1,US 2017/0050016 A1,053-124-776-924-751,2017-02-23,2017,US 201615340869 A,2016-11-01,US 201615340869 A;;US 201113310695 A;;US 41975510 P,2010-12-03,LEAD FIXATION DEVICE FOR SECURING A MEDICAL LEAD IN A HUMAN PATIENT,"A lead fixation device for securing a medical lead in a human patient includes: a single-piece structure comprising: a top surface; a bottom surface; an outer perimeter; and an inner perimeter, the inner perimeter comprising: a diameter approximately equal to or smaller than a diameter of a burr hole into which the lead fixation device is designed to be deployed; a central bore extending longitudinally from the top surface through to the bottom surface, a portion of the central bore being located in approximately a center of the lead fixation device and comprising a central bore diameter; and at least one retention tract formed in the top surface of a cap of the lead fixation device, the retention tract configured for retaining, with an interference fit, a portion of a body of the medical lead in the lead fixation device.",NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2012-03-05),https://lens.org/053-124-776-924-751,Patent Application,yes,8,0,4,070-230-048-005-55X;;159-132-276-049-827;;011-612-369-392-603;;053-124-776-924-751,US,4,070-230-048-005-55X;;159-132-276-049-827;;011-612-369-392-603;;053-124-776-924-751,US,0,A61N1/0539;;A61N1/0539;;A61N1/05;;A61N1/0526;;A61N1/0529;;A61N1/0534;;A61N1/0558,A61N1/05;;A61N1/375,,1,0,,,Schulte et al no US 2005/0182464 A1,ACTIVE
274,US,B2,US 9227067 B2,058-574-168-428-279,2016-01-05,2016,US 201414477543 A,2014-09-04,US 201414477543 A;;US 201113310571 A;;US 41979510 P;;US 201061424612 P,2010-12-03,"Systems, devices, and methods for monitoring and analyzing research animal behavior before, during and after brain electrical stimulation","Described are systems, devices and methods for facilitating the delivery of stimulation to, and the monitoring and recording of physiological signals (e.g., electroencephalographic signals) from a research subject. Devices include a headmount that includes a cranial frame and a headstage, and a connection between the headmount and external equipment used for stimulation, monitoring, and/or recording that is robust physically and electrically to optimize stimulation, monitoring and recording even while the subject remains ambulatory. In some embodiments, a hinged headmount allows the configuration to be easily manipulated during attachment and any subsequent adjustment or reattachment procedures and permits easy access to any wires or other components implanted in the subject. In some embodiments, a flexible cable extends out from the headmount at an acute angle relative to a horizontal plane of the headmount, to optimize strain relief as the subject moves about while attached to any stimulation, monitoring and/or recording equipment.",NEUROPACE INC,HASULAK NICHOLAS ROBERT,NEUROPACE INC (2012-03-02),https://lens.org/058-574-168-428-279,Granted Patent,yes,3,2,4,010-719-429-965-05X;;103-680-583-837-159;;159-703-893-140-649;;058-574-168-428-279,US,4,010-719-429-965-05X;;103-680-583-837-159;;159-703-893-140-649;;058-574-168-428-279,US,0,A61N1/0539;;A61N1/0534;;A61N1/36017;;A61N1/36025;;A61N1/36125;;A61N1/0529;;A61N1/0534;;A61N1/0539;;A61N1/36017;;A61N1/36025;;A61N1/36064,A61N1/36;;A61N1/05,,0,0,,,,INACTIVE
275,US,A1,US 2015/0051679 A1,103-680-583-837-159,2015-02-19,2015,US 201414477543 A,2014-09-04,US 201414477543 A;;US 201113310571 A;;US 41979510 P;;US 201061424612 P,2010-12-03,"SYSTEMS, DEVICES, AND METHODS FOR MONITORING AND ANALYZING RESEARCH ANIMAL BEHAVIOR BEFORE, DURING AND AFTER BRAIN ELECTRICAL STIMULATION","Described are systems, devices and methods for facilitating the delivery of stimulation to, and the monitoring and recording of physiological signals (e.g., electroencephalographic signals) from a research subject. Devices include a headmount that includes a cranial frame and a headstage, and a connection between the headmount and external equipment used for stimulation, monitoring, and/or recording that is robust physically and electrically to optimize stimulation, monitoring and recording even while the subject remains ambulatory. In some embodiments, a hinged headmount allows the configuration to be easily manipulated during attachment and any subsequent adjustment or reattachment procedures and permits easy access to any wires or other components implanted in the subject. In some embodiments, a flexible cable extends out from the headmount at an acute angle relative to a horizontal plane of the headmount, to optimize strain relief as the subject moves about while attached to any stimulation, monitoring and/or recording equipment.",NEUROPACE INC,HASULAK NICHOLAS ROBERT,NEUROPACE INC (2012-03-02),https://lens.org/103-680-583-837-159,Patent Application,yes,1,2,4,010-719-429-965-05X;;103-680-583-837-159;;159-703-893-140-649;;058-574-168-428-279,US,4,010-719-429-965-05X;;103-680-583-837-159;;159-703-893-140-649;;058-574-168-428-279,US,0,A61N1/0539;;A61N1/0534;;A61N1/36017;;A61N1/36025;;A61N1/36125;;A61N1/0529;;A61N1/0534;;A61N1/0539;;A61N1/36017;;A61N1/36025;;A61N1/36064,A61N1/36;;A61N1/05,607/116,0,0,,,,INACTIVE
276,US,B2,US 7146222 B2,161-115-362-396-611,2006-12-05,2006,US 12389102 A,2002-04-15,US 12389102 A,2002-04-15,Reinforced sensing and stimulation leads and use in detection systems,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",NEUROPACE INC,BOLING C LANCE,NEUROPACE INC (2002-06-28),https://lens.org/161-115-362-396-611,Granted Patent,yes,6,106,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61N1/05;;A61B5/308;;A61N1/08,607/116;;607/122,0,0,,,,EXPIRED
277,US,A1,US 2013/0345522 A1,140-084-366-972-769,2013-12-26,2013,US 201313966899 A,2013-08-14,US 201313966899 A;;US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,DEVICES AND METHODS FOR MONITORING PHYSIOLOGICAL INFORMATION RELATING TO SLEEP WITH AN IMPLANTABLE DEVICE,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/140-084-366-972-769,Patent Application,yes,0,11,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/00;;A61B5/374,600/300,0,0,,,,ACTIVE
278,US,A1,US 2011/0112381 A1,146-712-257-915-848,2011-05-12,2011,US 97145510 A,2010-12-17,US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/146-712-257-915-848,Patent Application,yes,19,15,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/00;;A61B5/374,600/300,0,0,,,,ACTIVE
279,US,B2,US 9033861 B2,134-035-146-767-319,2015-05-19,2015,US 54930309 A,2009-08-27,US 54930309 A;;US 43667606 A;;US 24599202 A;;US 65296400 A,2000-08-31,Low frequency neurostimulator for the treatment of neurological disorders,"A system for treating neurological conditions by low-frequency time varying electrical stimulation includes an electrical device for applying such low-frequency energy, in a range below approximately 10 Hz, to the patient's brain tissue. An implantable embodiment applies direct electrical stimulation to electrodes implanted in or on the patient's brain, while a non-invasive embodiment causes a magnetic field to induce electrical currents in the patient's brain.",FISCHELL DAVID R;;UPTON ADRIAN R M;;NEUROPACE INC,FISCHELL DAVID R;;UPTON ADRIAN R M,FILTER-PUR LLC (2020-10-27);;ARUENE CORPORATION (2021-01-29);;NEUROPACE INC (2000-08-30),https://lens.org/134-035-146-767-319,Granted Patent,yes,55,26,12,134-035-146-767-319;;063-625-412-026-457;;183-117-468-610-273;;086-607-447-296-268;;145-905-524-298-499;;185-299-912-241-367;;109-911-382-763-556;;143-139-684-274-733;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;159-561-963-127-802,US,12,145-905-524-298-499;;063-625-412-026-457;;086-607-447-296-268;;159-561-963-127-802;;185-299-912-241-367;;183-117-468-610-273;;109-911-382-763-556;;134-035-146-767-319;;017-064-467-229-598;;032-119-597-244-795;;149-299-558-743-667;;143-139-684-274-733,US,0,A61N2/006;;A61N1/32;;A61N1/36021;;A61N1/36025;;A61N1/36071;;A61N1/36082;;A61N2/008;;A61N2/02;;A61N2/006;;A61N1/36025;;A61N1/36064;;A61N1/36082;;A61N2/008;;A61N2/02,A61N2/04;;A61N1/32;;A61N1/36;;A61N2/00;;A61N2/02,600/14;;607/45,52,47,000-907-476-829-590;;070-549-885-927-855;;117-280-426-177-420;;020-862-494-916-996;;021-307-591-737-010;;002-610-549-523-468;;063-749-422-355-89X;;003-567-098-113-528;;121-395-139-132-160;;068-670-171-691-134;;017-065-379-332-717;;013-545-706-354-946;;030-983-039-493-075;;003-490-521-438-037;;038-125-139-467-43X;;003-243-554-446-676;;045-313-415-627-674;;032-584-602-403-660;;091-138-016-549-341;;058-790-540-596-874;;021-657-845-715-349;;064-273-086-002-360;;070-826-749-769-613;;035-990-338-077-706;;143-828-927-516-199;;038-980-231-466-699;;134-661-542-323-873;;013-676-649-177-997;;058-990-110-607-410;;002-344-382-871-989;;031-445-476-481-273;;058-904-960-260-878;;143-398-932-451-548;;021-154-759-818-769;;041-461-559-713-466;;150-796-039-433-379;;024-657-104-096-682;;029-497-167-480-309;;042-629-324-644-008;;085-169-832-606-660;;025-992-119-710-993;;018-769-436-346-405;;034-215-008-256-505;;049-764-006-876-782;;058-474-962-345-026;;100-329-685-384-712;;028-400-352-294-444,10482807;;10.1016/s0006-8993(99)01731-x;;3808255;;10.1097/00006123-198701000-00030;;10.1097/00019052-199806000-00003;;9642537;;10.1159/000125575;;402170;;1663448;;10.1016/0013-4694(85)91075-2;;2408867;;7250277;;10.1016/0014-4886(81)90057-1;;9448642;;10.1016/s0924-980x(97)00036-2;;10.1016/0013-4694(94)00249-k;;7530636;;10.1523/jneurosci.15-01-00604.1995;;pmc6578315;;7823167;;10.1016/0920-1211(95)00025-6;;8536671;;10.1111/j.1528-1157.1965.tb03782.x;;14337460;;9749744;;10.1046/j.1460-9568.1998.00090.x;;10.1016/s0006-8993(97)01118-9;;9439820;;10646759;;10.1016/s1361-8415(98)80008-x;;10.1111/j.1528-1157.1992.tb02192.x;;1396427;;7353566;;10.1111/j.1528-1157.1980.tb04046.x;;7388700;;7284903;;10.1017/s0317167100043286;;6512714;;10.1080/00223980.1984.9712600;;2429284;;10.1111/j.1540-8159.1986.tb05426.x;;10.1016/0014-4886(69)90128-9;;4981856;;6970503;;10.1007/978-3-7091-8592-6_31;;10910346;;10.1038/35018000;;10.1111/j.1600-0404.1994.tb05195.x;;8155315;;10.1016/0896-6273(94)90205-4;;10.1152/jn.1998.79.3.1592;;9497437;;10.1212/wnl.53.7.1462;;10534252;;10590958;;10.1097/00006123-199505000-00025;;7540735;;10.1227/00006123-199505000-00025;;3770122;;10.1016/0014-4886(86)90105-6;;10.3171/jns.1970.32.5.0553;;5438095;;10.1111/j.1528-1157.1998.tb01430.x;;9637604;;8190292;;10.1212/wnl.44.5.884;;6603358;;10.1111/j.1528-1157.1983.tb04915.x;;1162603;;10.1016/0013-4694(67)90188-5;;4168976;;14439711;;10.3171/jns.1960.17.1.0055;;3321152;;10.1016/0278-5846(87)90018-2;;10.1007/s004150050482;;10552238;;10.1177/155005948801900404;;3060288;;10.1016/0920-1211(89)90029-6;;2731520;;8730820;;10.1097/00001756-199601310-00035;;10.1097/00001756-199511000-00018;;8595196;;9875279;;10.1006/exnr.1998.6932;;10.1016/s0168-5597(97)00096-8;;9474057;;7225959;;10.1017/s0317167100042864,"Adamec, R.E., ""Evidence that Limbic Neural Plasticity in the Right Hemisphere Mediates Partial Kindling Induced Lasting Increases in Anxiety-Like Behavior,"" Brain Research (1999); 839: pp. 133-152.;;Agnew, W.F., et al., ""Considerations for Safety in the Use of Extracranial Stimulation for Motor Evoked Potentials,"" Neurosurgery (1987) 20: pp. 143-147.;;Aurora, S. K., et al., ""Brain Excitability in Migraine: Evidence from Transcranial Magnetic Stimulation Studies,"" Current Opinion in Neurology (1998) 11: pp. 205-209.;;Bartlett, J.R., et al., ""Deleterious Effects of Prolonged Electrical Excitation of Striate Cortex in macaques,"" Brain Behav. Evol. (1977) 14: pp. 46-666.;;Bridgers, S.L., ""The Safety of Transcranial Magnetic Stimulation Reconsidered: Evidence Regarding Cognitive and Other Cerebral Effects,"" Magnetic Motor Stimulation: Basic Principles and Clinical Experience (1991) EEG Suppl. 43: pp. 170-179.;;Buzsaki, G., et al., ""Depth Profiles of Hippocampal Rhythmic Slow Activity ('theta rhythm') Depend on Behavior,"" Electroencephologr. Clin. Neurophysiol. (1985) 61: pp. 77-88.;;Cain, D. P., et al., ""Kindling with Low-Frequency Stimulation: Generality, Transfer and Recruiting Effects,"" Experimental Neurology (1981) 73: pp. 219-232.;;Chen, R. et al., ""Safety of Different Inter-Train Intervals for Repetitive Transcranial Magnetic Stimulation and Recommendations for Safe Ranges of Stimulation Parameters,"" Electroencephalograpy and Clinical Neurophysiology (1997) 105: pp. 415-421.;;Classen, J. et al., ""Epileptic Seizures Triggered Directly by Focal Transcranial Magnetic Stimulation,"" Electroencephalography and Clinical Neurophysiology (1995) 94: pp. 19-25.;;Contreras, D., et al., ""Cellular Basis of EEG Slow Rhythms: A Study of Dynamic Corticothalmic Relationships,"" J. Neurosci. (1995) 15: pp. 604-622.;;Dennison, Z. et al., ""Persistence of Kindling: Effect of Partial Kindling, Retention Interval, Kindling Site, and Stimulation Parameters,"" Epilepsy Research (1995) 21: pp. 171-182.;;Dow, R.S., ""Extrinsic Regulatory Mechanisms of Seizure Activity,"" Epilepsia (1965) 6: pp. 122-140.;;Elger, C., et al., ""Short Communication Seizure Prediction by Non-Linear Time Series Analysis of Brain Electrical Activity,"" European Journal of Neuroscience (1998) 10: pp. 786-789.;;Emori, K., et al., ""Changes in Paired-Pulse Depression During the Triggering of Seizures by 2 Hz Dentate Gyrus Stimulation: the Effect of the Kindling,"" Brain Research (1997) 776: pp. 250-254.;;Ettinger, G.J., et al., ""Experimentation with a Transcranial Magnetic Stimulation System for Functional Brain Mapping,"" Medical Image Analysis (1998) vol. 2, No. 2, pp. 133-142.;;Fischer, R.S., et al., ""Placebo-Controlled Pilot Study of CentromedianThalamic Stimulation in Treatment of Intractable Seizures,"" Epilepsia (1992) 33: pp. 841-851.;;Gaito, J., et al., ""Interference Effect of 3 Hz Brain Stimulation on Kindling Behavior Induced by 60 Hz Stimulation,"" Epilepsia (1980) 21: pp. 73-84.;;Gaito, J., ""The Effect of Variable Duration One Hertz Interference on Kindling,"" Le Journal Canadien des Sciences Neurologiques (1980): 7: pp. 59-64.;;Gaito, J., et al., ""The Effect of Low Frequency and Direct Current Stimulation on the Kindling Phenomenon in Rats,"" Le Journal Canadiens des Sciences Neurologiques (1981) 8(3): pp. 249-253.;;Gaito, J., ""Suppression of Kindling Behavior,"" J. Psychology (1984) 118: pp. 113-125.;;Girvin, J.P., ""Cerebral (Cortical) Biostimulation,"" PACE (1986) 9: pp. 764-771.;;Goddard, G. V., et al., ""A Permanent Change in Brain Function Resulting From Daily Electrical Stimulation,"" Experimental Neurology (1967) 25: pp. 295-330.;;Goodman, J.H., ""Experimental Models of Status Epilepticus,"" in S. L. Peterson et al., eds., Neuropharmacology Methods in Epilepsy Research, CRC Press (1998) pp. 95-125.;;Gybels, J., et al., ""Electrical Stimulation of the Central Gray for Pain Relief in Human: Autopsy Data,"" Acta Neurochirugica (1980) Suppl. 30: pp. 259-268.;;Hallet, M., ""Transcranial Magnetic Stimulation and the Human Brain,"" Nature (2000) 406: pp. 147-150.;;Jennum, P., et al., ""Transcranial Magnetic Stimulation. Its Role in the Evaluation of Patients with Partial Epilepsy,"" Acta Neurol. Scand. (1994) Suppl. 152: pp. 93-96.;;Krauss, G. L., et al., ""Cerebellar and Thalamic Stimulation for Epilepsy,"" in O. Devinsky et al., eds., Electrical and Magnetic Stimulation of the Brain and Spinal Cord, New York: Raven Press, Ltd. (1993) pp. 231-245.;;Kreindler, A., ""Active Arrest Mechanisms of Epileptic Seizures,"" Epilepsia (1962) 2: pp. 329-337.;;Linden, D.J., ""Long-Term Synaptic Depression in the Mammalian Brain,"" Neuron (1994) 12: pp. 457-472.;;Leung, L.S., et al., ""Theta-Frequency Resonance in Hippocampal CA1 Neurons in Vitro Demonstrated by Sinusoidal Current Injection,"" J. Neurophysiol. (1998) 79: pp. 1592-1596.;;MacDonell, R.A.L., et al., ""Motor Cortex Localization Using Functional MRI and Transcranial Magnetic Stimulation,"" Neurology (1999) 53: pp. 1462-1467.;;Maertens De Noordhout, A., et al., ""Transcranial Magnetic Stiulation in Migraine,"" Transcranial Magnetic Stimulation (1999) EEG Suppl. 51: pp. 260-264.;;Migita, K., et al., ""Transcranial Magnetic Coil Stimulation of Motor Cortex in Patients with Central Pain,"" Neurosurgery (1995) vol. 36, No. 5, pp. 1037-1040.;;Minabe, Y. et al.,""Low-Frequency Kindling as a New Experimental Model of Epilepsy,"" Experimental Neurology (1986) 94: pp. 317-323.;;Mortimer, J.T., et al., ""Experimental Nondestructive Electrical Stimulation of the Brain and Spinal Cord,"" J. Neurosurg. (1970) 32: pp. 553-339.;;Ojemann, G.A., et al., ""Stereotactic and Other Procedures for Epilepsy,"" in D.P. Purpura et al., eds., Neurosurgical Management of the Epilepsies, Advances in Neurology (1975) 8: pp. 241-263.;;Osorio, L., et al., ""Real-Time Automated Dection and Quantitative Analysis of Seizures and Short-Term Prediction of Clinical Onset,"" Epilepsia (1998) 39: pp. 615-627.;;Pascual-Leone, A., et al., ""Akinesia in Parkinson's Disease,"" Neurology (1994) 44: pp. 884-891.;;Psatta, D.M., ""Control of Chronic Experimental Focal Epilepsy by Feedback Caudatum Stimulations,"" Epilepsia (1983) 24: pp. 444-454.;;Pudenz, R.H., et al., ""Electrical Stimulation of the Brain. II. Effects on the Blood-Brain Barrier,"" Surg. Neurol. (1975) 4: pp. 265-270.;;Reimer, G. R., et al., ""Effects of Cerebellar Stimulation on Cobalt-Induced Epilepsy in the Cat,"" Electroenceph. Clin. Neurophysiol. (1967) 23: pp. 456-462.;;Rowland, V., et al., ""The Production of Brain Lesions With Electric Currents,"" J. Neurosurg. (1960) 17: pp. 55-69.;;Schmutz, M., ""Relevance of Kindling and Related Processes to Human Epileptogenesis,"" Prog. Neuro-Psychopharmacolog. & Biol. Psychiat. (1987) 11: pp. 5050-5525.;;Schulze-Bonhage, A., et al., ""Safety of Single and Repetitive focal Transcranial Magnetic Stimuli as Assessed by Intracranial EEG Recordings in Patients with Partial Epilepsy,"" J. Neurol. (1999) 246: pp. 914-919.;;Sramka, M., et al., ""Observation of Kindling Phenomenon in Treatment of Pain by Stimulation in Thalamus,"" in W.H. Sweet et al., eds., Neurosurgical Treatment in Psychiatry, Pain and Epilepsy, Baltimore: University Park Press (1977) pp. 651-654.;;Staton, R.D., et al., ""The Electroencephalographic Pattern During Electroconvulsive Therapy: V. Observations on the Origin of Phase III Delta Energy and the Mechanism of Action of ECT,"" Clin. Electroencephalogr. (1988) 10: pp. 176-198.;;Ullal, G.R., et al., ""Low Frequency Stimulation Induces an Increase in After-Discharge Thresholds in Hippocampal and Amygdaloid Kindling,"" Epilepsy Res. 3 (1989) pp. 232-235.;;Wang, H. et al., ""LTD and LTP Induced by Transcranial Magnetic Stimulation in Auditory Cortex,"" Neuroreport (1996) 7: pp. 521-525.;;Weiss et al., S.R.B., et al., ""Quenching: Inhibition of Development and Expression of Amygdala Kindled Seizures with Low Frequency Stimulation,"" NeuroReport (1995) 6: pp. 2171-276.;;Weiss et al., S.R. et al., ""Quenching Revisited: Low Level Direct Current Inhibits Amygdala-Kindled Seizures,"" Experimental Neurology (1998) 154: pp. 185-192.;;E.M. Wasserman, ""Risk and Safety of Repetitive Transcranial Magnetic Stimulation: Report and Suggested Guidelines from the International Workshop on the Safety of Repetitive Transcranial Mag. Stim. . . . ,"" Electroenceph. and Clin Neurophys. 108 (1998), pp. 1-16.;;J. Gaito et al., ""The Effect of Several Intertrial Intervals on the 1 Hz Interference Effect,"" Le Journal Canadian des Sciences Neurologiques 1981; 8(1): pp. 61-65.",EXPIRED
280,US,A1,US 2009/0306750 A1,167-242-288-724-954,2009-12-10,2009,US 13505608 A,2008-06-06,US 13505608 A,2008-06-06,Lead Fixation Assembly and Methods of Using Same,"A lead fixation assembly and method of using the same are disclosed. The lead fixation assembly includes a cover and a cap. The cover includes an aperture extending through a cover body and is adapted to fit within an opening formed or occurring in a patient's body. One or more leads may be oriented through the aperture before or after fitting the cover in such an opening. The cover body includes a top surface having a plurality of elements. Each lead oriented through the aperture is arranged on or in and among the elements and may be secured thereby. The cap is adapted to be removably secured to the cover, minimize exposure to the patient via the opening, and, optionally, secure the leads. The leads are passed through an opening in the cap to enable the leads to extend away from the body.",NEUROPACE INC,BOLING C LANCE;;POTTS DENNIS,NEUROPACE INC (2008-06-05),https://lens.org/167-242-288-724-954,Patent Application,yes,64,11,1,167-242-288-724-954,US,1,167-242-288-724-954,US,0,A61N1/0531;;A61B2090/103;;A61N1/0534;;A61N1/0539;;A61N1/0558;;A61N1/0531;;A61B2090/103;;A61N1/0534;;A61N1/0539;;A61N1/0558,A61N1/05,607/116,0,0,,,,DISCONTINUED
281,US,B2,US 9186082 B2,196-087-925-463-182,2015-11-17,2015,US 81119007 A,2007-06-07,US 81119007 A;;US 24409302 A,2002-09-13,Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device,"A system and method for detecting and predicting neurological events with an implantable device uses a relatively low-power central processing unit in connection with signal processing circuitry to identify features (including half waves) and calculate window-based characteristics (including line lengths and areas under the curve of the waveform) in one or more electrographic signals received from a patient's brain. The features and window-based characteristics are employed within the framework of a programmable finite state machine to identify patterns and sequences in and across the electrographic signals, facilitating early and reliable detection and prediction of complex spatiotemporal neurological events in real time, and enabling responsive action by the implantable device.",WINGEIER BRETT M;;TCHENG THOMAS K;;NEUROPACE INC,WINGEIER BRETT M;;TCHENG THOMAS K,NEUROPACE INC (2003-01-31),https://lens.org/196-087-925-463-182,Granted Patent,yes,14,0,6,146-724-208-359-687;;196-087-925-463-182;;094-670-667-520-593;;001-478-838-231-224;;089-776-054-750-753;;162-237-890-566-997,US,6,146-724-208-359-687;;196-087-925-463-182;;001-478-838-231-224;;094-670-667-520-593;;089-776-054-750-753;;162-237-890-566-997,US,0,A61B5/0031;;A61B5/076;;A61B5/369;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/369;;A61B5/0031;;A61B5/076;;A61B5/165;;A61B5/374;;A61B5/377;;A61B5/4094;;A61B5/7257,A61B5/00;;A61B5/07;;A61B5/374,,15,12,143-388-558-467-689;;066-655-225-086-020;;032-832-759-355-695;;056-361-838-782-639;;064-968-594-730-904;;051-118-310-498-961;;080-476-358-354-096;;135-113-919-675-473;;011-361-025-719-111;;066-816-734-785-465;;124-403-369-942-149;;017-287-994-439-632,10.1016/0013-4694(90)90032-f;;1699724;;10.1212/wnl.45.12.2250;;8848202;;9214791;;10.1109/10.552241;;1592034;;10.1111/j.1528-1157.1992.tb01706.x;;10.1111/j.1528-1157.2000.tb00159.x;;10714401;;10.1016/s1388-2457(00)00259-5;;10825700;;10.1016/s1388-2457(00)00543-5;;11165525;;10.1155/np.2000.49;;10709214;;pmc2565365;;10.1111/j.1528-1157.1998.tb01390.x;;9578028;;10.1016/s0896-6273(01)00262-8;;11343644;;52443;;10.1016/0013-4694(75)90051-6;;10.1111/j.1528-1157.1990.tb05846.x;;2226364,"J. Gotman, Automatic Seizure Detection: Improvements and Evaluation, Electroencephalogr. Clin. Neurophysiol. 1990, 76(4): 317-24.;;H. Qu and J. Gotman, A Seizure Warning System for Long-Term Epilepsy Monitoring, Neurology 1995; 45: 2250-4.;;H. Qu and J. Gotman, A Patient-Specific Algorithm for the Detection of Seizure Onset in Long-Term EEG Monitoring: Possible Use as a Warning Device, 1997.;;Spencer S.S., Guimaraes P., Katz A., Kim J., Spencer D., Morphological Patterns of Seizures Recorded Intracranially, Epilepsia 1992; 33: 537-545.;;Lee S.A., Spencer D. D., Spencer S. S., Intracranial EEG Seizure-Onset Patterns in NeoCortical Epilepsy, Epilepsia 2000; 41: 297-307.;;Schiff S.J., Colella D., Jacyna G.M. et al., Brain Chirps: Spectrographic Signatures of Epileptic Seizures; Clin. Neurophysiol. 2000; 111: 953-958.;;Bergey G.K., Franaszczuk P.J., Epileptic Seizures are Characterized by Changing Signal Complexity, Clin. Neurophysiol. 2001; 112: 241-249.;;Velasco A.L., Wilson C.L., Babb T.L., Engel J. Jr., Functional and Anatomic Correlates of Two Frequently Observed Temporal Lobe Seizure-Onset Patterns, Neural Plasticity, 2000, 7:49-63.;;Schiller Y., Cascino G.D., Busacker N.E., Sharbrough F. W., Characterization and Comparison of Local Onset and Remote Propagated Electrographic Seizures Recorded with Intra-cranial electrodes; Epilepsia 1998; 39; 380-388.;;Litt B., Esteller R., Echauz J. et al., Epileptic Seizures May Begin Hours in Advance of Clinical Onset: A Report of Five Patients, Neuron, 2001: 30: 51-64.;;Wagner, H.R. et al., Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization, Electroencephalogr. Clin. Neurophysiol., 1975; 39(5): 499-506.;;http://www.medtronic.com/physician/activa/index.html (Medtronic Activa).;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;http://www.vnstherapy.com/epilepsylhcplvnstherapyldefaull.aspx (NeuroCybemetic Prosthesis (NCP, Accessed Jun. 5, 2007.;;Terry, Reese et al., ""An Implantable Neurocybernetic Prothesis System"", Epilepsia, 31 (Suppl. 2): S33-S37, Cyberonics, Inc, (1990).",INACTIVE
282,US,B2,US 6606521 B2,132-897-194-142-766,2003-08-12,2003,US 90185401 A,2001-07-09,US 90185401 A,2001-07-09,Implantable medical lead,The present invention generally provides an implantable medical lead having markings. The lead is easier to implant and improves the accurate localization of lead electrodes at a specific point of the brain for neurostimulation. Also provided is an implantable medical lead having a removable extension that advantageously provides a minimal length of excess lead protruding from the lead insertion site. The improved lead and method of implantation facilitates use of a neurostimulator device that is implanted directly in a patient's cranium.,NEUROPACE INC,PASPA PAUL M;;BOLING C LANCE,NEUROPACE INC (2001-07-03),https://lens.org/132-897-194-142-766,Granted Patent,yes,69,256,2,132-897-194-142-766;;124-746-910-283-183,US,2,132-897-194-142-766;;124-746-910-283-183,US,0,A61N1/0529;;A61N1/0529,A61N1/05,607/116,0,0,,,,EXPIRED
283,US,B2,US 9572973 B2,139-582-858-403-139,2017-02-21,2017,US 201313792165 A,2013-03-10,US 201313792165 A,2013-03-10,Recessed burr hole covers and methods for using the same,"A burr hole cover is configured to be recessed in a burr hole formed in a patient and includes a base and a cap provided with complementary features to allow a portion of a medical device, such as a brain lead, to be situated in the burr hole cover and then secured by rotation of the cap relative to the base. The features include channels on the base and matching cut-outs on the cap, and slots and locking pockets on the base that are configured to be aligned with locking tabs and locking protrusions on the cap. Because the burr hole cover is recessed in the burr hole, the medical device can extend proximally of the burr hole at the level of the cranium. A bottom surface of the cap may be provided with guides for the lead extending distally in towards the brain.",NEUROPACE INC,CHAVEZ ALFONSO;;WEBER PETER B,NEUROPACE INC (2013-03-11),https://lens.org/139-582-858-403-139,Granted Patent,yes,50,8,4,139-582-858-403-139;;089-515-786-584-185;;142-646-396-690-820;;056-897-730-348-860,US,4,089-515-786-584-185;;139-582-858-403-139;;142-646-396-690-820;;056-897-730-348-860,US,0,A61N1/0539;;A61N1/0534;;A61F2/2875;;A61N1/0534;;A61N1/0539,A61N1/05,,0,0,,,,ACTIVE
284,US,B2,US 8160720 B2,129-456-161-266-816,2012-04-17,2012,US 88117110 A,2010-09-13,US 88117110 A;;US 70453407 A,2007-02-08,Refillable reservoir lead systems,"Medical electrical lead systems and related methods are described. The medical electrical lead systems may be configured to be at least partially implanted in a body of a subject. Some variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and a lumen extending at least partially therebetween, at least one electrode in the proximity of the distal end of the lead body, and a reservoir in fluid communication with the lumen, where the reservoir is located at a position removed from the distal end of the lead body. Certain variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and first and second lumens extending at least partially therebetween, and at least one electrode in the proximity of the distal end of the lead body.",WINGEIER BRETT M;;MORRELL MARTHA;;BOLING CARL LANCE;;NEUROPACE INC,WINGEIER BRETT M;;MORRELL MARTHA;;BOLING CARL LANCE,NEUROPACE INC (2007-03-26),https://lens.org/129-456-161-266-816,Granted Patent,yes,68,8,6,044-530-454-860-377;;178-537-703-735-106;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,6,178-537-703-735-106;;044-530-454-860-377;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,0,A61N1/0529;;A61N1/0536;;A61N1/0568;;A61N1/0529;;A61N1/0536;;A61N1/0568,A61N1/00,607/116,17,6,078-011-754-012-619;;125-373-393-924-516;;011-003-220-418-314;;035-504-916-619-225;;017-151-528-619-262;;033-799-424-376-448,10.1097/00007691-200110000-00006;;11591899;;10.1126/science.290.5496.1532;;11090343;;10.1149/1.1393450;;10.1016/0966-7822(94)90032-9;;10.1517/17425247.1.1.37;;16296719;;pmc1361256;;pmc6792642;;9547224;;10.1523/jneurosci.18-09-03158.1998,"Nonfinal Office action, mailed Dec. 8, 2010 for U.S. Appl. No. 12/871,865, filed Aug. 30, 2010.;;Nonfinal Office action, mailed Feb. 23, 2010 for U.S. Appl. No. 11/704,549, filed Feb. 8, 2007.;;Notice of Allowability mailed Jun. 24, 2010 for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Non-Final Office Action mailed Feb. 25, 2010 for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Non-Final Office Action mailed on Sep. 8, 2009, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Non-Final Office Action mailed Mar. 31, 2009 for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Cengage, G., Thackery et al., eds., ""Ommaya Reservoir,"" Encyclopedia of Cancer, eNotes.com. 2002, 2006 (located at , last visited on Aug. 31, 2010).;;Cavuoto, J. (ed.) ""Biomaterials Key Factor in Next-Generation Electrodes,"" Neurotech Business Report (Jan. 2002) 2(1): 3-5.;;Christensen, J. et al. ""Plasma Concentration of Topiramate Correlates with Cerebrospinal Fluid Concentration,"" Therapeutic Drug Monitoring (Oct. 2001) 23(5): 529-535.;;Craighead, H.G. ""Nanoelectromechanical Systems,"" Science (Nov. 24, 2000) 290: 1532-1535.;;Doose, D.R. et al. ""Topiramate: Chemistry, Biotransformation, and Pharmacokinetics,"" Chapter 78, in Antiepileptic Drugs, 5th Ed., Levy, R.H. et al., eds., Lippincott Williams & Wilkins, Philadelphia, PA, publisher (2002) pp. 727-734.;;Ghosh, S. et al. ""Electrochemical Characterization of Poly(3,4-ethylene dioxythiophene) Based Conducting Hydrogel Networks,"" J. of the Electrochem. Soc. (May 2000) 147(5): 1872-1877.;;Gilmore, K. et al. ""Preparation of Hydrogel/Conducting Polymer Composites,"" Polymer Gels and Networks (1994) 2(2): 135-143.;;Martin, D.C. et al. ""Bio-Electronic Implantable Device Coating Applications,"" in White Paper: Bioactive Conducting Polymer Coatings for Biomedical Devices, University of Michigan.;;Olsen, R.W. ""Phenobarbital and Other Barbituates: Mechanisms of Action,"" Chapter 50 in Antiepileptic Drugs, 5th Ed., Levy, R.H. et al., eds., Lippincott Williams & Wilkins, Philadelphia, PA, publisher (2002) pp. 489-495.;;Pitt, W.G. et al. ""Ultrasonic Drug Delivery-A General Review,"" Expert Opinion on Drug Delivery (Nov. 2004) 1(1): 37-56.;;Rusakov, D.A. et al. ""Extrasynaptic Glutamate Diffusion in the Hippocampus: Ultrastructural Constraints, Uptake and Receptor Activation,"" The J. of Neurosci. (May 1, 1998) 18(9): 3158-3170.",INACTIVE
285,US,A1,US 2012/0109253 A1,059-542-707-815-033,2012-05-03,2012,US 201213347675 A,2012-01-10,US 201213347675 A;;US 88117110 A;;US 70453407 A,2007-02-08,Refillable Reservoir Lead Systems,"Medical electrical lead systems and related methods are described. The medical electrical lead systems may be configured to be at least partially implanted in a body of a subject. Some variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and a lumen extending at least partially therebetween, at least one electrode in the proximity of the distal end of the lead body, and a reservoir in fluid communication with the lumen, where the reservoir is located at a position removed from the distal end of the lead body. Certain variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and first and second lumens extending at least partially therebetween, and at least one electrode in the proximity of the distal end of the lead body.",WINGEIER BRETT M;;MORRELL MARTHA;;BOLING C LANCE;;NEUROPACE INC,WINGEIER BRETT M;;MORRELL MARTHA;;BOLING C LANCE,NEUROPACE INC (2007-03-26),https://lens.org/059-542-707-815-033,Patent Application,yes,1,4,6,044-530-454-860-377;;178-537-703-735-106;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,6,178-537-703-735-106;;044-530-454-860-377;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,0,A61N1/0529;;A61N1/0536;;A61N1/0568;;A61N1/0529;;A61N1/0536;;A61N1/0568,A61N1/36,607/45,0,0,,,,INACTIVE
286,US,B2,US 9597032 B2,013-652-993-005-610,2017-03-21,2017,US 201615047475 A,2016-02-18,US 201615047475 A;;US 201414525710 A;;US 201313966899 A;;US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/013-652-993-005-610,Granted Patent,yes,29,0,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374;;A61B5/00;;A61B5/01;;A61B5/0205;;A61B5/024;;A61B5/026;;A61B5/11;;A61B5/1455;;A61N1/36,,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A.C., ""Textbook of Medical Physiology"", 8th ed., Wonsiewicz M.J. ed., pp. wii-xli (Table of Contents only), (1991).;;Gotman, J. ""Automatic Seizure Detection: Improvements and Evaluation"", Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",ACTIVE
287,WO,A8,WO 2009/067323 A8,120-334-324-245-33X,2009-07-23,2009,US 2008/0081655 W,2008-10-29,US 92980107 A;;US 23429708 A;;US 24373308 A;;US 26095808 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC;;PLESS BENJAMIN;;CHAO DANIEL;;WINGELER BRETT;;TCHENG THOMAS,PLESS BENJAMIN;;CHAO DANIEL;;WINGELER BRETT;;TCHENG THOMAS,,https://lens.org/120-334-324-245-33X,Amended Application,yes,0,0,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05,,0,0,,,,PENDING
288,US,A1,US 2017/0119527 A1,056-897-730-348-860,2017-05-04,2017,US 201715402047 A,2017-01-09,US 201715402047 A;;US 201313792165 A,2013-03-10,RECESSED BURR HOLE COVERS AND METHODS FOR USING THE SAME,"A burr hole cover is configured to be recessed in a burr hole formed in a patient and includes a base and a cap provided with complementary features to allow a portion of a medical device, such as a brain lead, to be situated in the burr hole cover and then secured by rotation of the cap relative to the base. The features include channels on the base and matching cut-outs on the cap, and slots and locking pockets on the base that are configured to be aligned with locking tabs and locking protrusions on the cap. Because the burr hole cover is recessed in the burr hole, the medical device can extend proximally of the burr hole at the level of the cranium. A bottom surface of the cap may be provided with guides for the lead extending distally in towards the brain.",NEUROPACE INC,CHAVEZ ALFONSO;;WEBER PETER B,NEUROPACE INC (2013-03-11),https://lens.org/056-897-730-348-860,Patent Application,yes,6,4,4,139-582-858-403-139;;089-515-786-584-185;;142-646-396-690-820;;056-897-730-348-860,US,4,089-515-786-584-185;;139-582-858-403-139;;142-646-396-690-820;;056-897-730-348-860,US,0,A61N1/0539;;A61N1/0534;;A61F2/2875;;A61N1/0534;;A61N1/0539,A61F2/28;;A61N1/05,,0,0,,,,ACTIVE
289,US,A1,US 2014/0257325 A1,089-515-786-584-185,2014-09-11,2014,US 201313792165 A,2013-03-10,US 201313792165 A,2013-03-10,Recessed Burr Hole Covers and Methods for Using the Same,"A burr hole cover is configured to be recessed in a burr hole formed in a patient and includes a base and a cap provided with complementary features to allow a portion of a medical device, such as a brain lead, to be situated in the burr hole cover and then secured by rotation of the cap relative to the base. The features include channels on the base and matching cut-outs on the cap, and slots and locking pockets on the base that are configured to be aligned with locking tabs and locking protrusions on the cap. Because the burr hole cover is recessed in the burr hole, the medical device can extend proximally of the burr hole at the level of the cranium. A bottom surface of the cap may be provided with guides for the lead extending distally in towards the brain.",NEUROPACE INC,CHAVEZ ALFONSO;;WEBER PETER B,NEUROPACE INC (2013-03-11),https://lens.org/089-515-786-584-185,Patent Application,yes,3,21,4,139-582-858-403-139;;089-515-786-584-185;;142-646-396-690-820;;056-897-730-348-860,US,4,089-515-786-584-185;;139-582-858-403-139;;142-646-396-690-820;;056-897-730-348-860,US,0,A61N1/0539;;A61N1/0534;;A61F2/2875;;A61N1/0534;;A61N1/0539,A61N1/05;;A61F2/28,606/129,0,0,,,,ACTIVE
290,US,A1,US 2016/0166199 A1,013-895-775-183-597,2016-06-16,2016,US 201615047475 A,2016-02-18,US 201615047475 A;;US 201414525710 A;;US 201313966899 A;;US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,DEVICES AND METHODS FOR MONITORING PHYSIOLOGICAL INFORMATION RELATING TO SLEEP WITH AN IMPLANTABLE DEVICE,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/013-895-775-183-597,Patent Application,yes,0,8,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/00;;A61B5/374;;A61N1/36,,0,0,,,,ACTIVE
291,US,A1,US 2014/0031604 A1,110-213-700-091-829,2014-01-30,2014,US 201314043599 A,2013-10-01,US 201314043599 A;;US 201113011917 A;;US 37438006 A,2006-03-13,IMPLANTABLE SYSTEM ENABLING RESPONSIVE THERAPY FOR PAIN,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-28),https://lens.org/110-213-700-091-829,Patent Application,yes,0,3,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/36;;A61M5/172;;A61N2/00,600/12;;607/46;;604/66;;600/9,0,0,,,,ACTIVE
292,US,B2,US 8190270 B2,056-094-119-989-218,2012-05-29,2012,US 201213347675 A,2012-01-10,US 201213347675 A;;US 88117110 A;;US 70453407 A,2007-02-08,Refillable reservoir lead systems,"Medical electrical lead systems and related methods are described. The medical electrical lead systems may be configured to be at least partially implanted in a body of a subject. Some variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and a lumen extending at least partially therebetween, at least one electrode in the proximity of the distal end of the lead body, and a reservoir in fluid communication with the lumen, where the reservoir is located at a position removed from the distal end of the lead body. Certain variations of the medical electrical lead systems may comprise a lead body comprising a proximal end and a distal end and first and second lumens extending at least partially therebetween, and at least one electrode in the proximity of the distal end of the lead body.",WINGEIER BRETT M;;MORRELL MARTHA;;BOLING CARL LANCE;;NEUROPACE INC,WINGEIER BRETT M;;MORRELL MARTHA;;BOLING CARL LANCE,NEUROPACE INC (2007-03-26),https://lens.org/056-094-119-989-218,Granted Patent,yes,67,13,6,044-530-454-860-377;;178-537-703-735-106;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,6,178-537-703-735-106;;044-530-454-860-377;;059-542-707-815-033;;056-094-119-989-218;;045-435-339-869-510;;129-456-161-266-816,US,0,A61N1/0529;;A61N1/0536;;A61N1/0568;;A61N1/0529;;A61N1/0536;;A61N1/0568,A61N1/00,607/116,20,6,078-011-754-012-619;;125-373-393-924-516;;011-003-220-418-314;;035-504-916-619-225;;017-151-528-619-262;;033-799-424-376-448,10.1097/00007691-200110000-00006;;11591899;;10.1126/science.290.5496.1532;;11090343;;10.1149/1.1393450;;10.1016/0966-7822(94)90032-9;;10.1517/17425247.1.1.37;;16296719;;pmc1361256;;pmc6792642;;9547224;;10.1523/jneurosci.18-09-03158.1998,"Final Office action, mailed Jul. 12, 2011, for U.S. Appl. No. 12/881,171, filed Sep. 13, 2010.;;Nonfinal Office action, mailed Dec. 3, 2010, for U.S. Appl. No. 12/881,171, filed Sep. 13, 2010.;;Nonfinal Office action, mailed Aug. 9, 2011 for U.S. Appl. No. 12/871,865 filed Aug. 30, 2010.;;Nonfinal Office action, mailed Dec. 8, 2010 for U.S. Appl. No. 12/871,865, filed Aug. 30, 2010.;;Nonfinal Office action, mailed Feb. 23, 2010 for U.S. Appl. No. 11/704,549, filed Feb. 8, 2007.;;Notice of Allowability mailed Jun. 24, 2010 for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Nonfinal Office action mailed Feb. 25, 2010 for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Nonfinal Office action mailed on Sep. 8, 2009, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Nonfinal Office action mailed Mar. 31, 2009 for U.S. Appl. No. 11/704,534 filed Feb. 8, 2007.;;Cengage, G., Thackery et al., eds., ""Ommaya Reservoir,"" Encyclopedia of Cancer, eNotes.com. 2002, 2006 (located at , last visited on Aug. 31, 2010).;;Cavuoto, J. (ed.) ""Biomaterials Key Factor in Next-Generation Electrodes,"" Neurotech Business Report (Jan. 2002) 2(1): 3-5.;;Christensen, J. et al. ""Plasma Concentration of Topiramate Correlates with Cerebrospinal Fluid Concentration,"" Therapeutic Drug Monitoring (Oct. 2001) 23(5): 529-535.;;Craighead, H.G. ""Nanoelectromechanical Systems,"" Science (Nov. 24, 2000) 290: 1532-1535.;;Doose, D.R. et al. ""Topiramate: Chemistry, Biotransformation, and Pharmacokinetics,"" Chapter 78, in Antiepileptic Drugs, 5th Ed., Levy, R.H. et al., eds., Lippincott Williams & Wilkins, Philadelphia, PA, publisher (2002) pp. 727-734.;;Ghosh, S. et al. ""Electrochemical Characterization of Poly(3,4-ethylene dioxythiophene) Based Conducting Hydrogel Networks,"" J. of the Electrochem. Soc. (May 2000) 147(5): 1872-1877.;;Gilmore, K. et al. ""Preparation of Hydrogel/Conducting Polymer Composites,"" Polymer Gels and Networks (1994) 2(2): 135-143.;;Martin, D.C. et al. ""Bio-Electronic Implantable Device Coating Applications,"" in White Paper: Bioactive Conducting Polymer Coatings for Biomedical Devices, University of Michigan, four pages, internal database as of Aug. 30, 2006.;;Olsen, R.W. ""Phenobarbital and Other Barbituates: Mechanisms of Action,"" Chapter 50 in Antiepileptic Drugs, 5th Ed., Levy, R.H. et al., eds., Lippincott Williams & Wilkins, Philadelphia, PA, publisher (2002) pp. 489-495.;;Pitt, W.G. et al. ""Ultrasonic Drug Delivery-A General Review,"" Expert Opinion on Drug Delivery (Nov. 2004) 1(1): 37-56.;;Rusakov, D.A. et al. ""Extrasynaptic Glutamate Diffusion in the Hippocampus: Ultrastructural Constraints, Uptake and Receptor Activation,"" The J. of Neurosci. (May 1, 1998) 18(9): 3158-3170.",INACTIVE
293,US,B2,US 7894890 B2,136-810-236-011-950,2011-02-22,2011,US 70445107 A,2007-02-09,US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/136-810-236-011-950,Granted Patent,yes,19,27,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374,600/544;;600/545,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A. C. (1991). Textbook of Medical Physiology, 8th ed., Wonsiewicz M.J. ed., pp. vii-xli, (Table of Contents only.).;;Gotman, J. (1990). ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalography & Clinical Neurophysiology 76(4): 317-324.",ACTIVE
294,US,A1,US 2015/0112222 A1,129-163-026-946-780,2015-04-23,2015,US 201414525710 A,2014-10-28,US 201414525710 A;;US 201313966899 A;;US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,DEVICES AND METHODS FOR MONITORING PHYSIOLOGICAL INFORMATION RELATING TO SLEEP WITH AN IMPLANTABLE DEVICE,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/129-163-026-946-780,Patent Application,yes,0,10,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/00;;A61B5/374,600/544,0,0,,,,INACTIVE
295,US,B2,US 8538514 B2,173-959-172-463-700,2013-09-17,2013,US 201313733055 A,2013-01-02,US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/173-959-172-463-700,Granted Patent,yes,19,10,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374,600/544;;600/545,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A.C. ""Textbook of Medical Physiology"", 8th ed., Wonsiewicz M.J. ed., pp. vii-xli (Table of Contents only), (1991).;;Gotman, J. ""Automatic Seizure Detection: Improvements and Evaluation"", Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",ACTIVE
296,US,B2,US 9468765 B2,030-830-505-406-534,2016-10-18,2016,US 201514843785 A,2015-09-02,US 201514843785 A;;US 88627910 A,2010-09-20,Current management system for a stimulation output stage of an implantable neurostimulation system,"A current management system for use in the stimulation output stage of a neurostimulation system can be programmed to steer different amounts of current through different stimulation electrodes to vary how strongly the tissue adjacent each electrode is stimulated during a particular programmed stimulation episode. An stimulation electrode drive circuit associated with each electrode that is available for stimulation allows independent control of the flow of current through that electrode. A reference electrode is provided in the circuit to source or sink current as necessary to balance the currents going into and out of the patient, so that no stimulation electrode is required to serve that purpose. More specifically, by configuring the circuit to maintain a constant potential at the reference electrode (e.g., a potential that is approximately half way between a top and bottom voltage rail), the reference electrode will source or sink currents as necessary to cause the net current flow into the patient to be equal to the net current flowing out of the patient, thus satisfying Kirchhoff's current law.",NEUROPACE INC,ARCHER STEPHEN T,NEUROPACE INC (2010-09-20),https://lens.org/030-830-505-406-534,Granted Patent,yes,31,3,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;001-779-617-891-279;;030-830-505-406-534;;130-813-226-275-958,US,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;130-813-226-275-958;;001-779-617-891-279;;030-830-505-406-534,US,0,A61N1/36125;;A61N1/3616;;A61N1/36125;;A61N1/3616,A61N1/36,,0,0,,,,ACTIVE
297,US,B2,US 9238144 B2,046-522-419-858-936,2016-01-19,2016,US 201313830021 A,2013-03-14,US 201313830021 A,2013-03-14,Optimizing data retrieval from an active implantable medical device,"An external data retrieval apparatus includes a transceiver, and a processing system coupled to the transceiver. The processing system obtains a plurality of measures over a period of time. The measures relate to a quality of a communications channel between the data retrieval apparatus and an active implantable medical device. The processing system determines a trend in the plurality of measures over the period of time, and then determines a preferred time during which to retrieve data based on the trend.",NEUROPACE INC,GREENE DAVID A;;ARCHER STEVE T;;MULLIGAN IV PATRICK G,NEUROPACE INC (2013-04-10),https://lens.org/046-522-419-858-936,Granted Patent,yes,16,9,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;009-784-087-984-140;;190-321-968-016-483;;154-825-651-991-68X,US,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;154-825-651-991-68X;;190-321-968-016-483;;009-784-087-984-140,US,0,A61N1/37252;;A61N1/36128;;A61N1/37276;;A61N1/37252;;A61N1/37276,A61N1/372;;G01N33/48;;G08C17/02;;H04Q5/22;;H04Q9/00,,0,0,,,,ACTIVE
298,US,A1,US 2007/0213783 A1,145-216-267-168-517,2007-09-13,2007,US 37438006 A,2006-03-13,US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D,NEUROPACE INC (2006-05-05),https://lens.org/145-216-267-168-517,Patent Application,yes,44,204,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/00,607/42,0,0,,,,ACTIVE
299,US,B2,US 9326724 B2,012-505-471-966-936,2016-05-03,2016,US 201414525710 A,2014-10-28,US 201414525710 A;;US 201313966899 A;;US 201313733055 A;;US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/012-505-471-966-936,Granted Patent,yes,19,0,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374;;A61B5/00;;A61B5/01;;A61B5/0205;;A61B5/024;;A61B5/026;;A61B5/11;;A61B5/1455;;A61N1/36,,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A.C., ""Textbook of Medical Physiology"", 8th ed., Wonsiewicz M.J. ed., pp. wii-xli (Table of Contents only), 1991).;;Gotman, J. ""Automatic Seizure Detection: Improvements and Evaluation"", Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",INACTIVE
300,US,A1,US 2015/0321003 A1,051-011-458-698-134,2015-11-12,2015,US 201514795741 A,2015-07-09,US 201514795741 A;;US 201414321287 A;;US 201314043599 A;;US 201113011917 A;;US 37438006 A,2006-03-13,IMPLANTABLE SYSTEM ENABLING RESPONSIVE THERAPY FOR PAIN,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-28),https://lens.org/051-011-458-698-134,Patent Application,yes,1,12,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/36;;A61F7/00;;A61M5/172;;A61N2/00;;A61N5/06,,0,0,,,,INACTIVE
301,US,A1,US 2014/0323958 A1,073-104-946-983-971,2014-10-30,2014,US 201414321287 A,2014-07-01,US 201414321287 A;;US 201314043599 A;;US 201113011917 A;;US 37438006 A,2006-03-13,IMPLANTABLE SYSTEM ENABLING RESPONSIVE THERAPY FOR PAIN,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-28),https://lens.org/073-104-946-983-971,Patent Application,yes,2,0,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/36;;A61M5/172;;A61N5/06,604/66;;607/46;;607/88,0,0,,,,ACTIVE
302,US,B2,US 11547850 B2,040-814-768-254-408,2023-01-10,2023,US 201916692964 A,2019-11-22,US 201916692964 A;;US 201862773121 P,2018-11-29,Lead fixation devices for securing a lead to a cranium,"A lead fixation device for securing a first portion of a lead relative to a hole formed through a skull includes a skull attachment member having an upper surface and a lower surface and a bore extending through and between the upper surface and the lower surface. The lead fixation device also includes a lead compression mechanism integral with the skull attachment member and aligned with the bore of the skull attachment member. The lead compression mechanism defines a passageway through the lead fixation device, which passageway is characterized by a diameter that is defined by the lead compression mechanism. The lead compression mechanism is configured to transition the diameter from a first size to a second size greater than the first size upon insertion of an implant tool through the passageway, and from the second size to the first size upon removal of the implant tool from the passageway.",NEUROPACE INC,CHAVEZ ALFONSO;;GREENE DAVID A,NEUROPACE INC (2019-12-09),https://lens.org/040-814-768-254-408,Granted Patent,yes,57,0,3,089-030-980-853-400;;040-814-768-254-408;;143-797-677-326-974,US,3,089-030-980-853-400;;040-814-768-254-408;;143-797-677-326-974,US,0,A61N1/0539;;A61N1/0539,A61N1/05,,4,1,038-757-509-977-927,pmc4852184;;10.7759/cureus.549;;27158578,"Biomet Microfixation. Neuroimplant System. Product Brochure, 8 pgs. (2013).;;Aesculap Inc. Cranial Fixation Systems. Product Brochure, 11 pgs. (2014).;;Miller et al. “Stereotactic bony trajectory preservation for responsive neurostimulator lead placement following depth EEG recording.” Cureus 8(3):3549. DOI 10.7759/cureus.549, 6 pgs. (Mar. 30, 2016).;;Synthes Cmf. “MatrixNEURO. The next generation cranial plating system.” Product Brochure, 10 pgs. (2006).",ACTIVE
303,US,A1,US 2023/0104746 A1,089-030-980-853-400,2023-04-06,2023,US 202218077668 A,2022-12-08,US 202218077668 A;;US 201916692964 A;;US 201862773121 P,2018-11-29,LEAD FIXATION DEVICES FOR SECURING A LEAD TO A CRANIUM,"A lead fixation device for securing a first portion of a lead relative to a hole formed through a skull includes a skull attachment member having an upper surface and a lower surface and a bore extending through and between the upper surface and the lower surface. The lead fixation device also includes a lead compression mechanism integral with the skull attachment member and aligned with the bore of the skull attachment member. The lead compression mechanism defines a passageway through the lead fixation device, which passageway is characterized by a diameter that is defined by the lead compression mechanism. The lead compression mechanism is configured to transition the diameter from a first size to a second size greater than the first size upon insertion of an implant tool through the passageway, and from the second size to the first size upon removal of the implant tool from the passageway.",NEUROPACE INC,CHAVEZ ALFONSO;;GREENE DAVID A,NEUROPACE INC (2019-12-09),https://lens.org/089-030-980-853-400,Patent Application,yes,1,0,3,089-030-980-853-400;;040-814-768-254-408;;143-797-677-326-974,US,3,089-030-980-853-400;;040-814-768-254-408;;143-797-677-326-974,US,0,A61N1/0539;;A61N1/0539,A61N1/05,,0,0,,,,PENDING
304,US,A1,US 2020/0171299 A1,143-797-677-326-974,2020-06-04,2020,US 201916692964 A,2019-11-22,US 201916692964 A;;US 201862773121 P,2018-11-29,LEAD FIXATION DEVICES FOR SECURING A LEAD TO A CRANIUM,"A lead fixation device for securing a first portion of a lead relative to a hole formed through a skull includes a skull attachment member having an upper surface and a lower surface and a bore extending through and between the upper surface and the lower surface. The lead fixation device also includes a lead compression mechanism integral with the skull attachment member and aligned with the bore of the skull attachment member. The lead compression mechanism defines a passageway through the lead fixation device, which passageway is characterized by a diameter that is defined by the lead compression mechanism. The lead compression mechanism is configured to transition the diameter from a first size to a second size greater than the first size upon insertion of an implant tool through the passageway, and from the second size to the first size upon removal of the implant tool from the passageway.",NEUROPACE INC,CHAVEZ ALFONSO;;GREENE DAVID A,,https://lens.org/143-797-677-326-974,Patent Application,yes,2,2,3,089-030-980-853-400;;040-814-768-254-408;;143-797-677-326-974,US,3,089-030-980-853-400;;040-814-768-254-408;;143-797-677-326-974,US,0,A61N1/0539;;A61N1/0539,A61N1/05,,0,0,,,,ACTIVE
305,US,B2,US 9421371 B2,029-463-282-605-255,2016-08-23,2016,US 201514795741 A,2015-07-09,US 201514795741 A;;US 201414321287 A;;US 201314043599 A;;US 201113011917 A;;US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-28),https://lens.org/029-463-282-605-255,Granted Patent,yes,52,43,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/00;;A61F7/00;;A61M5/172;;A61N1/36;;A61N2/00;;A61N5/06,,6,6,137-629-505-294-208;;124-115-873-895-429;;027-934-053-698-027;;093-871-073-392-568;;059-350-361-082-031;;009-083-260-830-814,10.1016/j.neuroscience.2006.02.031;;16631315;;16326140;;10.1016/j.clinph.2005.09.012;;9092847;;10.1097/00006123-199704000-00015;;10.1016/s0304-3959(02)00277-4;;12507704;;16183660;;10.1093/brain/awh631;;10916262;;10.1109/10.846685,"Drewes A M, Sami S A, Dimcevski G, Nielsen K D, Funch-Jensen P, Valeriani M, Arendt-Nielsen L. ""Cerebral processing of painful oesophageal stimulation. A study based on independent component analysis of the EEG"". Gut. 2005.;;Krause P, Forderreuther S, Straube A. ""TMS motor cortical brain mapping in patients with complex regional pain syndrome type I"". Clin. Neurophysiol. Jan. 2006;117(1 ):169-76. Epub Dec. 2, 2005.;;Kumar et al., ""Deep Brain Stimulation for Intractable Pain: A 15-Year Experience,"" Neurosurgery 40(4): 736-747, Apr. 1997.;;D. Nandi et al.. ""Thalamic field potentials in chronic central pain treated by periventricular gray stimulation-a series of eight cases,"" Pain 101 (2003) 97-107.;;Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. ""Increased EEG power and slowed dominant frequency in patients with neurogenic pain"". Brain. Jan. 2006;129 (pt 1 ):55-64.;;Weiland and Anderson, ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",INACTIVE
306,US,A1,US 2007/0038265 A1,120-106-019-097-794,2007-02-15,2007,US 51778306 A,2006-09-08,US 51778306 A;;US 7266902 A,2002-02-05,Responsive electrical stimulation for movement disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of applying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/120-106-019-097-794,Patent Application,yes,7,116,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/32;;A61N1/08;;A61N1/36,607/48,0,0,,,,EXPIRED
307,US,A1,US 2011/0118661 A1,106-949-946-468-54X,2011-05-19,2011,US 201113011917 A,2011-01-23,US 201113011917 A;;US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-24),https://lens.org/106-949-946-468-54X,Patent Application,yes,46,38,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/36;;A61M37/00,604/66;;607/46,0,0,,,,ACTIVE
308,US,B2,US 7894905 B2,125-628-542-720-077,2011-02-22,2011,US 37438006 A,2006-03-13,US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2006-05-05),https://lens.org/125-628-542-720-077,Granted Patent,yes,44,211,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/00,607/46,7,7,055-633-804-475-50X;;137-629-505-294-208;;124-115-873-895-429;;027-934-053-698-027;;093-871-073-392-568;;059-350-361-082-031;;009-083-260-830-814,15979027;;10.1016/j.ejpain.2004.11.001;;10.1016/j.neuroscience.2006.02.031;;16631315;;16326140;;10.1016/j.clinph.2005.09.012;;9092847;;10.1097/00006123-199704000-00015;;10.1016/s0304-3959(02)00277-4;;12507704;;16183660;;10.1093/brain/awh631;;10916262;;10.1109/10.846685,"Apkarian A V, Bushnell M C, Treede R D, Zubieta J K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. Aug. 2005;9(4):463-84.;;Drewes A M, Sami S A, Dimcevski G, Nielsen K D, Funch-Jensen P, Valeriani M, Arendt-Nielsen L. ""Cerebral processing of painful oesophageal stimulation. A study based on independent component analysis of the EEG"". Gut. 2005.;;Krause P, Forderreuther S, Straube A. ""TMS motor cortical brain mapping in patients with complex regional pain syndrome type I"". Clin. Neurophysiol. Jan. 2006;117(1):169-76. Epub Dec. 2, 2005.;;Kumar et al., ""Deep Brain Stimulation for Intractable Pain: A 15-Year Experience,"" Neurosurgery 40(4): 736-747, Apr. 1997.;;D. Nandi et al., ""Thalamic field potentials in chronic central pain treated by periventricular gray stimulation-a series of eight cases,"" Pain 101 (2003) 97-107.;;Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. ""Increased EEG power and slowed dominant frequency in patients with neurogenic pain"". Brain. Jan. 2006; 129 (Pt 1):55-64.;;Weiland and Anderson, ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",ACTIVE
309,US,B2,US 9782595 B2,197-067-125-473-719,2017-10-10,2017,US 201514955978 A,2015-12-01,US 201514955978 A;;US 201313830021 A,2013-03-14,Optimizing data retrieval from an active implantable medical device,"An external data retrieval apparatus includes a transceiver, and a processing system coupled to the transceiver. The processing system obtains a plurality of measures over a period of time. The measures relate to a quality of a communications channel between the data retrieval apparatus and an active implantable medical device. The processing system determines a trend in the plurality of measures over the period of time, and then determines a preferred time during which to retrieve data based on the trend.",NEUROPACE INC,GREENE DAVID A;;ARCHER STEVE T;;MULLIGAN IV PATRICK G,NEUROPACE INC (2013-04-10),https://lens.org/197-067-125-473-719,Granted Patent,yes,42,2,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;009-784-087-984-140;;190-321-968-016-483;;154-825-651-991-68X,US,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;154-825-651-991-68X;;190-321-968-016-483;;009-784-087-984-140,US,0,A61N1/37252;;A61N1/36128;;A61N1/37276;;A61N1/37252;;A61N1/37276,A61N1/372;;G01N33/48;;G08C17/02;;H04Q5/22;;H04Q9/00,,0,0,,,,ACTIVE
310,US,B2,US 9114260 B2,136-993-143-788-28X,2015-08-25,2015,US 201414321287 A,2014-07-01,US 201414321287 A;;US 201314043599 A;;US 201113011917 A;;US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-28),https://lens.org/136-993-143-788-28X,Granted Patent,yes,51,4,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/00;;A61M5/172;;A61N1/36;;A61N2/00;;A61N5/06,,7,7,055-633-804-475-50X;;137-629-505-294-208;;124-115-873-895-429;;027-934-053-698-027;;093-871-073-392-568;;059-350-361-082-031;;009-083-260-830-814,15979027;;10.1016/j.ejpain.2004.11.001;;10.1016/j.neuroscience.2006.02.031;;16631315;;16326140;;10.1016/j.clinph.2005.09.012;;9092847;;10.1097/00006123-199704000-00015;;10.1016/s0304-3959(02)00277-4;;12507704;;16183660;;10.1093/brain/awh631;;10916262;;10.1109/10.846685,"Apkarian A V, Bushnell M C, Treede R D, Zubieta J K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. Aug. 2005;9(4):463-84.;;Drewes A M, Sami S A, Dimcevski G, Nielsen K D, Funch-Jensen P, Valeriani M, Arendt-Nielsen L. ""Cerebral processing of painful oesophageal stimulation. A study based on independent component analysis of the EEG"". Gut. 2005.;;Krause P, Forderreuther S, Straube A. ""TMS motor cortical brain mapping in patients with complex regional pain syndrome type I"". Clin. Neurophysiol. Jan. 2006;117(1 ):169-76. Epub Dec. 2, 2005.;;Kumar et al., ""Deep Brain Stimulation for Intractable Pain: A 15-Year Experience,"" Neurosurgery 40(4): 736-747, Apr. 1997.;;D. Nandi et al.. ""Thalamic field potentials in chronic central pain treated by periventricular gray stimulation-a series of eight cases,"" Pain 101 (2003) 97-107.;;Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. ""Increased EEG power and slowed dominant frequency in patients with neurogenic pain"". Brain. Jan. 2006;129 (pt 1 ):55-64.;;Weiland and Anderson, ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",ACTIVE
311,US,B2,US 8805520 B2,168-489-865-374-247,2014-08-12,2014,US 201314043599 A,2013-10-01,US 201314043599 A;;US 201113011917 A;;US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-28),https://lens.org/168-489-865-374-247,Granted Patent,yes,49,1,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/00,607/46,7,7,055-633-804-475-50X;;137-629-505-294-208;;124-115-873-895-429;;027-934-053-698-027;;093-871-073-392-568;;059-350-361-082-031;;009-083-260-830-814,15979027;;10.1016/j.ejpain.2004.11.001;;10.1016/j.neuroscience.2006.02.031;;16631315;;16326140;;10.1016/j.clinph.2005.09.012;;9092847;;10.1097/00006123-199704000-00015;;10.1016/s0304-3959(02)00277-4;;12507704;;16183660;;10.1093/brain/awh631;;10916262;;10.1109/10.846685,"Apkarian A V, Bushnell M C, Treede R D, Zubieta J K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. Aug. 2005;9(4):463-84.;;Drewes A M, Sami S A, Dimcevski G, Nielsen K D, Funch-Jensen P, Valeriani M, Arendt-Nielsen L. ""Cerebral processing of painful oesophageal stimulation. A study based on independent component analysis of the EEG"". Gut. 2005.;;Krause P, Forderreuther S, Straube A. ""TMS motor cortical brain mapping in patients with complex regional pain syndrome type I"". Clin. Neurophysiol. Jan. 2006;117(1 ):169-76. Epub Dec. 2, 2005.;;Kumar et al., ""Deep Brain Stimulation for Intractable Pain: A 15-Year Experience,"" Neurosurgery 40(4): 736-747, Apr. 1997.;;D. Nandi et al.. ""Thalamic field potentials in chronic central pain treated by periventricular gray stimulation-a series of eight cases,"" Pain 101 (2003) 97-107.;;Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. ""Increased EEG power and slowed dominant frequency in patients with neurogenic pain"". Brain. Jan. 2006;129 (pt 1 ):55-64.;;Weiland and Anderson, ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",ACTIVE
312,US,B2,US 9126042 B2,132-646-555-613-505,2015-09-08,2015,US 201414484701 A,2014-09-12,US 201414484701 A;;US 201314059090 A;;US 88114310 A;;US 51778306 A;;US 7266902 A,2002-02-05,Responsive electrical stimulation for movement disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of supplying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/132-646-555-613-505,Granted Patent,yes,35,0,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/00;;A61N1/08;;A61N1/36,,5,4,073-564-567-193-707;;007-661-152-207-362;;067-703-223-786-381;;058-095-107-674-216,10.1002/mds.870131321;;9827607;;10769817;;10.1080/01616412.2000.11740667;;10.1159/000101601;;6977333;;1607973;;10.3171/jns.1992.77.1.0062,"Dilorenzo, ""Optimal Method and Apparatus for Neural Modulation for the Treatment of Neurologic Disease, Particularly Movement Disorders"", U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Benabid et al., ""Long-Term Electrical Inhibition of Deep Brain Targets in Movement Disorders"", Movement Disorders 1998; 13 (Supp. 3) 119-125.;;Gross et al., ""Advances in Neurostimulation for Movement Disorders"", Neurological Research 2000, 22: 247-258.;;Cooper et al., ""Chronic Cerebellar Stimulation (CCS) and Deep Brain Stimulation (DBS) in Involuntary Movement Disorders"", Applied Neurophysiology 1982, 45(3); 209-17.;;Blond et al., ""Control of Tremor and Involuntary Movement Disorders by Chronic Stereotactic Stimulation of the Ventral Intermediate Thalamic Nucleus"", J. neurosurgery 1992.",EXPIRED
313,US,A1,US 2016/0089543 A1,154-825-651-991-68X,2016-03-31,2016,US 201514955978 A,2015-12-01,US 201514955978 A;;US 201313830021 A,2013-03-14,OPTIMIZING DATA RETRIEVAL FROM AN ACTIVE IMPLANTABLE MEDICAL DEVICE,"An external data retrieval apparatus includes a transceiver, and a processing system coupled to the transceiver. The processing system obtains a plurality of measures over a period of time. The measures relate to a quality of a communications channel between the data retrieval apparatus and an active implantable medical device. The processing system determines a trend in the plurality of measures over the period of time, and then determines a preferred time during which to retrieve data based on the trend.",NEUROPACE INC,GREENE DAVID A;;ARCHER STEVE T;;MULLIGAN PATRICK G,NEUROPACE INC (2013-04-10),https://lens.org/154-825-651-991-68X,Patent Application,yes,26,2,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;009-784-087-984-140;;190-321-968-016-483;;154-825-651-991-68X,US,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;154-825-651-991-68X;;190-321-968-016-483;;009-784-087-984-140,US,0,A61N1/37252;;A61N1/36128;;A61N1/37276;;A61N1/37252;;A61N1/37276,A61N1/372,,0,0,,,,ACTIVE
314,US,B2,US 9604061 B2,105-764-066-858-585,2017-03-28,2017,US 201615261822 A,2016-09-09,US 201615261822 A;;US 201514843785 A;;US 88627910 A,2010-09-20,Current management system for a stimulation output stage of an implantable neurostimulation system,"A current management system for use in the stimulation output stage of a neurostimulation system can be programmed to steer different amounts of current through different stimulation electrodes to vary how strongly the tissue adjacent each electrode is stimulated during a particular programmed stimulation episode. An stimulation electrode drive circuit associated with each electrode that is available for stimulation allows independent control of the flow of current through that electrode. A reference electrode is provided in the circuit to source or sink current as necessary to balance the currents going into and out of the patient, so that no stimulation electrode is required to serve that purpose. More specifically, by configuring the circuit to maintain a constant potential at the reference electrode (e.g., a potential that is approximately half way between a top and bottom voltage rail), the reference electrode will source or sink currents as necessary to cause the net current flow into the patient to be equal to the net current flowing out of the patient, thus satisfying Kirchhoff's current law.",NEUROPACE INC,ARCHER STEPHEN T,NEUROPACE INC (2010-09-20),https://lens.org/105-764-066-858-585,Granted Patent,yes,31,9,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;001-779-617-891-279;;030-830-505-406-534;;130-813-226-275-958,US,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;130-813-226-275-958;;001-779-617-891-279;;030-830-505-406-534,US,0,A61N1/36125;;A61N1/3616;;A61N1/36125;;A61N1/3616,A61N1/36,,0,0,,,,ACTIVE
315,US,B2,US 9480847 B2,009-784-087-984-140,2016-11-01,2016,US 201514955960 A,2015-12-01,US 201514955960 A;;US 201313830021 A,2013-03-14,Optimizing data retrieval from an active implantable medical device,"An external data retrieval apparatus includes a transceiver, and a processing system coupled to the transceiver. The processing system obtains a plurality of measures over a period of time. The measures relate to a quality of a communications channel between the data retrieval apparatus and an active implantable medical device. The processing system determines a trend in the plurality of measures over the period of time, and then determines a preferred time during which to retrieve data based on the trend.",NEUROPACE INC,GREENE DAVID A;;ARCHER STEVE T;;MULLIGAN IV PATRICK G,NEUROPACE INC (2013-04-10),https://lens.org/009-784-087-984-140,Granted Patent,yes,24,5,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;009-784-087-984-140;;190-321-968-016-483;;154-825-651-991-68X,US,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;154-825-651-991-68X;;190-321-968-016-483;;009-784-087-984-140,US,0,A61N1/37252;;A61N1/36128;;A61N1/37276;;A61N1/37252;;A61N1/37276,A61N1/372;;H04B7/00;;H04Q5/22;;H04R25/00,,0,0,,,,ACTIVE
316,US,A1,US 2017/0001018 A1,130-813-226-275-958,2017-01-05,2017,US 201615261822 A,2016-09-09,US 201615261822 A;;US 201514843785 A;;US 88627910 A,2010-09-20,CURRENT MANAGEMENT SYSTEM FOR A STIMULATION OUTPUT STAGE OF AN IMPLANTABLE NEUROSTIMULATION SYSTEM,"A current management system for use in the stimulation output stage of a neurostimulation system can be programmed to steer different amounts of current through different stimulation electrodes to vary how strongly the tissue adjacent each electrode is stimulated during a particular programmed stimulation episode. An stimulation electrode drive circuit associated with each electrode that is available for stimulation allows independent control of the flow of current through that electrode. A reference electrode is provided in the circuit to source or sink current as necessary to balance the currents going into and out of the patient, so that no stimulation electrode is required to serve that purpose. More specifically, by configuring the circuit to maintain a constant potential at the reference electrode (e.g., a potential that is approximately half way between a top and bottom voltage rail), the reference electrode will source or sink currents as necessary to cause the net current flow into the patient to be equal to the net current flowing out of the patient, thus satisfying Kirchhoff's current law.",NEUROPACE INC,ARCHER STEPHEN T,NEUROPACE INC (2010-09-20),https://lens.org/130-813-226-275-958,Patent Application,yes,0,1,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;001-779-617-891-279;;030-830-505-406-534;;130-813-226-275-958,US,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;130-813-226-275-958;;001-779-617-891-279;;030-830-505-406-534,US,0,A61N1/36125;;A61N1/3616;;A61N1/36125;;A61N1/3616,A61N1/36,,0,0,,,,ACTIVE
317,US,B2,US 7813802 B2,170-190-765-999-712,2010-10-12,2010,US 51778306 A,2006-09-08,US 51778306 A;;US 7266902 A,2002-02-05,Responsive electrical stimulation for movement disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of applying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/170-190-765-999-712,Granted Patent,yes,8,67,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/00;;A61N1/08;;A61N1/36,607/45,4,4,073-564-567-193-707;;007-661-152-207-362;;067-703-223-786-381;;058-095-107-674-216,10.1002/mds.870131321;;9827607;;10769817;;10.1080/01616412.2000.11740667;;10.1159/000101601;;6977333;;1607973;;10.3171/jns.1992.77.1.0062,"Benabid et al., ""Long-Term Electrical Inhibition of Deep Brain Targets in Movement Disorders,"" Movement Disorders 1998; 13(Supp. 3) 119-125.;;Gross et al., ""Advances in Neurostimulation for Movement Disorders,"" Neurological Research 2000, 22: 247-258.;;Cooper et al., ""Chronic Cerebellar Stimulation (CCS) and Deep Brain Stimulation (DBS) in Involuntary Movement Disorders,"" Applied Neurophysiology 1982, 45(3): 209-17.;;Blond, et al., ""Control of Tremor and Involuntary Movement Disorders by Chronic Stereotactic Stimulation of the Ventral Intermediate Thalamic Nucleus,"" J. Neurosurgery 1992, 77: 62-68.",EXPIRED
318,US,A1,US 2014/0379046 A1,105-437-830-931-437,2014-12-25,2014,US 201414484701 A,2014-09-12,US 201414484701 A;;US 201314059090 A;;US 88114310 A;;US 51778306 A;;US 7266902 A,2002-02-05,RESPONSIVE ELECTRICAL STIMULATION FOR MOVEMENT DISORDERS,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of supplying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/105-437-830-931-437,Patent Application,yes,0,17,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/36;;A61N1/08,607/48,0,0,,,,EXPIRED
319,US,A1,US 2011/0028859 A1,097-379-964-340-906,2011-02-03,2011,US 55224709 A,2009-09-01,US 55224709 A;;US 23067709 P,2009-07-31,"Methods, Systems and Devices for Monitoring a Target in a Neural System and Facilitating or Controlling a Cell Therapy","Methods, systems and devices for monitoring a target in a neural system involve delivering inputs to and recording output responses from the neural system and obtaining I/O characterizations of the neural system both before and during or after a change is introduced to the system, for example, a change associated with a stem cell therapy. Baseline and therapeutic I/O characterizations are compared, and interpretations of the results of the comparison may be used to adjust some aspect of the therapy to facilitate it or control it. An implantable neurostimulator with the capability of delivering electrical stimulation to an electrode and of measuring and recording responses sensed from electrodes, where the electrodes are strategically positioned at or near the target, can be used to deliver an electrical stimulation input and record the output responses for the I/O characterizations. An implantable neurostimulator also may be used to affect a cell therapy by delivering electrical stimulation to the neural system to encourage stem cell differentiation.",NEUROPACE INC,CHIAN MARTIN TSUPON,NEUROPACE INC (2009-09-01),https://lens.org/097-379-964-340-906,Patent Application,yes,15,129,1,097-379-964-340-906,US,1,097-379-964-340-906,US,0,A61B5/6814;;A61B5/24;;A61B5/4064;;A61B5/6846;;A61N1/205;;A61N1/326;;A61N1/37235;;A61B5/24;;A61B5/4064;;A61B5/6814;;A61B5/6846;;A61N1/205;;A61N1/326;;A61N1/37235,A61B5/05,600/554,5,5,046-362-959-622-107;;003-780-349-259-461;;038-877-976-698-595;;083-058-895-781-437;;150-376-976-343-510,10.1103/physreve.73.051908;;16802968;;10.1152/jn.00593.2004;;15496488;;7086472;;10.1152/jn.1982.47.5.845;;9316014;;10.1016/s0306-4522(97)00330-8;;12614396;;10.1046/j.1528-1157.2003.25702.x,"Aviel and Gerstner (2006) ""from spiking neurons to rate models: a cascade model as an approximation to spiking neuron models with refractoriness"" Physical Review E73:051908(1-10);;Feng and Durand. 2005 ""Decrease in synaptic transmission can reverse the propagation direction of epilptiform activity in hippocampus in vivo"" J.Neurophysiol 93:1158-1164;;Leung. 1982 ""Nonlinear Feedback model of neuronal populations in hippocampal CA1 region"" J.Neurophysiol 47(5):845-868;;Sinden et al. 1997 ""Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neuroepithelial cell line into the ischaemia-lesioned hippocampus"" Neuroscience 81(3):599-608;;Konermann et al. 2003 ""Presurgical evaluation of epilepsy by brain diffusion: MR-detected effects of flumazenil on the eplieptogenic focus"" Epilepsia 44(3):399-407",DISCONTINUED
320,US,A1,US 2015/0375000 A1,001-779-617-891-279,2015-12-31,2015,US 201514843785 A,2015-09-02,US 201514843785 A;;US 88627910 A,2010-09-20,CURRENT MANAGEMENT SYSTEM FOR A STIMULATION OUTPUT STAGE OF AN IMPLANTABLE NEUROSTIMULATION SYSTEM,"A current management system for use in the stimulation output stage of a neurostimulation system can be programmed to steer different amounts of current through different stimulation electrodes to vary how strongly the tissue adjacent each electrode is stimulated during a particular programmed stimulation episode. An stimulation electrode drive circuit associated with each electrode that is available for stimulation allows independent control of the flow of current through that electrode. A reference electrode is provided in the circuit to source or sink current as necessary to balance the currents going into and out of the patient, so that no stimulation electrode is required to serve that purpose. More specifically, by configuring the circuit to maintain a constant potential at the reference electrode (e.g., a potential that is approximately half way between a top and bottom voltage rail), the reference electrode will source or sink currents as necessary to cause the net current flow into the patient to be equal to the net current flowing out of the patient, thus satisfying Kirchhoff's current law.",NEUROPACE INC,ARCHER STEPHEN T,NEUROPACE INC (2010-09-20),https://lens.org/001-779-617-891-279,Patent Application,yes,1,0,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;001-779-617-891-279;;030-830-505-406-534;;130-813-226-275-958,US,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;130-813-226-275-958;;001-779-617-891-279;;030-830-505-406-534,US,0,A61N1/36125;;A61N1/3616;;A61N1/36125;;A61N1/3616,A61N1/36,,0,0,,,,ACTIVE
321,US,A1,US 2016/0089544 A1,190-321-968-016-483,2016-03-31,2016,US 201514955960 A,2015-12-01,US 201514955960 A;;US 201313830021 A,2013-03-14,OPTIMIZING DATA RETRIEVAL FROM AN ACTIVE IMPLANTABLE MEDICAL DEVICE,"An external data retrieval apparatus includes a transceiver, and a processing system coupled to the transceiver. The processing system obtains a plurality of measures over a period of time. The measures relate to a quality of a communications channel between the data retrieval apparatus and an active implantable medical device. The processing system determines a trend in the plurality of measures over the period of time, and then determines a preferred time during which to retrieve data based on the trend.",NEUROPACE INC,GREENE DAVID A;;ARCHER STEVE T;;MULLIGAN PATRICK G,NEUROPACE INC (2013-04-10),https://lens.org/190-321-968-016-483,Patent Application,yes,9,5,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;009-784-087-984-140;;190-321-968-016-483;;154-825-651-991-68X,US,6,197-067-125-473-719;;046-522-419-858-936;;041-128-493-892-027;;154-825-651-991-68X;;190-321-968-016-483;;009-784-087-984-140,US,0,A61N1/37252;;A61N1/36128;;A61N1/37276;;A61N1/37252;;A61N1/37276,A61N1/372,,0,0,,,,ACTIVE
322,US,B2,US 9186508 B2,167-729-015-656-17X,2015-11-17,2015,US 201314059090 A,2013-10-21,US 201314059090 A;;US 88114310 A;;US 51778306 A;;US 7266902 A,2002-02-05,Responsive electrical stimulation for movement disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of supplying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/167-729-015-656-17X,Granted Patent,yes,36,0,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/36;;A61N1/08,,5,4,073-564-567-193-707;;007-661-152-207-362;;067-703-223-786-381;;058-095-107-674-216,10.1002/mds.870131321;;9827607;;10769817;;10.1080/01616412.2000.11740667;;10.1159/000101601;;6977333;;1607973;;10.3171/jns.1992.77.1.0062,"Dilorenzo, ""Optimal Method and Apparatus for Neural Modulation for the Treatment of Neurologic Disease, Particularly Movement Disorders"", U.S. Appl. No. 60/095,413, Aug. 5, 1998.;;Benabid et al., ""Long-Term Electrical Inhibition of Deep Brain Targets in Movement Disorders"", Movement Disorders 1998; 13 (Supp. 3) 119-125.;;Gross et al., ""Advances in Neurostimulation for Movement Disorders"", Neurological Research 2000, 22: 247-258.;;Cooper et al., ""Chronic Cerebellar Stimulation (CCS) and Deep Brain Stimulation (DBS) In Involuntary Movement Disorders"", Applied Neurophysiology 1982, 45(3); 209-17.;;Blond et al., ""Control of Tremor and Involuntary Movement Disorders By Chronic Stereotactic Stimulation of the Ventral Intermediate Thalamic Nucleus"", J. neurosurgery 1992.",EXPIRED
323,US,B2,US 10543360 B2,106-493-320-643-438,2020-01-28,2020,US 201715721539 A,2017-09-29,US 201715721539 A;;US 201715721574 A,2017-09-29,"Lead fixation accessory, lead stabilization tool, and related procedures",A lead fixation accessory configured to be positioned over a skull hole and to transition between an opened state and a closed state during a lead implant procedure protects against lead migration by providing a mechanism for securing the lead in place at the skull hole while a stylet is removed from the lead. The lead fixation accessory remains in place after the implant procedure to provide chronic lead stability. A lead stabilization tool configured to access and grip a lead through a slotted cannula during the lead implant procedure also protects against lead migration by providing a mechanism for securing the lead in place at a point where the lead exits the skull hole while the slotted cannula is removed from the skull hole and peeled away from the lead.,NEUROPACE INC,MIRRO EMILY A;;MANDELL JACOB A;;GREENE DAVID A,NEUROPACE INC (2017-10-04),https://lens.org/106-493-320-643-438,Granted Patent,yes,54,0,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,0,A61B90/11;;A61B17/221;;A61B17/688;;A61B17/7055;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0534;;A61B17/221;;A61B17/3468;;A61B17/688;;A61B17/7055;;A61B17/7065;;A61B17/88;;A61B90/11;;A61B2017/0046;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0539,A61N1/05;;A61B17/00;;A61B17/34;;A61B17/70;;A61B17/88,,4,1,038-757-509-977-927,pmc4852184;;10.7759/cureus.549;;27158578,"Biomet MiICROFIXATION. Neuroimplant System. Product Brochure (2013).;;Aesculap Inc. Cranial Fixation Systems. Product Brochure (2014).;;Miller et al. “Stereotactic bony trajectory preservation for responsive neurostimulator lead placement following depth EEG recording.” Cureus 8(3):3549. DOI 10.7759/cureus.549 (Mar. 30, 2016).;;Synthes CMF. “MatrixNEURO. The next generation cranial plating system.” Product Brochure (2006).",ACTIVE
324,US,A1,US 2014/0046399 A1,080-251-560-840-218,2014-02-13,2014,US 201314059090 A,2013-10-21,US 201314059090 A;;US 88114310 A;;US 51778306 A;;US 7266902 A,2002-02-05,RESPONSIVE ELECTRICAL STIMULATION FOR MOVEMENT DISORDERS,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of supplying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/080-251-560-840-218,Patent Application,yes,1,0,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/36;;A61N1/08,607/48,0,0,,,,EXPIRED
325,US,A1,US 2003/0149457 A1,143-023-518-199-534,2003-08-07,2003,US 7266902 A,2002-02-05,US 7266902 A,2002-02-05,Responsive electrical stimulation for movement disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of applying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/143-023-518-199-534,Patent Application,yes,1,302,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/08;;A61N1/36,607/48,0,0,,,,EXPIRED
326,US,A1,US 2011/0004268 A1,081-820-476-794-734,2011-01-06,2011,US 88114310 A,2010-09-13,US 88114310 A;;US 51778306 A;;US 7266902 A,2002-02-05,Responsive Electrical Stimulation for Movement Disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of supplying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/081-820-476-794-734,Patent Application,yes,34,21,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/36;;A61N1/08,607/45,0,0,,,,EXPIRED
327,US,B2,US 8543208 B2,081-232-848-294-052,2013-09-24,2013,US 55495909 A,2009-09-07,US 55495909 A;;US 6004502 A,2002-01-29,Systems and methods for interacting with an implantable medical device,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M;;NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/081-232-848-294-052,Granted Patent,yes,7,9,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61N1/00;;A61B5/375;;A61N1/36;;A61N1/372,607/32,18,10,124-403-369-942-149;;007-553-739-295-906;;040-286-722-085-497;;112-169-644-935-501;;045-607-627-273-154;;035-148-804-864-21X;;054-255-897-176-362;;020-615-646-149-653;;044-769-545-418-781;;066-017-182-270-154,52443;;10.1016/0013-4694(75)90051-6;;8641236;;10.1111/j.1528-1157.1996.tb00612.x;;10.1111/j.1528-1157.1998.tb01278.x;;9578017;;7588453;;10.1111/j.1528-1157.1995.tb00467.x;;1556879;;10.1097/00005650-199204000-00002;;10.1111/j.1528-1157.2000.tb02220.x;;11156511;;10.1176/jnp.11.4.464;;10570759;;10.1176/ps.39.4.389;;3286472;;1627969;;10.1176/jnp.4.1.85;;10.1111/j.1528-1157.1980.tb04053.x;;7358037,"http://www.medtronic.com/physician/activa ""ACTIVA Therapy Overview"" 1996.;;http://www.siumed.edu/neuro/epilepsy/news/pressreleases/VNSpress.html, ""Cyberonics Inc. Receives FDA Approval to Market NeuroCybernetic Prosthesis System for the Treatment of Epilepsy"" Jul. 16, 1997.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. 1975; 39(5): 499-506.;;Sherman, D., ""High-Tech Heart Devices Deliver Data Over the Web,"" Reuters News Service (Aug. 8, 2001).;;MedSearch Technologies, Inc., ""MedSearch Technologies, Inc. Develops a Revolutionary Home-Care Wireless Technology Utilizing PDAs-Personal Organizers-As Patient Monitors,"" Business Wire (Sep. 25, 2000).;;Emerson, D., ""Technology Puts Help on the Line,"" Minneapolis-St. Paul Business Journal (Dec. 17, 1999).;;""Quality of Life in Epilepsy Inventory: QOLIE-10, Patient Inventory"" Professional Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-31 (Version 1.0), Scoring Manual and Patient Inventory,"" Professional Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-89 (Version 1.0), Scoring Manual and Patient Inventory,"" Professional Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Cramer, J.A., et al., ""A Brief Questionnaire to Screen for Quality of Life in Epilepsy: The QOLIE-10,"" Epilepsia (1996) 37(6): 577-582.;;Cramer, J., et al., ""Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory,"" Epilepsia (1998) 39(1): 81-88.;;Devinsky, Orrin, et al., ""Development of Quality of Life in Epilepsy Inventory,"" Epilepsia (1995) 36(11): 1089-1104.;;Vickrey, B., et al., ""A Health-Related Quality of Life Instrument for Patients Evaluated for Epilepsy Surgery,"" Medical Care (Apr. 1992), vol. 30, No. 4, pp. 299-319.;;Onuma, T., ""Symposium II: Classification of Psychiatric Symptoms in Patients with Epilepsy,"" Epilepsia (2000) 41 (Suppl. 9): 43-48.;;Lopez-Rodriguez, F., et al., ""Personality Disorders Among Medically Refractory Epileptic Patients,"" J. Neuropsychiatry Clin. Neurosci. (Fall 1999) 11(4): 464-469.;;Neppe, V. M., et al., ""Modern Perspectives on Epilepsy in Relation to Psychiatry: Behavioral Disturbances of Epilepsy,"" Hospital and Community Psychiatry (Apr. 1988) 39(4): 389-396.;;Neppe, V. M., et al., ""The Application of the Screening Cerebral Assessment of Neppe (Brocas Scan) to a Neuropsychiatric Population,"" Journal of Neuropsychiatry (Winter 1992) 4: 85-94.;;Dodrill, C.B., et al., ""An Objective Method for the Assessment of Psychological and Social Problems Among Epileptics,"" Epilepsia (1980) 21: 123-135.",EXPIRED
328,US,B2,US 8140160 B2,081-277-491-487-95X,2012-03-20,2012,US 43619006 A,2006-05-16,US 43619006 A;;US 6004502 A,2002-01-29,Systems and methods for interacting with an implantable medical device,"An interactive implantable medical device system includes an implantable medical device and a network-enabled external device capable of bi-directional communication and interaction with the implantable medical device. The external device is programmed to interact with other similarly-enabled devices. The system facilitates improved patient care by eliminating unnecessary geographic limitations on implantable medical device interrogation and programming, and by allowing patients, physicians, and other users to access medical records, history, and information and to receive status and care-related alerts and messages anywhere there is access to a communications network.",PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M;;NEUROPACE INC,PLESS BENJAMIN D;;FISCHELL DAVID R;;GIBB BARBARA;;GUZZO LISA;;UPTON ADRIAN R M,NEUROPACE INC (2002-05-28),https://lens.org/081-277-491-487-95X,Granted Patent,yes,7,159,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;081-277-491-487-95X;;160-623-908-763-861;;087-010-039-049-094,US,12,194-566-808-486-145;;173-509-107-841-842;;132-566-702-920-354;;093-696-327-167-745;;081-232-848-294-052;;167-692-945-162-794;;092-603-879-602-870;;000-621-022-112-807;;196-978-125-358-316;;160-623-908-763-861;;081-277-491-487-95X;;087-010-039-049-094,US,0,A61N1/36135;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282;;G16H20/40;;G16H40/63;;G16H40/67;;A61N1/36135;;A61B5/0006;;A61B5/0031;;A61B5/076;;A61B5/293;;A61B5/375;;A61B5/4094;;A61B5/686;;A61B5/742;;A61B5/7475;;A61N1/36064;;A61N1/37252;;A61N1/37258;;A61N1/37282,A61N1/36;;A61B5/375;;A61N1/372,607/31;;607/27;;607/59,18,10,124-403-369-942-149;;007-553-739-295-906;;040-286-722-085-497;;112-169-644-935-501;;045-607-627-273-154;;035-148-804-864-21X;;054-255-897-176-362;;020-615-646-149-653;;044-769-545-418-781;;066-017-182-270-154,52443;;10.1016/0013-4694(75)90051-6;;8641236;;10.1111/j.1528-1157.1996.tb00612.x;;10.1111/j.1528-1157.1998.tb01278.x;;9578017;;7588453;;10.1111/j.1528-1157.1995.tb00467.x;;1556879;;10.1097/00005650-199204000-00002;;10.1111/j.1528-1157.2000.tb02220.x;;11156511;;10.1176/jnp.11.4.464;;10570759;;10.1176/ps.39.4.389;;3286472;;1627969;;10.1176/jnp.4.1.85;;10.1111/j.1528-1157.1980.tb04053.x;;7358037,"http://www.medtronic.com/physician/activa ""ACTIVA Therapy Overview"" 1996.;;http://www.siumed.edu/neuro/epilepsy/news/pressreleases/VNSpress.html, ""Cyberonics Inc. Receives FDA Approval to Market NeuroCybernetic Prosthesis System for the Treatment of Epilepsy"" Jul. 16, 1997.;;Wagner, H.R., et al., ""Suppression of Cortical Epileptiform Activity by Generalized and Localized ECoG Desynchronization,"" Electroencephalogr. Clin. Neurophysiol. 1975; 39(5): 499-506.;;Sherman, D., ""High-Tech Heart Devices Deliver Data Over the Web,"" Reuters News Service (Aug. 8, 2001).;;Medsearch Technologies, Inc., ""MedSearch Technologies, Inc. Develops a Revolutionary Home-Care Wireless Technology Utilizing PDAs-Personal Organizers-As Patient Monitors,"" Business Wire (Sep. 25, 2000).;;Emerson, D., ""Technology Puts Help on the Line,"" Minneapolis-St. Paul Business Journal (Dec. 17, 1999).;;""Quality of Life in Epilepsy Inventory: QOLIE-10, Patient Inventory"" Professional Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-31 (Version 1.0), Scoring Manual and Patient Inventory,"" Professional Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Vickrey, B. et al., ""Quality of Life in Epilepsy QOLIE-89 (Version 1.0), Scoring Manual and Patient Inventory,"" Professional Postgraduate Services, a Division of Physician's World Communications Group (1993).;;Cramer, J.A., et al., ""A Brief Questionnaire to Screen for Quality of Life in Epilepsy: The QOLIE-10,"" Epilepsia (1996) 37(6): 577-582.;;Cramer, J., et al., ""Development and Cross-Cultural Translations of a 31-Item Quality of Life in Epilepsy Inventory,"" Epilepsia (1998) 39(1): 81-88.;;Devinsky, Orrin, et al., ""Development of Quality of Life in Epilepsy Inventory,"" Epilepsia (1995) 36(11): 1089-1104.;;Vickrey, B., et al., ""A Health-Related Quality of Life Instrument for Patients Evaluated for Epilepsy Surgery,"" Medical Care (Apr. 1992), vol. 30, No. 4, pp. 299-319.;;Onuma, T., ""Symposium II: Classification of Psychiatric Symptoms in Patients with Epilepsy,"" Epilepsia (2000) 41 (Suppl. 9): 43-48.;;Lopez-Rodriguez, F., et al., ""Personality Disorders Among Medically Refractory Epileptic Patients,"" J. Neuropsychiatry Clin. Neurosci. (Fall 1999) 11(4): 464-469.;;Neppe, V. M., et al., ""Modern Perspectives on Epilepsy in Relation to Psychiatry: Behavioral Disturbances of Epilepsy,"" Hospital and Community Psychiatry (Apr. 1988) 39(4): 389-396.;;Neppe, V. M., et al., ""The Application of the Screening Cerebral Assessment of Neppe (BROCAS SCAN) to a Neuropsychiatric Population,"" Journal of Neuropsychiatry (Winter 1992) 4: 85-94.;;Dodrill, C.B., et al., ""An Objective Method for the Assessment of Psychological and Social Problems Among Epileptics,"" Epilepsia (1980) 21: 123-135.",EXPIRED
329,US,B2,US 8761889 B2,149-328-370-535-76X,2014-06-24,2014,US 23429708 A,2008-09-19,US 23429708 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","A method is disclosed for conveying a form of neuromodulation (e.g., electrical, chemical, optical, or thermal) from an external neuromodulation source interiorly of the skull to modulate neural activity. The method involves forming one or more apertures through or partially through the skull to provide an interface for delivering the neuromodulation. A method is disclosed for sensing one or more parameters characteristic of one or more states of the brain through an interface formed with one or more apertures extending all the way or part of the way through the skull. A device is disclosed that is implantable in the skull of a human patient to provide an interface between the exterior of the skull and the brain that includes a channel of a length sufficient to traverse the entire thickness of the skull or at least a part of the thickness of the skull. The channels may be provided in a wide variety of shapes and sizes with or without inner lumens. The channels may be configured for ion conduction of electrical signals, enabling DC or near DC stimulation of target neurons. Methods and devices for transferring energy (e.g., thermal energy) generated inside the skull to the outside of the skull and vice versa are also disclosed.",WINGEIER BRETT;;PLESS BENJAMIN;;NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/149-328-370-535-76X,Granted Patent,yes,45,37,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/18,607/45;;607/116,51,36,005-290-287-801-26X;;011-472-054-292-323;;003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;011-472-054-292-323,18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18096677;;10.1136/jnnp.2007.135277,"International Preliminary Examination Report (IPER) for counterpart International Application PCT/US08/0816555, date of mailing May 14, 2010.;;Floel, A., et al., ""Noninvasive Brain Stimulation Improves Language Learning"" (Aug. 2008) J. Cognitive Neuroscience 20(8): 1415-1422.;;Monti, A., et al., ""Improved Naming After Transcranial Direct Current Simulation in Aphasia"" (first published Dec. 20, 2007) J. Neurol. Neurosurg. Psychiatry 79(4): 451-453.;;Besio et al., Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilepsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, J. Physiol. 557:175-190.;;Boggio et al. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Disord. 101:91-98.;;Clay et al., Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke, 2002, IEEE Trans. Med. Imaging 21:629-637.;;Fregni et al., Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21:1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilepsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS, 2007, Nat. Clin. Pract. Neurol. 3:383-393.;;Goodman et al., Low Frequency Sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilepsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilepsia 46:1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-875.;;Karkar et al., Focal cooling suppresses spontaneous epileptiform activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, J. Neurosci. 24:9985-9992, as corrected in J. Neurosci. 25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy, NIH Protocol No. 06-N-0187, www.clinialstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. Clin. Neurophysiol. 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez et al., Comparison of high resolution EEG methods having different theoretical bases, 1993, Brain Topogr. 5:361-364.;;Nunez et al., A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol. 90:40-57.;;Rhee et al., Clinical experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A Therapy for Intractable Neocortical Epilepsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh et al., Blood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic transcranial surgery and echographic imaging, 2005, J. Acoustical Soc. Amer. 118(3):1941.;;Trivedi, Electrify Your Mind, The New Scientist (2547), www.tmcnet.com/usubmit/2006/04/14/1573554.htm updated 2006.;;Medtronic Sofamor Danek, The METRx(TM) X-Tube(TM) Retraction System, www.sofamordanek.com/patient-minimal-metrx-xtube.html updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;""Office Action (Non-Final Rejection) mailed Jul. 5, 2012 for U.S. Appl. No. 11/929,801"".;;""Office Action (Non-Final Rejection) mailed Nov. 10, 2011 for U.S. Appl. No. 12/243,733"".;;""Office Action (Restriction) mailed Sep. 23, 2011 for U.S. Appl. No. 12/243,733"".;;""Office Action (Final Rejection) mailed Apr. 16, 2012 for U.S. Appl. No. 12/243,733"".;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009).;;Fregni et al., Transient tinnitus suppression induced by repetitive transcranial magnetic stimulation and transcranial direct current stimulation, 2006, Eur. J. Neurol. 13:996-1001.;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
330,US,B2,US 8131352 B2,165-987-529-594-438,2012-03-06,2012,US 76557407 A,2007-06-20,US 76557407 A,2007-06-20,System and method for automatically adjusting detection thresholds in a feedback-controlled neurological event detector,"Methods and systems for detecting neurological events and approximating a target detection rate are disclosed. A target detection rate may be identified for the neurological event. Electrographic signals incident on a neurological event detector may be monitored. Each signal may be compared to a threshold value for a parameter. As the threshold value varies, it has a predictable effect on a detection rate of the neurological event. A rate at which the electrographic signals exceed the threshold value may be measured and compared to the target detection rate. The threshold value may be adjusted to minimize the difference between the measured detection rate and the target detection rate.",GREENE DAVID A;;NEUROPACE INC,GREENE DAVID A,NEUROPACE INC (2007-06-15),https://lens.org/165-987-529-594-438,Granted Patent,yes,24,7,2,165-987-529-594-438;;113-215-911-780-104,US,2,165-987-529-594-438;;113-215-911-780-104,US,0,A61B5/4094;;A61B5/369;;A61B5/369;;A61B5/4094,A61B5/04,600/544;;600/545,6,4,083-661-822-506-828;;021-047-329-953-211;;166-048-352-638-36X;;143-388-558-467-689,6184684;;10.1111/j.1540-8159.1982.tb06564.x;;8945046;;10.1111/j.1540-8159.1996.tb03230.x;;7978723;;10.7326/0003-4819-121-12-199412150-00010;;10.1016/0013-4694(90)90032-f;;1699724,"Wirtzfeld et al, Central venous oxygen saturation for the control of automatic rate-responsive pacing, 1982, Pacing Clin. Electrophysiology 5(6):829-835.;;Gentzler et al., Automatic Sensor Adjustment in a Rate Modulated Pacemaker, 1996, Pacing and Clinical Electrophysiology 19(11):1809-1812.;;Benditt et al., Multiple-Sensor Systems for Physiologic Cardiac Pacing, 1994, Annals of Internal Med. 121(12):960-968.;;Guyton, Textbook of Medical Physiology 659, 8th ed., W.B. Saunders Company, Philadelphia, 1991 (TOC).;;Gotman, Automatic Seizure Detection: Improvements and Evaluation, 1990, Electroencephalogr. Clin. Neurophysiol. 76(4):317-324.;;U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.",ACTIVE
331,US,B2,US 9179850 B2,019-987-983-357-455,2015-11-10,2015,US 92980107 A,2007-10-30,US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","A form of neuromodulation is conveyed from an external source to an interior of the skull to modulate neural activity. One or more apertures are formed through or partially through the skull to provide an interface for neuromodulation delivery. Parameters of one or more states of the brain may be sensed through an interface formed with one or more apertures extending all or part of the way through the skull. A device provides an interface between the exterior of the skull and the brain that includes a channel of a length sufficient to traverse the entire thickness of the skull or at least a part of the thickness of the skull. The channels may be configured for ion conduction of electrical signals, enabling DC or near DC stimulation of target neurons.",WINGEIER BRETT;;PLESS BENJAMIN;;NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/019-987-983-357-455,Granted Patent,yes,53,30,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/05;;A61B5/04;;A61B5/0478;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,,94,71,011-908-987-650-668;;003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;059-312-847-088-030;;042-747-937-499-103;;005-290-287-801-26X;;011-472-054-292-323;;003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;006-722-904-453-663;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;042-747-937-499-103;;011-908-987-650-668;;011-472-054-292-323;;011-472-054-292-323,10.1111/j.1468-1331.2006.01414.x;;16930367;;17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;10.1121/1.4781082;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;15634731;;10.1093/brain/awh369;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;10.1111/j.1468-1331.2006.01414.x;;16930367;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277,"PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US208/081655 Apr. 16, 2009.;;Grill, W., ""Noninvasive Brain Stimulation Emerges As Treatment,"" NeuroTech Business Reports, Aug. 2007.;;Fregni, F. et al., ""Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation"" (2006), European J. Neurol. 13: 996-1001.;;Besio WG, Koka K, Cole AJ. ""Effects of Noninvasive Transcutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats"". Epilepsia 2007. (Published article online: Jul. 25, 2007).;;Bikson M, Inoue M, Akiyama H et al. ""Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro"". J Physiol 2004; 557: 175-190.;;Boggio PS, Rigonatti SP, Ribeiro RB et al. ""A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression"". Int.J Neuropsychopharmacol. 2007; 1-6.;;Boggio PS, Sultani N, Fecteau S et al. ""Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study"". Drug Alcohol Depend. 2007. Available online Jul. 19, 2007.;;Boggio PS, Bermpohl F, Vergara AO et al. ""Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression"". J Affect.Disord. 2007; 101: 91-98.;;Clay MT, Ferree TC. ""Weighted regularization in electrical impedance tomography with applications to acute cerebral stroke"". IEEE Trans.Med.Imaging 2002; 21: 629-637.;;Fregni F, Boggio PS, Nitsche M et al. ""Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory"". Exp.Brain Res. 2005; 166: 23-30.;;Fregni F, Boggio PS, Mansur CG et al. ""Transcranial direct current stimulation of the unaffected hemisphere in stroke patients"". Neuroreport 2005; 16: 1551-1555.;;Fregni F, Boggio PS, Santos MC et al. ""Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease"". Mov Disord. 2006; 21: 1693-1702.;;Fregni F, Thome-Souza S, Nitsche MA, Freedman SD, Valente KD, Pascual-Leone A. ""A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy"". Epilepsia 2006; 47: 335-342.;;Fregni F, Boggio PS, Lima MC et al. ""A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury"". Pain 2006; 122: 197-209.;;Fregni F, Pascual-Leone A. ""Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS"". Nat.Clin Pract.Neurol. 2007; 3: 383-393.;;Goodman, J.H., et al., ""Low Frequency Sine Wave Stimulation Decreases Seizure Frequency in Amygdala-Kindled Rats."" Epilepsia 2002; 43(S7): 10.;;Goodman JH, Berger RE, Tcheng TK. ""Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures"". Epilepsia 2005; 46: 1-7.;;Grill Wm. ""Safety considerations for deep brain stimulation: review and analysis"". Expert.Rev Med.Devices 2005; 2: 409-420.;;Hebden JC, Gibson A, Yusof RM et al. ""Three-dimensional optical tomography of the premature infant brain"". Phys.Med.Biol. 2002; 47: 4155-4166.;;Hummel F, Celnik P, Giraux P et al. ""Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke"". Brain 2005; 128: 490-499.;;Hummel FC, Voller B, Celnik P et al. ""Effects of brain polarization on reaction times and pinch force in chronic stroke"". BMC.Neurosci. 2006; 7: 73.;;Iyer MB, Mattu U, Grafman J, Lomarev M, Sato S, Wassermann EM. ""Safety and cognitive effect of frontal DC brain polarization in healthy individuals"". Neurology 2005; 64: 872-875.;;Karkar KM, Garcia PA, Bateman LM, Smyth MD, Barbaro NM, Berger M. ""Focal cooling suppresses spontaneous epileptiform activity without changing the cortical motor threshold"". Epilepsia 2002; 43: 932-935.;;Kennedy, P., ""Brain-O-Matic."" ""Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for The 'Brain Pod',"" The Phoenix, Feb. 7, 2007. available at: http://thephoenix.com/article-ektid33313.aspx, last updated Feb. 7, 2007.;;Lu M, Thorlin T, Ueno S, Persson M. ""Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model"" PIERS Online 2007; 3: 178-183.;;Marshall L, Molle M, Hallschmid M, Born J. ""Transcranial direct current stimulation during sleep improves declarative memory"". J Neurosci. 2004; 24: 9985-9992. as corrected in J. Neurosci. 25(2).;;Marshall L, Molle M, Siebner HR, Born J. ""Bifrontal transcranial direct current stimulation slows reaction time in a working memory task"". BMC.Neurosci. 2005; 6: 23.;;Merrill DR, Bikson M, Jefferys JG. ""Electrical stimulation of excitable tissue: design of efficacious and safe protocols"". J Neurosci.Methods 2005; 141: 171-198.;;National Institute of Neurological Disorders and Stroke, ""Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy-NIH Protocol Number: 06-N-0187."" available at: http://clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html, last updated 2006.;;Nitsche MA, Liebetanz D, Antal A, Lang N, Tergau F, Paulus W. ""Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects"". Suppl Clin Neurophysiol 2003; 56: 255-276.;;Nitsche MA, Doemkes S, Karakose T et al. ""Shaping the effects of transcranial direct current stimulation of the human motor cortex"". J Neurophysiol 2007; 97: 3109-3117.;;Nunez PL, Silberstein RB, Cadusch PJ, Wijesinghe R. ""Comparison of high resolution EEG methods having different theoretical bases"". Brain Topogr. 1993; 5: 361-364.;;Nunez PL, Silberstein RB, Cadusch PJ, Wijesinghe RS, Westdorp AF, Srinivasan R. ""A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging"". Electroencephalogr.Clin Neurophysiol 1994; 90: 40-57.;;Rhee SY, Chon S, Koh G et al. ""Clinical experience of an iontophoresis based glucose measuring system"". J Korean Med.Sci. 2007; 22: 70-73.;;Rothman S, Yang XF. ""Local Cooling: A Therapy for Intractable Neocortical Epilepsy"". Epilepsy Curr. 2003; 3: 153-156.;;Srinivasan R. ""Methods to Improve the Spatial Resolution of EEG"". International Journal of Bioelectromagnetism 1999; 1: 102-111.;;Suh M, Bahar S, Mehta AD, Schwartz TH. ""Blood volume and hemoglobin oxygenation response following electrical stimulation of human cortex"". Neuroimage. 2006; 31: 66-75.;;Sukstanskii AL, Yablonsky DA. ""An analytical model of temperature regulation in human head"". Journal of Thermal Biology 2004; 29: 583-587.;;Tanter, M., Aubry, J. F., Vignon, F., and Fink, M.""Time reversal for ultrasonic transcranial surgery and echographic imaging."" The Journal of the Acoustical Society of America 2005; 118(3): 1941.;;Trivedi, B. Electrify Your Mind. The New Scientist (2547). available at: http://www.tmcnet.com/usubmit/2006/04/14/1573554.htm, last updated 2006.;;Medtronic Sofamor Danek. ""The METRx(TM) X-Tube(TM) Retraction System."" available at: http://www.sofamordanek.com/patient-minimal-metrx-xtube.html, last updated Jun. 19, 2003.;;Deisseroth K, Feng G, Majewska AK, Miesenbock G, Ting A, Schnitzer MJ. ""Next-generation optical technologies for illuminating genetically targeted brain circuits"". J Neurosci. 2006; 26: 10380-10386.;;International Preliminary Examination Report (IPER) for counterpart PCT Application PCT/US2008/081655.;;Floel, A et al., ""Noninvasive Brain Stimulation Improves Language Learning"", Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti, et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"", Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online, (Sep. 26, 2008).;;Cappa, S. F. ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"", (Sep. 26, 2008), comment on MONTI et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;Office Action (Non-Final Rejection) mailed Jul. 5, 2012 for U.S. Appl. No. 11/929,801.;;Office Action (Non-Final Rejection) mailed Nov. 10, 2011 for U.S. Appl. No. 12/243,733.;;Office Action (Restriction) mailed Sep. 23, 2011 for U.S. Appl. No. 12/243,733.;;Office Action (Final Rejection) mailed Apr. 16, 2012 for U.S. Appl. No. 12/243,733.;;Besio et al., Effects of Noninvasive Transutaneous Electrical Stimulation via Concentric Ring Electrodes on Pilocarpine-induced Status Epilepticus in Rats, Epilespsia, published online Jul. 25, 2007.;;Bikson et al., Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro, 2004, j. physiol. 557:175-190.;;Boggio et al., A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression, 2007, Int. J. Neurophyschopharmacol, 1-6.;;Boggio et al., Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study, Drug Alcohol Depend, published online Jul. 19, 2007.;;Boggio et al., Go-no-go task performance improvement after anodal transcranial DC stimulation of the left dorsolateral prefrontal cortex in major depression, 2007, J. Affect. Discord. 101:91-98.;;Clay, et al., Weighted regularization in electrical impedance tomography with application to acute cerebral stroke, 2002, IEEE Trans, Med. Imaging 21:629-637.;;Fregni et al., Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory, 2005, Exp. Brain Res. 166:23-30.;;Fregni et al., Transcranial direct current stimulation of the unaffected hemisphere in stroke patients, 2005, Neuroreport 16:1551-1555.;;Fregni et al., Noninvavsive cortical stimulation with transcranial direct current stimulation in Parkinson's disease, 2006, Mov. Disord. 21:1693-1702.;;Fregni et al., A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy, 2006, Epilespsia 47:335-342.;;Fregni et al., A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury, 2006, Pain 122:197-209.;;Fregni et al., Technology Insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS, 2007, Nat. clinpract, Neurol. 3:383-393.;;Goodman et al., Low Frequency sine Wave Stimulation Decrease Seizure Frequency in Amygdala-Kindled Rats, 2002, Epilespsia 43(S7):10.;;Goodman et al., Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures, 2005, Epilsepsia 46:1-7.;;Grill, Safety considerations for deep brain stimulation: review and analysis, 2005, Expert. Rev. Med. Devices 2:409-420.;;Hebden et al., Three-dimensional optical tomography of the premature infant brain, 2002, Phys. Med. Biol. 47:4155-4166.;;Hummel et al., Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke, 2005, Brain 128:490-499.;;Hummel et al., Effects of brain polarization on reaction times and pinch force in chronic stroke, 2006, BMC Neurosci. 7:73.;;Iyer et al., Safety and cognitive effect of frontal DC brain polarization in healthy individuals, 2005, Neurology 64:872-575.;;Karkar et al., Focal cooling suppresses spontaneous epileptiform activity without changing the cortical motor threshold, 2002, Epilepsia 43:932-935.;;Kennedy et al., Brain-O-Matic. Can a jolt From a nine-Volt Battery Make you Smarter? Happier? Medical Researchers Revivea Discarded Technology and Set the Stage for the Brain Pod, The Phoenix, Feb. 7, 2007, www.thephoenix.com/article-ektid33313.aspx, updated Feb. 7, 2007.;;Lu et al., Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model, 2007, Piers online 3:178-183.;;Marshall et al., Transcranial direct current stimulation during sleep improves declarative memory, 2004, J. Neurosci. 24:9985-9992, as corrected in J. Neurosci.25(2).;;Marshall et al., Bifrontal transcranial direct current stimulation slows reaction time in a working memory task, 2005, BMC Neurosci. 6:23.;;Merrill et al., Electrical stimulation of excitable tissue: design of efficacious and safe protocols, 2005, J. Neurosci. Methods 141:171-198.;;National Institute of Neurological Disorders and Stroke, anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilespy, NIH Protocol Number: 06-N-0187, www.clinalstudies.info.nih.gov/detail/A-2006-N-0187.html updated 2006.;;Nitsche et al., Modulation of cortical excitability by weak direct current stimulation-technical, safety and functional aspects, 2003, Suppl. clin. Neurophysiol, 56:255-276.;;Nitsche et al., Shaping the effects of transcranial direct current stimulation of the human motor cortex, 2007, J. Neurophysiol. 97:3109-3117.;;Nunez, et al., comparison of high resolution EEG methods having different theorectical bases, 1993, Brain topogr. 5361-364.;;Nunez, et al. A theoretical and experimental study of high resolution EEG based on surface Laplacians and cortical imaging, 1994, Electroencephalogr. Neurophysiol, 90:40-57.;;Rhee, et al., Clincal experience of an iontophoresis based glucose measuring system, 2007, J. Korean Med. Sci. 22:70-73.;;Rothman et al., Local Cooling: A therapy for Intractable Neocortical Epilespsy, 2003, Epilepsy Curr. 3:153-156.;;Srinivasan, Methods to Improve the Spatial Resolution of EEG, 1999, International J. Bioelectromagnetism 1:102-111.;;Suh, et al., Bood volume and hemoglobin oxygenation response following electrixal stimulation of human cortex, 2006, Neuroimage 31:66-75.;;Sukstanskii et al., An analytical model of temperature regulation in human head, 2004, J. Thermal Biology 29:583-587.;;Tanter et al., Time reversal for ultrasonic trancranial surgery and echographic imaging, 2005, J. Acoustical Sco. Amer. 118(3):1941.;;Trivedi, Electrify your Mind, The New Scientist (2547), www.tmcnet.com/2006/04/14/1573554.htm updated 2006.;;Medtronic Sofamore Danek, The METRx X-Tube Retraction System, ww.sofaordanek.com/patient-minimal-metrx-xtube.html updated Jun. 19, 2003.;;Deisseroth et al., Next-generation optical technologies for illuminating genetically targeted brain circuits, 2006, J. Neurosci. 26:10380-10386.;;Grill, Noninvasive Brain Stimulation Emerges as Treatment, NeuroTech Business Reports, Aug. 2007.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Floel, A. et al., Noninvasive Brain Stimulation Improves Language Learning, Aug. 2008, J. Cogn. Neurosci., 20(8): 1415-22.;;Monti et al., Improved Naming After Transcranial Direct Current Stimulation in Aphasia, Dec. 20, 2007, J. Neurol, Neurosurg. Psychiatry, 79(4): 451-3.;;Sep. 26, 2008 comment on Monti et al., Improved Naming After Transcranial Direct Current Stimulation in Aphasia, Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.",ACTIVE
332,US,B2,US 8938290 B2,008-044-988-839-688,2015-01-20,2015,US 26214608 A,2008-10-30,US 26214608 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",WINGEIER BRETT;;PLESS BENJAMIN;;NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-30),https://lens.org/008-044-988-839-688,Granted Patent,yes,48,18,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61B5/0476;;A61B5/04;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,600/544,52,35,005-290-287-801-26X;;011-472-054-292-323;;011-472-054-292-323;;003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;042-747-937-499-103;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;011-908-987-650-668;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536,18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277;;18096677;;10.1136/jnnp.2007.135277;;17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;10.1111/j.1468-1331.2006.01414.x;;16930367;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028,"International Preliminary Examination Report (IPER) for counterpart International Application PCT/US08/0816555, date of mailing May 14, 2010.;;Floel, A., et al., ""Noninvasive Brain Stimulation Improves Language Learning"" (Aug. 2008) J. Cognitive Neuroscience 20(8): 1415-1422.;;Monti, A., et al., ""Improved Naming After Transcranial Direct Current Simulation in Aphasia"" (first published Dec. 20, 2007) J. Neurol. Neurosurg. Psychiatry 79(4): 451-453.;;Cappa, S. F., ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"" (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).;;Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.;;Non-Final Office Action mailed Jul. 5, 2012 for U.S. Appl. No. 11/929,801.;;Office Action (Non-Final Rejection) mailed Jul. 5, 2012 for U.S. Appl. No. 11/929,801.;;Office Action (Non-Final Rejection) mailed Nov. 10, 2011 for U.S. Appl. No. 12/243,733.;;Office Action (Restriction) mailed Sep. 23, 2011 for U.S. Appl. No. 12/243,733.;;Office Action (Final Rejection) mailed Apr. 16, 2012 for U.S. Appl. No. 12/243,733.;;Besio et al., ""Effects of Noninvasive Transcutaneous Electrical Stimulation Via Concentric Ring Electrodes on Pilocarpine-Induced Status Epilepticus in Rats,"" (Jul. 25, 2007), Epilepsia.;;Bikson et al., ""Effects of Uniform Extracellular DC Electric Fields on Excitability in Rat Hippocampal Slices In Vitro,"" J. Physiol. (2004) 557: 175-190.;;Boggio et al., ""A Randomized, Double-Blind Clinical Trial on the Efficacy of Cortical Direct Current Stimulation for the Treatment of Major Depression,"" (2007) Int. J. Neurophyschopharmacol., 1-6.;;Boggio et al., ""Prefrontal Cortex Modulation Using Transcranial DC Stimulation Reduces Alcohol Craving: A Double-Blind, Sham-Controlled Study,"" (published online Jul. 19, 2007) Drug Alcohol Depend.;;Boggio et al., ""Go-No-Go Task Performance Improvement After Anodal Trancranial DC Stimulation of the Left Dorsolateral Prefrontal Cortex in Major Depression,"" (2007) J. Affect. Disord. 101: 91-98.;;Clay et al., ""Weighted Regularization in Electrical Impendance Tomography with Applications to Acute Cerebral Stroke,"" (2002) IEEE Trans. Med. Imaging 21: 629-637.;;Deisseroth et al., ""Next-Generation Optical Technologies for Illuminating Genetically Targeted Brain Circuits,"" (2006) J. Neurosci. 26: 10380-10386.;;Fregni et al., ""Anodal Transcranial Direct Current Stimulation of Prefrontal Cortex Enhances Working Memory,"" (2005) Exp. Brain Res. 166:23-30.;;Fregni et al., ""Transcranial Direct Current Stimulation of the Unaffected Hemisphere in Stroke Patients,"" (2005) Neuroreport 16: 1551-1555.;;Fregni et al., ""Noninvasive Cortical Stimulation with Transcranial Direct Current Stimulation in Parkinson's Disease,"" (2006) Mov. Disord. 21: 1693-1702.;;Fregni et al., ""A Controlled Clinical Trial of Cathodal DC Polarization in Patients with Refractory Epilepsy,"" (2006) Epilepsia 47: 335-342.;;Fregni et al., ""A Sham-Controlled, Phase II Trial of Transcranial Direct Current Stimulation for the Treatment of Central Pain in Traumatic Spinal Cord Injury,"" (2006) Pain 122:197-209.;;Fregni et al., ""Technology Insight: Noninvasive Brain Stimulation in Neurology-Perspectives on the Therapeutic Potential of rTMS and tDCS,"" Nat. Clin. Pract. Neurol. 3: 383-393, Jul. 2007.;;Fregni et al., ""Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation,"" (Sep. 2006) Eur. J. Neurol. 13(9): 996-1001.;;Goodman et al., ""Low Frequency Sine Wave Stimuation Decreases Seizure Frequency in Amygdala-Kindled Rats,"" (2002) Epilepsia 43(S7): 10.;;Goodman et al., ""Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures,"" (2005) Epilepsia 46: 1-7.;;Grill, ""Safety Considerations for Deep Brain Stimualtion: Review and Analysis,"" (2005) Expert. Rev. Med. Devices 2: 409-420.;;Grill, ""Noninvasive Brain Stimulation Emerges as Treatment,"" (Aug. 2007) NeuroTech Business Reports.;;Hebden et al., ""Three-Dimensional Optical Tomography of the Premature Infant Brain,"" (2002) Phys. Med. Biol. 47: 4155-4166.;;Hummel et al., ""Effects of Noninvasive Cortical Stimulation on Skilled Motor Function in Chonic Stroke,"" (2006) BMC Neurosci. 7:73.;;Hummel et al., ""Effects of Brain Polarization on Reaction Times and Pinch Force in Chronic Stroke,"" (2006) BMC Neurosci. 7:73.;;Iyer et al., ""Safety and Cognitive Effect of Frontal DC Brain Polarization in Healthy Individuals,"" (2005) Neurology 64: 872-875.;;Karkar et al., ""Focal Cooling Suppresses Spontaneous Epileptiform Activity Without Changing the Cortical Motor Threshold,"" (2002) Epilepsia 43: 932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" (Feb. 7, 2007)The Phoenix, www.thephoenix.com/article-ektid3313.aspx.;;Lu et al, ""Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model,"" (2007) Piers online 3: 178-183.;;Marshall et al., ""Transcranial Direct Current Stimulation During Sleep Improves Declarative Memory,"" (2004) J. Neurosci. 24: 9985-9992, as corrected in J. Neurosci. 25(2).;;Marshall et al., ""Bifrontal Transcranial Direct Current Stimulation Slows Reaction Time in a Working Memory Task,"" (2005) BMC Neurosci. 6:23.;;Medtronic Sofamor Danek, The METRx (TM) X-Tube (TM) Retraction System, (updated Jun. 19, 2003) www.sofamordanek.com/patient-minimal-metrx-xtube.html.;;Merrill et al., ""Electrical Stimulation of Excitable Tissue: Design of Efficacious and Safe Protocols"" (2005) J. Neurosci. Methods 141: 171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effect of Traanscranial DC Stimulation in Focal Epilepsy, NIH Protocol Number: 06-N-0187 (updated 2006) www.clinicalstudies.info.nih.gov/detail/A-2006-N-0187.html.;;Nitsche et al., ""Modulation of Cortical Excitability by Weak Direct Current Stimulation-Technical, Safety, and Functional Aspects,"" (2003) Suppl. Clin. Neurophysiol. 56: 255-276.;;Nitsche et al., ""Shaping the Effects of Transcranial Direct Current Stimulation of the Human Motor Cortex,"" (2007) J. Neurophysiol. 97-3109-3117.;;Nunez et al., ""Comparison of High Resolution EEG Methods Having Different Theorectical Bases,"" (1993), Brain Topogr. 5:361-364.;;Nunez et al., ""A Theorectical and Experimental Study of High Resolution EEG Based on Surface Laplacians and Cortical Imaging,"" (1994) Electroencephalogr. Neurophysiol. 90: 40-57.;;Rhee et al, ""Clinical Experience of an Iontophoresis Based Glucose Measuring System,"" (2007) J. Korean Med. Sci. 22: 70-73.;;Rothman et al., ""Local Cooling: A Therapy for Intractable Neocortical Epilepsy,"" (2003) Epilepsy Curr. 3: 153-156.;;Srinivasan, ""Methods to Improve the Spatial Resolution of EEG,"" (1999) International J. Bioelectromagnetism 1: 102-111.;;Suh et al., ""Blood Volume and Hemoglobin Oxygenation Response Following Electrical Stimulation of Human Cortex,"" (2006) Neuroimage 31: 66-75.;;Sukstanskii et al., ""An Analytical Model of Temperature Regulation in Human Head,"" (2004) J. Thermal Biology 29: 583-587.;;Tanter et al., ""Time Reversal for Ultrasonic Transcranial Surgery and Echographic Imaging,"" (2005) J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, ""Electrify Your Mind,"" (updated 2006), The New Scientist (2547), www.tmcnet.com/usubmit/2006/04/14/1573554.htm.;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009) WIPO.",ACTIVE
333,US,A1,US 2019/0099596 A1,023-014-813-491-452,2019-04-04,2019,US 201715721539 A,2017-09-29,US 201715721539 A;;US 201715721574 A,2017-09-29,"LEAD FIXATION ACCESSORY, LEAD STABILIZATION TOOL, AND RELATED PROCEDURES",A lead fixation accessory configured to be positioned over a skull hole and to transition between an opened state and a closed state during a lead implant procedure protects against lead migration by providing a mechanism for securing the lead in place at the skull hole while a stylet is removed from the lead. The lead fixation accessory remains in place after the implant procedure to provide chronic lead stability. A lead stabilization tool configured to access and grip a lead through a slotted cannula during the lead implant procedure also protects against lead migration by providing a mechanism for securing the lead in place at a point where the lead exits the skull hole while the slotted cannula is removed from the skull hole and peeled away from the lead.,NEUROPACE INC,MIRRO EMILY A;;MANDELL JACOB A;;GREENE DAVID A,NEUROPACE INC (2017-10-04),https://lens.org/023-014-813-491-452,Patent Application,yes,3,4,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,0,A61B90/11;;A61B17/221;;A61B17/688;;A61B17/7055;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0534;;A61B17/221;;A61B17/3468;;A61B17/688;;A61B17/7055;;A61B17/7065;;A61B17/88;;A61B90/11;;A61B2017/0046;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0539,A61N1/05;;A61B17/34;;A61B17/70,,0,0,,,,ACTIVE
334,US,B2,US 8965513 B2,094-021-290-261-500,2015-02-24,2015,US 26095808 A,2008-10-29,US 26095808 A;;US 92980107 A,2007-10-30,"Systems, methods and devices for a skull/brain interface","Systems, methods and devices are disclosed for directing and focusing signals to the brain for neuromodulation and for directing and focusing signals or other energy from the brain for measurement, heat transfer and imaging. An aperture in the skull and/or a channel device implantable in the skull can be used to facilitate direction and focusing. Treatment and diagnosis of multiple neurological conditions may be facilitated with the disclosed systems, methods and devices.",WINGEIER BRETT;;PLESS BENJAMIN;;NEUROPACE INC,WINGEIER BRETT;;PLESS BENJAMIN,NEUROPACE INC (2007-10-20),https://lens.org/094-021-290-261-500,Granted Patent,yes,49,27,24,155-840-077-313-770;;149-328-370-535-76X;;119-376-235-425-689;;100-933-931-266-238;;105-495-511-338-180;;124-789-452-223-326;;117-795-738-878-878;;066-559-342-073-544;;179-924-638-786-13X;;066-216-291-032-392;;158-594-060-630-516;;119-200-191-559-618;;072-952-591-612-789;;094-021-290-261-500;;075-940-935-855-639;;156-507-297-866-390;;163-779-370-904-22X;;146-400-257-108-672;;008-044-988-839-688;;023-398-524-770-901;;141-823-174-236-188;;019-987-983-357-455;;195-365-374-612-110;;038-175-035-286-453,US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/0539;;A61B5/24;;A61B5/291;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N5/0601;;A61N5/0622;;A61N1/0539;;A61B5/293;;A61B18/02;;A61B18/14;;A61B90/98;;A61B2018/1807;;A61F7/0085;;A61F7/12;;A61F2007/0002;;A61F2007/0056;;A61F2007/126;;A61N1/0529;;A61N1/0531;;A61N1/0534;;A61N1/0536;;A61N1/20;;A61N1/303;;A61N1/36017;;A61N1/36025;;A61N1/36082;;A61N2/006;;A61N5/0601;;A61N5/0622;;A61N7/022;;A61N2007/0026,A61N1/04;;A61B5/04;;A61B18/02;;A61B18/14;;A61B18/18;;A61N1/05;;A61N1/20;;A61N1/30;;A61N1/36;;A61N5/06,607/45,52,36,011-472-054-292-323;;011-908-987-650-668;;003-597-415-415-587;;071-761-765-146-338;;083-092-383-664-228;;021-251-915-890-477;;003-731-295-277-291;;000-736-863-787-710;;042-747-937-499-103;;054-472-453-714-976;;017-784-867-752-244;;034-808-221-148-259;;050-990-328-920-281;;010-498-211-592-936;;080-847-900-160-743;;011-908-987-650-668;;052-004-551-432-446;;083-238-267-116-653;;137-254-911-509-624;;088-710-169-286-059;;023-121-728-277-869;;019-423-689-429-645;;049-616-525-618-721;;013-566-492-177-552;;087-556-688-961-993;;033-935-550-039-120;;043-985-525-216-664;;049-412-088-529-610;;049-806-484-196-004;;034-958-416-261-845;;011-023-189-831-773;;020-639-263-300-113;;092-397-881-924-153;;110-664-351-778-536;;005-290-287-801-26X;;011-472-054-292-323,18096677;;10.1136/jnnp.2007.135277;;10.1111/j.1468-1331.2006.01414.x;;16930367;;17651415;;10.1111/j.1528-1167.2007.01202.x;;10.1113/jphysiol.2003.055772;;pmc1665051;;14978199;;10.1017/s1461145707007833;;17559710;;pmc3372849;;10.1016/j.drugalcdep.2007.06.011;;17640830;;10.1016/j.jad.2006.10.026;;17166593;;12166859;;10.1109/tmi.2002.800572;;17035522;;10.1523/jneurosci.3863-06.2006;;pmc2820367;;15999258;;10.1007/s00221-005-2334-6;;10.1097/01.wnr.0000177010.44602.5e;;16148743;;16817194;;10.1002/mds.21012;;16499758;;10.1111/j.1528-1167.2006.00426.x;;16564618;;10.1016/j.pain.2006.02.023;;17611487;;10.1038/ncpneuro0530;;10.1111/j.1468-1331.2006.01414.x;;16930367;;15660762;;10.1111/j.0013-9580.2005.03804.x;;16293080;;10.1586/17434440.2.4.409;;10.1088/0031-9155/47/23/303;;12502040;;10.1186/1471-2202-7-73;;pmc1636653;;17083730;;10.1212/01.wnl.0000152986.07469.e9;;15753425;;12181015;;10.1046/j.1528-1157.2002.03902.x;;10.2529/piers060906193504;;15525784;;10.1523/jneurosci.2725-04.2004;;pmc6730231;;15819988;;pmc1090588;;10.1186/1471-2202-6-23;;10.1016/j.jneumeth.2004.10.020;;15661300;;14677403;;10.1016/s1567-424x(09)70230-2;;10.1152/jn.01312.2006;;17251360;;8357708;;10.1007/bf01128691;;10.1016/0013-4694(94)90112-0;;7509273;;17297254;;pmc2693572;;10.3346/jkms.2007.22.1.70;;pmc321206;;10.1046/j.1535-7597.2003.03501.x;;15346164;;16480899;;10.1016/j.neuroimage.2005.11.030;;10.1016/j.jtherbio.2004.08.028;;18303984;;10.1162/jocn.2008.20098;;18096677;;10.1136/jnnp.2007.135277,"Sep. 26, 2008 comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia,"" Dec. 20, 2007, J. Neurol. Neurosurg. Psychiatry, 79(4): 451-3 in JNNP Online.;;Fregni, F et al., Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation, Sep. 2006, Eur. J. Neurol., 13(9): 996-1001.;;Office Action (Non-Final Rejection) mailed Jul. 5, 2012 for U.S. Appl. No. 11/929,801.;;Office Action (Non-Final Rejection) mailed Nov. 10, 2011 for U.S. Appl. No. 12/243,733.;;Office Action (Restriction) mailed Sep. 23, 2011 for U.S. Appl. No. 12/243,733.;;Office Action (Final Rejection) mailed Apr. 16, 2012 for U.S. Appl. No. 12/243,733.;;Besio et al., ""Effects of Noninvasive Transcutaneous Electrical Stimulation Via Concentric Ring Electrodes on Pilocarpine-Induced Status Epilepticus in Rats,"" (Jul. 25, 2007), Epilepsia.;;Bikson et al., ""Effects of Uniform Extracellular DC Electric Fields on Excitability in Rat Hippocampal Slices In Vitro,"" J. Physiol. (2004) 557: 175-190.;;Boggio et al., ""A Randomized, Double-Blind Clinical Trial on the Efficacy of Cortical Direct Current Stimulation for the Treatment of Major Depression,"" (2007) Int. J. Neurophyschopharmacol., 1-6.;;Boggio et al., ""Prefrontal Cortex Modulation Using Transcranial DC Stimulation Reduces Alcohol Craving: A Double-Blind, Sham-Controlled Study,"" (published online Jul. 19, 2007) Drug Alcohol Depend.;;Boggio et al., ""Go-No-Go Task Performance Improvement After Anodal Trancranial DC Stimulation of the Left Dorsolateral Prefrontal Cortex in Major Depression,"" (2007) J. Affect. Disord. 101: 91-98.;;Clay et al., ""Weighted Regularization in Electrical Impendance Tomography with Applications to Acute Cerebral Stroke,"" (2002) IEEE Trans. Med. Imaging 21: 629-637.;;Deisseroth et al., ""Next-Generation Optical Technologies for Illuminating Genetically Targeted Brain Circuits,"" (2006) J. Neurosci. 26: 10380-10386.;;Fregni et al., ""Anodal Transcranial Direct Current Stimulation of Prefrontal Cortex Enhances Working Memory,"" (2005) Exp. Brain Res. 166:23-30.;;Fregni et al., ""Transcranial Direct Current Stimulation of the Unaffected Hemisphere in Stroke Patients,"" (2005) Neuroreport 16: 1551-1555.;;Fregni et al., ""Noninvasive Cortical Stimulation with Transcranial Direct Current Stimulation in Parkinson's Disease,"" (2006) Mov. Disord. 21: 1693-1702.;;Fregni et al., ""A Controlled Clinical Trial of Cathodal DC Polarization in Patients with Refractory Epilepsy,"" (2006) Epilepsia 47: 335-342.;;Fregni et al., ""A Sham-Controlled, Phase II Trial of Transcranial Direct Current Stimulation for the Treatment of Central Pain in Traumatic Spinal Cord Injury,"" (2006) Pain 122:197-209.;;Fregni et al., ""Technology Insight: Noninvasive Brain Stimulation in Neurology-Perspectives on the Therapeutic Potential of rTMS and tDCS,"" (200) Nat. Clin. Pract. Neurol. 3: 383-393.;;Fregni et al., ""Transient Tinnitus Suppression Induced by Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation,"" (Sep. 2006) Eur. J. Neurol. 13(9): 996-1001.;;Goodman et al., ""Low Frequency Sine Wave Stimuation Decreases Seizure Frequency in Amygdala-Kindled Rats,"" (2002) Epilepsia 43(S7): 10.;;Goodman et al., ""Preemptive Low Frequency Stimulation Decreases the Incidence of Amygdala Kindled Seizures,"" (2005) Epilepsia 46: 1-7.;;Grill, ""Safety Considerations for Deep Brain Stimualtion: Review and Analysis,"" (2005) Expert. Rev. Med. Devices 2: 409-420.;;Grill, ""Noninvasive Brain Stimulation Emerges As Treatment,"" (Aug. 2007) NeuroTech Business Reports.;;Hebden et al., ""Three-Dimensional Optical Tomography of the Premature Infant Brain,"" (2002) Phys. Med. Biol. 47: 4155-4166.;;Hummel et al., ""Effects of Noninvasive Cortical Stimulation on Skilled Motor Function in Chonic Stroke,"" (2006) BMC Neurosci. 7:73.;;Hummel et al., ""Effects of Brain Polarization on Reaction Times and Pinch Force in Chronic Stroke,"" (2006) BMC Neurosci. 7:73.;;Iyer et al., ""Safety and Cognitive Effect of Frontal DC Brain Polarization in Healthy Individuals,"" (2005) Neurology 64: 872-875.;;Karkar et al., ""Focal Cooling Suppresses Spontaneous Epileptiform Activity Without Changing the Cortical Motor Threshold,"" (2002) Epilepsia 43: 932-935.;;Kennedy et al., ""Brain-O-Matic. Can a Jolt From a Nine-Volt Battery Make You Smarter? Happier? Medical Researchers Revive a Discarded Technology and Set the Stage for the Brain Pod,"" (Feb. 7, 2007)The Phoenix, www.thephoenix.com/article-ektid3313.aspx.;;Lu et al, ""Comparison of Maximum Induced Current and Electric Field from Transcranial Direct Current and Magnetic Stimulations of a Human Head Model,"" (2007) Piers online 3: 178-183.;;Marshall et al., ""Transcranial Direct Current Stimulation During Sleep Improves Declarative Memory,"" (2004) J. Neurosci. 24: 9985-9992, as corrected in J. Neurosci. 25(2).;;Marshall et al., ""Bifrontal Transcranial Direct Current Stimulation Slows Reaction Time in a Working Memory Task,"" (2005) BMC Neurosci. 6:23.;;Medtronic Sofamor Danek, The METRx (TM) X-Tube (TM) Retraction System, (updated Jun. 19, 2003) www.sofamordanek.com/patient-minimal-metrx-xtube.html.;;Merrill et al., ""Electrical Stimulation of Excitable Tissue: Design of Efficacious and Safe Protocols"" (2005) J. Neurosci. Methods 141: 171-198.;;National Institute of Neurological Disorders and Stroke, Anticonvulsive Effect of Traanscranial DC Stimulation in Focal Epilepsy, NIH Protocol No. 06-N-0187 (updated 2006) www.clinicalstudiesinfo.nih.gov/detail/A-2006-N-0187.html.;;Nitsche et al., ""Modulation of Cortical Excitability by Weak Direct Current Stimulation-Technical, Safety, and Functional Aspects,"" (2003) Suppl. Clin. Neurophysiol. 56: 255-276.;;Nitsche et al., ""Shaping the Effects of Transcranial Direct Current Stimulation of the Human Motor Cortex,"" (2007) J. Neurophysiol. 97-3109-3117.;;Nunez et al., ""Comparison of High Resolution EEG Methods Having Different Theorectical Bases,"" (1993), Brain Topogr. 5:361-364.;;Nunez et al., ""A Theorectical and Experimental Study of High Resolution EEG Based on Surface Laplacians and Cortical Imaging,"" (1994) Electroencephalogr. Neurophysiol. 90: 40-57.;;Rhee et al, ""Clinical Experience of an Iontophoresis Based Glucose Measuring System,"" (2007) J. Korean Med. Sci. 22: 70-73.;;Rothman et al., ""Local Cooling: A Therapy for Intractable Neocortical Epilepsy,"" (2003) Epilepsy Curr. 3: 153-156.;;Srinivasan, ""Methods to Improve the Spatial Resolution of EEG,"" (1999) International J. Bioelectromagnetism 1: 102-111.;;Suh et al., ""Blood Volume and Hemoglobin Oxygenation Response Following Electrical Stimulation of Human Cortex,"" (2006) Neuroimage 31: 66-75.;;Sukstanskii et al., ""An Analytical Model of Temperature Regulation in Human Head,"" (2004) J. Thermal Biology 29: 583-587.;;Tanter et al., ""Time Reversal for Ultrasonic Transcranial Surgery and Echographic Imaging,"" (2005) J. Acoustical Soc. Amer. 118(3): 1941.;;Trivedi, ""Electrify Your Mind,"" (updated 2006), The New Scientist (2547), www.tmcnet.com/usubmit/2006/04/14/1573554.htm.;;PCT International Search Report and Written Opinion for corresponding International Application No. PCT/US2008/081655 (Apr. 16, 2009) WIPO.;;International Preliminary Examination Report (IPER) for counterpart International Application PCT/US08/0816555, date of mailing May 14, 2010.;;Floel, A., et al., ""Noninvasive Brain Stimulation Improves Language Learning"" (Aug. 2008) J. Cognitive Neuroscience 20(8): 1415-1422.;;Monti, A., et al., ""Improved Naming After Transcranial Direct Current Simulation in Aphasia"" (first published Dec. 20, 2007) J. Neurol. Neurosurg. Psychiatry 79(4): 451-453.;;Cappa, S. F., ""Current to the Brain Improves Word-Finding Difficulties in Aphasia Patients"" (Sep. 26, 2008), comment on Monti et al., ""Improved Naming After Transcranial Direct Current Stimulation in Aphasia"" (Dec. 20, 2007), J. Neuro. Neurosurg. Psychiatry 79(4): 451-453 (Online).",ACTIVE
335,US,B2,US 10532205 B2,010-710-662-650-23X,2020-01-14,2020,US 201715721574 A,2017-09-29,US 201715721574 A;;US 201715721539 A,2017-09-29,"Lead fixation accessory, lead stabilization tool, and related procedures",A lead fixation accessory configured to be positioned over a skull hole and to transition between an opened state and a closed state during a lead implant procedure protects against lead migration by providing a mechanism for securing the lead in place at the skull hole while a stylet is removed from the lead. The lead fixation accessory remains in place after the implant procedure to provide chronic lead stability. A lead stabilization tool configured to access and grip a lead through a slotted cannula during the lead implant procedure also protects against lead migration by providing a mechanism for securing the lead in place at a point where the lead exits the skull hole while the slotted cannula is removed from the skull hole and peeled away from the lead.,NEUROPACE INC,MANDELL JACOB A;;MIRRO EMILY A,NEUROPACE INC (2017-10-04),https://lens.org/010-710-662-650-23X,Granted Patent,yes,12,0,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,0,A61B90/11;;A61B17/221;;A61B17/688;;A61B17/7055;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0534;;A61B17/221;;A61B17/3468;;A61B17/688;;A61B17/7055;;A61B17/7065;;A61B17/88;;A61B90/11;;A61B2017/0046;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0539,A61N1/05;;A61B17/00;;A61B17/34;;A61B17/70;;A61B17/88,,1,0,,,Agilis EPI Steerable Introducer. Dual-Reach 40 cm Sheath. Product Highlights (2013).,ACTIVE
336,US,A1,US 2019/0099597 A1,036-413-561-718-621,2019-04-04,2019,US 201715721574 A,2017-09-29,US 201715721574 A;;US 201715721539 A,2017-09-29,"LEAD FIXATION ACCESSORY, LEAD STABILIZATION TOOL, AND RELATED PROCEDURES",A lead fixation accessory configured to be positioned over a skull hole and to transition between an opened state and a closed state during a lead implant procedure protects against lead migration by providing a mechanism for securing the lead in place at the skull hole while a style(is removed from the lead. The lead fixation accessory remains in place after the implant procedure to provide chronic lead stability. A lead stabilization tool configured to access and grip a lead through a slotted cannula during the lead implant procedure also protects against lead migration by providing a mechanism for securing the lead in place at a point where the lead exits the skull hole while the slotted cannula is removed from the skull hole and peeled away from the lead.,NEUROPACE INC,MIRRO EMILY A;;MANDELL JACOB A,NEUROPACE INC (2017-10-04),https://lens.org/036-413-561-718-621,Patent Application,yes,0,3,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,4,010-710-662-650-23X;;106-493-320-643-438;;023-014-813-491-452;;036-413-561-718-621,US,0,A61B90/11;;A61B17/221;;A61B17/688;;A61B17/7055;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0534;;A61B17/221;;A61B17/3468;;A61B17/688;;A61B17/7055;;A61B17/7065;;A61B17/88;;A61B90/11;;A61B2017/0046;;A61B2017/22035;;A61B2090/103;;A61N1/0531;;A61N1/0539,A61N1/05;;A61B17/34;;A61B17/70,,0,0,,,,ACTIVE
337,US,B2,US 7747318 B2,052-340-018-918-782,2010-06-29,2010,US 63588506 A,2006-12-07,US 63588506 A,2006-12-07,Functional ferrule,"Described here are intracranial ferrules, systems, and methods for sensing and stimulating neural tissues. The ferrules are generally designed to include a holding area for retaining an implantable device. In some variations, the ferrule itself may perform the sensing and stimulating functions. In other variations, the ferrule may function to sense data from neural tissues and the implantable device may function to stimulate neural tissues. In yet other variations, the ferrule may function to stimulate, and the implantable device may function to sense data from, the neural tissues. The sensing and stimulating functions may be used to detect and/or treat various neurological conditions.",NEUROPACE INC,JOHN MICHAEL S;;WINGEIER BRETT;;TCHENG THOMAS K;;PLESS BENJAMIN D,NEUROPACE INC (2007-02-27),https://lens.org/052-340-018-918-782,Granted Patent,yes,21,77,4,065-378-302-648-260;;192-590-653-695-141;;052-340-018-918-782;;187-965-876-513-162,US,4,192-590-653-695-141;;065-378-302-648-260;;052-340-018-918-782;;187-965-876-513-162,US,0,A61N1/0529;;A61B8/0808;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0529;;A61B8/0808;;A61N1/0531;;A61N1/0534;;A61N1/0539,A61N1/00,607/2,10,8,065-737-236-763-085;;026-411-412-395-329;;015-917-037-614-17X;;002-061-369-326-310;;033-183-436-795-724;;089-754-552-446-175;;025-350-236-578-392;;026-096-928-304-427,10.1016/0304-3940(94)90534-7;;7700591;;10.1111/j.1528-1167.2005.00299.x;;16393153;;5541653;;10.1126/science.171.3974.907;;10.3171/jns.2006.104.1.150;;16509160;;16871623;;10.1002/lsm.20358;;16315972;;10.1117/1.2121772;;16409069;;12853295;;10.1111/j.1749-6632.2003.tb07511.x,"Allegre, G., Avrillier, S., Albe-Fessard, D. (1994). ""Stimulation in the rat of a nerve fiber bundle by a short UV pulse from an excimer laser,"" Neuroscience Letters 180: 261-264.;;Bio-Chem Valve Inc. and Omnifit. (2003) ""Standard Product Lines,"" located at , last visited on Jun. 6, 2007. (1 page).;;Bio-Chem Valve Inc. and Omnifit. (2003) ""Welcome to Bio-Chem Valve and Omnifit,"" located at , last visited on Jun. 6, 2007. (1 page).;;Burton, J.M., Peebles, G.A., Binder, D.K., Rothman, S.M., Smyth, M.D., (2005) ""Transcortical Cooling Inhibits Hippocampal-kindled Seizures in the Rat,"" Epilepsia 46(12): 1881-1887.;;Fork, R.L. (Mar. 5, 1971). ""Laser Stimulation of Nerve Cells in Aplysia,"" Science 171: 907-908.;;Imoto, H., Fujii, M., Uchiyama, J., Fujisawa, H., Nakano, K., Kunitsugu, I., Nomura, S., Saito, T., Suzuki, M. (Jan. 2006) ""Use of a Peltier chip with a newly devised local brain-cooling system for neocortical seizures in the rat,"" J. Neurosurg. 104(1): 150-156.;;Izzo, A.D., Richter, C.P., Jansen, E.D., Walsh, J.T. (2006) ""Laser Stimulation of the Auditory Nerve,"" Laser in Surgery and Medicine 38(8): 745-753.;;Safavi-Farokhi, Z., Bakhtiary, A. H. (2005). ""The Effect of Infrared Laser on Sensory Radial Nerve Electrophysiological Parameters,"" Electromyogr. Clini. Neurophysiol. 45: 353-356.;;Wells, J., Kao, C., Jansen, E.D., Konrad, P., Mahadevan-Jansen, A. (Nov./Dec. 2005). ""Application of infrared light for in vivo neural stimulation,"" Journal of Biomedical Optics 10(6): 064003-1-064003-12.;;Yenari, M.A., Zhao, H., Giffard, R.G., Sobel, R.A., Sapolsky, R.M., Steinberg, G.K. (2003) ""Gene Therapy and Hypothermia for Stroke Treatment,"" Ann. NY Acd. Sci. 993: 54-68; 79-81.",ACTIVE
338,US,A1,US 2012/0232628 A1,197-204-756-346-538,2012-09-13,2012,US 201213370269 A,2012-02-09,US 201213370269 A;;US 87186510 A;;US 70454907 A,2007-02-08,DRUG ELUTING LEAD SYSTEMS,"Medical electrical lead systems and related methods are described. The lead systems may be configured to be at least partially implanted in neural tissue of a subject, such as a brain of a subject. Some variations of the lead systems may comprise a lead body, an electrode connected to the lead body, and a bioactive agent. The electrode and/or lead body may comprise a substrate, and the bioactive agent may be supported by the substrate (e.g., by a substantial portion of the area of the substrate). Methods described herein may comprise contacting the substrate of a lead body and/or an electrode of a medical electrical lead system with at least one bioactive agent, where the lead body and the electrode are connected to each other.",BOLING C LANCE;;CHAO DANIEL;;MORRELL MARTHA J;;PLESS BENJAMIN D;;TCHENG THOMAS K;;WINGEIER BRETT M;;NEUROPACE INC,BOLING C LANCE;;CHAO DANIEL;;MORRELL MARTHA J;;PLESS BENJAMIN D;;TCHENG THOMAS K;;WINGEIER BRETT M,NEUROPACE INC (2007-04-18),https://lens.org/197-204-756-346-538,Patent Application,yes,1,0,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,0,A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10;;A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10,A61N1/05,607/116,0,0,,,,ACTIVE
339,US,B2,US 8423156 B2,147-814-469-763-683,2013-04-16,2013,US 201213370269 A,2012-02-09,US 201213370269 A;;US 87186510 A;;US 70454907 A,2007-02-08,Drug eluting lead systems,"Medical electrical lead systems and related methods are described. The lead systems may be configured to be at least partially implanted in neural tissue of a subject, such as a brain of a subject. Some variations of the lead systems may comprise a lead body, an electrode connected to the lead body, and a bioactive agent. The electrode and/or lead body may comprise a substrate, and the bioactive agent may be supported by the substrate (e.g., by a substantial portion of the area of the substrate). Methods described herein may comprise contacting the substrate of a lead body and/or an electrode of a medical electrical lead system with at least one bioactive agent, where the lead body and the electrode are connected to each other.",BOLING C LANCE;;CHAO DANIEL;;MORRELL MARTHA J;;PLESS BENJAMIN D;;TCHENG THOMAS K;;WINGEIER BRETT M;;NEUROPACE INC,BOLING C LANCE;;CHAO DANIEL;;MORRELL MARTHA J;;PLESS BENJAMIN D;;TCHENG THOMAS K;;WINGEIER BRETT M,NEUROPACE INC (2007-04-18),https://lens.org/147-814-469-763-683,Granted Patent,yes,68,2,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,5,197-204-756-346-538;;147-814-469-763-683;;109-551-255-125-088;;042-997-482-963-986;;044-133-050-614-381,US,0,A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10;;A61N1/0529;;A61N1/0536;;A61N1/0539;;A61N1/0551;;A61N1/36082;;B22F3/10;;B22F2003/241;;B22F2003/242;;B22F2998/10,A61N1/00,607/116,20,6,078-011-754-012-619;;125-373-393-924-516;;011-003-220-418-314;;035-504-916-619-225;;017-151-528-619-262;;033-799-424-376-448,10.1097/00007691-200110000-00006;;11591899;;10.1126/science.290.5496.1532;;11090343;;10.1149/1.1393450;;10.1016/0966-7822(94)90032-9;;10.1517/17425247.1.1.37;;16296719;;pmc1361256;;pmc6792642;;9547224;;10.1523/jneurosci.18-09-03158.1998,"Final Office Action, mailed Jul. 12, 2011 for U.S. Appl. No. 12/881,171, filed Sep. 13, 2010.;;Notice of Allowance, mailed Mar. 6, 2012 for U.S. Appl. No. 12/881,171, filed Sep. 13, 2010.;;Notice of Allowance, mailed Mar. 20, 2012 for U.S. Appl. No. 13/347,675, filed Jan. 10, 2012.;;Cavuoto, J. ""Biomaterials Key Factor in Next-Generation Electrodes"", Neurotech Business Report 2(1):3-5,(Jan. 2002).;;Anonymous, ""Ommaya Reservoir"", located at last visited on Sep. 18, 2006, six pages,(2006).;;Christensen, J. et al., ""Plasma Concentration of Topiramate Correlates with Cerebralspinal Fluid Concentration"", Therapeutic Drug Monitoring 23(5):529-535,(Oct. 2001).;;Craighead, H.G. ""Nanoelectromechanical Systems"", Science 290:1532-1535,(Nov. 24, 2000).;;Doose, D.R. et al., ""Topiramate: Chemistry, Biotransformation, and Pharmacokinetics"", Chapter 78, in Antiepileptic Drugs, 5th Edition, Levy, R.H. et al. eds., Lippincott Williams & Wilkins: Philadelphia, PA, pp. 727-734,(2002).;;Ghosh, S. et al., ""Electrochemical Characterization of Poly(3,4-ethylene dioxythiophene) Based Conducting Hydrogel Networks"", J. of the Electrochem. Soc. 147(5):1872-1877,(May 2000).;;Gilmore, K. et al., ""Preparation of Hydrogel/Conducting Polymer Composites"", Polymer Gels and Networks 2(2):135-143,(1994).;;Martin, D.C. et al., ""Bio-Electronic Implantable Device Coating Applications"", in White Paper: Bioactive Conducting Polymer Coatings for Biomedical Devices, University of Michigan, four pages. (in internal database as of Aug. 30, 2006).;;Olsen, R.W. ""Phenobarbital and Other Barbiturates: Mechanisms of Action"", Chapter 50, in Antiepileptic Drugs 5th Edition, Levy, R.H. et al. eds., Lippincott Williams & Wilkins: Philadelphia, PA, pp. 489-495,(2002).;;Pitt, W.G. et al., ""Ultrasonic Drug Delivery-A General Review"", Expert Opinion on Drug Delivery 1(1):37-56, (Nov. 2004).;;Rusakov, D.A. et al., ""Extrasynaptic Glutamate Diffusion in the Hippocampus:Ultrastructural Constraints, Uptake, and Receptor Activation"", The J. of Neurosci. 18(9):3158-3170, (May 1, 1998).;;Non-Final Office Action, mailed on Sep. 8, 2009, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007, eight pages.;;Non-Final Office Action, mailed on Mar. 31, 2009, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007, twenty-seven pages.;;Non-Final Office Action, mailed on Feb. 25, 2010, for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007, ten pages.;;Notice of Allowability, mailed Jun. 24,2010 for U.S. Appl. No. 11/704,534, filed Feb. 8, 2007.;;Cengage, G. T., et al., eds., ""Ommaya Reservoir"", Encyclopedia of Cancer, eNotes.com. 2002, 2006 (located at , last visited on Aug. 31, 2010).;;Non-Final Office Action, mailed Dec. 3, 2010 for U.S. Appl. No. 12/881,171, filed Sep. 13, 2010.",ACTIVE
340,US,A1,US 2013/0172774 A1,088-148-197-388-452,2013-07-04,2013,US 201213539301 A,2012-06-30,US 201213539301 A;;US 201161504164 P,2011-07-01,Systems and Methods for Assessing the Effectiveness of a Therapy Including a Drug Regimen Using an Implantable Medical Device,"Systems and methods rely on feedback from an active medical device or devices (e.g., neurostimulator coupled to sensing and stimulation elements such as electrodes) to assess the effectiveness of a patient's drug regimen. Such reliance may include analyzing characteristics in physiological data acquired by the medical device(s), for example, in the form of responses evoked from the patient by electrical stimulation waveforms. Systems and methods further involved adjusting one or more parameters according to which a combination therapy consisting of at least a drug regimen and an electrical stimulation therapy are delivered to a patient, in an effort to optimize the therapeutic effect of the combination. The adjustments may be automatically by one or more implanted or external hosts working together or alone, and/or with the input of a physician.",CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS;;NEUROPACE INC,CROWDER TARA L;;WINGEIER BRETT M;;MORRELL MARTHA J;;SUN FELICE;;TCHENG THOMAS,NEUROPACE INC (2012-07-02),https://lens.org/088-148-197-388-452,Patent Application,yes,16,145,6,013-543-225-511-569;;088-148-197-388-452;;027-517-067-401-231;;142-233-704-121-377;;086-034-979-357-994;;112-648-625-812-547,US,6,013-543-225-511-569;;027-517-067-401-231;;086-034-979-357-994;;142-233-704-121-377;;112-648-625-812-547;;088-148-197-388-452,US,0,A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;G16H20/10;;G16H40/63;;G16H50/20;;G16H20/40;;A61B5/24;;A61B5/377;;A61B5/0002;;A61B5/14539;;A61B5/14553;;A61B5/4082;;A61B5/4094;;A61B5/4848;;A61B5/0022;;A61B5/24;;A61B5/377;;A61B5/0031,A61B5/04;;A61B5/00,600/544;;600/300,0,0,,,,DISCONTINUED
341,US,A1,US 2013/0261706 A1,166-055-481-737-618,2013-10-03,2013,US 201213444683 A,2012-04-11,US 201213444683 A;;US 201261618565 P,2012-03-30,SYSTEMS AND METHODS FOR APPLYING RAPID SEQUENTIAL ELECTRODE STIMULATION,"Described herein are methods and systems for delivering a burst of stimulation pulses or pulse segments sequentially to a plurality of stimulation pathways. The stimulation pulses may be generated by a stimulation device, which may comprise an implantable neurostimulator. The stimulation pathways may comprise one or more electrodes electrically connected to the stimulation device. In some variations, the stimulation pathway may comprise a monopolar stimulation pathway and/or a bipolar stimulation pathway.",MIRRO EMILY A;;ARCHER STEPHEN T;;NEUROPACE INC,MIRRO EMILY A;;ARCHER STEPHEN T,NEUROPACE INC (2012-04-05),https://lens.org/166-055-481-737-618,Patent Application,yes,3,66,1,166-055-481-737-618,US,1,166-055-481-737-618,US,0,A61N1/36185;;A61N1/36064;;A61N1/36178;;A61N1/36185;;A61N1/36064;;A61N1/36178,A61N1/36,607/74,0,0,,,,DISCONTINUED
342,US,B2,US 9545509 B2,159-132-276-049-827,2017-01-17,2017,US 201113310695 A,2011-12-02,US 201113310695 A;;US 41975510 P,2010-12-03,Lead fixation device for securing a medical lead in a human patient,"A lead fixation device for securing a medical lead in a human patient includes: a single-piece structure comprising: a top surface; a bottom surface; an outer perimeter; and an inner perimeter, the inner perimeter comprising: a diameter approximately equal to or smaller than a diameter of a burr hole into which the lead fixation device is designed to be deployed; a central bore extending longitudinally from the top surface through to the bottom surface, a portion of the central bore being located in approximately a center of the lead fixation device and comprising a central bore diameter; and at least one retention tract formed in the top surface of a cap of the lead fixation device, the retention tract configured for retaining, with an interference fit, a portion of a body of the medical lead in the lead fixation device.",GREENE DAVID;;NEUROPACE INC,GREENE DAVID,NEUROPACE INC (2012-03-05),https://lens.org/159-132-276-049-827,Granted Patent,yes,49,3,4,070-230-048-005-55X;;159-132-276-049-827;;011-612-369-392-603;;053-124-776-924-751,US,4,070-230-048-005-55X;;159-132-276-049-827;;011-612-369-392-603;;053-124-776-924-751,US,0,A61N1/0539;;A61N1/0539;;A61N1/05;;A61N1/0526;;A61N1/0529;;A61N1/0534;;A61N1/0558,A61N1/05;;A61N1/375,,0,0,,,,INACTIVE
343,US,B2,US 8914118 B2,010-719-429-965-05X,2014-12-16,2014,US 201113310571 A,2011-12-02,US 201113310571 A;;US 41979510 P;;US 201061424612 P,2010-12-03,"Systems, devices, and methods for monitoring and analyzing research animal behavior before, during and after brain electrical stimulation","Described are systems, devices and methods for facilitating the delivery of stimulation to, and the monitoring and recording of physiological signals (e.g., electroencephalographic signals) from a research subject. Devices include a headmount that includes a cranial frame and a headstage, and a connection between the headmount and external equipment used for stimulation, monitoring, and/or recording that is robust physically and electrically to optimize stimulation, monitoring and recording even while the subject remains ambulatory. In some embodiments, a hinged headmount allows the configuration to be easily manipulated during attachment and any subsequent adjustment or reattachment procedures and permits easy access to any wires or other components implanted in the subject. In some embodiments, a flexible cable extends out from the headmount at an acute angle relative to a horizontal plane of the headmount, to optimize strain relief as the subject moves about while attached to any stimulation, monitoring and/or recording equipment.",HASULAK NICHOLAS ROBERT;;NEUROPACE INC,HASULAK NICHOLAS ROBERT,NEUROPACE INC (2007-03-02),https://lens.org/010-719-429-965-05X,Granted Patent,yes,2,5,4,010-719-429-965-05X;;103-680-583-837-159;;159-703-893-140-649;;058-574-168-428-279,US,4,010-719-429-965-05X;;103-680-583-837-159;;159-703-893-140-649;;058-574-168-428-279,US,0,A61N1/0539;;A61N1/0534;;A61N1/36017;;A61N1/36025;;A61N1/36125;;A61N1/0529;;A61N1/0534;;A61N1/0539;;A61N1/36017;;A61N1/36025;;A61N1/36064,A61N1/36;;A61N1/05,607/45,0,0,,,,INACTIVE
344,US,B2,US 8694130 B2,096-882-343-907-49X,2014-04-08,2014,US 68881410 A,2010-01-15,US 68881410 A;;US 46785306 A;;US 12389102 A,2002-04-15,Reinforced sensing and stimulation leads and use in detection systems,"A reinforced medical electrical lead for neurological applications has a reinforced construction for resisting the detachment of electrodes and lead connection terminals, thereby improving the robustness of the lead and extending the life of the lead by reducing the likelihood that a further surgical procedure will be required to remove the lead for repair or replacement thereof. The present reinforced lead construction maintains the integrity of the electrical connection between the conductor and the respective electrode and lead connection terminal by incorporating several reinforcing features in the lead construction in contrast to conventional lead constructions where it is possible to pull the electrodes and lead connection terminals away from their contact points with relatively little force.",BOLING C LANCE;;NEUROPACE INC,BOLING C LANCE,NEUROPACE INC (2002-06-28),https://lens.org/096-882-343-907-49X,Granted Patent,yes,9,0,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,8,029-437-336-020-000;;099-857-122-133-253;;096-882-343-907-49X;;100-438-243-348-346;;161-115-362-396-611;;143-130-584-397-954;;118-491-744-333-982;;112-833-646-095-801,US,0,A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;Y10T29/53204;;Y10T29/49117;;Y10T29/53204;;Y10T29/49117;;A61N1/05;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61B5/31;;A61N1/0529,A61N1/05;;A61B5/308;;A61N1/08,607/122;;607/116;;29/746,3,3,129-566-571-935-311;;068-676-618-067-23X;;132-849-338-722-860,9949771;;10.1227/00006123-198706000-00016;;3614572;;312191,"Ajmone-Marsan, C., ""Electrocorticography: Historical Comments on its Development and the Evolution of its Practical Applications,"" Electroencephalogr. Clin. Neurophysiol. Suppl. (1998) 48: 10-16.;;Black, P.M. et al., ""Cortical Mapping for Defining the Limits of Tumor Resection,"" Neurosurgery (1987) 20: 914-919.;;Cooper, I.S., et al., ""Effects of Cerebellar Stimulation of Epilepsy, the EEG and Cerebral Palsy in Man,"" Electroencephalogr. Clin. Neurophysiol. Suppl. (1978) 34: 349-354.",ACTIVE
345,US,B2,US 9155891 B2,129-860-303-182-963,2015-10-13,2015,US 88627910 A,2010-09-20,US 88627910 A,2010-09-20,Current management system for a stimulation output stage of an implantable neurostimulation system,"A current management system for use in the stimulation output stage of a neurostimulation system can be programmed to steer different amounts of current through different stimulation electrodes to vary how strongly the tissue adjacent each electrode is stimulated during a particular programmed stimulation episode. An stimulation electrode drive circuit associated with each electrode that is available for stimulation allows independent control of the flow of current through that electrode. A reference electrode is provided in the circuit to source or sink current as necessary to balance the currents going into and out of the patient, so that no stimulation electrode is required to serve that purpose. More specifically, by configuring the circuit to maintain a constant potential at the reference electrode (e.g., a potential that is approximately half way between a top and bottom voltage rail), the reference electrode will source or sink currents as necessary to cause the net current flow into the patient to be equal to the net current flowing out of the patient, thus satisfying Kirchhoff's current law.",ARCHER STEPHEN T;;NEUROPACE INC,ARCHER STEPHEN T,NEUROPACE INC (2010-09-20),https://lens.org/129-860-303-182-963,Granted Patent,yes,29,33,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;001-779-617-891-279;;030-830-505-406-534;;130-813-226-275-958,US,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;130-813-226-275-958;;001-779-617-891-279;;030-830-505-406-534,US,0,A61N1/36125;;A61N1/3616;;A61N1/36125;;A61N1/3616,A61N1/36,,0,0,,,,ACTIVE
346,WO,A1,WO 2009/067323 A1,149-781-930-575-352,2009-05-28,2009,US 2008/0081655 W,2008-10-29,US 92980107 A;;US 23429708 A;;US 24373308 A;;US 26095808 A,2007-10-30,"SYSTEMS, METHODS AND DEVICES FOR A SKULL/BRAIN INTERFACE","Disclosed are methods, devices, and systems for inducing neuromodulation by focusing a source of stimulation through a skull/brain interface in the form of an aperture formed in the skull, a naturally occurring fenestration in the skull, or a transcranial channel. Also disclosed are methods, devices, and systems for directing and focusing signals or other energy sensed from the brain for measurement, heat transfer and/or imaging. Further disclosed are methods, devices, and systems for identifying where to locate skull/brain interfaces, accessories that can be used with the interfaces, and features for controlling stimulation delivered through the interfaces. Multiple indications for the skull/brain interfaces are also disclosed, including diagnosis and treatment of neurological disorders and conditions such as epilepsy, movement disorders, depression, Alzheimer's disease, autism, coma, and pain.",NEUROPACE INC;;PLESS BENJAMIN;;CHAO DANIEL;;WINGELER BRETT;;TCHENG THOMAS,PLESS BENJAMIN;;CHAO DANIEL;;WINGELER BRETT;;TCHENG THOMAS,,https://lens.org/149-781-930-575-352,Patent Application,yes,7,20,19,019-053-764-103-587;;085-792-055-592-624;;164-124-168-542-789;;120-334-324-245-33X;;024-906-001-418-962;;051-241-347-481-139;;115-973-925-589-672;;029-698-356-065-877;;149-781-930-575-352;;161-945-437-443-949;;042-262-060-172-466;;184-821-520-147-964;;191-986-122-665-001;;098-376-108-031-492;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;069-404-211-987-648;;192-731-136-866-068,WO;;EP;;AU;;CA;;US,43,155-840-077-313-770;;119-376-235-425-689;;117-795-738-878-878;;124-789-452-223-326;;100-933-931-266-238;;120-334-324-245-33X;;024-906-001-418-962;;115-973-925-589-672;;019-987-983-357-455;;184-821-520-147-964;;042-262-060-172-466;;156-507-297-866-390;;098-376-108-031-492;;191-986-122-665-001;;008-044-988-839-688;;023-398-524-770-901;;101-671-075-442-727;;135-949-388-289-951;;162-044-130-570-562;;141-823-174-236-188;;192-731-136-866-068;;019-053-764-103-587;;105-495-511-338-180;;085-792-055-592-624;;149-328-370-535-76X;;179-924-638-786-13X;;164-124-168-542-789;;051-241-347-481-139;;158-594-060-630-516;;066-216-291-032-392;;119-200-191-559-618;;029-698-356-065-877;;149-781-930-575-352;;072-952-591-612-789;;161-945-437-443-949;;075-940-935-855-639;;163-779-370-904-22X;;094-021-290-261-500;;146-400-257-108-672;;066-559-342-073-544;;069-404-211-987-648;;195-365-374-612-110;;038-175-035-286-453,WO;;AU;;EP;;CA;;US,0,A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B2018/1807;;A61B2090/103;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/303;;A61N1/36017;;A61N5/0601;;A61N1/36025;;A61B5/4064;;A61B5/4076;;A61B5/4094;;A61B5/6864;;A61B8/0808;;A61B18/02;;A61B18/14;;A61B90/10;;A61B2018/1807;;A61B2090/103;;A61N1/0484;;A61N1/0492;;A61N1/0529;;A61N1/0534;;A61N1/0536;;A61N1/0539;;A61N1/205;;A61N1/303;;A61N1/36017;;A61N5/0601,A61N1/05,,1,0,,,See references of EP 2205313A4,PENDING
347,US,A1,US 2012/0071950 A1,167-828-974-257-063,2012-03-22,2012,US 88627910 A,2010-09-20,US 88627910 A,2010-09-20,Current Management System for a Stimulation Output Stage of an Implantable Neurostimulation System,"A current management system for use in the stimulation output stage of a neurostimulation system can be programmed to steer different amounts of current through different stimulation electrodes to vary how strongly the tissue adjacent each electrode is stimulated during a particular programmed stimulation episode. An stimulation electrode drive circuit associated with each electrode that is available for stimulation allows independent control of the flow of current through that electrode. A reference electrode is provided in the circuit to source or sink current as necessary to balance the currents going into and out of the patient, so that no stimulation electrode is required to serve that purpose. More specifically, by configuring the circuit to maintain a constant potential at the reference electrode (e.g., a potential that is approximately half way between a top and bottom voltage rail), the reference electrode will source or sink currents as necessary to cause the net current flow into the patient to be equal to the net current flowing out of the patient, thus satisfying Kirchhoff's current law.",ARCHER STEPHEN T;;NEUROPACE INC,ARCHER STEPHEN T,NEUROPACE INC (2010-09-20),https://lens.org/167-828-974-257-063,Patent Application,yes,2,62,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;001-779-617-891-279;;030-830-505-406-534;;130-813-226-275-958,US,6,129-860-303-182-963;;167-828-974-257-063;;105-764-066-858-585;;130-813-226-275-958;;001-779-617-891-279;;030-830-505-406-534,US,0,A61N1/36125;;A61N1/3616;;A61N1/36125;;A61N1/3616,A61N1/08;;A61N1/36,607/66,0,0,,,,ACTIVE
348,WO,A2,WO 2002/038031 A2,003-182-694-505-416,2002-05-16,2002,US 0041704 W,2000-10-30,US 0041704 W,2000-10-30,SYSTEM AND METHOD FOR DETERMINING STIMULATION PARAMETERS FOR THE TREATMENT OF EPILEPTIC SEIZURES,"A method for selecting electrical stimulation parameters for controlling epileptiform activity in a patient includes implanting brain electrodes (6, 11, 12) in the patient, connecting the brain electrodes to an EEG analysis system (19) including a display workstation (16) and a stimulator (18), and collecting and analyzing EEG signals to determine whether electrical stimulation applied via the stimulator is effective to initiate or terminate epileptiform activity. If not, parameters are adjusted and stimulation, collection, and analysis steps are repeated.",NEUROPACE INC;;FISCHELL ROBERT;;FISCHELL DAVID R;;MORRELL MARTHA J;;GIBB BARBARA,FISCHELL ROBERT E;;FISCHELL DAVID R;;MORRELL MARTHA J;;GIBB BARBARA,,https://lens.org/003-182-694-505-416,Patent Application,yes,0,68,3,179-985-041-374-705;;070-219-073-547-847;;003-182-694-505-416,WO;;AU,3,179-985-041-374-705;;070-219-073-547-847;;003-182-694-505-416,WO;;AU,0,A61N1/36064;;A61N1/36135;;A61N1/36064;;A61N1/36135,A61N1/36,,0,0,,,,PENDING
349,US,B2,US 8583239 B2,127-035-858-164-256,2013-11-12,2013,US 201113011917 A,2011-01-23,US 201113011917 A;;US 37438006 A,2006-03-13,Implantable system enabling responsive therapy for pain,"An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.",PLESS BENJAMIN D;;JOHN MICHAEL SASHA;;NEUROPACE INC,PLESS BENJAMIN D;;JOHN MICHAEL SASHA,NEUROPACE INC (2009-04-24),https://lens.org/127-035-858-164-256,Granted Patent,yes,46,16,10,106-949-946-468-54X;;125-628-542-720-077;;029-463-282-605-255;;051-011-458-698-134;;127-035-858-164-256;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,10,106-949-946-468-54X;;125-628-542-720-077;;127-035-858-164-256;;051-011-458-698-134;;029-463-282-605-255;;110-213-700-091-829;;168-489-865-374-247;;136-993-143-788-28X;;145-216-267-168-517;;073-104-946-983-971,US,0,A61N1/36071;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622;;A61N1/36071;;A61F7/007;;A61F2007/0075;;A61M5/1723;;A61M2005/1726;;A61N1/36135;;A61N2/006;;A61N5/0622,A61N1/36,607/46,7,7,055-633-804-475-50X;;137-629-505-294-208;;124-115-873-895-429;;027-934-053-698-027;;093-871-073-392-568;;059-350-361-082-031;;009-083-260-830-814,15979027;;10.1016/j.ejpain.2004.11.001;;10.1016/j.neuroscience.2006.02.031;;16631315;;16326140;;10.1016/j.clinph.2005.09.012;;9092847;;10.1097/00006123-199704000-00015;;10.1016/s0304-3959(02)00277-4;;12507704;;16183660;;10.1093/brain/awh631;;10916262;;10.1109/10.846685,"Apkarian A V, Bushnell M C, Treede R D, Zubieta J K. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. Aug. 2005;9(4):463-84.;;Drewes A M, Sami S A, Dimcevski G, Nielsen K D, Funch-Jensen P, Valeriani M, Arendt-Nielsen L. ""Cerebral processing of painful oesophageal stimulation. A study based on independent component analysis of the EEG"". Gut. 2005.;;Krause P, Forderreuther S, Straube A. ""TMS motor cortical brain mapping in patients with complex regional pain syndrome type I"". Clin. Neurophysiol. Jan. 2006;117(1):169-76. Epub Dec. 2, 2005.;;Kumar et al., ""Deep Brain Stimulation for Intractable Pain: A 15-Year Experience,"" Neurosurgery 40(4): 736-747, Apr. 1997.;;D. Nandi et al., ""Thalamic field potentials in chronic central pain treated by periventricular gray stimulation-a series of eight cases,"" Pain 101 (2003) 97-107.;;Sarnthein J, Stern J, Aufenberg C, Rousson V, Jeanmonod D. ""Increased EEG power and slowed dominant frequency in patients with neurogenic pain"". Brain. Jan. 2006;129 (Pt 1):55-64.;;Weiland and Anderson, ""Chronic Neural Stimulation with Thin-Film, Iridium Oxide Electrodes,"" IEEE Transactions on Biomedical Engineering, 47: 911-918 (2000).",ACTIVE
350,US,A1,US 2012/0035431 A1,157-935-350-037-485,2012-02-09,2012,US 201113274037 A,2011-10-14,US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA;;NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/157-935-350-037-485,Patent Application,yes,0,12,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374;;A61N1/36;;A61B5/00;;A61M37/00,600/300;;607/62;;604/503,0,0,,,,INACTIVE
351,US,B2,US 8068904 B2,147-049-556-703-608,2011-11-29,2011,US 97145510 A,2010-12-17,US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA;;NEUROPACE INC,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/147-049-556-703-608,Granted Patent,yes,19,10,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374,600/544;;600/545,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A. C. (1991). Textbook of Medical Physiology, 8th ed., Wonsiewicz M.J. ed., pp. vii-xli, (Table of Contents only.).;;Gotman, J. (1990). ""Automatic Seizure Detection: Improvements and Evaluation,"" Electroencephalography & Clinical Neurophysiology 76(4): 317-324.",ACTIVE
352,US,B2,US 8369940 B2,140-977-589-660-461,2013-02-05,2013,US 201113274037 A,2011-10-14,US 201113274037 A;;US 97145510 A;;US 70445107 A,2007-02-09,Devices and methods for monitoring physiological information relating to sleep with an implantable device,"Described here are implantable devices and methods for monitoring physiological information relating to sleep. The implantable devices are generally designed to include at least one sensor for sensing physiological information, a processor for processing the physiological information using low computational power to detect a sleep stage, and a battery. The detected sleep stage information may then be used to indicate sleep quality, identify or monitor a medical condition, or guide treatment thereof.",NEUROPACE INC;;SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,SUN FELICE;;PLESS BENJAMIN D;;GIBB BARBARA,NEUROPACE INC (2007-03-26),https://lens.org/140-977-589-660-461,Granted Patent,yes,19,11,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,14,136-810-236-011-950;;188-710-738-600-753;;012-505-471-966-936;;013-895-775-183-597;;140-084-366-972-769;;146-712-257-915-848;;112-206-073-723-125;;157-935-350-037-485;;147-049-556-703-608;;129-163-026-946-780;;161-942-618-164-830;;013-652-993-005-610;;173-959-172-463-700;;140-977-589-660-461,US,0,A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/4812;;A61N1/36135;;A61B5/291;;A61B5/02438;;A61B5/11;;A61B5/4815;;A61N1/36082;;A61B5/293;;A61B5/374;;A61B5/4812;;A61B5/01;;A61B5/0205;;A61B5/026;;A61B5/1118;;A61B5/14551;;A61B5/686;;A61N1/36135,A61B5/374,600/544;;600/545,2,1,143-388-558-467-689,10.1016/0013-4694(90)90032-f;;1699724,"Guyton, A.C. ""Textbook of Medical Physiology"", 8th ed., Wonsiewicz M.J. ed., pp. vii-xli (Table of Contents only.), (1991).;;Gotman, J. ""Automatic Seizure Detection: Improvements and Evaluation"", Electroencephalography and Clinical Neurophysiology 76(4): 317-324, (1990).",INACTIVE
353,US,B2,US 8140152 B2,187-965-876-513-162,2012-03-20,2012,US 77470710 A,2010-05-05,US 77470710 A;;US 63588506 A,2006-12-07,Functional ferrule,"Described here are intracranial ferrules, systems, and methods for sensing and stimulating neural tissues. The ferrules are generally designed to include a holding area for retaining an implantable device. In some variations, the ferrule itself may perform the sensing and stimulating functions. In other variations, the ferrule may function to sense data from neural tissues and the implantable device may function to stimulate neural tissues. In yet other variations, the ferrule may function to stimulate, and the implantable device may function to sense data from, the neural tissues. The sensing and stimulating functions may be used to detect and/or treat various neurological conditions.",JOHN MICHAEL S;;WINGEIER BRETT;;TCHENG THOMAS K;;PLESS BENJAMIN D;;NEUROPACE INC,JOHN MICHAEL S;;WINGEIER BRETT;;TCHENG THOMAS K;;PLESS BENJAMIN D,NEUROPACE INC (2007-02-27),https://lens.org/187-965-876-513-162,Granted Patent,yes,24,63,4,065-378-302-648-260;;192-590-653-695-141;;052-340-018-918-782;;187-965-876-513-162,US,4,192-590-653-695-141;;065-378-302-648-260;;052-340-018-918-782;;187-965-876-513-162,US,0,A61N1/0529;;A61B8/0808;;A61N1/0531;;A61N1/0534;;A61N1/0539;;A61N1/0529;;A61B8/0808;;A61N1/0531;;A61N1/0534;;A61N1/0539,A61N1/00,607/2,10,8,065-737-236-763-085;;026-411-412-395-329;;015-917-037-614-17X;;002-061-369-326-310;;033-183-436-795-724;;089-754-552-446-175;;025-350-236-578-392;;026-096-928-304-427,10.1016/0304-3940(94)90534-7;;7700591;;10.1111/j.1528-1167.2005.00299.x;;16393153;;5541653;;10.1126/science.171.3974.907;;10.3171/jns.2006.104.1.150;;16509160;;16871623;;10.1002/lsm.20358;;16315972;;10.1117/1.2121772;;16409069;;12853295;;10.1111/j.1749-6632.2003.tb07511.x,"Allegre, G., Avrillier, S., Albe-Fessard, D. (1994). ""Stimulation in the rat of a nerve fiber bundle by a short UV pulse from an excimer laser,"" Neuroscience Letters 180: 261-264.;;Bio-Chem Valve Inc. and Omnifit. (2003) ""Standard Product Lines,"" located at , last visited on Jun. 6, 2007. (1 page).;;Bio-Chem Valve Inc. and Omnifit. (2003) ""Welcome to Bio-Chem Valve and Omnifit,"" located at , last visited on Jun. 6, 2007. (1 page).;;Burton, J.M., Peebles, G.A., Binder, D.K., Rothman, S.M., Smyth, M.D., (2005) ""Transcortical Cooling Inhibits Hippocampal-kindled Seizures in the Rat,"" Epilepsia 46(12): 1881-1887.;;Fork, R.L. (Mar. 5, 1971). ""Laser Stimulation of Nerve Cells in Aplysia,"" Science 171: 907-908.;;Imoto, H., Fujii, M., Uchiyama, J., Fujisawa, H., Nakano, K., Kunitsugu, I, Nomura, S., Saito, T., Suzuki, M. (Jan. 2006) ""Use of a Peltier chip with a newly devised local brain-cooling system for neocortical seizures in the rat,"" J. Neurosurg. 104(1): 150-156.;;Izzo, A.D., Richter, C.P., Jansen, E.D., Walsh, J.T. (2006) ""Laser Stimulation of the Auditory Nerve,"" Laser in Surgery and Medicine 38(8): 745-753.;;Safavi-Farokhi, Z., Bakhtiary, A. H. (2005). ""The Effect of Infrared Laser on Sensory Radial Nerve Electrophysiological Parameters,"" Electromyogr. Clini. Neurophysiol. 45: 353-356.;;Wells, J., Kao, C., Jansen, E.D., Konrad, P., Mahadevan-Jansen, A. (Nov./Dec. 2005). ""Application of infrared light for in vivo neural stimulation,"" Journal of Biomedical Optics 10(6): 064003-1-064003-12.;;Yenari, M.A., Zhao, H., Giffard, R.G., Sobel, R.A., Sapolsky, R.M., Steinberg, G.K. (2003) ""Gene Therapy and Hypothermia for Stroke Treatment,"" Ann. NY Acd. Sci. 993: 54-68; 79-81.",INACTIVE
354,US,B2,US 8594795 B2,136-554-319-960-414,2013-11-26,2013,US 88114310 A,2010-09-13,US 88114310 A;;US 51778306 A;;US 7266902 A,2002-02-05,Responsive electrical stimulation for movement disorders,"An implantable neurostimulator system for treating movement disorders includes a sensor, a detection subsystem capable of identifying episodes of a movement disorder by analyzing a signal received from the sensor, and a therapy subsystem capable of supplying therapeutic electrical stimulation to treat the movement disorder. The system treats movement disorders by detecting physiological conditions characteristic of an episode of symptoms of the movement disorder and selectively initiating therapy when such conditions are detected.",TCHENG THOMAS K;;FISCHELL ROBERT;;PLESS BENJAMIN D;;NEUROPACE INC,TCHENG THOMAS K;;FISCHELL ROBERT E;;PLESS BENJAMIN D,NEUROPACE INC (2002-05-28),https://lens.org/136-554-319-960-414,Granted Patent,yes,34,6,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;081-820-476-794-734;;132-646-555-613-505;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;136-554-319-960-414;;080-251-560-840-218,US,10,167-729-015-656-17X;;142-179-797-124-491;;143-023-518-199-534;;132-646-555-613-505;;081-820-476-794-734;;105-437-830-931-437;;170-190-765-999-712;;120-106-019-097-794;;080-251-560-840-218;;136-554-319-960-414,US,0,A61N1/36067;;A61N1/36135;;A61N1/36067;;A61N1/36135,A61N1/00;;A61N1/08;;A61N1/36,607/45,5,4,073-564-567-193-707;;007-661-152-207-362;;067-703-223-786-381;;058-095-107-674-216,10.1002/mds.870131321;;9827607;;10769817;;10.1080/01616412.2000.11740667;;10.1159/000101601;;6977333;;1607973;;10.3171/jns.1992.77.1.0062,"Dilorenzo, ""Optimal Method and Apparatus for Neural Modulation for the Treatment of Neurologic Disease, Particularly Movement Disorders,"" U.S. Appl. No. 60/095,413, filed Aug. 5, 1998.;;Benabid et al., ""Long-Term Electrical Inhibition of Deep Brain Targets in Movement Disorders,"" Movement Disorders 1998; 13 (Supp. 3) 119-125.;;Gross et al., ""Advances in Neurostimulation for Movement Disorders,"" Neurological Research 2000, 22: 247-258.;;Cooper et al., ""Chronic Cerebellar Stimulation (CCS) and Deep Brain Stimulation (DBS) in Involuntary Movement Disorders,"" Applied Neurophysiology 1982, 45(3): 209-17.;;Blond, et al., ""Control of Tremor and Involuntary Movement Disorders by Chronic Stereotactic Stimulation of the Ventral Intermediate Thalamic Nucleus,"" J. Neurosurgery 1992.",EXPIRED
